Bivalent, bispecific binding proteins for prevention or treatment of HIV infection

Abstract

Provided herein are bivalent, bispecific binding proteins that specifically bind to two different HIV-1 Env protein epitopes.

Description

SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE

The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 183952027001SEQLIST.txt, date recorded: Oct. 21, 2019, size: 1,064 KB).

FIELD OF THE INVENTION

The disclosure relates to trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins for treating and/or preventing HIV/AIDS.

BACKGROUND

One of the challenges in treating HIV/AIDS with neutralizing antibodies is potential breakthrough infection due to the high mutation rate of HIV-1 viruses. Additionally, virological events in the early weeks following HIV-1 transmission set the stage for lifelong chronic infection that remains incurable with currently available combination antiretroviral therapy (cART). This is due, at least in part, to the early establishment of viral reservoirs, including latently infected cells, which persist despite cART, leading to recrudescent infection when treatment is interrupted. Newly discovered anti-HIV-1 neutralizing antibodies with improved breadth and potency may provide more options for HIV/AIDS treatment and prevention; however, breakthrough infection remains a major issue in the field.

BRIEF SUMMARY

In one embodiment, the disclosure provides a binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I];a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II];a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1  [III];and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV];whereinV_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is an immunoglobulin C_H1 heavy chain constant domain; andL₁, L₂, L₃, and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

In some embodiments, the second polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains. In some embodiments, the third polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

In one embodiment, the disclosure provides a binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1-hinge-C_H2-C_H3  [II]and a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1-hinge-C_H2-C_H3  [III]and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is an immunoglobulin C_H1 heavy chain constant domain;C_H2 is an immunoglobulin C_H2 heavy chain constant domain;C_H3 is an immunoglobulin C_H3 heavy chain constant domain;hinge is an immunoglobulin hinge region connecting the C_H1 and C_H2 domains; andL₁, L₂, L₃ and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

In some embodiments, the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the C_H3 domains of the second and the third polypeptide chains both comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

In some embodiments, the one or more HIV target protein is selected from the group consisting of glycoprotein 120, glycoprotein 41 and glycoprotein 160. In some embodiments, the binding protein is trispecific and capable of specifically binding three different epitopes on a single HIV target protein. In some embodiments, the binding protein is trispecific and capable of specifically binding two different epitopes on a first HIV target protein, and one epitope on a second HIV target protein, wherein the first and second HIV target proteins are different. In some embodiments, the binding protein is trispecific and capable of specifically binding three different antigen targets. In some embodiments, the binding protein is capable of inhibiting the function of one or more HIV target proteins. In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; or a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively. In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521. In some embodiments, V_L1 comprises a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521. In some embodiments, V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; or a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively. In some embodiments, V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521. In some embodiments, V_L2 comprises a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521. In some embodiments, V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; or a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively. In some embodiments, V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521. In some embodiments, V_L3 comprises a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521. In some embodiments, V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; or a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively. In some embodiments, V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508. In some embodiments, V_H1 comprises a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508. In some embodiments, V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; or a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively. In some embodiments, V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508. In some embodiments, V_H2 comprises a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508. In some embodiments, V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; or a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively. In some embodiments, V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508. In some embodiments, V_H3 comprises a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508. In some embodiments, V_L1 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 500, a CDR-L2 comprising the sequence of SEQ ID NO: 501, and a CDR-L3 comprising the sequence of SEQ ID NO: 274; V_L2 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 275, a CDR-L2 comprising the sequence of SEQ ID NO: 276, and a CDR-L3 comprising the sequence of SEQ ID NO: 277; V_L3 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 266, a CDR-L2 comprising the sequence of SEQ ID NO: 267, and a CDR-L3 comprising the sequence of SEQ ID NO: 268; V_H1 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 254, a CDR-H2 comprising the sequence of SEQ ID NO: 255, and a CDR-H3 comprising the sequence of SEQ ID NO: 256; V_H2 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 257, a CDR-H2 comprising the sequence of SEQ ID NO: 258, and a CDR-H3 comprising the sequence of SEQ ID NO: 259; and V_H3 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 248, a CDR-H2 comprising the sequence of SEQ ID NO: 497, and a CDR-H3 comprising the sequence of SEQ ID NO: 250. In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 518; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 519; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 512; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 504; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 506; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 502. In some embodiments, V_L1 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 518; V_L2 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 519; V_L3 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 512; V_H1 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 504; V_H2 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 506; and V_H3 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 502. In some embodiments, V_L1 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 500, a CDR-L2 comprising the sequence of SEQ ID NO: 501, and a CDR-L3 comprising the sequence of SEQ ID NO: 274; V_L2 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 275, a CDR-L2 comprising the sequence of SEQ ID NO: 276, and a CDR-L3 comprising the sequence of SEQ ID NO: 277; V_L3 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 269, a CDR-L2 comprising the sequence of SEQ ID NO: 270, and a CDR-L3 comprising the sequence of SEQ ID NO: 271; V_H1 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 254, a CDR-H2 comprising the sequence of SEQ ID NO: 255, and a CDR-H3 comprising the sequence of SEQ ID NO: 256; V_H2 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 257, a CDR-H2 comprising the sequence of SEQ ID NO: 258, and a CDR-H3 comprising the sequence of SEQ ID NO: 259; and V_H3 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 251, a CDR-H2 comprising the sequence of SEQ ID NO: 252, and a CDR-H3 comprising the sequence of SEQ ID NO: 253. In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 518; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 519; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 513; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 504; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 506; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 503. In some embodiments, V_L1 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 518; V_L2 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 519; V_L3 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 513; V_H1 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 504; V_H2 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 506; and V_H3 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 503. In some embodiments, V_L1 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 275, a CDR-L2 comprising the sequence of SEQ ID NO: 276, and a CDR-L3 comprising the sequence of SEQ ID NO: 277; V_L2 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 500, a CDR-L2 comprising the sequence of SEQ ID NO: 501, and a CDR-L3 comprising the sequence of SEQ ID NO: 274; V_L3 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 269, a CDR-L2 comprising the sequence of SEQ ID NO: 270, and a CDR-L3 comprising the sequence of SEQ ID NO: 271; V_H1 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 257, a CDR-H2 comprising the sequence of SEQ ID NO: 258, and a CDR-H3 comprising the sequence of SEQ ID NO: 259; V_H2 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 254, a CDR-H2 comprising the sequence of SEQ ID NO: 255, and a CDR-H3 comprising the sequence of SEQ ID NO: 256; and V_H3 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 251, a CDR-H2 comprising the sequence of SEQ ID NO: 252, and a CDR-H3 comprising the sequence of SEQ ID NO: 253. In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 519; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 518; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 513; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 506; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 504; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 503. In some embodiments, V_L1 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 519; V_L2 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 518; V_L3 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 513; V_H1 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 506; V_H2 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 504; and V_H3 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 503. In some embodiments, at least one of L₁, L₂, L₃, or L₄ is independently 0 amino acids in length. In some embodiments, L₁, L₂, L₃, or L₄ are each independently at least one amino acid in length. In some embodiments, L₁ comprises Asp-Lys-Thr-His-Thr (SEQ ID NO: 525).

In one embodiment, the disclosure provides a binding protein comprising four polypeptide chains that form three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II]and a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1  [III]and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain; andL₁, L₂, L₃, and L₄ are amino acid linkers;wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair;wherein:

(a) V_L1, V_L2 and V_L3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, 52, 58, 60, 66, 68, 74, 76, 82, 84, 90, 92, 98, 100, 106, 108, 114, 116, 122, 124, 130, 132, 138, 140, 146, 148, 154, 156, 162, 164, 170, 172, 178, 180, 186, 188, 194, 196, 202, 204, 210,212, 218, 220, 226, 228, 233, 235, 241, 243; or

(b) V_L1, V_L2 and V_L3 each independently comprise light chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs:266-283; and

wherein:

(a) V_H1, V_H2, and V_H3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 1, 3, 9, 11, 17, 10, 25, 27, 33, 35, 41, 43, 49, 51, 57, 59, 65, 67, 73, 75, 81, 83, 89, 91, 97, 99, 105, 107, 113, 115, 121, 123, 129, 131, 137, 139, 145, 147, 153, 155, 161, 163, 169, 171, 177, 179, 185, 187, 193, 195, 201, 203, 209, 211, 217, 219, 225, 227, 232, 234, 240, 242; or

(b) V_H1, V_H2, and V_H3 each independently comprise heavy chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 248-265.

In some embodiments, the second polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains. In some embodiments, the third polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

In one embodiment, the disclosure provides a binding protein comprising four polypeptide chains that form three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1-hinge-C_H2-C_H3  [II]and a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1-hinge-C_H2-C_H3  [III]and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain;C_H2 is an immunoglobulin C_H2 heavy chain constant domain;C_H3 is an immunoglobulin C_H3 heavy chain constant domain;hinge is an immunoglobulin hinge region connecting the C_H1 and C_H2 domains; andL₁, L₂, L₃, and L₄ are amino acid linkers;wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair;wherein:

(a) V_L1, V_L2 and V_L3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, 52, 58, 60, 66, 68, 74, 76, 82, 84, 90, 92, 98, 100, 106, 108, 114, 116, 122, 124, 130, 132, 138, 140, 146, 148, 154, 156, 162, 164, 170, 172, 178, 180, 186, 188, 194, 196, 202, 204, 210,212, 218, 220, 226, 228, 233, 235, 241, 243; or

(b) V_L1, V_L2 and V_L3 each independently comprise light chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs:266-283; and

wherein:

(a) V_H1, V_H2, and V_H3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 1, 3, 9, 11, 17, 10, 25, 27, 33, 35, 41, 43, 49, 51, 57, 59, 65, 67, 73, 75, 81, 83, 89, 91, 97, 99, 105, 107, 113, 115, 121, 123, 129, 131, 137, 139, 145, 147, 153, 155, 161, 163, 169, 171, 177, 179, 185, 187, 193, 195, 201, 203, 209, 211, 217, 219, 225, 227, 232, 234, 240, 242; or

(b) V_H1, V_H2, and V_H3 each independently comprise heavy chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 248-265.

In some embodiments, the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the C_H3 domains of the second and the third polypeptide chains both comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

In some embodiments, at least one of L₁, L₂, L₃, or L₄ is independently 0 amino acids in length. In some embodiments, L₁, L₂, L₃, or L₄ are each independently at least one amino acid in length. In some embodiments, L₁ comprises Asp-Lys-Thr-His-Thr (SEQ ID NO: 525).

In one embodiment, the disclosure provides a trispecific and/or trivalent binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind three different HIV target proteins, wherein a first polypeptide chain has a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain has a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II]and a third polypeptide chain has a structure represented by the formula:V_H3-C_H1  [III]and a fourth polypeptide chain has a structure represented by the formula:V_L3-C_L  [IV]wherein:

V_L1 is a first immunoglobulin light chain variable domain;

V_L2 is a second immunoglobulin light chain variable domain;

V_L3 is a third immunoglobulin light chain variable domain;

V_H1 is a first immunoglobulin heavy chain variable domain;

V_H2 is a second immunoglobulin heavy chain variable domain;

V_H3 is a third immunoglobulin heavy chain variable domain;

C_L is an immunoglobulin light chain constant domain;

C_H1 is the immunoglobulin C_H1 heavy chain constant domain; and

L₁, L₂, L₃ and L₄ are amino acid linkers;

and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

In one embodiment, the disclosure provides a binding protein comprising four polypeptide chains that form three antigen binding sites, wherein a first polypeptide chain has a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain has a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II]and a third polypeptide chain has a structure represented by the formula:V_H3-C_H1  [III]and a fourth polypeptide chain has a structure represented by the formula:V_L3-C_L  [IV]wherein:

V_L1 is a first immunoglobulin light chain variable domain;

V_L2 is a second immunoglobulin light chain variable domain;

V_L3 is a third immunoglobulin light chain variable domain;

V_H1 is a first immunoglobulin heavy chain variable domain;

V_H2 is a second immunoglobulin heavy chain variable domain;

V_H3 is a third immunoglobulin heavy chain variable domain;

C_L is an immunoglobulin light chain constant domain;

C_H1 is the immunoglobulin C_H1 heavy chain constant domain; and

L₁, L₂, L₃, and L₄ are amino acid linkers;

wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair;

wherein:

(a) V_L1, V_L2 and V_L3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, 52, 58, 60, 66, 68, 74, 76, 82, 84, 90, 92, 98, 100, 106, 108, 114, 116, 122, 124, 130, 132, 138, 140, 146, 148, 154, 156, 162, 164, 170, 172, 178, 180, 186, 188, 194, 196, 202, 204, 210,212, 218, 220, 226, 228, 233, 235, 241, 243; or

(b) V_L1, V_L2 and V_L3 each independently comprise light chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs:266-283; and

wherein:

(a) V_H1, V_H2, and V_H3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 1, 3, 9, 11, 17, 10, 25, 27, 33, 35, 41, 43, 49, 51, 57, 59, 65, 67, 73, 75, 81, 83, 89, 91, 97, 99, 105, 107, 113, 115, 121, 123, 129, 131, 137, 139, 145, 147, 153, 155, 161, 163, 169, 171, 177, 179, 185, 187, 193, 195, 201, 203, 209, 211, 217, 219, 225, 227, 232, 234, 240, 242; or(b) V_H1, V_H2, and V_H3 each independently comprise heavy chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 248-265.

In another embodiment, the disclosure provides a binding protein comprising a first polypeptide chain, a second polypeptide chain, a third polypeptide chain and a fourth polypeptide chain wherein:

(a) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 4; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 3; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 2;

(b) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 12; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 11; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 9; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 10 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 10;

(c) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 20 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 20; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 19; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 17; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 18;

(d) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 28 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 28; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 27 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 27; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 25 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 25; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 26 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 26;

(e) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 36 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 36; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 35 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 35; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 33 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 33; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 34 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 34;

(f) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 44 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 44; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 43 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 43; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 41 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 41; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 42 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 42;

(g) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 52 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 52; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 51 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 51; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 49 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 49; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 50 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 50;

(h) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 60 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 60; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 59 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 59; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 57 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 57; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 58 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 58;

(i) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 68 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 68; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 67 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 67; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 65 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 65; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 66 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 66;

(j) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 76 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 76; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 75 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 75; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 73 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 73; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 74 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 74;

(k) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 84 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 84; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 83 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 83; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 81 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 81; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 82 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 82;

(l) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 92 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:92; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 91 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 91; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 89 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 89; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 90 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 90;

(m) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 100 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 100; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 99 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 99; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 97 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 97; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 98 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 98;

(n) the first polypeptide comprises the amino acid sequence of SEQ ID NO: 108 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 108; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 107 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 107; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 105 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 105; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 106 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 106;

(o) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 116 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 116; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 115 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 115; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 113 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 113; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 114 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 114;

(p) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 124; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 123 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 123; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 121 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 121; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 122 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 122;

(q) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 132 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 132; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 131 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 131; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 129 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 129; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 130 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 130;

(r) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 140 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 140; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 139 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 139; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 137 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 137; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 138 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 138;

(s) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 148 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 148; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 147 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 147; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 145 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 145; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 146 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 146;

(t) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 156 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 156; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 155 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 155; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 153 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 153; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 154 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 154;

(u) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 164 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 164; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 163 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 163; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 161 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 161; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 162 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 162;

(v) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 172 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 172; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 171 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 171; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 169 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 169; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 170 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 170;

(w) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 180 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 180; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 179 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 179; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 177 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 177; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 178 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 178;

(x) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 188 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 188; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 187 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 187; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 185 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 185; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 186 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 186;

(y) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 196 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 196; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 195 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 195; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 193 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 193; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 194 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 194;

(z) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 204 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 204; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 203 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 203; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 201 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 201; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 202 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 202;

(aa) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 212 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 212; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 211 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 211; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 209 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 209; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 210 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 210;

(bb) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 220 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 220; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 219 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 219; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 217 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 217; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 218 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 218;

(cc) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 228 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 228; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 227 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 227; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 225 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 225; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 226 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 226;

(dd) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 235 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 235; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 234 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 234; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 232 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 232; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 233 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 233; or

(ee) first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 243 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 243; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 242 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 242; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 240 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 240; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 241 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 241.

In one embodiment, the disclosure provides a binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins and one or more T cell target proteins, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I];a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II];a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1  [III];and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV];whereinV_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain; andL₁, L₂, L₃, and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

In some embodiments, the second polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains. In some embodiments, the third polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

In one embodiment, the disclosure provides a binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins and one or more T cell target proteins, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I];a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1-hinge-C_H2-C_H3  [II];a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1-hinge-C_H2-C_H3  [III];and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV];whereinV_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain;C_H2 is an immunoglobulin C_H2 heavy chain constant domain;C_H3 is an immunoglobulin C_H3 heavy chain constant domain;hinge is an immunoglobulin hinge region connecting the C_H1 and C_H2 domains; andL₁, L₂, L₃, and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

In some embodiments, the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the C_H3 domains of the second and the third polypeptide chains both comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

In some embodiments, the one or more HIV target proteins are selected from the group consisting of glycoprotein 120, glycoprotein 41 and glycoprotein 160. In some embodiments, the one or more T cell target proteins are CD3 or CD28. In some embodiments, the binding protein is trispecific and capable of specifically binding an HIV target protein and two different epitopes on a single T cell target protein. In some embodiments, the binding protein is trispecific and capable of specifically binding an HIV target protein and two different T cell target proteins. In some embodiments, the binding protein is trispecific and capable of specifically binding a T cell target protein and two different epitopes on a single HIV target protein. In some embodiments, the binding protein is trispecific and capable of specifically binding a T cell target protein and two different HIV target proteins. In some embodiments, the first and second polypeptide chains form two antigen binding sites that specifically target two T cell target proteins, and the third and fourth polypeptide chains form an antigen binding site that specifically binds an HIV target protein. In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively; a sequence as set forth in SEQ ID NOs: 488, 489, and 490, respectively; a sequence as set forth in SEQ ID NOs: 491, 492, and 493, respectively; or a sequence as set forth in SEQ ID NOs: 494, 495, and 496, respectively. In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524. In some embodiments, V_L1 comprises a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524. In some embodiments, V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively; a sequence as set forth in SEQ ID NOs: 488, 489, and 490, respectively; a sequence as set forth in SEQ ID NOs: 491, 492, and 493, respectively; or a sequence as set forth in SEQ ID NOs: 494, 495, and 496, respectively. In some embodiments, V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524. In some embodiments, V_L2 comprises a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524. In some embodiments, V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively; a sequence as set forth in SEQ ID NOs: 488, 489, and 490, respectively; a sequence as set forth in SEQ ID NOs: 491, 492, and 493, respectively; or a sequence as set forth in SEQ ID NOs: 494, 495, and 496, respectively. In some embodiments, V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524. In some embodiments, V_L3 comprises a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524. In some embodiments, V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively; a sequence as set forth in SEQ ID NOs: 479, 480, and 481, respectively; a sequence as set forth in SEQ ID NOs: 482, 483, and 484, respectively; or a sequence as set forth in SEQ ID NOs: 485, 486, and 487, respectively. In some embodiments, V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511. In some embodiments, V_H1 comprises a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511. In some embodiments, V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively; a sequence as set forth in SEQ ID NOs: 479, 480, and 481, respectively; a sequence as set forth in SEQ ID NOs: 482, 483, and 484, respectively; or a sequence as set forth in SEQ ID NOs: 485, 486, and 487, respectively. In some embodiments, V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511. In some embodiments, V_H2 comprises a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511. In some embodiments, V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively; a sequence as set forth in SEQ ID NOs: 479, 480, and 481, respectively; a sequence as set forth in SEQ ID NOs: 482, 483, and 484, respectively; or a sequence as set forth in SEQ ID NOs: 485, 486, and 487, respectively. In some embodiments, V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511. In some embodiments, V_H3 comprises a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511. In some embodiments, V_L1 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 488, a CDR-L2 comprising the sequence of SEQ ID NO: 489, and a CDR-L3 comprising the sequence of SEQ ID NO: 490; V_L2 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 494, a CDR-L2 comprising the sequence of SEQ ID NO: 495, and a CDR-L3 comprising the sequence of SEQ ID NO: 496; V_L3 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 269, a CDR-L2 comprising the sequence of SEQ ID NO: 270, and a CDR-L3 comprising the sequence of SEQ ID NO: 271; V_H1 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 479, a CDR-H2 comprising the sequence of SEQ ID NO: 480, and a CDR-H3 comprising the sequence of SEQ ID NO: 481; V_H2 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 485, a CDR-H2 comprising the sequence of SEQ ID NO: 486, and a CDR-H3 comprising the sequence of SEQ ID NO: 487; and V_H3 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 251, a CDR-H2 comprising the sequence of SEQ ID NO: 252, and a CDR-H3 comprising the sequence of SEQ ID NO: 253. In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 522; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 524; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 513; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 509; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 511; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 503. In some embodiments, V_L1 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 522; V_L2 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 524; V_L3 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 513; V_H1 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 509; V_H2 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 511; and V_H3 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 503. In some embodiments, V_L1 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 494, a CDR-L2 comprising the sequence of SEQ ID NO: 495, and a CDR-L3 comprising the sequence of SEQ ID NO: 496; V_L2 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 488, a CDR-L2 comprising the sequence of SEQ ID NO: 489, and a CDR-L3 comprising the sequence of SEQ ID NO: 490; V_L3 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 269, a CDR-L2 comprising the sequence of SEQ ID NO: 270, and a CDR-L3 comprising the sequence of SEQ ID NO: 271; V_H1 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 485, a CDR-H2 comprising the sequence of SEQ ID NO: 486, and a CDR-H3 comprising the sequence of SEQ ID NO: 487; V_H2 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 479, a CDR-H2 comprising the sequence of SEQ ID NO: 480, and a CDR-H3 comprising the sequence of SEQ ID NO: 481; and V_H3 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 251, a CDR-H2 comprising the sequence of SEQ ID NO: 252, and a CDR-H3 comprising the sequence of SEQ ID NO: 253. In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 524; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 522; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 513; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 511; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 509; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 503. In some embodiments, V_L1 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 524; V_L2 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 522; V_L3 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 513; V_H1 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 511; V_H2 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 509; and V_H3 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 503. In some embodiments, at least one of L₁, L₂, L₃, or L₄ is independently 0 amino acids in length. In some embodiments, L₁, L₂, L₃, or L₄ are each independently at least one amino acid in length. In some embodiments, L₁ is Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 299).

In one embodiment, the disclosure provides a binding protein comprising four polypeptide chains that form three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II]and a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1  [III]and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain; andL₁, L₂, L₃, and L₄ are amino acid linkers;wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair;wherein:

(a) V_L1, V_L2 and V_L3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 303, 305, 311, 313, 319, 321, 327, 329, 335, 337, 343, 345, 351, 353, 359, 361, 367, 369, 375, 377, 383, 385, 391, 393, 399, 401, 407, 409, 415, 417, 423, 425, 431, 433, 439, 441, 447, 449, 455, 457, 463, 465, 471, 473; or

(b) V_L1, V_L2 and V_L3 each independently comprise light chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 266-271, 275-277, 488-496; and

wherein:

(a) V_H1, V_H2, and V_H3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 302, 304, 310, 312, 318, 320, 326, 328, 334, 336, 342, 344, 350, 352, 358, 360, 366, 368, 374, 376, 382, 384, 390, 392, 398, 400, 406, 408, 414, 416, 422, 424, 430, 432, 438, 440, 446, 448, 454, 456, 462, 464, 470, 472; or

(b) V_H1, V_H2, and V_H3 each independently comprise heavy chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 248-253, 257-259, 479-487.

In some embodiments, the second polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains. In some embodiments, the third polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

In one embodiment, the disclosure provides a binding protein comprising four polypeptide chains that form three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1-hinge-C_H2-C_H3  [II]and a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1-hinge-C_H2-C_H3  [III]and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain;C_H2 is an immunoglobulin C_H2 heavy chain constant domain;C_H3 is an immunoglobulin C_H3 heavy chain constant domain;hinge is an immunoglobulin hinge region connecting the C_H1 and C_H2 domains; andL₁, L₂, L₃, and L₄ are amino acid linkers;wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair;wherein:

(a) V_L1, V_L2 and V_L3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 303, 305, 311, 313, 319, 321, 327, 329, 335, 337, 343, 345, 351, 353, 359, 361, 367, 369, 375, 377, 383, 385, 391, 393, 399, 401, 407, 409, 415, 417, 423, 425, 431, 433, 439, 441, 447, 449, 455, 457, 463, 465, 471, 473; or

(b) V_L1, V_L2 and V_L3 each independently comprise light chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 266-271, 275-277, 488-496; and

wherein:

(a) V_H1, V_H2, and V_H3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 302, 304, 310, 312, 318, 320, 326, 328, 334, 336, 342, 344, 350, 352, 358, 360, 366, 368, 374, 376, 382, 384, 390, 392, 398, 400, 406, 408, 414, 416, 422, 424, 430, 432, 438, 440, 446, 448, 454, 456, 462, 464, 470, 472; or

(b) V_H1, V_H2, and V_H3 each independently comprise heavy chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 248-253, 257-259, 479-487.

In some embodiments, the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the C_H3 domains of the second and the third polypeptide chains both comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

In some embodiments, at least one of L₁, L₂, L₃, or L₄ is independently 0 amino acids in length. In some embodiments, L₁, L₂, L₃, or L₄ are each independently at least one amino acid in length. In some embodiments, L₁ is Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 299).

In one embodiment, the disclosure provides a binding protein comprising four polypeptide chains that form three antigen binding sites, wherein a first polypeptide chain has a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain has a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II]and a third polypeptide chain has a structure represented by the formula:V_H3-C_H1  [III]and a fourth polypeptide chain has a structure represented by the formula:V_L3-C_L  [IV]wherein:

V_L1 is a first immunoglobulin light chain variable domain;

V_L2 is a second immunoglobulin light chain variable domain;

V_L3 is a third immunoglobulin light chain variable domain;

V_H1 is a first immunoglobulin heavy chain variable domain;

V_H2 is a second immunoglobulin heavy chain variable domain;

V_H3 is a third immunoglobulin heavy chain variable domain;

C_L is an immunoglobulin light chain constant domain;

C_H1 is the immunoglobulin C_H1 heavy chain constant domain; and

L₁, L₂, L₃, and L₄ are amino acid linkers;

wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair;

wherein:

(a) V_L1, V_L2 and V_L3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 303, 305, 311, 313, 319, 321, 327, 329, 335, 337, 343, 345, 351, 353, 359, 361, 367, 369, 375, 377, 383, 385, 391, 393, 399, 401, 407, 409, 415, 417, 423, 425, 431, 433, 439, 441, 447, 449, 455, 457, 463, 465, 471, 473; or

(b) V_L1, V_L2 and V_L3 each independently comprise light chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 266-271, 275-277, 488-496; and

wherein:

(a) V_H1, V_H2, and V_H3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 302, 304, 310, 312, 318, 320, 326, 328, 334, 336, 342, 344, 350, 352, 358, 360, 366, 368, 374, 376, 382, 384, 390, 392, 398, 400, 406, 408, 414, 416, 422, 424, 430, 432, 438, 440, 446, 448, 454, 456, 462, 464, 470, 472; or

(b) V_H1, V_H2, and V_H3 each independently comprise heavy chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 248-253, 257-259, 479-487.

In another embodiment, the disclosure provides a binding protein comprising a first polypeptide chain, a second polypeptide chain, a third polypeptide chain and a fourth polypeptide chain wherein:

(a) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 305 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 305; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 304 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 304; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 302 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 302; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 303 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 303;

(b) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 313 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 313; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 312 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 312; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 310 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 310; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 311 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 311;

(c) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 321 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 321; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 320 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 320; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 318 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 318; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 319 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 319;

(d) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 329 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 329; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 328 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 328; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 326 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 326; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 327 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 327;

(e) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 337 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 337; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 336 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 336; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 334 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 334; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 335 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 335;

(f) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 345 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 345; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 344 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 344; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 342 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 342; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 343 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 343;

(g) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 353 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 353; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 352 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:352; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 350 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 350; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 351 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 351;

(h) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 361 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 361; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 360 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 360; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 358 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 358; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 359 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 359;

(i) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 369 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 369; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 368 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 368; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 366 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 366; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 367 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 367;

(j) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 377 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 377; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 376 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 376; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 374 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 374; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 375 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 375;

(k) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 385 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 385; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 384 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 384; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 382 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 382; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 383 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 383;

(l) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 393 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 393; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 392 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 392; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 390 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 390; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 391 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 391;

(m) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 401 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 401; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 400 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 400; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 398 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 398; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 399 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 399;

(n) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 409 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 409; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 408 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 408; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 406 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 406; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 407 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 407;

(p) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 417 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 417; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 416 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 416; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 414 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 414; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 415 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 415;

(q) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 425 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 425; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 424 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 424; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 422 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 422; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 423 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 423;

(r) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 433 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:433; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 432 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 432; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 430 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 430; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 431 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 431;

(s) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 441 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 441; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 440 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 440; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 438 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 438; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 439 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 439;

(t) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 449 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 449; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 448 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 448; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 446 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 446; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 447 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 447;

(u) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 457 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 457; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 456 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 456; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 454 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 454; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 455 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 455;

(v) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 465 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 465; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 464 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 464; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 462 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 462; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 463 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 463; or

(w) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 473 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 473; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 472 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 472; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 470 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 470; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 471 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 471.

In one embodiment, the disclosure provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding the binding protein according to any of the above embodiments. In one embodiment, the disclosure provides an expression vector comprising the nucleic acid molecule according to any of the above embodiments. In one embodiment, the disclosure provides an isolated host cell comprising the nucleic acid molecule according to any of the above embodiments. In one embodiment, the disclosure provides an isolated host cell comprising the expression vector according to any of the above embodiments. In some embodiments, the isolated host cell is a mammalian cell or an insect cell. In one embodiment, the disclosure provides a vector system comprising one or more vectors encoding a first, second, third, and fourth polypeptide chain of a binding protein according to any of the above embodiments. In some embodiments, the vector system comprises a first vector encoding the first polypeptide chain of the binding protein, a second vector encoding the second polypeptide chain of the binding protein, a third vector encoding the third polypeptide chain of the binding protein, and a fourth vector encoding the fourth polypeptide chain of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first and second polypeptide chains of the binding protein, and a second vector encoding the third and fourth polypeptide chains of the binding protein. In some embodiments, the one or more vectors are expression vectors. In one embodiment, the disclosure provides an isolated host cell comprising the vector system according to any of the above embodiments. In some embodiments, the isolated host cell is a mammalian cell or an insect cell. In one embodiment, the disclosure provides a method of producing a binding protein, the method comprising: a) culturing a host cell according to any of the above embodiments under conditions such that the host cell expresses the binding protein; and b) isolating the binding protein from the host cell.

In one embodiment, the disclosure provides a method of preventing and/or treating HIV infection in a patient comprising administering to the patient a therapeutically effective amount of at least one binding protein according to any of the above embodiments. In some embodiments, the binding protein is co-administered with standard anti-retroviral therapy. In some embodiments, administration of the at least one binding protein results in the neutralization of one or more HIV virions. In some embodiments, administration of the at least one binding protein results in the elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, the patient is a human.

In one embodiment, the disclosure provides a binding protein according to any of the above embodiments for the prevention or treatment of an HIV infection in a patient. In some embodiments, the binding protein is co-administered with standard anti-retroviral therapy. In some embodiments, the binding protein causes the neutralization of one or more HIV virions in the patient. In some embodiments, the binding protein causes the elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, the patient is a human.

Specific embodiments of the invention will become evident from the following more detailed description of certain embodiments and the claims.

It is to be understood that one, some, or all of the properties of the various embodiments described herein may be combined to form other embodiments of the present invention. These and other aspects of the invention will become apparent to one of skill in the art.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-D show schematic representations of trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind three different epitopes on one or more antigens, wherein a first pair of polypeptides possess dual variable domains having a cross-over orientation forming two antigen binding sites (comprising V_H1-V_L1 and V_H2-V_L2) and wherein a second pair of polypeptides possess a single antigen binding site (comprising V_H3-V_L3), in accordance with some embodiments. FIG. 1A shows a trispecific binding protein comprising a “knobs-into-holes” modification, wherein the knob is on the first pair of polypeptides. FIG. 1B shows a trispecific binding protein comprising a “knobs-into-holes” modification, wherein the knob is on the second pair of polypeptides. FIG. 1C shows the orientation of variable domains on the polypeptide chains, and the knob/hole orientation for binding proteins 1-31 shown in Tables 1 and 2. “Heavy chain A” (e.g., a third polypeptide chain of the present disclosure) indicates the variable domain of heavy chain A. “Light chain A” (e.g., a fourth polypeptide chain of the present disclosure) indicates the variable domain of light chain A. “Heavy chain B” (e.g., a second polypeptide chain of the present disclosure) indicates variable domain 1 and variable domain 2 of heavy chain B. “Light chain B” (e.g., a first polypeptide chain of the present disclosure) indicates variable domain 1 and variable domain 2 of light chain B. FIG. 1D shows the orientation of variable domains on the polypeptide chains, and the knob/hole orientation for binding proteins 32-53 shown in Tables 1 and 2. “Heavy chain A” (e.g., a third polypeptide chain of the present disclosure) indicates the variable domain of heavy chain A. “Light chain A” (e.g., a fourth polypeptide chain of the present disclosure) indicates the variable domain of light chain A. “Heavy chain B” (e.g., a second polypeptide chain of the present disclosure) indicates variable domain 1 and variable domain 2 of heavy chain B. “Light chain B” (e.g., a first polypeptide chain of the present disclosure) indicates variable domain 1 and variable domain 2 of light chain B.

FIGS. 2A-B show purification of three trispecific binding proteins first using affinity chromatography, and then using preparative size exclusion chromatography. FIG. 2A shows the elution profile of the trispecific binding proteins during purification using protein A affinity chromatography. FIG. 2B shows purification of monomeric proteins by Superdex200 size exclusion chromatography.

FIGS. 3A-B show purification of the MPER Ab, CD4BS Ab “b”, and V1/V2 directed Ab “a” parental antibodies first using affinity chromatography, and then using preparative size exclusion chromatography. FIG. 3A shows the elution profile of the parental antibodies during purification using protein A affinity chromatography. FIG. 3B shows purification of monomeric proteins by Superdex200 size exclusion chromatography.

FIGS. 4A-B show the size exclusion chromatography profiles of bispecific and trispecific binding proteins. FIG. 4A shows the size exclusion chromatography profiles of the bispecific binding proteins. FIG. 4B shows the size exclusion chromatography profiles of the trispecific binding proteins.

FIG. 5 shows the Biacore sensograms of the binding kinetics of three trispecific binding proteins and the parental MPER Ab antibody for an HIV gp41-derived peptide (the MPER binding site), as assessed by the standard Biacore-based kinetic assay.

FIG. 6 shows the Biacore sensograms of the binding kinetics of three trispecific binding proteins and the parental CD4BS Ab “b” antibody for recombinant HIV gp120, as assessed by the standard Biacore-based kinetic assay.

FIG. 7 shows the results of a pharmacokinetic (PK) study of the indicated proteins after intravenous (IV) injection in rhesus macaques.

FIGS. 8A-8B show schematic representations of trispecific T-cell engagers, in accordance with some embodiments. The binding sites are indicated by the dotted circles.

FIG. 9 shows binding properties of the trispecific binding proteins “Binding Protein 32” and “CD3×CD28/CD4BS Ab ‘b’” to CD3 (CD3E represents CD3epsilon protein; CD3D represents CD3delta protein), CD28, and Resurfaced Stabilized Core 3 (RSC3) protein of gp120, as well as a negative control (human IgG).

FIG. 10 shows CD8 T-cell activation using the trispecific proteins “Binding Protein 32” and “CD3×CD28/CD4BS Ab ‘b’” compared to the parental CD4BS IgG4 antibody, as well as a negative control (No mAb).

FIG. 11 shows CD4 T-cell activation using the trispecific proteins “Binding Protein 32” and “CD3×CD28/CD4BS Ab ‘b’” compared to the parental CD4BS IgG4 antibody, as well as a negative control (No mAb).

FIG. 12 shows CD3 downregulation after T cell activation by the trispecific proteins “Binding Protein 32” and “CD3×CD28/CD4BS Ab ‘b’” compared to the parental CD4BS IgG4 antibody, as well as a negative control (No mAb).

FIGS. 13A-C show fluorescence-activated cell sorting (FACS)-based cytotoxicity assay results for trispecific binding proteins against latently infected HIV-1⁺ T cells. FIG. 13A shows the results for trispecific binding proteins incubated with CEM-BaL cells. FIG. 13B shows the results for trispecific binding proteins incubated with ACH2 cells. FIG. 13C shows the results for trispecific binding proteins incubated with J1.1 cells.

DETAILED DESCRIPTION

The present disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind to one or more human immunodeficiency virus (HIV) target proteins and/or one or more T-cell receptor target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain.

The following description sets forth exemplary methods, parameters, and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.

Definitions

As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

The term “polynucleotide” as used herein refers to single-stranded or double-stranded nucleic acid polymers of at least 10 nucleotides in length. In certain embodiments, the nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. Such modifications include base modifications such as bromuridine, ribose modifications such as arabinoside and 2′,3′-dideoxyribose, and intemucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phoshoraniladate and phosphoroamidate. The term “polynucleotide” specifically includes single-stranded and double-stranded forms of DNA.

An “isolated polynucleotide” is a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, which: (1) is not associated with all or a portion of a polynucleotide in which the isolated polynucleotide is found in nature, (2) is linked to a polynucleotide to which it is not linked in nature, or (3) does not occur in nature as part of a larger sequence.

An “isolated polypeptide” is one that: (1) is free of at least some other polypeptides with which it would normally be found, (2) is essentially free of other polypeptides from the same source, e.g., from the same species, (3) is expressed by a cell from a different species, (4) has been separated from at least about 50 percent of polynucleotides, lipids, carbohydrates, or other materials with which it is associated in nature, (5) is not associated (by covalent or noncovalent interaction) with portions of a polypeptide with which the “isolated polypeptide” is associated in nature, (6) is operably associated (by covalent or noncovalent interaction) with a polypeptide with which it is not associated in nature, or (7) does not occur in nature. Such an isolated polypeptide can be encoded by genomic DNA, cDNA, mRNA or other RNA, of synthetic origin, or any combination thereof. Preferably, the isolated polypeptide is substantially free from polypeptides or other contaminants that are found in its natural environment that would interfere with its use (therapeutic, diagnostic, prophylactic, research or otherwise).

Naturally occurring antibodies typically comprise a tetramer. Each such tetramer is typically composed of two identical pairs of polypeptide chains, each pair having one full-length “light” chain (typically having a molecular weight of about 25 kDa) and one full-length “heavy” chain (typically having a molecular weight of about 50-70 kDa). The terms “heavy chain” and “light chain” as used herein refer to any immunoglobulin polypeptide having sufficient variable domain sequence to confer specificity for a target antigen. The amino-terminal portion of each light and heavy chain typically includes a variable domain of about 100 to 110 or more amino acids that typically is responsible for antigen recognition. The carboxy-terminal portion of each chain typically defines a constant domain responsible for effector function. Thus, in a naturally occurring antibody, a full-length heavy chain immunoglobulin polypeptide includes a variable domain (V_H) and three constant domains (C_H1, C_H2, and C_H3), wherein the V_H domain is at the amino-terminus of the polypeptide and the C_H3 domain is at the carboxyl-terminus, and a full-length light chain immunoglobulin polypeptide includes a variable domain (V_L) and a constant domain (C_L), wherein the V_L domain is at the amino-terminus of the polypeptide and the C_L domain is at the carboxyl-terminus.

Human light chains are typically classified as kappa and lambda light chains, and human heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. IgG has several subclasses, including, but not limited to, IgG1, IgG2, IgG3, and IgG4. IgM has subclasses including, but not limited to, IgM1 and IgM2. IgA is similarly subdivided into subclasses including, but not limited to, IgA1 and IgA2. Within full-length light and heavy chains, the variable and constant domains typically are joined by a “J” region of about 12 or more amino acids, with the heavy chain also including a “D” region of about 10 more amino acids. See, e.g., FUNDAMENTAL IMMUNOLOGY (Paul, W., ed., Raven Press, 2nd ed., 1989), which is incorporated by reference in its entirety for all purposes. The variable regions of each light/heavy chain pair typically form an antigen binding site. The variable domains of naturally occurring antibodies typically exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair typically are aligned by the framework regions, which may enable binding to a specific epitope. From the amino-terminus to the carboxyl-terminus, both light and heavy chain variable domains typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

The term “CDR set” refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat et al., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST (National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs. These CDRs may be referred to as Kabat CDRs. Chothia and coworkers (Chothia and Lesk, 1987, J. Mol. Biol. 196: 901-17; Chothia et al., 1989, Nature 342: 877-83) found that certain sub-portions within Kabat CDRs adopt nearly identical peptide backbone conformations, despite having great diversity at the level of amino acid sequence. These sub-portions were designated as L1, L2, and L3 or H1, H2, and H3 where the “L” and the “H” designates the light chain and the heavy chain regions, respectively. These regions may be referred to as Chothia CDRs, which have boundaries that overlap with Kabat CDRs. Other boundaries defining CDRs overlapping with the Kabat CDRs have been described by Padlan, 1995, FASEB J. 9: 133-39; MacCallum, 1996, J. Mol. Biol. 262(5): 732-45; and Lefranc, 2003, Dev. Comp. Immunol. 27: 55-77. Still other CDR boundary definitions may not strictly follow one of the herein systems, but will nonetheless overlap with the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding. The methods used herein may utilize CDRs defined according to any of these systems, although certain embodiments use Kabat or Chothia defined CDRs. Identification of predicted CDRs using the amino acid sequence is well known in the field, such as in Martin, A. C. “Protein sequence and structure analysis of antibody variable domains,” In Antibody Engineering, Vol. 2. Kontermann R., Dübel S., eds. Springer-Verlag, Berlin, p. 33-51 (2010). The amino acid sequence of the heavy and/or light chain variable domain may be also inspected to identify the sequences of the CDRs by other conventional methods, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. The numbered sequences may be aligned by eye, or by employing an alignment program such as one of the CLUSTAL suite of programs, as described in Thompson, 1994, Nucleic Acids Res. 22: 4673-80. Molecular models are conventionally used to correctly delineate framework and CDR regions and thus correct the sequence-based assignments.

The term “Fc” as used herein refers to a molecule comprising the sequence of a non-antigen-binding fragment resulting from digestion of an antibody or produced by other means, whether in monomeric or multimeric form, and can contain the hinge region. The original immunoglobulin source of the native Fc is preferably of human origin and can be any of the immunoglobulins, although IgG1 and IgG2 are preferred. Fc molecules are made up of monomeric polypeptides that can be linked into dimeric or multimeric forms by covalent (i.e., disulfide bonds) and non-covalent association. The number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4 depending on class (e.g., IgG, IgA, and IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1, and IgGA2). One example of a Fc is a disulfide-bonded dimer resulting from papain digestion of an IgG. The term “Fc” as used herein is generic to the monomeric, dimeric, and multimeric forms.

A F(ab) fragment typically includes one light chain and the V_H and C_H1 domains of one heavy chain, wherein the V_H-C_H1 heavy chain portion of the F(ab) fragment cannot form a disulfide bond with another heavy chain polypeptide. As used herein, a F(ab) fragment can also include one light chain containing two variable domains separated by an amino acid linker and one heavy chain containing two variable domains separated by an amino acid linker and a C_H1 domain.

A F(ab′) fragment typically includes one light chain and a portion of one heavy chain that contains more of the constant region (between the C_H1 and C_H2 domains), such that an interchain disulfide bond can be formed between two heavy chains to form a F(ab′)₂ molecule.

The term “binding protein” as used herein refers to a non-naturally occurring (or recombinant or engineered) molecule that specifically binds to at least one target antigen, and which comprises four polypeptide chains that form at least three antigen binding sites, wherein a first polypeptide chain has a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain has a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II]and a third polypeptide chain has a structure represented by the formula:V_H3-C_H1  [III]and a fourth polypeptide chain has a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain; andL₁, L₂, L₃, and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

A “recombinant” molecule is one that has been prepared, expressed, created, or isolated by recombinant means.

One embodiment of the disclosure provides binding proteins having biological and immunological specificity to between one and three target antigens. Another embodiment of the disclosure provides nucleic acid molecules comprising nucleotide sequences encoding polypeptide chains that form such binding proteins. Another embodiment of the disclosure provides expression vectors comprising nucleic acid molecules comprising nucleotide sequences encoding polypeptide chains that form such binding proteins. Yet another embodiment of the disclosure provides host cells that express such binding proteins (i.e., comprising nucleic acid molecules or vectors encoding polypeptide chains that form such binding proteins).

The term “swapability” as used herein refers to the interchangeability of variable domains within the binding protein format and with retention of folding and ultimate binding affinity. “Full swapability” refers to the ability to swap the order of both V_H1 and V_H2 domains, and therefore the order of V_L1 and V_L2 domains, in the polypeptide chain of formula I or the polypeptide chain of formula II (i.e., to reverse the order) while maintaining full functionality of the binding protein as evidenced by the retention of binding affinity. Furthermore, it should be noted that the designations V_H and V_L refer only to the domain's location on a particular protein chain in the final format. For example, V_H1 and V_H2 could be derived from V_L1 and V_L2 domains in parent antibodies and placed into the V_H1 and V_H2 positions in the binding protein. Likewise, V_L1 and V_L2 could be derived from V_H1 and V_H2 domains in parent antibodies and placed in the V_H1 and V_H2 positions in the binding protein. Thus, the V_H and V_L designations refer to the present location and not the original location in a parent antibody. V_H and V_L domains are therefore “swappable.”

The term “antigen” or “target antigen” or “antigen target” as used herein refers to a molecule or a portion of a molecule that is capable of being bound by a binding protein, and additionally is capable of being used in an animal to produce antibodies capable of binding to an epitope of that antigen. A target antigen may have one or more epitopes. With respect to each target antigen recognized by a binding protein, the binding protein is capable of competing with an intact antibody that recognizes the target antigen.

The term “HIV” as used herein means Human Immunodeficiency Virus. As used herein, the term “HIV infection” generally encompasses infection of a host, particularly a human host, by the human immunodeficiency virus (HIV) family of retroviruses including, but not limited to, HIV I, HIV II, HIV III (also known as HTLV-II, LAV-1, LAV-2). HIV can be used herein to refer to any strains, forms, subtypes, clades and variations in the HIV family. Thus, treating HIV infection will encompass the treatment of a person who is a carrier of any of the HIV family of retroviruses or a person who is diagnosed with active AIDS, as well as the treatment or prophylaxis of the AIDS-related conditions in such persons.

The term “AIDS” as used herein means Acquired Immunodeficiency Syndrome. AIDS is caused by HIV.

The terms “CD4bs” or “CD4 binding site” refer to the binding site for CD4 (cluster of differentiation 4), which is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells.

The term “CD3” is cluster of differentiation factor 3 polypeptide and is a T-cell surface protein that is typically part of the T cell receptor (TCR) complex.

“CD28” is cluster of differentiation 28 polypeptide and is a T-cell surface protein that provides co-stimulatory signals for T-cell activation and survival.

The term “glycoprotein 160” or “gp160 protein” refers to the envelope glycoprotein complex of HIV and which is a homotrimer that is cleaved into gp120 and gp41 subunits.

The term “MPER” refers to the membrane-proximal external region of glycoprotein 41 (gp41), which is a subunit of the envelope protein complex of retroviruses, including HIV.

The term “glycan” refers to the carbohydrate portion of a glycoconjugate, such as a glycoprotein, glycolipid, or a proteoglycan. In the disclosed binding proteins, glycan refers to the HIV-1 envelope glycoprotein gp120.

The term “T-cell engager” refers to binding proteins directed to a host's immune system, more specifically the T cells' cytotoxic activity as well as directed to a HIV target protein.

The term “trimer apex” refers to apex of HIV-1 envelope glycoprotein gp120.

The term “monospecific binding protein” refers to a binding protein that specifically binds to one antigen target.

The term “monovalent binding protein” refers to a binding protein that has one antigen binding site.

The term “bispecific binding protein” refers to a binding protein that specifically binds to two different antigen targets.

The term “bivalent binding protein” refers to a binding protein that has two binding sites.

The term “trispecific binding protein” refers to a binding protein that specifically binds to three different antigen targets.

The term “trivalent binding protein” refers to a binding protein that has three binding sites. In particular embodiments the trivalent binding protein can bind to one antigen target. In other embodiments, the trivalent binding protein can bind to two antigen targets. In other embodiments, the trivalent binding protein can bind to three antigen targets.

An “isolated” binding protein is one that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the binding protein, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, the binding protein will be purified: (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated binding proteins include the binding protein in situ within recombinant cells since at least one component of the binding protein's natural environment will not be present.

The terms “substantially pure” or “substantially purified” as used herein refer to a compound or species that is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition). In some embodiments, a substantially purified fraction is a composition wherein the species comprises at least about 50% (on a molar basis) of all macromolecular species present. In other embodiments, a substantially pure composition will comprise more than about 80%, 85%, 90%, 95%, or 99% of all macromolar species present in the composition. In still other embodiments, the species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.

A “neutralizing” binding protein as used herein refers to a molecule that is able to block or substantially reduce an effector function of a target antigen to which it binds. As used herein, “substantially reduce” means at least about 60%, preferably at least about 70%, more preferably at least about 75%, even more preferably at least about 80%, still more preferably at least about 85%, most preferably at least about 90% reduction of an effector function of the target antigen.

The term “epitope” includes any determinant, preferably a polypeptide determinant, capable of specifically binding to an immunoglobulin or T-cell receptor. In certain embodiments, epitope determinants include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and, in certain embodiments, may have specific three-dimensional structural characteristics and/or specific charge characteristics. An epitope is a region of an antigen that is bound by an antibody or binding protein. In certain embodiments, a binding protein is said to specifically bind an antigen when it preferentially recognizes its target antigen in a complex mixture of proteins and/or macromolecules. In some embodiments, a binding protein is said to specifically bind an antigen when the equilibrium dissociation constant is ≤10⁻⁸ M, more preferably when the equilibrium dissociation constant is ≤10⁻⁹ M, and most preferably when the dissociation constant is ≤10⁻¹⁰ M.

The dissociation constant (K_D) of a binding protein can be determined, for example, by surface plasmon resonance. Generally, surface plasmon resonance analysis measures real-time binding interactions between ligand (a target antigen on a biosensor matrix) and analyte (a binding protein in solution) by surface plasmon resonance (SPR) using the BIAcore system (Pharmacia Biosensor; Piscataway, N.J.). Surface plasmon analysis can also be performed by immobilizing the analyte (binding protein on a biosensor matrix) and presenting the ligand (target antigen). The term “K_D,” as used herein refers to the dissociation constant of the interaction between a particular binding protein and a target antigen.

The term “specifically binds” as used herein refers to the ability of a binding protein or an antigen-binding fragment thereof to bind to an antigen containing an epitope with an Kd of at least about 1×10⁻⁶ M, 1×10⁻⁷ M, 1×10⁻⁸ M, 1×10⁻⁹ M, 1×10⁻¹⁰ M, 1×10⁻¹¹ M, 1×10⁻¹² M, or more, and/or to bind to an epitope with an affinity that is at least two-fold greater than its affinity for a nonspecific antigen.

The term “linker” as used herein refers to one or more amino acid residues inserted between immunoglobulin domains to provide sufficient mobility for the domains of the light and heavy chains to fold into cross over dual variable region immunoglobulins. A linker is inserted at the transition between variable domains or between variable and constant domains, respectively, at the sequence level. The transition between domains can be identified because the approximate size of the immunoglobulin domains are well understood. The precise location of a domain transition can be determined by locating peptide stretches that do not form secondary structural elements such as beta-sheets or alpha-helices as demonstrated by experimental data or as can be assumed by techniques of modeling or secondary structure prediction. The linkers described herein are referred to as L₁, which is located on the light chain between the C-terminus of the V_L2 and the N-terminus of the V_L1 domain; and L₂, which is located on the light chain between the C-terminus of the V_L1 and the N-terminus of the C_L domain. The heavy chain linkers are known as L₃, which is located between the C-terminus of the V_H1 and the N-terminus of the V_H2 domain; and L₄, which is located between the C-terminus of the V_H2 and the N-terminus of the C_H1 domain.

The term “vector” as used herein refers to any molecule (e.g., nucleic acid, plasmid, or virus) that is used to transfer coding information to a host cell. The term “vector” includes a nucleic acid molecule that is capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid,” which refers to a circular double-stranded DNA molecule into which additional DNA segments may be inserted. Another type of vector is a viral vector, wherein additional DNA segments may be inserted into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell and thereby are replicated along with the host genome. In addition, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors” (or simply, “expression vectors”). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. The terms “plasmid” and “vector” may be used interchangeably herein, as a plasmid is the most commonly used form of vector. However, the disclosure is intended to include other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses, and adeno-associated viruses), which serve equivalent functions.

The phrase “recombinant host cell” (or “host cell”) as used herein refers to a cell into which a recombinant expression vector has been introduced. A recombinant host cell or host cell is intended to refer not only to the particular subject cell, but also to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but such cells are still included within the scope of the term “host cell” as used herein. A wide variety of host cell expression systems can be used to express the binding proteins, including bacterial, yeast, baculoviral, and mammalian expression systems (as well as phage display expression systems). An example of a suitable bacterial expression vector is pUC 19. To express a binding protein recombinantly, a host cell is transformed or transfected with one or more recombinant expression vectors carrying DNA fragments encoding the polypeptide chains of the binding protein such that the polypeptide chains are expressed in the host cell and, preferably, secreted into the medium in which the host cells are cultured, from which medium the binding protein can be recovered.

The term “transformation” as used herein refers to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain a new DNA. For example, a cell is transformed where it is genetically modified from its native state. Following transformation, the transforming DNA may recombine with that of the cell by physically integrating into a chromosome of the cell, or may be maintained transiently as an episomal element without being replicated, or may replicate independently as a plasmid. A cell is considered to have been stably transformed when the DNA is replicated with the division of the cell. The term “transfection” as used herein refers to the uptake of foreign or exogenous DNA by a cell, and a cell has been “transfected” when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art. Such techniques can be used to introduce one or more exogenous DNA molecules into suitable host cells.

The term “naturally occurring” as used herein and applied to an object refers to the fact that the object can be found in nature and has not been manipulated by man. For example, a polynucleotide or polypeptide that is present in an organism (including viruses) that can be isolated from a source in nature and that has not been intentionally modified by man is naturally-occurring. Similarly, “non-naturally occurring” as used herein refers to an object that is not found in nature or that has been structurally modified or synthesized by man.

As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids; unnatural amino acids and analogs such as α-, α-disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for the polypeptide chains of the binding proteins. Examples of unconventional amino acids include: 4-hydroxyproline, γ-carboxyglutamate, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ-N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxyl-terminal direction, in accordance with standard usage and convention.

Naturally occurring residues may be divided into classes based on common side chain properties:

(1) hydrophobic: Met, Ala, Val, Leu, Ile, Phe, Trp, Tyr, Pro;

(2) polar hydrophilic: Arg, Asn, Asp, Gln, Glu, His, Lys, Ser, Thr;

(3) aliphatic: Ala, Gly, Ile, Leu, Val, Pro;

(4) aliphatic hydrophobic: Ala, Ile, Leu, Val, Pro;

(5) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;

(6) acidic: Asp, Glu;

(7) basic: His, Lys, Arg;

(8) residues that influence chain orientation: Gly, Pro;

(9) aromatic: His, Trp, Tyr, Phe; and

(10) aromatic hydrophobic: Phe, Trp, Tyr.

Conservative amino acid substitutions may involve exchange of a member of one of these classes with another member of the same class. Non-conservative substitutions may involve the exchange of a member of one of these classes for a member from another class.

A skilled artisan will be able to determine suitable variants of the polypeptide chains of the binding proteins using well-known techniques. For example, one skilled in the art may identify suitable areas of a polypeptide chain that may be changed without destroying activity by targeting regions not believed to be important for activity. Alternatively, one skilled in the art can identify residues and portions of the molecules that are conserved among similar polypeptides. In addition, even areas that may be important for biological activity or for structure may be subject to conservative amino acid substitutions without destroying the biological activity or without adversely affecting the polypeptide structure.

The term “patient” as used herein includes human and animal subjects.

The terms “treatment” or “treat” as used herein refer to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those having the disorder as well as those prone to have a disorder or those in which the disorder is to be prevented. In particular embodiments, binding proteins can be used to treat humans infected with HIV, or humans susceptible to HIV infection, or ameliorate HIV infection in a human subject infected with HIV. The binding proteins can also be used to prevent HIV in a human patient.

It should be understood as that treating humans infected with HIV include those subjects who are at any one of the several stages of HIV infection progression, which, for example, include acute primary infection syndrome (which can be asymptomatic or associated with an influenza-like illness with fevers, malaise, diarrhea and neurologic symptoms such as headache), asymptomatic infection (which is the long latent period with a gradual decline in the number of circulating CD4⁺ T cells), and AIDS (which is defined by more serious AIDS-defining illnesses and/or a decline in the circulating CD4 cell count to below a level that is compatible with effective immune function). In addition, treating or preventing HIV infection will also encompass treating suspected infection by HIV after suspected past exposure to HIV by e.g., contact with HIV-contaminated blood, blood transfusion, exchange of body fluids, “unsafe” sex with an infected person, accidental needle stick, receiving a tattoo or acupuncture with contaminated instruments, or transmission of the virus from a mother to a baby during pregnancy, delivery or shortly thereafter.

The terms “pharmaceutical composition” or “therapeutic composition” as used herein refer to a compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient.

The term “pharmaceutically acceptable carrier” or “physiologically acceptable carrier” as used herein refers to one or more formulation materials suitable for accomplishing or enhancing the delivery of a binding protein.

The terms “effective amount” and “therapeutically effective amount” when used in reference to a pharmaceutical composition comprising one or more binding proteins refer to an amount or dosage sufficient to produce a desired therapeutic result. More specifically, a therapeutically effective amount is an amount of a binding protein sufficient to inhibit, for some period of time, one or more of the clinically defined pathological processes associated with the condition being treated. The effective amount may vary depending on the specific binding protein that is being used, and also depends on a variety of factors and conditions related to the patient being treated and the severity of the disorder. For example, if the binding protein is to be administered in vivo, factors such as the age, weight, and health of the patient as well as dose response curves and toxicity data obtained in preclinical animal work would be among those factors considered. The determination of an effective amount or therapeutically effective amount of a given pharmaceutical composition is well within the ability of those skilled in the art.

One embodiment of the disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a binding protein.

Trispecific and/or Trivalent Binding Proteins

In one embodiment, the binding protein of the disclosure is a trispecific and/or trivalent binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more (e.g., three different) HIV target proteins, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II]and a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1  [III]and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is an immunoglobulin C_H1 heavy chain constant domain; andL₁, L₂, L₃ and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

In one embodiment, the binding protein of the disclosure is a trispecific and/or trivalent binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more (e.g., three different) HIV target proteins, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1-hinge-C_H2-C_H3  [II]and a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1-hinge-C_H2-C_H3  [III]and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is an immunoglobulin C_H1 heavy chain constant domain;C_H2 is an immunoglobulin C_H2 heavy chain constant domain;C_H3 is an immunoglobulin C_H3 heavy chain constant domain;hinge is an immunoglobulin hinge region connecting the C_H1 and C_H2 domains; andL₁, L₂, L₃ and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

In some embodiments, the first polypeptide chain and the second polypeptide chain have a cross-over orientation that forms two distinct antigen binding sites. In some embodiments, the V_H1 and V_L1 form a binding pair and form the first antigen binding site. In some embodiments, the V_H2 and V_L2 form a binding pair and form the second antigen binding site. In some embodiments, the third polypeptide and the fourth polypeptide form a third antigen binding site. In some embodiments, the V_H3 and V_L3 form a binding pair and form the third antigen binding site.

In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, 52, 58, 60, 66, 68, 74, 76, 82, 84, 90, 92, 98, 100, 106, 108, 114, 116, 122, 124, 130, 132, 138, 140, 146, 148, 154, 156, 162, 164, 170, 172, 178, 180, 186, 188, 194, 196, 202, 204, 210,212, 218, 220, 226, 228, 233, 235, 241, 243; and V_H1, V_H2 and V_H3, are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs:1, 3, 9, 11, 17, 10, 25, 27, 33, 35, 41, 43, 49, 51, 57, 59, 65, 67, 73, 75, 81, 83, 89, 91, 97, 99, 105, 107, 113, 115, 121, 123, 129, 131, 137, 139, 145, 147, 153, 155, 161, 163, 169, 171, 177, 179, 185, 187, 193, 195, 201, 203, 209, 211, 217, 219, 225, 227, 232, 234, 240, 242. In other embodiments, V_L1, V_L2 and V_L3 each independently comprise light chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 266-283; and V_H1, V_H2 and V_H3 each independently comprise heavy chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 248-265. In some embodiments, V_L1, V_L2 and V_L3 are each independently a light chain variable domain comprising a light chain variable domain sequence of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein. In some embodiments, V_H1, V_H2 and V_H3 are each independently a heavy chain variable domain comprising a heavy chain variable domain sequence of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein. In some embodiments, V_L1, V_L2 and V_L3 are each independently a light chain variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain sequence of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein. In some embodiments, V_H1, V_H2 and V_H3 are each independently a heavy chain variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain sequence of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein.

In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 303, 305, 311, 313, 319, 321, 327, 329, 335, 337, 343, 345, 351, 353, 359, 361, 367, 369, 375, 377, 383, 385, 391, 393, 399, 401, 407, 409, 415, 417, 423, 425, 431, 433, 439, 441, 447, 449, 455, 457, 463, 465, 471, 473; and V_H1, V_H2 and V_H3, are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 302, 304, 310, 312, 318, 320, 326, 328, 334, 336, 342, 344, 350, 352, 358, 360, 366, 368, 374, 376, 382, 384, 390, 392, 398, 400, 406, 408, 414, 416, 422, 424, 430, 432, 438, 440, 446, 448, 454, 456, 462, 464, 470, 472. In other embodiments, V_L1, V_L2 and V_L3 each independently comprise light chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 266-271, 275-277, 488-496; and V_H1, V_H2 and V_H3 each independently comprise heavy chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 248-253, 257-259, 479-487.

In particular embodiments, the order of the V_H1 and V_H2 domains, and therefore the order of V_L1 and V_L2 domains, in the polypeptide chain of formula I or the polypeptide chain of formula II (i.e., to reverse the order) are swapped.

In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 4; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 3; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 2.

In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 12; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 11; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 9; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 10 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 10.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 20 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 20; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 19; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 17; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 18.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 28 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 28; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 27 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 27; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 25 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 25; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 26 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 26.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 36 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 36; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 35 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 35; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 33 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 33; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 34 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 34.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 44 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 44; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 43 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 43; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 41 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 41; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 42 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 42.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 52 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 52; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 51 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 51; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 49 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 49; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 50 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 50.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 60 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 60; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 59 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 59; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 57 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 57; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 58 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 58.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 68 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 68; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 67 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 67; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 65 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 65; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 66 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 66.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 76 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 76; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 75 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 75; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 73 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 73; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 74 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 74.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 84 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 84; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 83 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 83; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 81 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 81; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 82 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 82.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 92 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:92; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 91 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 91; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 89 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 89; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 90 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 90.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 100 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 100; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 99 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 99; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 97 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 97; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 98 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 98.

In other embodiments, the first polypeptide comprises the amino acid sequence of SEQ ID NO: 108 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 108; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 107 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 107; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 105 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 105; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 106 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 106.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 116 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 116; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 115 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 115; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 113 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 113; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 114 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 114.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 124; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 123 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 123; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 121 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 121; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 122 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 122.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 132 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 132; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 131 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 131; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 129 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 129; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 130 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 130.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 140 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 140; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 139 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 139; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 137 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 137; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 138 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 138.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 148 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 148; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 147 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 147; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 145 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 145; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 146 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 146.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 156 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 156; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 155 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 155; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 153 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 153; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 154 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 154.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 164 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 164; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 163 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 163; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 161 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 161; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 162 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 162.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 172 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 172; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 171 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 171; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 169 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 169; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 170 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 170.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 180 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 180; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 179 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 179; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 177 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 177; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 178 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 178.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 188 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 188; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 187 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 187; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 185 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 185; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 186 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 186.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 196 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 196; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 195 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 195; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 193 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 193; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 194 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 194.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 204 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 204; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 203 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 203; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 201 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 201; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 202 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 202.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 212 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 212; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 211 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 211; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 209 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 209; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 210 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 210.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 220 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 220; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 219 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 219; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 217 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 217; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 218 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 218.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 228 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 228; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 227 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 227; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 225 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 225; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 226 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 226.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 235 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 235; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 234 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 234; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 232 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 232; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 233 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 233.

In other embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 243 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 243; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 242 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 242; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 240 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 240; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 241 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 241.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 305 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 305; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 304 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 304; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 302 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 302; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 303 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 303.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 313 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 313; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 312 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 312; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 310 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 310; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 311 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 311.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 321 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 321; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 320 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 320; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 318 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 318; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 319 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 319.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 329 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 329; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 328 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 328; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 326 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 326; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 327 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 327.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 337 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 337; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 336 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 336; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 334 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 334; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 335 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 335.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 345 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 345; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 344 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 344; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 342 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 342; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 343 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 343.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 353 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 353; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 352 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:352; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 350 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 350; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 351 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 351.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 361 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 361; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 360 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 360; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 358 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 358; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 359 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 359.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 369 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 369; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 368 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 368; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 366 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 366; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 367 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 367.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 377 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 377; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 376 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 376; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 374 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 374; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 375 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 375.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 385 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 385; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 384 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 384; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 382 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 382; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 383 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 383.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 393 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 393; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 392 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 392; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 390 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 390; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 391 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 391.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 401 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 401; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 400 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 400; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 398 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 398; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 399 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 399.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 409 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 409; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 408 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 408; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 406 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 406; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 407 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 407.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 417 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 417; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 416 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 416; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 414 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 414; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 415 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 415.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 425 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 425; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 424 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 424; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 422 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 422; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 423 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 423.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 433 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:433; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 432 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 432; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 430 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 430; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 431 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 431.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 441 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 441; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 440 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 440; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 438 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 438; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 439 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 439.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 449 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 449; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 448 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 448; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 446 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 446; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 447 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 447.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 457 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 457; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 456 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 456; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 454 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 454; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 455 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 455.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 465 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 465; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 464 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 464; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 462 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 462; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 463 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 463.

In another embodiment, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 473 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 473; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 472 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 472; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 470 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 470; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 471 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 471.

In other embodiments, the binding protein of the disclosure is a trispecific and/or trivalent binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more (e.g., three) HIV target antigens, wherein a first polypeptide chain has a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain has a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1-hinge-C_H2-C_H3 (hole)  [II]and a third polypeptide chain has a structure represented by the formula:V_H3-C_H1-hinge-C_H2-C_H3 (knob)  [III]and a fourth polypeptide chain has a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain; andL₁, L₂, L₃ and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

In other embodiments, the binding protein of the disclosure is a trispecific and/or trivalent binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more (e.g., three) HIV target antigens, wherein a first polypeptide chain has a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain has a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1-hinge-C_H2-C_H3 (knob)  [II]and a third polypeptide chain has a structure represented by the formula:V_H3-C_H1-hinge-C_H2-C_H3 (hole)  [III]and a fourth polypeptide chain has a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain; andL₁, L₂, L₃ and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

Additional Examples of Trispecific Binding Proteins

In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521. In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain comprising an amino acid sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to a sequence as set forth in any one of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521.

In some embodiments, V_H1, V_H2 and V_H3 are each independently a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508. In some embodiments, V_H1, V_H2 and V_H3 are each independently a variable domain comprising an amino acid sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to a sequence as set forth in any one of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508.

In some embodiments, V_L1, V_L2, and V_L3 comprise an amino acid sequence as set forth in SEQ ID NOs: 518, 519, and 512, respectively, and V_H1, V_H2, and V_H3 comprise an amino acid sequence as set forth in SEQ ID NOs: 504, 506, and 502, respectively. In some embodiments, V_L1, V_L2, and V_L3 comprise an amino acid sequence as set forth in SEQ ID NOs: 518, 519, and 513, respectively, and V_H1, V_H2, and V_H3 comprises an amino acid sequence as set forth in SEQ ID NOs: 504, 506, and 503, respectively. In some embodiments, V_L1, V_L2, and V_L3 comprises an amino acid sequence as set forth in SEQ ID NOs: 519, 518, and 513, respectively, and V_H1, V_H2, and V_H3 comprises an amino acid sequence as set forth in SEQ ID NOs: 506, 504, and 503, respectively.

In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521. In some embodiments, V_H1, V_H2 and V_H3 are each independently a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508. In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a light chain variable domain sequence shown in Table C. In some embodiments, V_H1, V_H2 and V_H3 are each independently a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a heavy chain variable domain sequence shown in Table C.

In some embodiments, V_L1 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 518, V_L2 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 519, V_L3 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 512, V_H1 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 504, V_H2 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 506, and V_H3 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 502. In some embodiments, V_L1 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 518, V_L2 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 519, V_L3 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 513, V_H1 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 504, V_H2 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 506, and V_H3 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 503. In some embodiments, V_L1 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 519, V_L2 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 518, V_L3 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 513, and V_H1 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 506, V_H2 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 504, and V_H3 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 503.

In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain comprising: (a) a CDR-L1 comprising a sequence selected from the group consisting of SEQ ID NOs: 266, 269, 275, 278, 281, and 500; (b) a CDR-L2 comprising a sequence selected from the group consisting of SEQ ID NOs: 267, 270, 276, 279, 282, and 501; and/or (c) a CDR-L3 comprising a sequence selected from the group consisting of SEQ ID NOs: 268, 271, 274, 277, 280, and 283. In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 comprising amino acid sequences as shown in Table B. In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; or a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively.

In some embodiments, V_H1, V_H2 and V_H3 are each independently a variable domain comprising: (a) a CDR-H1 comprising a sequence selected from the group consisting of SEQ ID NOs: 248, 251, 254, 257, 263, and 499; (b) a CDR-H2 comprising a sequence selected from the group consisting of SEQ ID NOs: 252, 255, 258, 261, 264, and 497; and/or (c) a CDR-H3 comprising a sequence selected from the group consisting of SEQ ID NOs: 250, 253, 256, 259, 262, 265, and 498. In some embodiments, V_H1, V_H2 and V_H3 are each independently a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 comprising amino acid sequences as shown in Table B. In some embodiments, V_H1, V_H2 and V_H3 are each independently a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; or a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively.

In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 500, 501, and 274, respectively; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 275, 276, and 277, respectively; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 266, 267, and 268, respectively; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 254, 255, and 256, respectively; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 257, 258, and 259, respectively; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 248, 497, and 250, respectively. In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 500, 501, and 274, respectively; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 275, 276, and 277, respectively; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 269, 270, and 271, respectively; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 254, 255, and 256, respectively; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 257, 258, and 259, respectively; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 251, 252, and 253, respectively. In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 275, 276, and 277, respectively; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 500, 501, and 274, respectively; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 269, 270, and 271, respectively; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 257, 258, and 259, respectively; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 254, 255, and 256, respectively; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 251, 252, and 253, respectively.

Additional Trispecific Binding Proteins Targeting One or More HIV Target Proteins and One or More T Cell Target Proteins

In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more (e.g., one or two) HIV target proteins and one or more (e.g., one or two) T cell target proteins, wherein a first polypeptide chain has a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I];a second polypeptide chain has a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II];a third polypeptide chain has a structure represented by the formula:V_H3-C_H1  [III];and a fourth polypeptide chain has a structure represented by the formula:V_L3-C_L  [IV];whereinV_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is an immunoglobulin C_H1 heavy chain constant domain; andL₁, L₂, L₃, and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more (e.g., one or two) HIV target proteins and one or more (e.g., one or two) T cell target proteins, wherein a first polypeptide chain has a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I];a second polypeptide chain has a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1-hinge-C_H2-C_H3  [II];a third polypeptide chain has a structure represented by the formula:V_H3-C_H1-hinge-C_H2-C_H3  [III];and a fourth polypeptide chain has a structure represented by the formulaV_L3-C_L  [IV];whereinV_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is an immunoglobulin C_H1 heavy chain constant domain;C_H2 is an immunoglobulin C_H2 heavy chain constant domain;C_H3 is an immunoglobulin C_H3 heavy chain constant domain;hinge is an immunoglobulin hinge region connecting the C_H1 and C_H2 domains; andL₁, L₂, L₃, and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

In some embodiments, the first polypeptide chain and the second polypeptide chain have a cross-over orientation that forms two distinct antigen binding sites. In some embodiments, the V_H1 and V_L1 form a binding pair and form the first antigen binding site. In some embodiments, the V_H2 and V_L2 form a binding pair and form the second antigen binding site. In some embodiments, the third polypeptide and the fourth polypeptide form a third antigen binding site. In some embodiments, the V_H3 and V_L3 form a binding pair and form the third antigen binding site.

In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524. In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain comprising an amino acid sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to a sequence as set forth in any one of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524.

In some embodiments, V_H1, V_H2 and V_H3 are each independently a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511. In some embodiments, V_H1, V_H2 and V_H3 are each independently a variable domain comprising an amino acid sequence having at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to a sequence as set forth in any one of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511.

In some embodiments, V_L1, V_L2, and V_L3 comprise an amino acid sequence as set forth in SEQ ID NOs: 522, 524, and 513, respectively, and V_H1, V_H2, and V_H3 comprise an amino acid sequence as set forth in SEQ ID NOs: 509, 511, and 503, respectively. In some embodiments, V_L1, V_L2, and V_L3 comprise an amino acid sequence as set forth in SEQ ID NOs: 524, 522, and 513, respectively, and V_H1, V_H2, and V_H3 comprise an amino acid sequence as set forth in SEQ ID NOs: 511,509, and 503, respectively.

In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524.

In some embodiments, V_H1, V_H2 and V_H3 are each independently a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511.

In some embodiments, V_L1 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 522, V_L2 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 524, V_L3 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 513, V_H1 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 509, V_H2 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 511, and V_H3 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 503. In some embodiments, V_L1 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 524, V_L2 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence of SEQ ID NO: 522, V_L3 is a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a light chain variable domain sequence of SEQ ID NO: 513, V_H1 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 511, V_H2 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 509, and V_H3 is a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence of SEQ ID NO: 503.

In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain comprising: (a) a CDR-L1 comprising a sequence selected from the group consisting of SEQ ID NOs: 266, 269, 275, 278, 281, 488, 491, 494 and 500; (b) a CDR-L2 comprising a sequence selected from the group consisting of SEQ ID NOs: 267, 270, 276, 279, 282, 489, 492, 495, and 501; and (c) a CDR-L3 comprising a sequence selected from the group consisting of SEQ ID NOs: 268, 271, 274, 277, 280, 283, 490, 493, and 496. In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 comprising amino acid sequences as shown in Table B. In some embodiments, V_L1, V_L2 and V_L3 are each independently a variable domain comprising a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively; a sequence as set forth in SEQ ID NOs: 488, 489, and 490, respectively; a sequence as set forth in SEQ ID NOs: 491, 492, and 493, respectively; or a sequence as set forth in SEQ ID NOs: 494, 495, and 496, respectively.

In some embodiments, V_H1, V_H2 and V_H3 are each independently a variable domain comprising: (a) a CDR-H1 comprising a sequence selected from the group consisting of SEQ ID NOs: 248, 251, 254, 257, 263, 479, 482, 485, and 499; (b) a CDR-H2 comprising a sequence selected from the group consisting of SEQ ID NOs: 252, 255, 258, 261, 264, 480, 483, 486, and 497; and (c) a CDR-H3 comprising a sequence selected from the group consisting of SEQ ID NOs: 250, 253, 256, 259, 262, 265, 481, 484, 487, and 498. In some embodiments, V_H1, V_H2 and V_H3 are each independently a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 comprising amino acid sequences as shown in Table B. In some embodiments, V_H1, V_H2 and V_H3 are each independently a variable domain comprising a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively; a sequence as set forth in SEQ ID NOs: 479, 480, and 481, respectively; a sequence as set forth in SEQ ID NOs: 482, 483, and 484, respectively; or a sequence as set forth in SEQ ID NOs: 485, 486, and 487, respectively.

In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 488, 489, and 490, respectively; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 494, 495, and 496, respectively; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 269, 270, and 271, respectively; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 479, 480, and 481, respectively; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 485, 486, and 487, respectively; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 251, 252, and 253, respectively. In some embodiments, V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 494, 495, and 496, respectively; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 488, 489, and 490, respectively; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising the sequence of SEQ ID NOs: 269, 270, and 271, respectively; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 485, 486, and 487, respectively; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 479, 480, and 481, respectively; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising the sequence of SEQ ID NOs: 251, 252, and 253, respectively.

In some embodiments, V_L1 and V_H1 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD28 or CD28_2 described herein, V_L2 and V_H2 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD3 described herein, and V_L3 and V_H3 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein. In some embodiments, V_L1 and V_H1 are light and heavy chain variable domains comprising the six CDRs of antibody CD28 or CD28_2 described herein, V_L2 and V_H2 are light and heavy chain variable domains comprising the six CDRs of antibody CD3 described herein, and V_L3 and V_H3 are light and heavy chain variable domains comprising the six CDRs of antibody CD4BS “a”, CD4BS “b”, MPER, MPER 100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein.

In some embodiments, V_L1 and V_H1 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD28 or CD28_2 described herein, V_L2 and V_H2 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD4BS “a”, CD4BS “b”, MPER, MPER 100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein, and V_L3 and V_H3 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD3 described herein. In some embodiments, V_L1 and V_H1 are light and heavy chain variable domains comprising the six CDRs of antibody CD28 or CD28_2 described herein, V_L2 and V_H2 are light and heavy chain variable domains comprising the six CDRs of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein, and V_L3 and V_H3 are light and heavy chain variable domains comprising the six CDRs of antibody CD3 described herein.

In some embodiments, V_L1 and V_H1 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD3 described herein, V_L2 and V_H2 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD28 or CD28_2 described herein, and V_L3 and V_H3 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein. In some embodiments, V_L1 and V_H1 are light and heavy chain variable domains comprising the six CDRs of antibody CD3 described herein, V_L2 and V_H2 are light and heavy chain variable domains comprising the six CDRs of antibody CD28 or CD28_2 described herein, and V_L3 and V_H3 are light and heavy chain variable domains comprising the six CDRs of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein.

In some embodiments, V_L1 and V_H1 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD3 described herein, V_L2 and V_H2 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein, and V_L3 and V_H3 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD28 or CD28_2 described herein. In some embodiments, V_L1 and V_H1 are light and heavy chain variable domains comprising the six CDRs of antibody CD3 described herein, V_L2 and V_H2 are light and heavy chain variable domains comprising the six CDRs of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein, and V_L3 and V_H3 are light and heavy chain variable domains comprising the six CDRs of antibody CD28 or CD28_2 described herein.

In some embodiments, V_L1 and V_H1 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein, V_L2 and V_H2 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD28 or CD28_2 described herein, and V_L3 and V_H3 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD3 described herein. In some embodiments, V_L1 and V_H1 are light and heavy chain variable domains comprising the six CDRs of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein, V_L2 and V_H2 are light and heavy chain variable domains comprising the six CDRs of antibody CD28 or CD28_2 described herein, and V_L3 and V_H3 are light and heavy chain variable domains comprising the six CDRs of antibody CD3 described herein.

In some embodiments, V_L1 and V_H1 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein, V_L2 and V_H2 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD3 described herein, and V_L3 and V_H3 are light and heavy chain variable domains comprising a light and heavy chain variable sequence of antibody CD28 or CD28_2 described herein. In some embodiments, V_L1 and V_H1 are light and heavy chain variable domains comprising the six CDRs of antibody CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 directed “a”, V1/V2 directed “b”, or V3 directed described herein, V_L2 and V_H2 are light and heavy chain variable domains comprising the six CDRs of antibody CD3 or CD28_2 described herein, and V_L3 and V_H3 are light and heavy chain variable domains comprising the six CDRs of antibody CD28 or CD28_2 described herein.

Target Proteins

In one embodiment, the binding proteins specifically bind to one or more HIV target proteins. In some embodiments, the binding proteins are trispecific and specifically bind to MPER of the HIV-1 gp41 protein, a CD4 binding site of the HIV-1 gp120 protein, a glycan in the V3 loop of the HIV-1 gp120 protein, a trimer apex of the HIV-1 gp120 protein or gp160. In other embodiments, the binding proteins specifically bind to one or more HIV target proteins and one or more target proteins on a T-cell including T cell receptor complex. These T-cell engager binding proteins are capable of recruiting T cells transiently to target cells and, at the same time, activating the cytolytic activity of the T cells. The T-cell engager trispecific antibodies can be used to activate HIV-1 reservoirs and redirect/activate T cells to lyse latently infected HIV-1+ T cells. Examples of target proteins on T cells include but are not limited to CD3 and CD28, among others. In some embodiments, the trispecific binding proteins may be generated by combining the antigen binding domains of two or more monospecific antibodies (parent antibodies) into one antibody. See International Publication Nos. WO 2011/038290 A2, WO 2013/086533 A1, WO 2013/070776 A1, WO 2012/154312 A1, and WO 2013/163427 A1, which are hereby incorporated into this disclosure by reference. The binding proteins of the disclosure may be prepared using domains or sequences obtained or derived from any human or non-human antibody, including, for example, human, murine, or humanized antibodies.

In some embodiments of the disclosure, the trivalent binding protein is capable of binding three different antigen targets. In one embodiment, the binding protein is trispecific and one light chain-heavy chain pair is capable of binding two different antigen targets or epitopes and one light chain-heavy chain pair is capable of binding one antigen target or epitope. In another embodiment, the binding protein is capable of binding three different HIV antigen targets that are located on the HIV envelope glycoprotein structure composed of gp120 and gp41 subunits. In other embodiments, the binding protein is capable of inhibiting the function of one or more of the antigen targets.

In some embodiments, a binding protein of the present disclosure binds one or more HIV target proteins. In some embodiments, the binding protein is capable of specifically binding three different epitopes on a single HIV target protein. In some embodiments, the binding protein is capable of binding two different epitopes on a first HIV target protein, and one epitope on a second HIV target protein. In some embodiments, the first and second HIV target proteins are different. In some embodiments, the binding protein is capable of specifically binding three different HIV target protein. In some embodiments, the one or more HIV target proteins are one or more of glycoprotein 120, glycoprotein 41, and glycoprotein 160.

In some embodiments, a binding protein of the present disclosure binds one or more HIV target proteins and one or more T cell target proteins. In some embodiments, the binding protein is capable of specifically binding one HIV target protein and two different epitopes on a single T cell target protein. In some embodiments, the binding protein is capable of specifically binding one HIV target protein and two different T cell target proteins (e.g., CD28 and CD3). In some embodiments, the binding protein is capable of specifically binding one T cell target protein and two different epitopes on a single HIV target protein. In some embodiments, the binding protein is capable of specifically binding one T cell target protein and two different HIV target proteins. In some embodiments, the first and second polypeptide chains of the binding protein form two antigen binding sites that specifically target two T cell target proteins, and the third and fourth polypeptide chains of the binding protein form an antigen binding site that specifically binds an HIV target protein. In some embodiments, the one or more HIV target proteins are one or more of glycoprotein 120, glycoprotein 41, and glycoprotein 160. In some embodiments, the one or more T cell target proteins are one or more of CD3 and CD28.

Linkers

In some embodiments, the linkers L₁, L₂, L₃, and L₄ range from no amino acids (length=0) to about 100 amino acids long, or less than 100, 50, 40, 30, 20, or 15 amino acids or less. The linkers can also be 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acids long. L₁, L₂, L₃, and L₄ in one binding protein may all have the same amino acid sequence or may all have different amino acid sequences.

Examples of suitable linkers include a single glycine (Gly) residue; a diglycine peptide (Gly-Gly); a tripeptide (Gly-Gly-Gly); a peptide with four glycine residues (Gly-Gly-Gly-Gly; SEQ ID NO: 285); a peptide with five glycine residues (Gly-Gly-Gly-Gly-Gly; SEQ ID NO: 286); a peptide with six glycine residues (Gly-Gly-Gly-Gly-Gly-Gly; SEQ ID NO: 287); a peptide with seven glycine residues (Gly-Gly-Gly-Gly-Gly-Gly-Gly; SEQ ID NO: 288); a peptide with eight glycine residues (Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly; SEQ ID NO: 289). Other combinations of amino acid residues may be used such as the peptide Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 290), the peptide Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 291) and the peptide Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 292). Other suitable linkers include a single Ser, and Val residue; the dipeptide Arg-Thr, Gln-Pro, Ser-Ser, Thr-Lys, and Ser-Leu; Thr-Lys-Gly-Pro-Ser (SEQ ID NO: 293), Thr-Val-Ala-Ala-Pro (SEQ ID NO: 294), Gln-Pro-Lys-Ala-Ala (SEQ ID NO: 295), Gln-Arg-Ile-Glu-Gly (SEQ ID NO: 296); Ala-Ser-Thr-Lys-Gly-Pro-Ser (SEQ ID NO: 297), Arg-Thr-Val-Ala-Ala-Pro-Ser (SEQ ID NO: 298), Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 299), and His-Ile-Asp-Ser-Pro-Asn-Lys (SEQ ID NO: 300). The examples listed above are not intended to limit the scope of the disclosure in any way, and linkers comprising randomly selected amino acids selected from the group consisting of valine, leucine, isoleucine, serine, threonine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, glycine, and proline have been shown to be suitable in the binding proteins.

The identity and sequence of amino acid residues in the linker may vary depending on the type of secondary structural element necessary to achieve in the linker. For example, glycine, serine, and alanine are best for linkers having maximum flexibility. Some combination of glycine, proline, threonine, and serine are useful if a more rigid and extended linker is necessary. Any amino acid residue may be considered as a linker in combination with other amino acid residues to construct larger peptide linkers as necessary depending on the desired properties.

In some embodiments, the length of L₁ is at least twice the length of L₃. In some embodiments, the length of L₂ is at least twice the length of L₄. In some embodiments, the length of L₁ is at least twice the length of L₃, and the length of L₂ is at least twice the length of L₄. In some embodiments, L₁ is 3 to 12 amino acid residues in length, L₂ is 3 to 14 amino acid residues in length, L₃ is 1 to 8 amino acid residues in length, and L₄ is 1 to 3 amino acid residues in length. In some embodiments, L₁ is 5 to 10 amino acid residues in length, L₂ is 5 to 8 amino acid residues in length, L₃ is 1 to 5 amino acid residues in length, and L₄ is 1 to 2 amino acid residues in length. In some embodiments, L₁ is 7 amino acid residues in length, L₂ is 5 amino acid residues in length, L₃ is 1 amino acid residue in length, and L₄ is 2 amino acid residues in length.

In some embodiments, L₁, L₂, L₃, and/or L₄ comprise the sequence Asp-Lys-Thr-His-Thr (SEQ ID NO: 525). In some embodiments, L₁ comprises the sequence Asp-Lys-Thr-His-Thr (SEQ ID NO: 525). In some embodiments, L₃ comprises the sequence Asp-Lys-Thr-His-Thr (SEQ ID NO: 525).

In some embodiments, L₁, L₂, L₃, and/or L₄ comprise the sequence Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 299). In some embodiments, L₁ comprises the sequence Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 299). In some embodiments, L₁ comprises the sequence Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 299), L₂ comprises the sequence Thr-Lys-Gly-Pro-Ser-Arg (SEQ ID NO: 526), L₃ comprises the sequence Ser, and L₄ comprises the sequence Arg-Thr. In some embodiments, L₃ comprises the sequence Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 299). In some embodiments, L₁ comprises the sequence Ser, L₂ comprises the sequence Arg-Thr, L₃ comprises the sequence Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 299) and L₄ comprises the sequence Thr-Lys-Gly-Pro-Ser-Arg (SEQ ID NO: 526).

Fc Regions and Constant Domains

In some embodiments, a binding protein of the present disclosure comprises a second polypeptide chain further comprising an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains. In some embodiments, a binding protein of the present disclosure comprises a third polypeptide chain further comprising an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains. In some embodiments, a binding protein of the present disclosure comprises a second polypeptide chain further comprising an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains.

To improve the yields of the binding proteins, in some embodiments, the C_H3 domains can be altered by the “knob-into-holes” technology which is described in detail with several examples in, for example, International Publication No. WO 96/027011, Ridgway et al., 1996, Protein Eng. 9: 617-21; and Merchant et al., 1998, Nat. Biotechnol. 16: 677-81. Specifically, the interaction surfaces of the two C_H3 domains are altered to increase the heterodimerisation of both heavy chains containing these two C_H3 domains. Each of the two C_H3 domains (of the two heavy chains) can be the “knob,” while the other is the “hole.” The introduction of a disulfide bridge further stabilizes the heterodimers (Merchant et al., 1998; Atwell et al., 1997, J. Mol. Biol. 270: 26-35) and increases the yield. In particular embodiments, the knob is on the second pair of polypeptides with a single variable domain. In other embodiments, the knob is on the first pair of polypeptides having the cross-over orientation. In yet other embodiments, the C_H3 domains do not include a knob in hole.

In some embodiments, a binding protein of the present disclosure comprises a “knob” mutation on the second polypeptide chain and a “hole” mutation on the third polypeptide chain. In some embodiments, a binding protein of the present disclosure comprises a “knob” mutation on the third polypeptide chain and a “hole” mutation on the second polypeptide chain. In some embodiments, the “knob” mutation comprises substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are S354C and T366W. In some embodiments, the “hole” mutation comprises substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W.

In some embodiments, a binding protein of the present disclosure comprises one or more mutations to improve serum half-life (See e.g., Hinton, P. R. et al. (2006) J. Immunol. 176(1):346-56). In some embodiments, the mutation comprises substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S. In some embodiments, the binding protein comprises a second polypeptide chain further comprising a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first and second Fc regions comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S. In some embodiments, a binding protein of the present disclosure comprises knob and hole mutations and one or more mutations to improve serum half-life.

In some embodiments, C_H1, C_H2, C_H3 and C_L of the trispecific binding proteins described herein may comprise any of C_H1, C_H2, C_H3 and C_L sequences of binding proteins 1-53.

Nucleic Acids

Standard recombinant DNA methodologies are used to construct the polynucleotides that encode the polypeptides which form the binding proteins, incorporate these polynucleotides into recombinant expression vectors, and introduce such vectors into host cells. See e.g., Sambrook et al., 2001, MOLECULAR CLONING: A LABORATORY MANUAL (Cold Spring Harbor Laboratory Press, 3rd ed.). Enzymatic reactions and purification techniques may be performed according to manufacturer's specifications, as commonly accomplished in the art, or as described herein. Unless specific definitions are provided, the nomenclature utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Similarly, conventional techniques may be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, delivery, and treatment of patients.

Other aspects of the present disclosure relate to isolated nucleic acid molecules comprising a nucleotide sequence encoding any of the binding proteins described herein. In some embodiments, the isolated nucleic acid is operably linked to a heterologous promoter to direct transcription of the binding protein-coding nucleic acid sequence. A promoter may refer to nucleic acid control sequences which direct transcription of a nucleic acid. A first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence of a binding protein if the promoter affects the transcription or expression of the coding sequence. Examples of promoters may include, but are not limited to, promoters obtained from the genomes of viruses (such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus, Simian Virus 40 (SV40), and the like), from heterologous eukaryotic promoters (such as the actin promoter, an immunoglobulin promoter, from heat-shock promoters, and the like), the CAG-promoter (Niwa et al., Gene 108(2): 193-9, 1991), the phosphoglycerate kinase (PGK)-promoter, a tetracycline-inducible promoter (Masui et al., Nucleic Acids Res. 33:e43, 2005), the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, and the promoter of the yeast alpha-mating factors. Polynucleotides encoding binding proteins of the present disclosure may be under the control of a constitutive promoter, an inducible promoter, or any other suitable promoter described herein or other suitable promoter that will be readily recognized by one skilled in the art.

In some embodiments, the isolated nucleic acid is incorporated into a vector. In some embodiments, the vector is an expression vector. Expression vectors may include one or more regulatory sequences operatively linked to the polynucleotide to be expressed. The term “regulatory sequence” includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Examples of suitable enhancers may include, but are not limited to, enhancer sequences from mammalian genes (such as globin, elastase, albumin, α-fetoprotein, insulin and the like), and enhancer sequences from a eukaryotic cell virus (such as SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, adenovirus enhancers, and the like). Examples of suitable vectors may include, for example, plasmids, cosmids, episomes, transposons, and viral vectors (e.g., adenoviral, vaccinia viral, Sindbis-viral, measles, herpes viral, lentiviral, retroviral, adeno-associated viral vectors, etc.). Expression vectors can be used to transfect host cells, such as, for example, bacterial cells, yeast cells, insect cells, and mammalian cells. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art, and can be used to transfect any cell of interest.

Other aspects of the present disclosure relate to a vector system comprising one or more vectors encoding a first, second, third, and fourth polypeptide chain of any of the binding proteins described herein. In some embodiments, the vector system comprises a first vector encoding the first polypeptide chain of the binding protein, a second vector encoding the second polypeptide chain of the binding protein, a third vector encoding the third polypeptide chain of the binding protein, and a fourth vector encoding the fourth polypeptide chain of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first and second polypeptide chains of the binding protein, and a second vector encoding the third and fourth polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first and third polypeptide chains of the binding protein, and a second vector encoding the second and fourth polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first and fourth polypeptide chains of the binding protein, and a second vector encoding the second and third polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first, second, third, and fourth polypeptide chains of the binding protein. The one or more vectors of the vector system may be any of the vectors described herein. In some embodiments, the one or more vectors are expression vectors.

Host Cells

Other aspects of the present disclosure relate to a host cell (e.g., an isolated host cell) comprising one or more isolated polynucleotides, vectors, and/or vector systems described herein. In some embodiments, an isolated host cell of the present disclosure is cultured in vitro. In some embodiments, the host cell is a bacterial cell (e.g., an E. coli cell). In some embodiments, the host cell is a yeast cell (e.g., an S. cerevisiae cell). In some embodiments, the host cell is an insect cell. Examples of insect host cells may include, for example, Drosophila cells (e.g., S2 cells), Trichoplusia ni cells (e.g., High Five™ cells), and Spodopterafrugiperda cells (e.g., Sf21 or Sf9 cells). In some embodiments, the host cell is a mammalian cell. Examples of mammalian host cells may include, for example, human embryonic kidney cells (e.g., 293 or 293 cells subcloned for growth in suspension culture), Expi293™ cells, CHO cells, baby hamster kidney cells (e.g., BHK, ATCC CCL 10), mouse sertoli cells (e.g., TM4 cells), monkey kidney cells (e.g., CV1 ATCC CCL 70), African green monkey kidney cells (e.g., VERO-76, ATCC CRL-1587), human cervical carcinoma cells (e.g., HELA, ATCC CCL 2), canine kidney cells (e.g., MDCK, ATCC CCL 34), buffalo rat liver cells (e.g., BRL 3A, ATCC CRL 1442), human lung cells (e.g., W138, ATCC CCL 75), human liver cells (e.g., Hep G2, HB 8065), mouse mammary tumor cells (e.g., MMT 060562, ATCC CCL51), TRI cells, MRC 5 cells, FS4 cells, a human hepatoma line (e.g., Hep G2), and myeloma cells (e.g., NSO and Sp2/0 cells).

Other aspects of the present disclosure relate to a method of producing any of the binding proteins described herein. In some embodiments, the method includes a) culturing a host cell (e.g., any of the host cells described herein) comprising an isolated nucleic acid, vector, and/or vector system (e.g., any of the isolated nucleic acids, vectors, and/or vector systems described herein) under conditions such that the host cell expresses the binding protein; and b) isolating the binding protein from the host cell. Methods of culturing host cells under conditions to express a protein are well known to one of ordinary skill in the art. Methods of isolating proteins from cultured host cells are well known to one of ordinary skill in the art, including, for example, by affinity chromatography (e.g., two step affinity chromatography comprising protein A affinity chromatography followed by size exclusion chromatography).

Use for Binding Proteins

The binding proteins can be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays for the detection and quantitation of one or more target antigens. The binding proteins will bind the one or more target antigens with an affinity that is appropriate for the assay method being employed.

For diagnostic applications, in certain embodiments, binding proteins can be labeled with a detectable moiety. The detectable moiety can be any one that is capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety can be a radioisotope, such as ³H, ¹⁴C, ³²P, ³⁵S, ¹²⁵I, ⁹⁹Tc, ¹¹¹In, or ⁶⁷Ga; a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; or an enzyme, such as alkaline phosphatase, β-galactosidase, or horseradish peroxidase.

The binding proteins are also useful for in vivo imaging. A binding protein labeled with a detectable moiety can be administered to an animal, e.g., into the bloodstream, and the presence and location of the labeled antibody in the host assayed. The binding protein can be labeled with any moiety that is detectable in an animal, whether by nuclear magnetic resonance, radiology, or other detection means known in the art.

The disclosure also relates to a kit comprising a binding protein and other reagents useful for detecting target antigen levels in biological samples. Such reagents can include a detectable label, blocking serum, positive and negative control samples, and detection reagents. In some embodiments, the kit comprises a composition comprising any binding protein, polynucleotide, vector, vector system, and/or host cell described herein. In some embodiments, the kit comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing a condition (e.g., HIV infection) and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). In some embodiments, the label or package insert indicates that the composition is used for preventing, diagnosing, and/or treating the condition of choice. Alternatively, or additionally, the article of manufacture or kit may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

Therapeutic or pharmaceutical compositions comprising binding proteins are within the scope of the disclosure. Such therapeutic or pharmaceutical compositions can comprise a therapeutically effective amount of a binding protein, or binding protein-drug conjugate, in admixture with a pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration.

Acceptable formulation materials are nontoxic to recipients at the dosages and concentrations employed.

The pharmaceutical composition can contain formulation materials for modifying, maintaining, or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption, or penetration of the composition. Suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine, or lysine), antimicrobials, antioxidants (such as ascorbic acid, sodium sulfite, or sodium hydrogen-sulfite), buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates, or other organic acids), bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)), complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin), fillers, monosaccharides, disaccharides, and other carbohydrates (such as glucose, mannose, or dextrins), proteins (such as serum albumin, gelatin, or immunoglobulins), coloring, flavoring and diluting agents, emulsifying agents, hydrophilic polymers (such as polyvinylpyrrolidone), low molecular weight polypeptides, salt-forming counterions (such as sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide), solvents (such as glycerin, propylene glycol, or polyethylene glycol), sugar alcohols (such as mannitol or sorbitol), suspending agents, surfactants or wetting agents (such as pluronics; PEG; sorbitan esters; polysorbates such as polysorbate 20 or polysorbate 80; triton; tromethamine; lecithin; cholesterol or tyloxapal), stability enhancing agents (such as sucrose or sorbitol), tonicity enhancing agents (such as alkali metal halides—e.g., sodium or potassium chloride—or mannitol sorbitol), delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants (see, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES (18th Ed., A. R. Gennaro, ed., Mack Publishing Company 1990), and subsequent editions of the same, incorporated herein by reference for any purpose).

The optimal pharmaceutical composition will be determined by a skilled artisan depending upon, for example, the intended route of administration, delivery format, and desired dosage. Such compositions can influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the binding protein.

The primary vehicle or carrier in a pharmaceutical composition can be either aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier for injection can be water, physiological saline solution, or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which can further include sorbitol or a suitable substitute. In one embodiment of the disclosure, binding protein compositions can be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents in the form of a lyophilized cake or an aqueous solution. Further, the binding protein can be formulated as a lyophilizate using appropriate excipients such as sucrose.

The pharmaceutical compositions of the disclosure can be selected for parenteral delivery or subcutaneous. Alternatively, the compositions can be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art.

The formulation components are present in concentrations that are acceptable to the site of administration. For example, buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8.

When parenteral administration is contemplated, the therapeutic compositions for use can be in the form of a pyrogen-free, parenterally acceptable, aqueous solution comprising the desired binding protein in a pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water in which a binding protein is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, bio-erodible particles, polymeric compounds (such as polylactic acid or polyglycolic acid), beads, or liposomes, that provides for the controlled or sustained release of the product which can then be delivered via a depot injection. Hyaluronic acid can also be used, and this can have the effect of promoting sustained duration in the circulation. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

In one embodiment, a pharmaceutical composition can be formulated for inhalation. For example, a binding protein can be formulated as a dry powder for inhalation. Binding protein inhalation solutions can also be formulated with a propellant for aerosol delivery. In yet another embodiment, solutions can be nebulized.

It is also contemplated that certain formulations can be administered orally. In one embodiment of the disclosure, binding proteins that are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule can be designed to release the active portion of the formulation at the point in the gastrointestinal tract where bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of the binding protein. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders can also be employed.

Another pharmaceutical composition can involve an effective quantity of binding proteins in a mixture with non-toxic excipients that are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or another appropriate vehicle, solutions can be prepared in unit-dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

Additional pharmaceutical compositions of the disclosure will be evident to those skilled in the art, including formulations involving binding proteins in sustained- or controlled-delivery formulations. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices can include polyesters, hydrogels, polylactides, copolymers of L-glutamic acid and gamma ethyl-L-glutamate, poly(2-hydroxyethyl-methacrylate), ethylene vinyl acetate, or poly-D(−)-3-hydroxybutyric acid. Sustained-release compositions can also include liposomes, which can be prepared by any of several methods known in the art.

Pharmaceutical compositions to be used for in vivo administration typically must be sterile. This can be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using this method can be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration can be stored in lyophilized form or in a solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Once the pharmaceutical composition has been formulated, it can be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or as a dehydrated or lyophilized powder. Such formulations can be stored either in a ready-to-use form or in a form (e.g., lyophilized) requiring reconstitution prior to administration.

The disclosure also encompasses kits for producing a single-dose administration unit. The kits can each contain both a first container having a dried protein and a second container having an aqueous formulation. Also included within the scope of this disclosure are kits containing single and multi-chambered pre-filled syringes (e.g., liquid syringes and lyosyringes).

The effective amount of a binding protein pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the binding protein is being used, the route of administration, and the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician can titer the dosage and modify the route of administration to obtain the optimal therapeutic effect.

Dosing frequency will depend upon the pharmacokinetic parameters of the binding protein in the formulation being used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition can therefore be administered as a single dose, as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages can be ascertained through use of appropriate dose-response data.

The route of administration of the pharmaceutical composition is in accord with known methods, e.g., orally; through injection by intravenous, intraperitoneal, intracerebral (intraparenchymal), intracerebroventricular, intramuscular, intraocular, intraarterial, intraportal, or intralesional routes; by sustained release systems; or by implantation devices. Where desired, the compositions can be administered by bolus injection or continuously by infusion, or by implantation device.

The composition can also be administered locally via implantation of a membrane, sponge, or other appropriate material onto which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device can be implanted into any suitable tissue or organ, and delivery of the desired molecule can be via diffusion, timed-release bolus, or continuous administration.

The pharmaceutical compositions can be used to prevent and/or treat HIV infection. The pharmaceutical compositions can be used as a standalone therapy or in combination with standard anti-retroviral therapy.

In some embodiments, the present disclosure relates to a method of preventing and/or treating HIV infection in a patient. In some embodiments, the method comprises administering to the patient a therapeutically effective amount of at least one of the binding proteins described herein. In some embodiments, the at least one binding protein is administered in combination with an anti-retroviral therapy (e.g., an anti-HIV therapy). In some embodiments, the at least one binding protein is administered before the anti-retroviral therapy. In some embodiments, the at least one binding protein is administered concurrently with the anti-retroviral therapy. In some embodiments, the at least one binding protein is administered after the anti-retroviral therapy. In some embodiments, the at least one binding protein is co-administered with any standard anti-retroviral therapy known in the art. In some embodiments, administration of the at least one binding protein results in neutralization of one or more HIV virions. In some embodiments, administration of the at least one binding protein results in elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, administration of the at least one binding protein results in neutralization of one or more HIV virions and results in elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, the patient is a human.

Without limiting the present disclosure, a number of embodiments of the present disclosure are described below for purpose of illustration.

Item 1: A binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II]and a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1  [III]and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain; andL₁, L₂, L₃, and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

Item 2: A binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1-hinge-C_H2-C_H3  [II]and a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1-hinge-C_H2-C_H3  [III]and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is an immunoglobulin C_H1 heavy chain constant domain;C_H2 is an immunoglobulin C_H2 heavy chain constant domain;C_H3 is an immunoglobulin C_H3 heavy chain constant domain;hinge is an immunoglobulin hinge region connecting the C_H1 and C_H2 domains; andL₁, L₂, L₃ and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

Item 3: The binding protein of item 1 or item 2, wherein the one or more HIV target proteins is selected from the group consisting of glycoprotein 120, glycoprotein 41 and glycoprotein 60.

Item 4: The binding protein of item 1 or item 2, wherein the binding protein is trispecific and capable of specifically binding three different epitopes on a single HIV target protein.

Item 5: The binding protein of item 1 or item 2, wherein the binding protein is trispecific and capable of specifically binding two different epitopes on a first HIV target protein, and one epitope on a second HIV target protein, wherein the first and second HIV target proteins are different.

Item 6: The binding protein of item 1 or item 2, wherein the binding protein is trispecific and capable of specifically binding three different antigen targets.

Item 7: The binding protein of item 1 or item 2, wherein the binding protein is capable of inhibiting the function of one or more HIV target proteins.

Item 8: The binding protein of any one of items 1-7, wherein V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; or a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively.

Item 9: The binding protein of any one of items 1-7, wherein V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521.

Item 10: The binding protein of any one of items 1-9, wherein V_L1 comprises a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521.

Item 11: The binding protein of any one of items 1-10, wherein V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; or a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively.

Item 12: The binding protein of any one of items 1-10, wherein V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521.

Item 13: The binding protein of any one of items 1-12, wherein V_L2 comprises a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521.

Item 14: The binding protein of any one of items 1-13, wherein V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; or a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively.

Item 15: The binding protein of any one of items 1-13, wherein V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521.

Item 16: The binding protein of any one of items 1-15, wherein V_L3 comprises a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, and 521.

Item 17: The binding protein of any one of items 1-16, wherein V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; or a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively.

Item 18: The binding protein of any one of items 1-16, wherein V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508.

Item 19: The binding protein of any one of items 1-18, wherein V_H1 comprises a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508.

Item 20: The binding protein of any one of items 1-19, wherein V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; or a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively.

Item 21: The binding protein of any one of items 1-19, wherein V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508.

Item 22: The binding protein of any one of items 1-21, wherein V_H2 comprises a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508.

Item 23: The binding protein of any one of items 1-22, wherein V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; or a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively.

Item 24: The binding protein of any one of items 1-22, wherein V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508.

Item 25: The binding protein of any one of items 1-24, wherein V_H3 comprises a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, and 508.

Item 26: The binding protein of any one of items 1-25, wherein V_L1 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 500, a CDR-L2 comprising the sequence of SEQ ID NO: 501, and a CDR-L3 comprising the sequence of SEQ ID NO: 274; V_L2 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 275, a CDR-L2 comprising the sequence of SEQ ID NO: 276, and a CDR-L3 comprising the sequence of SEQ ID NO: 277; V_L3 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 266, a CDR-L2 comprising the sequence of SEQ ID NO: 267, and a CDR-L3 comprising the sequence of SEQ ID NO: 268; V_H1 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 254, a CDR-H2 comprising the sequence of SEQ ID NO: 255, and a CDR-H3 comprising the sequence of SEQ ID NO: 256; V_H2 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 257, a CDR-H2 comprising the sequence of SEQ ID NO: 258, and a CDR-H3 comprising the sequence of SEQ ID NO: 259; and V_H3 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 248, a CDR-H2 comprising the sequence of SEQ ID NO: 497, and a CDR-H3 comprising the sequence of SEQ ID NO: 250.

Item 27: The binding protein of any one of items 1-25, wherein V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 518; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 519; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 512; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 504; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 506; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 502.

Item 28: The binding protein of any one of items 1-27, wherein V_L1 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 518; V_L2 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 519; V_L3 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 512; V_H1 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 504; V_H2 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 506; and V_H3 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 502.

Item 29: The binding protein of any one of items 1-25, wherein V_L1 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 500, a CDR-L2 comprising the sequence of SEQ ID NO: 501, and a CDR-L3 comprising the sequence of SEQ ID NO: 274; V_L2 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 275, a CDR-L2 comprising the sequence of SEQ ID NO: 276, and a CDR-L3 comprising the sequence of SEQ ID NO: 277; V_L3 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 269, a CDR-L2 comprising the sequence of SEQ ID NO: 270, and a CDR-L3 comprising the sequence of SEQ ID NO: 271; V_H1 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 254, a CDR-H2 comprising the sequence of SEQ ID NO: 255, and a CDR-H3 comprising the sequence of SEQ ID NO: 256; V_H2 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 257, a CDR-H2 comprising the sequence of SEQ ID NO: 258, and a CDR-H3 comprising the sequence of SEQ ID NO: 259; and V_H3 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 251, a CDR-H2 comprising the sequence of SEQ ID NO: 252, and a CDR-H3 comprising the sequence of SEQ ID NO: 253.

Item 30: The binding protein of any one of items 1-25, wherein V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 518; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 519; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 513; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 504; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 506; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 503.

Item 31: The binding protein of any one of items 1-25 and 29-30, wherein V_L1 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 518; V_L2 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 519; V_L3 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 513; V_H1 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 504; V_H2 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 506; and V_H3 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 503.

Item 32: The binding protein of any one of items 1-25, wherein V_L1 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 275, a CDR-L2 comprising the sequence of SEQ ID NO: 276, and a CDR-L3 comprising the sequence of SEQ ID NO: 277; V_L2 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 500, a CDR-L2 comprising the sequence of SEQ ID NO: 501, and a CDR-L3 comprising the sequence of SEQ ID NO: 274; V_L3 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 269, a CDR-L2 comprising the sequence of SEQ ID NO: 270, and a CDR-L3 comprising the sequence of SEQ ID NO: 271; V_H1 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 257, a CDR-H2 comprising the sequence of SEQ ID NO: 258, and a CDR-H3 comprising the sequence of SEQ ID NO: 259; V_H2 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 254, a CDR-H2 comprising the sequence of SEQ ID NO: 255, and a CDR-H3 comprising the sequence of SEQ ID NO: 256; and V_H3 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 251, a CDR-H2 comprising the sequence of SEQ ID NO: 252, and a CDR-H3 comprising the sequence of SEQ ID NO: 253.

Item 33: The binding protein of any one of items 1-25, wherein V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 519; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 518; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 513; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 506; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 504; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 503.

Item 34: The binding protein of any one of items 1-25 and 32-33, wherein V_L1 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 519; V_L2 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 518; V_L3 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 513; V_H1 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 506; V_H2 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 504; and V_H3 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 503.

Item 35: The binding protein of item 1, wherein the second polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains.

Item 36: The binding protein of item 1, wherein the third polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains.

Item 37: The binding protein of item 1, wherein the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

Item 38: The binding protein of item 1, wherein the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W.

Item 39: The binding protein of any one of items 1, 37, and 38, wherein the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

Item 40: The binding protein of item 2, wherein the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

Item 41: The binding protein of item 2, wherein the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W.

Item 42: The binding protein of any one of items 2, 40, and 41, wherein the C_H3 domains of the second and the third polypeptide chains both comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

Item 43: The binding protein of item 1 or item 2, wherein at least one of L₁, L₂, L₃, or L₄ is independently 0 amino acids in length.

Item 44: The binding protein of item 1 or item 2, wherein L₁, L₂, L₃, or L₄ are each independently at least one amino acid in length.

Item 45: The binding protein of any one of items 1-44, wherein L₁ comprises Asp-Lys-Thr-His-Thr (SEQ ID NO: 525).

Item 46: A binding protein comprising four polypeptide chains that form three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II]and a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1  [III]and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain; andL₁, L₂, L₃, and L₄ are amino acid linkers;wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair;wherein:

(a) V_L1, V_L2 and V_L3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, 52, 58, 60, 66, 68, 74, 76, 82, 84, 90, 92, 98, 100, 106, 108, 114, 116, 122, 124, 130, 132, 138, 140, 146, 148, 154, 156, 162, 164, 170, 172, 178, 180, 186, 188, 194, 196, 202, 204, 210,212, 218, 220, 226, 228, 233, 235, 241, 243; or

(b) V_L1, V_L2 and V_L3 each independently comprise light chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs:266-283; and

wherein:

(a) V_H1, V_H2, and V_H3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 1, 3, 9, 11, 17, 10, 25, 27, 33, 35, 41, 43, 49, 51, 57, 59, 65, 67, 73, 75, 81, 83, 89, 91, 97, 99, 105, 107, 113, 115, 121, 123, 129, 131, 137, 139, 145, 147, 153, 155, 161, 163, 169, 171, 177, 179, 185, 187, 193, 195, 201, 203, 209, 211, 217, 219, 225, 227, 232, 234, 240, 242; or

(b) V_H1, V_H2, and V_H3 each independently comprise heavy chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 248-265.

Item 47: A binding protein comprising four polypeptide chains that form three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1-hinge-C_H2-C_H3  [II]and a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1-hinge-C_H2-C_H3  [III]and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain;C_H2 is an immunoglobulin C_H2 heavy chain constant domain;C_H3 is an immunoglobulin C_H3 heavy chain constant domain;hinge is an immunoglobulin hinge region connecting the C_H1 and C_H2 domains; andL₁, L₂, L₃, and L₄ are amino acid linkers;wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair;wherein:

(a) V_L1, V_L2 and V_L3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, 52, 58, 60, 66, 68, 74, 76, 82, 84, 90, 92, 98, 100, 106, 108, 114, 116, 122, 124, 130, 132, 138, 140, 146, 148, 154, 156, 162, 164, 170, 172, 178, 180, 186, 188, 194, 196, 202, 204, 210,212, 218, 220, 226, 228, 233, 235, 241, 243; or

(b) V_L1, V_L2 and V_L3 each independently comprise light chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs:266-283; and

wherein:

(a) V_H1, V_H2, and V_H3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 1, 3, 9, 11, 17, 10, 25, 27, 33, 35, 41, 43, 49, 51, 57, 59, 65, 67, 73, 75, 81, 83, 89, 91, 97, 99, 105, 107, 113, 115, 121, 123, 129, 131, 137, 139, 145, 147, 153, 155, 161, 163, 169, 171, 177, 179, 185, 187, 193, 195, 201, 203, 209, 211, 217, 219, 225, 227, 232, 234, 240, 242; or

(b) V_H1, V_H2, and V_H3 each independently comprise heavy chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 248-265.

Item 48: The binding protein of item 46, wherein the second polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains.

Item 49: The binding protein of item 46, wherein the third polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains.

Item 50: The binding protein of item 46, wherein the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

Item 51: The binding protein of item 46, wherein the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W.

Item 52: The binding protein of any one of items 46, 50, and 51, wherein the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

Item 53: The binding protein of item 47, wherein the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

Item 54: The binding protein of item 47, wherein the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W.

Item 55: The binding protein of any one of items 47, 53, and 54, wherein the C_H3 domains of the second and the third polypeptide chains both comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

Item 56: The binding protein of item 46 or item 47, wherein at least one of L₁, L₂, L₃ or L₄ is independently 0 amino acids in length.

Item 57: The binding protein of item 46 or item 47, wherein L₁, L₂, L₃ or L₄ are each independently at least one amino acid in length.

Item 58: The binding protein of any one of items 46-57, wherein L₁ comprises Asp-Lys-Thr-His-Thr (SEQ ID NO: 525).

Item 59: A binding protein comprising a first polypeptide chain, a second polypeptide chain, a third polypeptide chain and a fourth polypeptide chain wherein:

(a) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 4; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 3; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 2;

(b) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 12; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 11; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 9; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 10 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 10;

(c) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 20 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 20; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 19; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 17; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 18;

(d) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 28 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 28; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 27 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 27; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 25 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 25; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 26 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 26;

(e) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 36 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 36; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 35 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 35; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 33 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 33; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 34 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 34;

(f) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 44 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 44; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 43 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 43; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 41 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 41; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 42 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 42;

(g) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 52 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 52; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 51 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 51; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 49 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 49; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 50 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 50;

(h) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 60 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 60; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 59 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 59; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 57 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 57; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 58 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 58;

(i) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 68 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 68; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 67 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 67; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 65 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 65; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 66 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 66;

(j) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 76 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 76; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 75 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 75; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 73 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 73; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 74 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 74;

(k) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 84 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 84; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 83 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 83; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 81 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 81; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 82 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 82;

(l) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 92 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:92; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 91 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 91; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 89 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 89; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 90 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 90;

(m) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 100 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 100; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 99 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 99; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 97 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 97; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 98 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 98;

(n) the first polypeptide comprises the amino acid sequence of SEQ ID NO: 108 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 108; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 107 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 107; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 105 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 105; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 106 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 106;

(o) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 116 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 116; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 115 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 115; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 113 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 113; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 114 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 114;

(p) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 124 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 124; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 123 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 123; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 121 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 121; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 122 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 122;

(q) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 132 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 132; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 131 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 131; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 129 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 129; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 130 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 130;

(r) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 140 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 140; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 139 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 139; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 137 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 137; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 138 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 138;

(s) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 148 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 148; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 147 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 147; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 145 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 145; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 146 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 146;

(t) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 156 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 156; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 155 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 155; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 153 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 153; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 154 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 154;

(u) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 164 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 164; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 163 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 163; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 161 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 161; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 162 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 162;

(v) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 172 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 172; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 171 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 171; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 169 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 169; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 170 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 170;

(w) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 180 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 180; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 179 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 179; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 177 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 177; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 178 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 178;

(x) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 188 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 188; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 187 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 187; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 185 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 185; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 186 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 186;

(y) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 196 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 196; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 195 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 195; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 193 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 193; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 194 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 194;

(z) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 204 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 204; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 203 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 203; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 201 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 201; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 202 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 202;

(aa) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 212 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 212; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 211 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 211; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 209 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 209; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 210 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 210;

(bb) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 220 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 220; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 219 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 219; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 217 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 217; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 218 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 218;

(cc) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 228 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 228; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 227 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 227; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 225 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 225; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 226 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 226;

(dd) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 235 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 235; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 234 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 234; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 232 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 232; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 233 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 233; or

(ee) first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 243 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 243; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 242 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 242; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 240 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 240; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 241 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 241.

Item 60: A binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins and one or more T cell target proteins, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I];a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II];a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1  [III];and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV];whereinV_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain; andL₁, L₂, L₃, and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

Item 61: A binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins and one or more T cell target proteins, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I];a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1-hinge-C_H2-C_H3  [II];a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1-hinge-C_H2-C_H3  [III];and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV];whereinV_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain;C_H2 is an immunoglobulin C_H2 heavy chain constant domain;C_H3 is an immunoglobulin C_H3 heavy chain constant domain;hinge is an immunoglobulin hinge region connecting the C_H1 and C_H2 domains; andL₁, L₂, L₃, and L₄ are amino acid linkers;and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

Item 62: The binding protein of item 60 or item 61, wherein the one or more HIV target proteins are selected from the group consisting of glycoprotein 120, glycoprotein 41 and glycoprotein 160.

Item 63: The binding protein of item 60 or item 61, wherein the one or more T cell target proteins are CD3 or CD28.

Item 64: The binding protein of item 60 or item 61, wherein the binding protein is trispecific and capable of specifically binding an HIV target protein and two different epitopes on a single T cell target protein.

Item 65: The binding protein of item 60 or item 61, wherein the binding protein is trispecific and capable of specifically binding an HIV target protein and two different T cell target proteins.

Item 66: The binding protein of item 60 or item 61, wherein the binding protein is trispecific and capable of specifically binding a T cell target protein and two different epitopes on a single HIV target protein.

Item 67: The binding protein of item 60 or item 61, wherein the binding protein is trispecific and capable of specifically binding a T cell target protein and two different HIV target proteins.

Item 68: The binding protein of item 60 or item 61, wherein the first and second polypeptide chains form two antigen binding sites that specifically target two T cell target proteins, and the third and fourth polypeptide chains form an antigen binding site that specifically binds an HIV target protein.

Item 69: The binding protein of any one of items 60-68, wherein V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively; a sequence as set forth in SEQ ID NOs: 488, 489, and 490, respectively; a sequence as set forth in SEQ ID NOs: 491, 492, and 493, respectively; or a sequence as set forth in SEQ ID NOs: 494, 495, and 496, respectively.

Item 70: The binding protein of any one of items 60-68, wherein V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524.

Item 71: The binding protein of any one of items 60-70, wherein V_L1 comprises a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524.

Item 72: The binding protein of any one of items 60-71, wherein V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively; a sequence as set forth in SEQ ID NOs: 488, 489, and 490, respectively; a sequence as set forth in SEQ ID NOs: 491, 492, and 493, respectively; or a sequence as set forth in SEQ ID NOs: 494, 495, and 496, respectively.

Item 73: The binding protein of any one of items 60-71, wherein V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524.

Item 74: The binding protein of any one of items 60-73, wherein V_L2 comprises a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524.

Item 75: The binding protein of any one of items 60-74, wherein V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 comprising a sequence as set forth in SEQ ID NOs: 266, 267, and 268, respectively; a sequence as set forth in SEQ ID NOs: 269, 270, and 271, respectively; a sequence as set forth in SEQ ID NOs: 500, 501, and 274, respectively; a sequence as set forth in SEQ ID NOs: 275, 276, and 277, respectively; a sequence as set forth in SEQ ID NOs: 281, 282, and 283, respectively; a sequence as set forth in SEQ ID NOs: 278, 279, and 280, respectively; a sequence as set forth in SEQ ID NOs: 488, 489, and 490, respectively; a sequence as set forth in SEQ ID NOs: 491, 492, and 493, respectively; or a sequence as set forth in SEQ ID NOs: 494, 495, and 496, respectively.

Item 76: The binding protein of any one of items 60-74, wherein V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524.

Item 77: The binding protein of any one of items 60-76, wherein V_L3 comprises a light chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, and 524.

Item 78: The binding protein of any one of items 60-77, wherein V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively; a sequence as set forth in SEQ ID NOs: 479, 480, and 481, respectively; a sequence as set forth in SEQ ID NOs: 482, 483, and 484, respectively; or a sequence as set forth in SEQ ID NOs: 485, 486, and 487, respectively.

Item 79: The binding protein of any one of items 60-77, wherein V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511.

Item 80: The binding protein of any one of items 60-79, wherein V_H1 comprises a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511.

Item 81: The binding protein of any one of items 60-80, wherein V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively; a sequence as set forth in SEQ ID NOs: 479, 480, and 481, respectively; a sequence as set forth in SEQ ID NOs: 482, 483, and 484, respectively; or a sequence as set forth in SEQ ID NOs: 485, 486, and 487, respectively.

Item 82: The binding protein of any one of items 60-80, wherein V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511.

Item 83: The binding protein of any one of items 60-82, wherein V_H2 comprises a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511.

Item 84: The binding protein of any one of items 60-83, wherein V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 comprising a sequence as set forth in SEQ ID NOs: 248, 497, and 250, respectively; a sequence as set forth in SEQ ID NOs: 251, 252, and 253, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 256, respectively; a sequence as set forth in SEQ ID NOs: 254, 255, and 498, respectively; a sequence as set forth in SEQ ID NOs: 257, 258, and 259, respectively; a sequence as set forth in SEQ ID NOs: 263, 264, and 265, respectively; a sequence as set forth in SEQ ID NOs: 499, 261, and 262, respectively; a sequence as set forth in SEQ ID NOs: 479, 480, and 481, respectively; a sequence as set forth in SEQ ID NOs: 482, 483, and 484, respectively; or a sequence as set forth in SEQ ID NOs: 485, 486, and 487, respectively.

Item 85: The binding protein of any one of items 60-83, wherein V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511.

Item 86: The binding protein of any one of items 60-85, wherein V_H3 comprises a heavy chain variable domain comprising a sequence selected from the group consisting of SEQ ID NOs: 502, 503, 504, 505, 506, 507, 508, 509, 510, and 511.

Item 87: The binding protein of any one of items 60-86, wherein V_L1 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 488, a CDR-L2 comprising the sequence of SEQ ID NO: 489, and a CDR-L3 comprising the sequence of SEQ ID NO: 490; V_L2 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 494, a CDR-L2 comprising the sequence of SEQ ID NO: 495, and a CDR-L3 comprising the sequence of SEQ ID NO: 496; V_L3 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 269, a CDR-L2 comprising the sequence of SEQ ID NO: 270, and a CDR-L3 comprising the sequence of SEQ ID NO: 271; V_H1 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 479, a CDR-H2 comprising the sequence of SEQ ID NO: 480, and a CDR-H3 comprising the sequence of SEQ ID NO: 481; V_H2 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 485, a CDR-H2 comprising the sequence of SEQ ID NO: 486, and a CDR-H3 comprising the sequence of SEQ ID NO: 487; and V_H3 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 251, a CDR-H2 comprising the sequence of SEQ ID NO: 252, and a CDR-H3 comprising the sequence of SEQ ID NO: 253.

Item 88: The binding protein of any one of items 60-86, wherein V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 522; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 524; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 513; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 509; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 511; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 503.

Item 89: The binding protein of any one of items 60-88, wherein V_L1 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 522; V_L2 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 524; V_L3 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 513; V_H1 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 509; V_H2 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 511; and V_H3 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 503.

Item 90: The binding protein of any one of items 60-86, wherein V_L1 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 494, a CDR-L2 comprising the sequence of SEQ ID NO: 495, and a CDR-L3 comprising the sequence of SEQ ID NO: 496; V_L2 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 488, a CDR-L2 comprising the sequence of SEQ ID NO: 489, and a CDR-L3 comprising the sequence of SEQ ID NO: 490; V_L3 comprises a CDR-L1 comprising the sequence of SEQ ID NO: 269, a CDR-L2 comprising the sequence of SEQ ID NO: 270, and a CDR-L3 comprising the sequence of SEQ ID NO: 271; V_H1 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 485, a CDR-H2 comprising the sequence of SEQ ID NO: 486, and a CDR-H3 comprising the sequence of SEQ ID NO: 487; V_H2 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 479, a CDR-H2 comprising the sequence of SEQ ID NO: 480, and a CDR-H3 comprising the sequence of SEQ ID NO: 481; and V_H3 comprises a CDR-H1 comprising the sequence of SEQ ID NO: 251, a CDR-H2 comprising the sequence of SEQ ID NO: 252, and a CDR-H3 comprising the sequence of SEQ ID NO: 253.

Item 91: The binding protein of any one of items 60-86, wherein V_L1 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 524; V_L2 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 522; V_L3 comprises a CDR-L1, CDR-L2, and CDR-L3 of a light chain variable domain comprising the light chain variable domain sequence of SEQ ID NO: 513; V_H1 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 511; V_H2 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 509; and V_H3 comprises a CDR-H1, CDR-H2, and CDR-H3 of a heavy chain variable domain comprising the heavy chain variable domain sequence of SEQ ID NO: 503.

Item 92: The binding protein of any one of items 60-86 and 90-91, wherein V_L1 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 524; V_L2 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 522; V_L3 comprises a light chain variable domain comprising the sequence of SEQ ID NO: 513; V_H1 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 511; V_H2 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 509; and V_H3 comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 503.

Item 93: The binding protein of item 60, wherein the second polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains.

Item 94: The binding protein of item 60, wherein the third polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains.

Item 95: The binding protein of item 60, wherein the second polypeptide chain further comprises a first Fc region linked to CHI, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to CHI, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

Item 96: The binding protein of item 60, wherein the second polypeptide chain further comprises a first Fc region linked to CHI, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to CHI, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W.

Item 97: The binding protein of any one of items 60, 95, and 96, wherein the second polypeptide chain further comprises a first Fc region linked to CHI, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

Item 98: The binding protein of item 61, wherein the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

Item 99: The binding protein of item 61, wherein the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W.

Item 100: The binding protein of any one of items 61, 98, and 99, wherein the C_H3 domains of the second and the third polypeptide chains both comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

Item 101: The binding protein of item 60 or item 61, wherein at least one of L₁, L₂, L₃, or L₄ is independently 0 amino acids in length.

Item 102: The binding protein of item 60 or item 61, wherein L₁, L₂, L₃, or L₄ are each independently at least one amino acid in length.

Item 103: The binding protein of any one of items 60-102, wherein L₁ is Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 299).

Item 104: A binding protein comprising four polypeptide chains that form three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1  [II]and a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1  [III]and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain; andL₁, L₂, L₃, and L₄ are amino acid linkers;wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair;wherein:

(a) V_L1, V_L2 and V_L3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 303, 305, 311, 313, 319, 321, 327, 329, 335, 337, 343, 345, 351, 353, 359, 361, 367, 369, 375, 377, 383, 385, 391, 393, 399, 401, 407, 409, 415, 417, 423, 425, 431, 433, 439, 441, 447, 449, 455, 457, 463, 465, 471, 473; or

(b) V_L1, V_L2 and V_L3 each independently comprise light chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 266-271, 275-277, 488-496; and

wherein:

(a) V_H1, V_H2, and V_H3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 302, 304, 310, 312, 318, 320, 326, 328, 334, 336, 342, 344, 350, 352, 358, 360, 366, 368, 374, 376, 382, 384, 390, 392, 398, 400, 406, 408, 414, 416, 422, 424, 430, 432, 438, 440, 446, 448, 454, 456, 462, 464, 470, 472; or

(b) V_H1, V_H2, and V_H3 each independently comprise heavy chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 248-253, 257-259, 479-487.

Item 105: A binding protein comprising four polypeptide chains that form three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:V_L2-L₁-V_L1-L₂-C_L  [I]and a second polypeptide chain comprises a structure represented by the formula:V_H1-L₃-V_H2-L₄-C_H1-hinge-C_H2-C_H3  [II]and a third polypeptide chain comprises a structure represented by the formula:V_H3-C_H1-hinge-C_H2-C_H3  [III]and a fourth polypeptide chain comprises a structure represented by the formula:V_L3-C_L  [IV]wherein:V_L1 is a first immunoglobulin light chain variable domain;V_L2 is a second immunoglobulin light chain variable domain;V_L3 is a third immunoglobulin light chain variable domain;V_H1 is a first immunoglobulin heavy chain variable domain;V_H2 is a second immunoglobulin heavy chain variable domain;V_H3 is a third immunoglobulin heavy chain variable domain;C_L is an immunoglobulin light chain constant domain;C_H1 is the immunoglobulin C_H1 heavy chain constant domain;C_H2 is an immunoglobulin C_H2 heavy chain constant domain;C_H3 is an immunoglobulin C_H3 heavy chain constant domain;hinge is an immunoglobulin hinge region connecting the C_H1 and C_H2 domains; andL₁, L₂, L₃, and L₄ are amino acid linkers;wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair;wherein:

(a) V_L1, V_L2 and V_L3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 303, 305, 311, 313, 319, 321, 327, 329, 335, 337, 343, 345, 351, 353, 359, 361, 367, 369, 375, 377, 383, 385, 391, 393, 399, 401, 407, 409, 415, 417, 423, 425, 431, 433, 439, 441, 447, 449, 455, 457, 463, 465, 471, 473; or

(b) V_L1, V_L2 and V_L3 each independently comprise light chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 266-271, 275-277, 488-496; and

wherein:

(a) V_H1, V_H2, and V_H3 are each independently a variable domain derived from an amino acid sequence as set forth in any one of SEQ ID NOs: 302, 304, 310, 312, 318, 320, 326, 328, 334, 336, 342, 344, 350, 352, 358, 360, 366, 368, 374, 376, 382, 384, 390, 392, 398, 400, 406, 408, 414, 416, 422, 424, 430, 432, 438, 440, 446, 448, 454, 456, 462, 464, 470, 472; or

(b) V_H1, V_H2, and V_H3 each independently comprise heavy chain complementarity determining regions of a variable domain comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 248-253, 257-259, 479-487.

Item 106: The binding protein of item 104, wherein the second polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains.

Item 107: The binding protein of item 104, wherein the third polypeptide chain further comprises an Fc region linked to C_H1, the Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains.

Item 108: The binding protein of item 104, wherein the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

Item 109: The binding protein of item 104, wherein the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W.

Item 110: The binding protein of any one of items 104, 108, and 109, wherein the second polypeptide chain further comprises a first Fc region linked to C_H1, the first Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains, and wherein the third polypeptide chain further comprises a second Fc region linked to C_H1, the second Fc region comprising an immunoglobulin hinge region and C_H2 and C_H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

Item 111: The binding protein of item 105, wherein the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

Item 112: The binding protein of item 105, wherein the C_H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the C_H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 according to EU Index, wherein the amino acid substitutions are S354C and T366W.

Item 113: The binding protein of any one of items 105, 111, and 112, wherein the C_H3 domains of the second and the third polypeptide chains both comprise amino acid substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to EU Index, wherein the amino acid substitutions are M428L and N434S.

Item 114: The binding protein of item 104 or item 105, wherein at least one of L₁, L₂, L₃, or L₄ is independently 0 amino acids in length.

Item 115: The binding protein of item 104 or item 105, wherein L₁, L₂, L₃, or L₄ are each independently at least one amino acid in length.

Item 116: The binding protein of any one of items 104-115, wherein L₁ is Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 299).

Item 117: A binding protein comprising a first polypeptide chain, a second polypeptide chain, a third polypeptide chain and a fourth polypeptide chain wherein:

(a) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 305 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 305; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 304 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 304; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 302 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 302; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 303 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 303;

(b) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 313 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 313; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 312 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 312; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 310 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 310; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 311 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 311;

(c) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 321 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 321; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 320 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 320; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 318 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 318; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 319 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 319;

(d) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 329 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 329; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 328 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 328; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 326 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 326; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 327 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 327;

(e) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 337 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 337; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 336 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 336; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 334 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 334; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 335 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 335;

(f) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 345 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 345; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 344 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 344; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 342 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 342; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 343 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 343;

(g) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 353 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 353; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 352 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:352; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 350 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 350; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 351 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 351;

(h) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 361 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 361; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 360 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 360; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 358 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 358; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 359 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 359;

(i) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 369 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 369; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 368 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 368; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 366 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 366; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 367 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 367;

(j) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 377 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 377; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 376 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 376; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 374 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 374; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 375 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 375;

(k) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 385 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 385; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 384 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 384; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 382 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 382; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 383 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 383;

(l) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 393 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 393; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 392 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 392; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 390 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 390; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 391 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 391;

(m) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 401 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 401; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 400 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 400; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 398 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 398; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 399 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 399;

(n) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 409 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 409; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 408 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 408; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 406 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 406; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 407 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 407;

(p) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 417 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 417; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 416 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 416; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 414 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 414; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 415 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 415;

(q) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 425 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 425; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 424 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 424; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 422 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 422; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 423 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 423;

(r) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 433 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:433; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 432 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 432; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 430 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 430; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 431 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 431;

(s) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 441 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 441; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 440 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 440; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 438 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 438; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 439 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 439;

(t) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 449 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 449; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 448 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 448; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 446 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 446; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 447 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 447;

(u) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 457 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 457; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 456 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 456; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 454 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 454; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 455 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 455;

(v) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 465 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 465; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 464 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 464; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 462 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 462; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 463 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 463; or

(w) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 473 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 473; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 472 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 472; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO: 470 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 470; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO: 471 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 471.

Item 118: An isolated nucleic acid molecule comprising a nucleotide sequence encoding the binding protein of any one of items 1-117.

Item 119: An expression vector comprising the nucleic acid molecule of item 118.

Item 120: An isolated host cell comprising the nucleic acid molecule of item 118.

Item 121: An isolated host cell comprising the expression vector of item 119.

Item 122: The isolated host cell of item 120 or item 121, wherein the host cell is a mammalian cell or an insect cell.

Item 123: A vector system comprising one or more vectors encoding a first, second, third, and fourth polypeptide chain of a binding protein of any one of items 1-117.

Item 124: The vector system of item 123, wherein the vector system comprises a first vector encoding the first polypeptide chain of the binding protein, a second vector encoding the second polypeptide chain of the binding protein, a third vector encoding the third polypeptide chain of the binding protein, and a fourth vector encoding the fourth polypeptide chain of the binding protein.

Item 125: The vector system of item 123, wherein the vector system comprises a first vector encoding the first and second polypeptide chains of the binding protein, and a second vector encoding the third and fourth polypeptide chains of the binding protein.

Item 126: The vector system of any one of items 123-125, wherein the one or more vectors are expression vectors.

Item 127: An isolated host cell comprising the vector system of any one of items 123-126.

Item 128: The isolated host cell of item 127, wherein the host cell is a mammalian cell or an insect cell.

Item 129: A method of producing a binding protein, the method comprising:

a) culturing a host cell of any one of items 120-122 and items 127-128 under conditions such that the host cell expresses the binding protein; and

b) isolating the binding protein from the host cell.

Item 130: A method of preventing and/or treating HIV infection in a patient comprising administering to the patient a therapeutically effective amount of at least one binding protein of any one of items 1-117.

Item 131: The method of item 130, wherein the binding protein is co-administered with standard anti-retroviral therapy.

Item 132: The method of item 130 or item 131, wherein administration of the at least one binding protein results in the neutralization of one or more HIV virions.

Item 133: The method of any one of items 130-132, wherein administration of the at least one binding protein results in the elimination of one or more latently and/or chronically HIV-infected cells in the patient.

Item 134: The method of any one of items 130-133, wherein the patient is a human.

Item 135: The binding protein of any one of items 1-117 for the prevention or treatment of an HIV infection in a patient.

Item 136: The binding protein of item 135, wherein the binding protein is co-administered with standard anti-retroviral therapy.

Item 137: The binding protein of item 135 or item 136, wherein the binding protein causes the neutralization of one or more HIV virions in the patient.

Item 138: The binding protein of any one of items 135-137, wherein the binding protein causes the elimination of one or more latently and/or chronically HIV-infected cells in the patient.

Item 139: The binding protein of any one of items 135-138, wherein the patient is a human.

EXAMPLES

The Examples that follow are illustrative of specific embodiments of the disclosure, and various uses thereof. They are set forth for explanatory purposes only, and should not be construed as limiting the scope of the invention in any way.

Example 1: Production of Trispecific Binding Proteins Targeting the HIV-1 Env Glycoprotein

The HIV-1 envelope glycoprotein (Env/gp160) is located on the surface of the virus particle, and is composed of a homo-trimer comprising three non-covalently-linked transmembrane gp41 and gp120 complexes. Env enables viral entry into target cells by the binding of gp120 to HIV's main receptor (CD4) and co-receptor (CCR5 or CXCR4), followed by the induction of viral/cellular membrane fusion facilitated by conformational changes in gp41, resulting in entry of the viral capsid and delivery of the viral genome into the host cell. Additionally, Env is expressed on the surface of infected cells.

Env acts as the only target for neutralizing antibodies on the HIV-1 virion. Binding of neutralizing antibodies to viral Env inhibits viral attachment/entry. Moreover, binding of neutralizing antibodies to HIV-1 infected, Env expressing cells leads to their destruction by Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Complement Dependent Cytotoxicity (CDC), resulting in reduction of the latent viral reservoir. Thus, neutralizing antibodies targeting Env are an attractive area for anti-viral therapy development. However, because of the high sequence diversity and mutation rate of the HIV-1 virus, developing neutralizing antibodies targeting Env has proven challenging due to the high likelihood that a given HIV-1 strain either lacks the epitope of any given neutralizing antibody, or the strain has evolved a mutation to become resistant to the antibody. Strategies must be developed to mitigate the breakthrough of viral strains when developing novel neutralizing antibodies targeting HIV-1. The studies described herein explore the development of novel trispecific binding proteins comprising four polypeptides forming three antigen binding sites that specifically bind three different epitopes on the HIV Env glycoprotein, and use of these novel trispecific binding proteins in neutralizing HIV-1.

Methods

Binding Protein Production and Purification

The vectors expressing the trispecific binding proteins were constructed by inserting the designed heavy and light chain genes into a mammalian expression vector. Corresponding heavy and light chain pairing occurred spontaneously, and heterodimer formation was promoted by Knob-in-Hole mutations engineered in the Fc region.

Binding proteins were produced in Expi293 cells by cotransfection of four expression plasmids (Life Technologies, Expi293™ Expression System Kit, Cat. No. A14635). Binding proteins were purified using a two-step purification scheme. First, binding proteins were captured on protein A affinity chromatography resin, washed, and then eluted in glycine at pH 3.0. The eluted proteins were then dialyzed in PBS, concentrated, and filtered. The filtered antibodies were further purified using a Superdex 200 SEC column to obtain monomeric binding proteins.

Affinity Measurements of the Binding Proteins

Binding affinities of anti-HIV trispecific binding proteins were measured by surface plasmon resonance (SPR) using a Biacore3000 instrument (GE Healthcare). The assay buffer used was HBS-EP (GE Healthcare).

The affinity of the indicated proteins for the MPER binding site on the HIV-1 protein gp41 was measured by surface plasmon resonance (SPR) analysis using a Biacore Instrument as follows: binding proteins were first captured on a CM5 chip coupled with anti-human Fc antibody, followed by flow through of varying concentrations (100 nM-6.25 nM) of the MPER binding peptide (Acetyl-RRRNEQELLELDKWASLWNWFDITNWLWYIRRR-Ttds-Lys-(Biotin)-NH2) (SEQ ID NO: 284) at 30 μL per minute, and binding was detected by measurement of association for 240 seconds, and dissociation for 300 seconds on a Biacore 3000 at 25° C. HBS-EP buffer was used for sample dilution, as well as running buffer. Regeneration of the chip was done with 3 M MgCl₂ at 30 μL per minute. For data analysis the BIAevaluation software v.4.1 (GE Healthcare) was used. Data were fit globally using a 1:1 Langmuir model with mass transfer. After software-based curve fitting, the ON and OFF reates at each concentration of MPER binding peptide was calculated and used to obtain a binding affinity for each binding protein.

The affinity of the indicated proteins for the CD4BS binding site on the HIV-1 protein gp120 was measured by SPR as follows: recombinant HIV-1 gp120 (Thr27-Arg498) protein (HIV-1/Clade B/C (CN54), ARCO Biosystems (Cat. # GP4-V15227)) was captured on a CM5 chip, followed by flow through of varying concentrations (100 nM-6.25 nM) of the binding proteins, and binding was detected by measurement of association for 240 seconds, and dissociation for 300 seconds on a Biacore 3000 at 25° C. HBS-EP buffer was used for sample dilution, as well as running buffer. Regenration of the chip was done with 3 M MgCl₂ at 30 μL per minute. For data analysis the BIAevaluation software v.4.1 (GE Healthcare) was used. Data were fit globally using a 1:1 Langmuir model with mass transfer. After software-based curve fitting, the ON and OFF reates at each concentration of Binding Protein was calculated and used to obtain a binding affinity for each binding protein.

Conformational Stability and Aggregation Assays

Conformational stability of the trispecific binding proteins was assessed by determining the melting point T_m and aggregation onset temperature (T_agg).

Melting point T_m measurements were performed by differential scanning fluorimetry (DSF). Samples were diluted in D-PBS buffer (Invitrogen) to a final concentration of 0.2 μg/L including a 4× concentration solution of SYPRO-Orange dye (Invitrogen, 5000× stock in DMSO) in D-PBS in white sem-skirt 96-well plates (BIORAD). All measurements were done in duplicate using a MyiQ2 real time PCR instrument (BIORAD). Negative first derivative curves (−d(RFU)/dT) of the melting curves were generated in the iQ5 software v2.1 (BIORAD). Data were then exported into Excel for T_m determination and graphical display.

Melting Point T_m and aggregation onset temperature (T_agg) were also measured by static light scattering (SLS) using a Unit instrument (Unchained Labs). 9 μL of each sample was loaded undiluted into a multicuvette array. The samples were then heated from 20° C. to 95° C. at a heating rate of 0.3° C./minute. The barycentric mean (BCM) of the tryptophan fluorescence spectra was used to measure the protein melting curve, and determine the T_m values. The 266 nm static light scattering (SLS) signal was used to measure the aggregation curve and determine the T_agg. Data analysis was performed using the Unit analysis software v2.1.

Results

A novel strategy was developed for improving neutralizing antibody efficacy against HIV-1, while concomitantly limiting the likelihood of viral breakthrough due to high sequence diversity and/or viral mutation. This strategy involved the generation of trispecific binding proteins comprising four polypeptides that formed three antigen binding sites that specifically bind three different epitopes on the HIV Env glycoprotein (FIG. 1). Each antigen binding site comprised the V_H and V_L domain from a different HIV-1 neutralizing antibody that targeted a distinct epitope on the Env glycoprotein. The trispecific binding proteins contained a first pair of polypeptides that possessed dual variable domains having a cross-over orientation forming two distinct antigen binding sites (called the CODV Ig format), and a second pair of polypeptides, each with a single variable domain that formed a third antigen binding site (FIGS. 1A and 1B).

The first pair of polypeptides (that possessed the dual variable domains) comprised a first polypeptide having the structure V_L2-Linker-V_L1-Linker-Immunoglobulin light chain constant domain, and a second polypeptide having the structure V_H1-Linker-V_H2-Linker-Immunoglobulin C_H1, hinge, C_H2, and C_H3 heavy chain constant domains, resulting in a pair of polypeptides which had a cross over orientation that formed two distinct antigen binding sites: V_H1-V_L1 and V_H2-V_L2 (FIGS. 1C and 1D, see light and heavy chains B). The second pair of polypeptides (that each possessed a single variable domain) comprised a first polypeptide having the structure V_H3-Immunoglobulin C_H1, hinge, C_H2, and C_H3 heavy chain constant domains, and a second polypeptide having the structure V_L3-Immunoglobulin light chain constant domain, resulting in a pair of polypeptides that formed a third antigen binding site: V_H3-V_L3 (FIGS. 1C and 1D, see light and heavy chains A). In addition, the trispecific binding proteins were constructed to include an LS mutation. Furthermore, the trispecific binding proteins were constructed such that within one binding protein, one C_H3 domain included a knob mutation and the other C_H3 domain included a hole mutation to facilitate heterodimerization of the heavy chains (FIG. 1).

Using the above described approach for trivalent binding protein design, three trispecific binding proteins (Binding Proteins 2, 3, and 24) were generated. These trispecific binding proteins were created by grafting onto a trispecific binding protein framework the V_H and V_L domains isolated from antibodies targeting three distinct epitopes on the HIV-1 Env glycoprotein: MPER Ab (targeting the MPER epitope on gp41), CD4BS Ab “b” (targeting the CD4 Binding Site on gp120), and V1/V2 directed Ab “a” (targeting the V1/V2 domain on gp120). Binding Protein 2 was constructed such that the first pair of polypeptides (which formed two antigen binding sites) targeted the HIV-1 Env glycoprotein epitopes MPER and V1/V2, and the second pair of polypeptides (which formed the single antigen binding site) targeted the HIV-1 Env glycoprotein epitope CD4BS (Binding Protein 2=MPER×V1/V2/CD4BS). Binding Protein 3 was constructed such that the first pair of polypeptides (which formed two antigen binding sites) targeted the HIV-1 Env glycoprotein epitopes V1/V2 and MPER, and the second pair of polypeptides (which formed the single antigen binding site) targeted the HIV-1 Env glycoprotein epitope CD4BS (Binding Protein 3=V1/V2×MPER/CD4BS). Binding Protein 24 was constructed such that the first pair of polypeptides (which formed two antigen binding sites) targeted the HIV-1 Env glycoprotein epitopes V1/V2 and CD4BS, and the second pair of polypeptides (which formed the single antigen binding site) targeted the HIV-1 Env glycoprotein epitope MPER (Binding Protein 24=V1/V2×CD4BS/MPER). The three trispecific binding proteins, as well as their parental antibodies, were purified over protein A affinity resin (FIGS. 2A and 3A) followed by size exclusion chromatography (FIGS. 2B and 3B) to obtain monomeric proteins suitable for further characterization. All three trispecific binding proteins were stable and formed monomers at high frequency.

To test the potential for developing binding proteins targeting two different HIV-1 Env protein epitopes (instead of three), bispecific binding proteins were designed based upon the above described CODV Ig format (See WO 2012/135345), using two different V_H and V_L domains from the same parental antibodies used to create the trispecific binding proteins. However, the bispecific binding proteins with these specific variable domains did not purify well as monomers, showing significantly increased aggregate formation when compared to the corresponding trispecific binding proteins (FIGS. 4A and 4B).

Next, the binding affinity of the purified trispecific binding proteins (and their parental antibodies) was measured for the HIV-1 Env glycoprotein epitopes on gp41 and gp120. First, the binding affinity for gp41 was measured for the three trispecific binding proteins, as well as the parental MPER antibody, by Biacore assay using the MPER binding peptide (FIG. 5). The binding affinity for the MPER antibody was calculated to be 18.7 nM. Surprisingly, the three trispecific binding proteins all had a higher affinity for the MPER binding peptide than did the parental antibody (Table 3), with Binding Protein 2 having an approximately 3.1 fold higher affinity than the MPER antibody (6.05 nM vs. 18.7 nM, respectively).

TABLE 3
Affinity measurements for the MPER binding peptide
								MW
				Rmax				MPER
Antibody	Analyte	ka (1/Ms)	kd (1/s)	(RU)	KA (1/M)	KD (M)	Chi2	(kDa)
MPER Ab	Gp41-	5.85E+04	1.09E−03	47.5	5.35E+07	1.87E−08	0.55	5.25
	MPER JPT
Binding	Gp41-	1.15E+05	6.97E−04	29.0	1.65E+08	6.05E−09	0.27	2.29
Protein 2	MPER JPT
Binding	Gp41-	4.67E+04	7.79E−04	38.5	6.00E+07	1.67E−08	0.41	5.14
Protein 3	MPER JPT
Binding	Gp41-	6.28E+04	8.06E−04	35.5	7.80E+07	1.28E−08	0.48	5.24
Protein 24	MPER JPT

Similarly, the binding affinity for the CD4 Binding Site on gp120 was measured for the three trispecific binding proteins, as well as the parental CD4BS antibody, by Biacore assay (FIG. 6). The three trispecific binding proteins all had a similar affinity for the CD4 Binding Site when compared to the parental antibody (Table 4).

TABLE 4
Affinity measurements for the CD4BS binding site
Antibody	ka (1/Ms)	kd (1/s)	Rmax (RU)	KD (M)	Chi2
CD4BS	2.79E+05	2.32E−04	31.4	8.30E−10	1.17
Ab “b”
Binding	2.31E+05	2.41E−04	34.0	1.04E−09	0.74
Protein 2
Binding	7.58E+04	2.75E−04	38.2	3.63E−09	0.19
Protein 3
Binding	1.46E+05	2.52E−04	41.6	1.73E−09	0.38
Protein 24

Thus, the trispecific binding proteins were able to bind both of the tested target epitopes on the HIV-1 Env glycoprotein (Table 5). Moreover, all three trispecific binding proteins bound the target epitopes with affinities approximately equal to or exceeding those of their parental antibodies. Binding affinity of the V1/V2 directed Ab “a”, as well as of the V1/V2 directed Ab “a” binding sites within the three trispecific binding proteins 2, 3, and 24 could not be determined by Biacore analysis because this required a specific gp120 protein antigen which was unavailable.

TABLE 5
Summary of binding capabilities of tested binding proteins
		Binding on
	Sample	gp120?	Binding on gp41?
	MPER Ab	No	Yes
	CD4BS Ab	Yes	No
	“b”
	V1/V2 directed	No	No
	Ab “a”
	Binding	Yes	Yes
	Protein 2
	Binding	Yes	Yes
	Protein 3
	Binding	Yes	Yes
	Protein 24

The biophysical properties were tested for the trispecific binding proteins and parental antibodies (Table 6). All of the tested proteins had similar stabilities and limited propensities to form aggregates.

TABLE 6
Conformational stability/aggregation of the binding proteins
	DSF	Intrinsic AA Fluo	SLS at 266 nm
Sample	Tm (° C.)	Tm (° C.)	Tagg (° C.)
MPER Ab	69/75	68	71
CD4BS Ab	69	66	68
“b”
V1/V2 directed	69	64	67
Ab “a”
Binding	60/70	54	58
Protein 2
Binding	57/70	55	56
Protein 3
Binding	56/71	53	54
Protein 24

These experiments indicated that stable, monomeric, trispecific binding proteins targeting three distinct epitopes on the HIV-1 Env glycoprotein could be constructed and efficiently purified. Furthermore, the trispecific binding proteins retained their ability to bind their target epitopes, having similar or improved affinity relative to their parental antibodies. Finally, the trispecific binding proteins had suitable biophysical properties, and showed significantly less aggregation than the corresponding bispecific binding proteins.

Example 2: Characterization of the Binding Proteins

Due to the success of developing three trispecific binding proteins with appropriate biophysical properties and binding abilities (as described in Example 1), 21 additional trispecific binding proteins were developed and tested. The experiments described herein explored the ability of the 24 trispecific binding proteins to neutralize HIV-1 in vitro, and the pharmacokinetic properties of a number of these trispecific binding proteins in vivo.

Neutralization assays were performed using the TZM-bl assay which measures neutralization as a function of reductions in HIV-1 Tat-regulated firefly luciferase (Luc) reporter gene expression after a single round of infection with Env-pseudotyped viruses. The assays were performed as described in Marcella Sarzotti-Kelsoe et al., J. Immunological Methods, 409:131-146 (2014). The neutralization results of various antibodies are shown in Tables 8-10.

Methods

Production of Env-Pseudotyped Viruses

Assay stocks of Env-pseudotyped viruses were produced in 293T/17 cells by co-transfection with two plasmids: an Env expression plasmid and a plasmid expressing the entire HIV-1 genome except for Env. Co-transfection of these plasmids produced infectious pseudovirus particles which were capable of delivering the Tat gene into target cells, but infections with these pseudovirions could not themselves produce infectious viral progeny.

Viral Neutralization Assay

Neutralization of HIV infection using TZM-bl cells (also known as JC53BL-13 cells) was performed as described previously (Marcella Sarzotti-Kelsoe et al., J. Immunological Methods, 409:131-146 (2014)). Briefly, a single round of infection using the Env-pseudotyped HIV-1 virions was carried out in TZM-bl cells (a CXCR-4-positivie HeLa cell clone). TZM-bl cells were engineered to express CD4 and CCR5, and to contain integrated reporter genes for firefly luciferase and E. coli β-galactosidase under the control of an HIV long-terminal repeat. Reporter gene expression was induced in trans by viral Tat protein (delivered by the pseudotyped viruses) soon after single cycle infection. Luciferase activity was quantified as relative luminescence units (RLU), and was directly proportional to the number of infectious virus particles present in the initial inoculum over a wide range of values. Neutralization was measured as a function of decreased Tat-regulated Firefly luciferase (Luc) reporter gene expression after administration of varying concentrations of the indicated binding proteins. Neutralization titers were identified as the protein dilution at which RLUs were reduced by 80% compared to virus control wells after subtraction of background RLUs. The assay was performed in 96-well plates for high throughput capacity, and well-characterized reference strains were utilized for uniformity across studies.

Pharmacokinetic (PK) Measurements

Female Indian rhesus macaques weighing between 3 and 6 kg were randomly assigned to groups according to body weight (two macaques per group) and were intravenously injected with the indicated concentration of binding proteins. Blood was collected from the animals before the injection on day 0, and 30 minutes, 6 hours, 1 day, 2 days, 4 days, 7 days, 14 days, 21 days and 28 days after injection. The serum concentration of each binding protein was quantified in the plasma from the collected blood using an RSC3-based ELISA assay.

Results

21 additional trispecific binding proteins targeting three distinct HIV-1 Env glycoprotein epitopes were generated and purified as described in Example 1. These 21 additional trispecific binding proteins (Binding Proteins 1 and 4-23) were created by grafting onto a trispecific binding protein framework the V_H and V_L domains isolated from antibodies targeting distinct HIV-1 epitopes on the HIV-1 Env glycoprotein: the anti-MPER antibodies MPER Ab “a” and MPER Ab “b” (targeting the MPER epitope on gp41), the anti-CD4BS antibodies CD4BSAb “a” and CD4BSAb “b” (targeting the CD4 Binding Site on gp120), the anti-V1/V2 antibodies V1/V2 directedAb “a” and V1/V2 directedAb “b” (targeting the V1/V2 domain on gp120), and the anti-V3 antibody V3 directedAb (targeting the V3 loop on gp120) (Table 7).

TABLE 7
Epitope binding site composition of the trispecific binding proteins
Binding Protein: Epitope Binding Site:
1                MPER × V1/V2 directed/CD4BS
2                MPER × V1/V2 directed/CD4BS
3                V1/V2 directed × MPER/CD4BS
4                MPER × V1/V2 directed/CD4BS
5                MPER × V3 directed/CD4BS
6                V1/V2 directed × MPER/CD4BS
7                V3 directed × V1/V2 directed/CD4BS
8                MPER × V1/V2 directed/CD4BS
9                MPER × V1/V2 directed/CD4BS
10               V1/V2 directed × MPER/CD4BS
11               MPER × V1/V2 directed/CD4BS
12               MPER × V3 directed/CD4BS
13               MPER × V3 directed/V1/V2 directed
14               V1/V2 directed × MPER/CD4BS
15               MPER × V3 directed/V1/V2 directed
16               MPER × V3 directed/CD4BS
17               V1/V2 directed × V3 directed/CD4BS
18               V3 directed × MPER/CD4BS
19               V3 directed × V1/V2 directed/MPER
20               V3 directed × V1/V2 directed/CD4BS
21               MPER × CD4BS/V1/V2 directed
22               CD4BS × MPER/V1/V2 directed
23               CD4BS × V1/V2 directed/MPER
24               V1/V2 directed × CD4BS/MPER

The viral neutralization capabilities of five of the trispecific binding proteins (and their parental antibodies) at varying concentrations were tested against a panel of 208 different HIV-1 Env-pseudotyped viruses (Table 8). Binding protein-mediated neutralization of the pseudotyped HIV-1 isolates was measured using the TZM-bl luciferase reporter gene assay. The inhibitory dose for each binding protein was calculated for each pseudotyped virus as the dilution that caused an 80% reduction in luminescence (IC₈₀) after infection. Surprisingly, the IC₈₀ geometric means calculated for each of the tested trispecific binding proteins was lower than the parental antibodies, suggesting that these trispecific binding proteins were more potent at neutralizing pseudotyped HIV-1 than their parental neutralizing antibodies.

TABLE 8
IC80 measurements from viral neutralization assay
							Parental Antibody:
								V1/V2	V3
	Binding Protein:	MPER	directed Ab	directed	CD4BS	CD4BS
	15	1	2	19	20	3	Ab	“a”	Ab	Ab “b”	Ab “a”
# Viruses	208	208	208	208	208	208	208	208	208	208	208
Total VS
Neutralized:
IC80 <50 μg/mL	190	202	206	198	206	206	203	151	113	202	183
IC80 <10 μg/mL	180	199	206	180	206	206	193	149	109	200	175
IC80 <1.0 μg/mL	166	169	191	145	188	186	61	133	98	184	108
IC80 <0.1 μg/mL	122	109	136	80	144	123	10	99	72	79	10
IC80 <0.01 μg/mL	74	7	70	22	54	47	5	24	26	6	0
% VS
Neutralized:
IC80 <50 μg/mL	91	97	99	95	99	99	98	73	54	97	88
IC80 <10 μg/mL	87	96	99	87	99	99	93	72	52	96	84
IC80 <1.0 μg/mL	80	81	92	70	90	89	29	64	47	88	52
IC80 <0.1 μg/mL	59	52	65	38	69	59	5	48	35	38	5
IC80 <0.01 μg/mL	36	3	34	11	26	23	2	12	13	3	0
Median IC80	0.033	0.088	0.026	0.164	0.029	0.045	1.69	0.037	0.054	0.149	0.780
Geometric Mean	0.033	0.135	0.028	0.199	0.034	0.051	1.34	0.063	0.057	0.144	0.814

Next, the viral neutralization capabilities of a larger panel of trispecific binding proteins (and their parental antibodies) at varying concentrations were tested against 20 pseudotyped viruses representing 10 different HIV-1 clades (Table 9). The trispecific binding proteins provided robust protection against infection with these 20 viruses (Table 10).

TABLE 9
20 representative viruses used for viral neutralization assay
Virus           Clade
KER2008.12.SG3  A
620345.c1.SG3   AE
DJ263.8.SG3     AG
T266-60.SG3     AG
T278-50.SG3     AG
BL01.DG.SG3     B
BR07.DG.SG3     B
CNE57.SG3       B
H086.8.SG3      B
QH0692.42.SG3   B
SS1196.01.SG3   B
CNE21.SG3       BC
6471.V1.C16.SG3 C
CAP210.E8.SG3   C
DU156.12.SG3    C
DU422.01.SG3    C
TV1.29.SG3      C
ZM106.9.SG3     C
3817.v2.c59.SG3 CD
X2088.c9.SG3    G

TABLE 10
IC80 measurements from viral neutralization assay of 20 representative
viruses
		Total VS Neutralized	% VS Neutralized
		IC80	IC80	IC80 <50	IC80	Median	Geometric
	# Viruses	<50 μg/mL	<1 μg/mL	μg/mL	<1 μg/mL	IC80	Mean
Binding Protein 4	20	17	11	85	55	0.474	0.398
Binding Protein 5	20	14	11	70	55	0.199	0.324
Binding Protein 6	20	16	9	80	45	0.453	0.449
Binding Protein 7	20	16	9	80	45	0.523	0.312
Binding Protein 8	20	17	12	85	60	0.578	0.488
Binding Protein 9	20	14	9	70	45	0.836	0.531
Binding Protein 10	20	16	12	80	60	0.222	0.173
Binding Protein 11	20	18	15	90	75	0.310	0.181
Binding Protein 12	20	17	12	85	60	0.526	0.566
Binding Protein 13	20	19	12	95	60	0.202	0.189
Binding Protein 14	20	17	15	85	75	0.208	0.088
Binding Protein 15	20	17	10	85	50	0.345	0.378
Binding Protein 16	20	18	11	90	55	0.228	0.314
Binding Protein 17	20	17	12	85	60	0.086	0.180
Binding Protein 18	20	15	10	75	50	0.536	0.501
Binding Protein 19	20	18	11	90	55	0.563	0.538
Binding Protein 20	20	18	14	90	70	0.224	0.229
Binding Protein 21	20	15	9	75	45	0.627	0.501
Binding Protein 2	20	18	13	90	65	0.375	0.222
Binding Protein 22	20	13	8	65	40	0.856	0.634
Binding Protein 23	20	17	6	85	30	1.930	1.129
Binding Protein 3	20	18	12	90	60	0.469	0.287
Binding Protein 24	20	16	7	80	35	2.130	1.054
MPER Ab “a”	20	16	8	80	40	1.007	0.981
MPER Ab “b”	20	16	16	80	80	0.071	0.024
CD4BS Ab “b”	20	15	9	75	45	0.181	0.399
V1/V2 directed Ab “a”	20	11	9	55	45	0.060	0.094
V3 directed Ab	20	12	10	60	50	0.183	0.136
CD4BS Ab “a”	20	10	1	50	5	1.530	1.811
V1/V2 directed Ab “b”	20	9	9	45	45	0.051	0.039

Finally, the pharmacokinetics (PK) of a subset of the trispecific binding proteins and parental antibodies were tested in rhesus macaques. Briefly, 10 or 20 mg/kg of the proteins were intravenously injected into female rhesus macaques, and ELISA assays were performed on the plasma from blood samples taken prior to injection, and on the plasma from blood samples taken at many time points after the injection (up to 42 days) (FIG. 7). All of the trispecific binding proteins could be detected at least 14 days after IV administration, with Binding Protein 1 remaining detectable at least 35 days after injection, showing that the binding proteins were stable in vivo.

Taken together, this data suggested that broadly neutralizing trispecific binding proteins could be constructed which targeted three distinct epitopes on the HIV-1 Env glycoprotein. These binding proteins showed similar or increased potency/much improved neutralizing capabilities (breadth) relative to the parental neutralizing antibodies. Furthermore, these trispecific binding proteins appeared to be well tolerated in vivo. Without wishing to be bound by theory, the development of broadly neutralizing trispecific binding proteins targeting multiple epitopes on HIV may allow for improved anti-viral therapy relative to monospecific or bispecific antibodies, as HIV viral particles are less likely to be resistant to all three antigen binding sites on the neutralizing trispecific binding proteins than the single or dual antigen binding sites on monospecific or bispecific neutralizing antibodies, respectively.

Example 3: Characterization of T-Cell Engagers

As noted above, Env is expressed on the surface of HIV-infected cells. Because of this, Env can act as an antibody target to identify infected cells, and induce Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Complement Dependent Cytotoxicity (CDC), resulting in reduction of the latent viral reservoir. The studies described herein explore the development of novel trispecific binding proteins (termed “T cell engagers”) that contain three antigen binding sites targeting three different antigens (HIV-1 Env glycoprotein, CD3, and CD28). These novel proteins not only include antigen binding sites from neutralizing antibodies, but also the ability to bind effector T cells, bringing them into close proximity to infected target cells, thus inducing HIV-infected cell lysis.

Methods

Binding Properties of T-Cell Engagers

The binding properties of the T-cell engagers was measured by ELISA assay using a horse radish peroxidase-conjugated anti-Fab probe to detect T-cell engager binding to the surface of ELISA plates coated with CD3, CD28, or Resurfaced Stabilized Core 3 (RSC3) protein of gp120. Human CD3ge-hIgG4 (KIH) (Cat. No: 03-01-0051) from Cambridge Biologics, MA, USA; Human CD28-hIgG4 (Cat. No: 03-01-0303) from Cambridge Biologics, MA, USA.

T-Cell Activation Assay

CD4 and CD8 T cell activation were measured as follows: peripheral blood mononuclear cells (PBMCs) were enriched from buffy coats obtained from naïve donors (NIH blood bank) using magnetic beads (Miltenyi Biotec). These cells were co-cultured for 14-16 hours with either uninfected or HIV-1 infected CEM cells in the presence of increasing concentrations of the binding proteins (0.01-1.0 μg/mL) with brefeldin A. The cells were then stained for surface expression of T-cell markers (CD3, CD4, and CD8) and activation markers (CD25 and CD69), followed by intracellular staining for cytokines (IFN-γ, TNF-α, and IL-2) using fluorescently conjugated antibodies (BD Biosciences, eBiosciences, Biolegend). The number of CD4 and CD8 T cells expressing each cytokine or activation marker was determined by running the samples on an LSRII flow cytometer and analyzing the data with Flowjo software (Treeestar).

CD3 Downregulation

CD3 downregulation after T cell activation by the T-cell engagers was measured by staining activated PBMCs with non-competing mouse anti-human CD3 antibody and quantitated using flow cytometry.

Cytotoxicity Assay

Cytotoxicity of the T-cell engagers to CEM-BaL, ACH2, and J1.1 cells was monitored by flow cytometry as follows: latent cell lines (ACH2, J1.1, OM10) were obtained from the NIH AIDS Reagent Program. The activation of these cells was performed by culturing the cells in the presence or absence of TNF-α (10 ng/mL) for 14-16 hours. Activation was measured by determining the expression of cell surface HIV envelope glycoprotein by flow cytometry using an allophycocyanin-conjugated anti-HIV Env antibody (2G12). The CEM-IIIb, ACH2, J1.1 and OM10 cells were labeled with the membrane dye PKH-26 (Sigma) and used as target cells in a cytotoxicity assay. These labeled target cells were co-cultured for 14-16 hours at an E:T ratio of 10:1 with enriched human T cells as effector cells in the presence of increasing amounts of the binding proteins. The extent of cell lysis in the target cells was determined by staining with a live/dead cell marker (Life technologies) and measuring the number of dead cells in the labeled target cell population by running the samples on an LSRII flow cytometer followed by analysis using Flowjo software (Treestar).

Results

The capacity to develop T cell engagers with antigen binding sites targeting both T cell surface proteins and neutralizing epitopes on HIV-1 was explored. T cell engagers were constructed which contained two antigen binding sites targeting two different T cell surface receptors (CD3 and CD28), and a third antigen binding site targeting the HIV-1 Env glycoprotein (FIGS. 8A and 8B). In addition, the T cell engagers were constructed to include an LS mutation. Furthermore, the T cell engagers were constructed such that within one binding protein, one C_H3 domain included a knob mutation and the other C_H3 domain included a hole mutation to facilitate heterodimerization of the heavy chains (FIGS. 8A and 8B).

Using this approach, two T cell engagers were constructed which targeted both T cell surface proteins and the HIV-1 Env glycoprotein (Binding Protein 32 and CD3×CD28/CD4BS “b” Ab). These two T cell engagers were created by grafting onto a trispecific binding protein framework the V_H and V_L domains isolated from parental antibodies targeting the T cell surface proteins CD3 and CD28, and the anti-HIV-1 antibody CD4BS Ab “b” (targeting the CD4 Binding Site on gp120). Binding Protein 32 was constructed such that the first pair of polypeptides (which formed two antigen binding sites) targeted the T cell surface receptors CD28 and CD3, and the second pair of polypeptides (which formed the single antigen binding site) targeted the HIV-1 antigen CD4BS (Binding Protein 32=CD28×CD3/CD4BS). The CD3×CD28/CD4BS “b” Ab trispecific binding protein was constructed such that the first pair of polypeptides (which formed two antigen binding sites) targeted the T cell surface receptors CD3 and CD28, and the second pair of polypeptides (which formed the single antigen binding site) targeted the HIV-1 antigen CD4BS (Table 11).

TABLE 11
Format of T-cell engagers
		Arm 1	Arm 2	Arm 3
Format	Name of Construct	Antigen	Antigen	Antigen
T cell engagers,	CD3 × CD28/	CD4BS	CD3	CD28
trispecific	CD4BS Ab “b”
T cell engagers,	Binding Protein 32	CD4BS	CD28	CD3
trispecific
Monospecific	CD4BS IgG4	CD4BS	CD4BS	—

The ability of the two T cell engagers to bind to each of their three target antigens was tested by ELISA assay. The T cell engagers were capable of binding both the CD3 and CD28 T cell surface proteins with the CD3 and CD28 antigen binding sites in either orientation in the bispecific arms of the T cell engagers (i.e., CD3×CD28 for CD3×CD28/CD4BS Ab “b” or CD28×CD3 for Binding Protein 32). Both T cell engagers were also capable of binding to gp120 (as measured using the HIV-1 RSC3 protein, a gp120 variant lacking the V1, V2, and V3 variable regions) (FIG. 9).

The effect on T cell activity was next tested for both of the T cell engagers. Incubation of the T cell engagers with monocytes revealed that the T cell engagers induced robust CD8⁺ T cell activation (FIG. 10). Similarly, the T cell engagers were capable of inducing significant CD4⁺ T cell activation on PBMCs alone, or PBMCs incubated with either of the HIV-1 infected T cell lines CEM-NKr cells or CEM-BaL cells (FIG. 11). Additionally, both of the T cell engagers reduced cell surface expression of CD3 on activated T cells (FIG. 12).

Finally, the ability of the T cell engagers to induce lysis of HIV-infected cells was tested. The T cell engagers (and positive and negative control bispecific binding proteins targeting CD3 and an HIV antigen) were incubated with the HIV-1 infected T cell line CEM-BaL cells. Incubation of the T cell engagers with the infected cells induced robust cell lysis over a wide range of concentrations (FIG. 13A). Likewise, incubation of these T cell engagers induced lysis of the latently infected T cell line ACH2 cells (FIG. 13B), as well as J1.1 cells (FIG. 13C). Surprisingly, the T cell engagers showed comparable or better cytotoxic activity against chronic and latent HIV-infected cell lines when compared to the bispecific binding proteins.

Taken together, the novel T cell engagers described herein retained the ability from their parental antibodies to bind their target antigens on the HIV-1 Env glycoprotein gp120 on HIV-infected cells, as well as the cell-surface exposed T cell proteins CD3 and CD28. The T cell engagers induced robust CD4⁺ and CD8⁺ T cell activation, and diminished CD3 surface expression. Finally, these T cell engagers induced significant lysis of HIV-1 infected T cells. Without wishing to be bound by theory, these T cell engagers may provide a novel strategy for anti-viral therapeutics by reducing/eliminating the latent viral reservoir through T cell engagement in HIV/AIDS patients.

While the present disclosure includes various embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent variations that come within the scope of the disclosure. In addition, the section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

Each embodiment herein described may be combined with any other embodiment or embodiments unless clearly indicated to the contrary. In particular, any feature or embodiment indicated as being preferred or advantageous may be combined with any other feature or features or embodiment or embodiments indicated as being preferred or advantageous, unless clearly indicated to the contrary.

All references cited in this application are expressly incorporated by reference herein.

TABLE 1
SEQUENCES
Heavy and light chain SEQ ID NOs for binding proteins 1-53 and
the target antigens to which the binding proteins are directed.
Binding
Protein	SEQ ID NOs	Target
1	4, 3, 1, 2	MPER × V1/V2 directed/CD4BS
2	12, 11, 9, 10	MPER × V1/V2 directed/CD4BS
3	20, 19, 17, 18	V1/V2 directed × MPER/CD4BS
4	28, 27, 25, 26	MPER × V1/V2 directed/CD4BS
5	36, 35, 33, 34	MPER × V3 directed/CD4BS
6	44, 43, 41, 42	V1/V2 directed × MPER/CD4BS
7	52, 51, 49, 50	V3 directed × V1/V2 directed/CD4BS
8	60, 59, 57, 58	MPER × V1/V2 directed/CD4BS
9	68, 67, 65, 66	MPER × V1/V2 directed/CD4BS
10	76, 75, 73, 74	V1/V2 directed × MPER/CD4BS
11	84, 83, 81, 82	MPER × V1/V2 directed/CD4BS
12	92, 91, 89, 90	MPER × V3 directed/CD4BS
13	100, 99, 97, 98	MPER × V3 directed/V1/V2 directed
14	108, 107, 105, 106	V1/V2 directed × MPER/CD4BS
15	116, 115, 113, 114	MPER × V3 directed/V1/V2 directed
16	124, 123, 121, 122	MPER × V3 directed/CD4BS
17	132, 131, 129, 130	V1/V2 directed × V3 directed/CD4BS
18	140, 139, 137, 138	V3 directed × MPER/CD4BS
19	148, 147, 145, 146	V3 directed × V1/V2 directed/MPER
20	156, 155, 153, 154	V3 directed × V1/V2 directed/CD4BS
21	164, 163, 161, 162	MPER × CD4BS/V1/V2 directed
22	172, 171, 169, 170	CD4BS × MPER/V1/V2 directed
23	180, 179, 177, 178	CD4BS × V1/V2 directed/MPER
24	188, 187, 185, 186	V1/V2 directed × CD4BS/MPER
25	196, 195, 193, 194	MPER × V1/V2 directed/CD4BS
26	204, 203, 201, 202	MPER × V1/V2 directed/CD4BS
27	212, 211, 209, 210	MPER × V1/V2 directed/CD4BS
28	220, 219, 217, 218	MPER × V1/V2 directed/CD4BS
29	228, 227, 225, 226	MPER × V1/V2 directed/CD4BS
30	235, 234, 232, 233	MPER × V1/V2 directed/CD4BS
31	243, 242, 240, 241	MPER × V1/V2 directed/CD4BS
32	305, 304, 302, 303	CD28 × CD3/CD4BS
33	313, 312, 310, 311	CD28 × CD3/CD4BS
34	321, 320, 318, 319	CD28 × CD3/V1/V2 directed
35	329, 328, 326, 327	CD28 × CD3/V1/V2 directed
36	337, 336, 334, 335	CD28 × CD3/CD4BS
37	345, 344, 342, 343	CD28 × CD3/CD4BS
38	353, 352, 350, 351	CD4BS × CD3/CD28
39	361, 360, 358, 359	CD4BS × CD3/CD28
40	369, 368, 366, 367	CD3 × CD4BS/CD28
41	377, 376, 374, 375	CD3 × CD4BS/CD28
42	385, 384, 382, 383	CD4BS × CD3/CD28
43	393, 392, 390, 391	CD4BS × CD3/CD28
44	401, 400, 398, 399	CD3 × CD4BS/CD28
45	409, 408, 406, 407	CD3 × CD4BS/CD28
46	417, 416, 414, 415	V1/V2 directed × CD3/CD28
47	425, 424, 422, 423	V1/V2 directed × CD3/CD28
48	433, 432, 430, 431	CD3 × V1/V2 directed/CD28
49	441, 440, 438, 439	CD3 × V1/V2 directed/CD28
50	449, 448, 446, 447	V1/V2 directed × CD3/CD28
51	457, 456, 454, 455	V1/V2 directed × CD3/CD28
52	465, 464, 462, 463	CD3 × V1/V2 directed/CD28
53	473, 472, 470, 471	CD3 × V1/V2 directed/CD28

TABLE 2
Heavy and light chain sequences of binding proteins. CDR sequences are
bolded and italicized.
Binding Protein 1 Amino Acid Sequences
Heavy	Qvqlvqsggqmkkpgesmriscrasgyefi wirlapgkrpewmg	SEQ ID
chain	rvtmtrdvysdtaflelrsltvddtavyfctr	NO: 1
A	wgrgtpvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswn
	sgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve
	pkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedp
	evkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvs
	nkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiave
	wesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvlhealhsh
	ytqkslslspg
Light	Eivltqspgtlslspgetaiisc wyqqrpgqaprlviy gipd	SEQ ID
chain	rfsgsrwgpdynltisnlesgdfgvyyc fgqgtkvqvdikrtvaapsvfif	NO: 2
A	ppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdst
	yslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Evrlvesggglvkpggslrlscsas mtwvrqppgkglewvgr	SEQ ID
chain	dyaesvkgrftisrdntkntlylemnnvrtedtgyyfcar	NO: 3
B	wgqgtlvivssdkthtqvhltqsgpevrkpgtsvkvsckapg
	ntlktydlhwvrsvpgqglqwmgwishegdkkviverfkakvtidwdrstnta
	ylqlsgltsgdtavyy gq
	gtavtvssdkthtastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswns
	galtsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep
	kscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpe
	vkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvs
	nkalpapiektiskakgqprepqvytlppcrdeltknqvslwclvkgfypsdiave
	wesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvlhealhsh
	ytqkslslspg
Light	Dfvltqsphslsvtpgesasisckss lawyvqkpgrspqlliy	SEQ ID
chain	ssrasgvpdrfsgsgsdkdftlkisrvetedvgtyy gqgtkvdik	NO: 4
B	dktht
	aseltqdpavsvalkqtvtltc wyqkkpgqapvllfy
	gipdrfsgsasgnrasltitgaqaedeadyyc fgggtkltvldkth
	trtvaapsvfifppsdeqlksgtasvvclinnfypreakvqwkvdnalqsgnsqes
	vteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 1 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcggccagatgaagaaacccggcgagagcatgc	SEQ ID
chain	ggatcagctgcagagccagcggctacgagttcatcgactgcaccctgaactggatc	NO: 5
A	agactggcccctggcaagcggcctgagtggatgggatggctgaagcctagaggcg
	gagccgtgaactacgccagacctctgcagggcagagtgaccatgacccgggacgt
	gtacagcgataccgccttcctggaactgcggagcctgaccgtggatgataccgccgt
	gtacttctgcacccggggcaagaactgcgactacaactgggacttcgagcactggg
	gcagaggcacccctgtgatcgtgtcaagcgcgtcgaccaagggccccagcgtgttc
	cctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctgcct
	cgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctgac
	cagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctgag
	cagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaacgt
	gaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagagctg
	cgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcccttc
	cgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccg
	aagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttcaatt
	ggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagaggaac
	agtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggactgg
	ctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccccat
	cgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtgcac
	actgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgtgcc
	gtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggccagcc
	cgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttcct
	ggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgttcagct
	gctccgtgctgcacgaggccctgcacagccactacacccagaagtccctgagcctg
	agccccggc
Light	Gagatcgtgctgacacagagccctggcaccctgagcctgtctccaggcgagacag	SEQ ID
chain	ccatcatcagctgccggacaagccagtacggcagcctggcctggtatcagcagag	NO: 6
A	gcctggacaggcccccagactcgtgatctacagcggcagcacaagagccgccgg
	aatccccgatagattcagcggctccagatggggccctgactacaacctgaccatcag
	caacctggaaagcggcgacttcggcgtgtactactgccagcagtacgagacttcgg
	ccagggcaccaaggtgcaggtggacatcaagcgtacggtggccgctcccagcgtg
	ttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcc
	tgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgcc
	ctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactc
	cacctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcac
	aaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaaga
	gcttcaaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 7
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggc
	gaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaaa
	cccatacccaggtgcacctgacacagagcggacccgaagtgcggaagcctggca
	cctctgtgaaggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgc
	actgggtgcgcagcgtgccaggacagggactgcagtggatgggctggatcagcca
	cgagggcgacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcgac
	tgggacagaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcg
	ataccgccgtgtactactgcgccaagggcagcaagcaccggctgagagactacgc
	cctgtacgacgatgacggcgccctgaactgggccgtggatgtggactacctgagca
	acctggaattctggggccagggcacagccgtgaccgtgtcatctgataagacccac
	accgcttccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacc
	tctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggt
	gacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctg
	tcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagca
	gcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaag
	gtggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgc
	ccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaag
	gacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgag
	ccacgaagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtgcataa
	tgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc
	gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggt
	ctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaaggg
	cagccccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgacca
	agaatcaagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgccgt
	ggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgt
	gctggactccgacggctccttcttcctctactcaaaactcaccgtggacaagagcag
	gtggcagcaggggaacgtcttctcatgctccgtgctgcatgaggctctgcacagcca
	ctacacgcagaagagcctctccctgtctccgggt
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcg	SEQ ID
chain	ccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta	NO: 8
B	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggc
	cagcagcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaag
	gacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactg
	tatgcagggcagagagagcccctggacctttggccagggcaccaaggtggacatc
	aaggacaaaacccataccgcatccgaactgactcaggaccctgccgtctctgtggc
	actgaagcagactgtgactattacttgccgaggcgactcactgcggagccactacgc
	ttcctggtatcagaagaaacccggccaggcacctgtgctgctgttctacggaaagaa
	caataggccatctggcatccccgaccgcttttctggcagtgcatcagggaaccgagc
	cagtctgaccattaccggcgcccaggctgaggacgaagccgattactattgcagctc
	ccgggataagagcggctccagactgagcgtgttcggaggaggaactaaactgacc
	gtcctcgataagacccatacccgtacggtggccgctcccagcgtgttcatcttcccac
	ctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaact
	tctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcg
	gcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcc
	tgagcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgc
	ctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccggg
	gcgagtgt
Binding Protein 2 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqts fwfrqapgrglewvgw	SEQ ID
chain	nfgggfrdrvtltrdvyreiaymdirglkpddtavyycar	NO: 9
A	wgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswns
	galtsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep
	kscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpe
	vkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsn
	kalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiavew
	esngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvlhealhshyt
	qkslslspg
Light	yihvtqspsslsvsigdrvtincqts hwyqhkpgrapkllihhtssved	SEQ ID
chain	gvpsrfsgsg fnltisdlqaddiatyyc grgsrlhikrtvaapsvfifpp	NO: 10
A	sdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstysl
	sstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewv	SEQ ID
chain	gritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcar	NO: 11
B	tgkyydfwsgyppgeeyfqdwgqgtlvivssdkthtqvhltqsgpevrk
	pgtsvkvsckapgntlktydlhwvrsvpgqglqwmgwishegdkkviv
	erfkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyalyddd
	galnwavdvdylsnlefwgqgtavtvssdkthtastkgpsvfplapsskst
	sggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvt
	vpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellgg
	psvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhn
	aktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektis
	kakgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewesngq
	pennykttppvldsdgsfflyskltvdksrwqqgnvfscsvlhealhshyt
	qkslslspg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylass	SEQ ID
chain	rasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikd	NO: 12
B	kthtaseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnr
	psgipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldk
	thtrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsq
	esvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 2 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggttccg	NO: 13
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtg
	ttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctg
	cctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctg
	accagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctg
	agcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaa
	cgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagag
	ctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcc
	cttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggaccc
	ccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttca
	attggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagagg
	aacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggac
	tggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccc
	catcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtg
	cacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgt
	gccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattct
	tcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgttc
	agctgctccgtgctgcacgaggccctgcacagccactacacccagaagtccctgag
	cctgagccccggc
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagt	SEQ ID
chain	gaccatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagc	NO: 14
A	acaagcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaaga
	tggcgtgcccagcagattttccggcagcggcttccacaccagcttcaacctgaccat
	cagcgatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttc
	ggcagaggcagcagactgcacatcaagcgtacggtggccgctcccagcgtgttcat
	cttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgct
	gaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctg
	cagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccac
	ctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcacaag
	gtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagctt
	caaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgactgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 15
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggc
	gaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaaa
	cccatacccaggtgcacctgacacagagcggacccgaagtgcggaagcctggca
	cctctgtgaaggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgc
	actgggtgcgcagcgtgccaggacagggactgcagtggatgggctggatcagcca
	cgagggcgacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcgac
	tgggacagaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcg
	ataccgccgtgtactactgcgccaagggcagcaagcaccggctgagagactacgc
	cctgtacgacgatgacggcgccctgaactgggccgtggatgtggactacctgagca
	acctggaattctggggccagggcacagccgtgaccgtgtcatctgataagacccac
	accgcttccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacc
	tctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggt
	gacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctg
	tcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagca
	gcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaag
	gtggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgc
	ccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaag
	gacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgag
	ccacgaagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtgcataa
	tgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc
	gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggt
	ctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaaggg
	cagccccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgacca
	agaatcaagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgccgt
	ggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgt
	gctggactccgacggctccttcttcctctactcaaaactcaccgtggacaagagcag
	gtggcagcaggggaacgtcttctcatgctccgtgctgcatgaggctctgcacagcca
	ctacacgcagaagagcctctccctgtctccgggt
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcg	SEQ ID
chain	ccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta	NO: 16
B	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggc
	cagcagcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaag
	gacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactg
	tatgcagggcagagagagcccctggacctttggccagggcaccaaggtggacatc
	aaggacaaaacccataccgcatccgaactgactcaggaccctgccgtctctgtggc
	actgaagcagactgtgactattacttgccgaggcgactcactgcggagccactacgc
	ttcctggtatcagaagaaacccggccaggcacctgtgctgctgttctacggaaagaa
	caataggccatctggcatccccgaccgcttttctggcagtgcatcagggaaccgagc
	cagtctgaccattaccggcgcccaggctgaggacgaagccgattactattgcagctc
	ccgggataagagcggctccagactgagcgtgttcggaggaggaactaaactgacc
	gtcctcgataagacccatacccgtacggtggccgctcccagcgtgttcatcttcccac
	ctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaact
	tctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcg
	gcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcc
	tgagcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgc
	ctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccggg
	gcgagtgt
Binding Protein 3 Amino Acid Sequences
Heavy	rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwikpqy	SEQ ID
chain	gavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsygdsswalda	NO: 17
A	wgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsg
	altsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk
	scdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpev
	kfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnk
	alpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiavewe
	sngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvlhealhshytq
	kslslspg
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved	SEQ ID
chain	gvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifpp	NO: 18
A	sdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstysl
	sstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwm	SEQ ID
chain	gwishegdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakg	NO: 19
B	skhrlrdyalydddgalnwavdvdylsnlefwgqgtavtvssdkthtevrl
	vesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewvgritg
	pgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcartgky
	ydfwsgyppgeeyfqdwgqgtlvivssdkthtastkgpsvfplapsskst
	sggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvt
	vpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellgg
	psvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhn
	aktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektis
	kakgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewesngq
	pennykttppvldsdgsfflyskltvdksrwqqgnvfscsvlhealhshyt
	qkslslspg
Light	aseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsg	SEQ ID
chain	ipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldkthtd	NO: 20
B	fvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylassr
	asgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikdk
	thtrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsq
	esvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 3 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggttccg	NO: 21
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtg
	ttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctg
	cctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctg
	accagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctg
	agcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaa
	cgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagag
	ctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcc
	cttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggaccc
	ccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttca
	attggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagagg
	aacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggac
	tggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccc
	catcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtg
	cacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgt
	gccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattct
	tcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgttc
	agctgctccgtgctgcacgaggccctgcacagccactacacccagaagtccctgag
	cctgagccccggc
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagt	SEQ ID
chain	gaccatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagc	NO: 22
A	acaagcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaaga
	tggcgtgcccagcagattttccggcagcggcttccacaccagcttcaacctgaccat
	cagcgatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttc
	ggcagaggcagcagactgcacatcaagcgtacggtggccgctcccagcgtgttcat
	cttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgct
	gaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctg
	cagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccac
	ctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcacaag
	gtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagctt
	caaccggggcgagtgt
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctc	SEQ ID
chain	tgtgaaggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctg	NO: 23
B	cactgggtgcgcagcgtgccaggacagggactgcagtggatgggctggat
	cagccacgagggcgacaagaaagtgatcgtggaacggttcaaggccaaag
	tgaccatcgactgggacagaagcaccaacaccgcctacctgcagctgagcg
	gcctgacctctggcgataccgccgtgtactactgcgccaagggcagcaagc
	accggctgagagactacgccctgtacgacgatgacggcgccctgaactgg
	gccgtggatgtggactacctgagcaacctggaattctggggccagggcaca
	gccgtgaccgtgtcatctgacaaaacccataccgaggttagactggtggagt
	caggaggggggcttgtgaagcccggtgggtctctccgcctgagctgttctgc
	ctccggctttgatttcgataacgcctggatgacctgggtcaggcagcctccag
	gtaagggactggagtgggtgggaagaatcacaggtccaggcgagggctgg
	tccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggacaa
	taccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccg
	gatattacttctgtgccagaacaggcaaatactacgacttctggtccggctatc
	cccctggcgaggaatattttcaagactggggtcagggaacccttgttatcgtgt
	cctccgataagacccacaccgcttccaccaagggcccatcggtcttccccct
	ggcaccctcctccaagagcacctctgggggcacagcggccctgggctgcct
	ggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcgc
	cctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactct
	actccctcagcagcgtggtgaccgtgccctccagcagcttgggcacccaga
	cctacatctgcaacgtgaatcacaagcccagcaacaccaaggtggacaaga
	aagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagc
	acctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaag
	gacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacg
	tgagccacgaagaccctgaggtcaagttcaactggtatgttgacggcgtgga
	ggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgt
	accgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaa
	ggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaa
	aaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccct
	gcccccatgccgggatgagctgaccaagaatcaagtcagcctgtggtgcct
	ggtaaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgg
	gcagccggagaacaactacaagaccacgcctcccgtgctggactccgacg
	gctccttcttcctctactcaaaactcaccgtggacaagagcaggtggcagcag
	gggaacgtcttctcatgctccgtgctgcatgaggctctgcacagccactacac
	gcagaagagcctctccctgtctccgggt
Light	gcatccgaactgactcaggaccctgccgtctctgtggcactgaagcagactgtgact	SEQ ID
chain	attacttgccgaggcgactcactgcggagccactacgcttcctggtatcagaagaaa	NO: 24
B	cccggccaggcacctgtgctgctgttctacggaaagaacaataggccatctggcatc
	cccgaccgcttttctggcagtgcatcagggaaccgagccagtctgaccattaccggc
	gcccaggctgaggacgaagccgattactattgcagctcccgggataagagcggctc
	cagactgagcgtgttcggaggaggaactaaactgaccgtcctcgacaaaacccata
	ccgacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagc
	gccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaact
	acctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctgg
	ccagcagcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaa
	ggacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactact
	gtatgcagggcagagagagcccctggacctttggccagggcaccaaggtggacat
	caaggataagacccatacccgtacggtggccgctcccagcgtgttcatcttcccacct
	agcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttc
	tacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggc
	aacagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctg
	agcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgcct
	gcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccgggg
	cgagtgt
Binding Protein 4 Amino Acid Sequences
Heavy	qvqlvqsggqmkkpgesmriscrasgyefidctlnwirlapgkrpewmgwlk	SEQ ID
chain	prggavnyarplqgrvtmtrdvysdtaflelrsltvddtavyfctrgkncdynwdf	NO: 25
A	ehwgrgtpvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswn
	sgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve
	pkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedp
	evkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvs
	nkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiave
	wesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvmhealh
	nhytqkslslspg
Light	Eivltqspgtlslspgetaiiscrtsqygslawyqqrpgqaprlviysgstraagipdr	SEQ ID
chain	fsgsrwgpdynltisnlesgdfgvyycqqyeffgqgtkvqvdikrtvaapsvfifp	NO: 26
A	psdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewv	SEQ ID
chain	gritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfca	NO: 27
B	rtgkyydfwwgyppgeeyfqdwgqgtlvivssdkthtqvhltqsgpevr
	kpgtsvkvsckapgntlktydlhwvrsvpgqglqwmgwishegdkkv
	iverfkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyalyd
	ddgalnwavdvdylsnlefwgqgtavtvssdkthtastkgpsvfplapss
	kstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslss
	vvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapell
	ggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgve
	vhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapie
	ktiskakgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewes
	ngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmheal
	hnhytqkslslspg
Light	dfvliqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlhylas	SEQ ID
chain	srasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdik	NO: 28
B	dkthtaseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygkn
	nrpsgipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvl
	dkthtrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgn
	sqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 4 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcggccagatgaagaaacccggcgagagcatgc	SEQ ID
chain	ggatcagctgcagagccagcggctacgagttcatcgactgcaccctgaactggatc	NO: 29
A	agactggcccctggcaagcggcctgagtggatgggatggctgaagcctagaggcg
	gagccgtgaactacgccagacctctgcagggcagagtgaccatgacccgggacgt
	gtacagcgataccgccttcctggaactgcggagcctgaccgtggatgataccgccgt
	gtacttctgcacccggggcaagaactgcgactacaactgggacttcgagcactggg
	gcagaggcacccctgtgatcgtgtcaagcgcgtcgaccaagggccccagcgtgttc
	cctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctgcct
	cgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctgac
	cagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctgag
	cagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaacgt
	gaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagagctg
	cgacaagacccacacctgtcccccctgtcctgcccccgaactgctgggaggcccttc
	cgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccg
	aagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttcaatt
	ggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagaggaac
	agtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggactgg
	ctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccccat
	cgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtgcac
	actgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgtgcc
	gtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggccagcc
	cgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttcct
	ggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgttcagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgagcctg
	agccccggc
Light	Gagatcgtgctgacacagagccctggcaccctgagcctgtctccaggcgagacag	SEQ ID
chain	ccatcatcagctgccggacaagccagtacggcagcctggcctggtatcagcagag	NO: 30
A	gcctggacaggcccccagactcgtgatctacagcggcagcacaagagccgccgg
	aatccccgatagattcagcggctccagatggggccctgactacaacctgaccatcag
	caacctggaaagcggcgacttcggcgtgtactactgccagcagtacgagttcttcgg
	ccagggcaccaaggtgcaggtggacatcaagcgtacggtggccgctcccagcgtg
	ttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcc
	tgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgcc
	ctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactc
	cacctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcac
	aaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaaga
	gcttcaaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgactgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 31
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtggggctatccccctgg
	cgaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaa
	acccatacccaggtgcacctgacacagagcggacccgaagtgcggaagcctggc
	acctctgtgaaggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctg
	cactgggtgcgcagcgtgccaggacagggactgcagtggatgggctggatcagcc
	acgagggcgacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcga
	ctgggacagaagcaccaacaccgcctacctgcagctgagcggcctgacctctggc
	gataccgccgtgtactactgcgccaagggcagcaagcaccggctgagagactacg
	ccctgtacgacgatgacggcgccctgaactgggccgtggatgtggactacctgagc
	aacctggaattctggggccagggcacagccgtgaccgtgtcatctgataagaccca
	caccgcttccaccaagggcccatcggtcttccccctggcaccctcctccaagagcac
	ctctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccgg
	tgacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggct
	gtcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagc
	agcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaa
	ggtggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtg
	cccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaa
	ggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtga
	gccacgaagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtgcata
	atgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcag
	cgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaagg
	tctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaaggg
	cagccccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgacca
	agaatcaagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgccgt
	ggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgt
	gctggactccgacggctccttcttcctctactcaaaactcaccgtggacaagagcag
	gtggcagcaggggaacgtcttctcatgctccgtgctgcatgaggctctgcacagcca
	ctacacgcagaagagcctctccctgtctccgggt
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcg	SEQ ID
chain	ccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta	NO: 32
B	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggc
	cagcagcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaag
	gacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactg
	tatgcagggcagagagagcccctggacctttggccagggcaccaaggtggacatc
	aaggacaaaacccataccgcatccgaactgactcaggaccctgccgtctctgtggc
	actgaagcagactgtgactattacttgccgaggcgactcactgcggagccactacgc
	ttcctggtatcagaagaaacccggccaggcacctgtgctgctgttctacggaaagaa
	caataggccatctggcatccccgaccgcttttctggcagtgcatcagggaaccgagc
	cagtctgaccattaccggcgcccaggctgaggacgaagccgattactattgcagctc
	ccgggataagagcggctccagactgagcgtgttcggaggaggaactaaactgacc
	gtcctcgataagacccatacccgtacggtggccgctcccagcgtgttcatcttcccac
	ctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaact
	tctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcg
	gcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcc
	tgagcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgc
	ctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccggg
	gcgagtgt
Binding Protein 5 Amino Acid Sequences
Heavy	Qvqlvqsggqmkkpgesmriscrasgyefidctlnwirlapgkrpewmgwlk	SEQ ID
chain	prggavnyarplqgrvtmtrdvysdtaflelrsltvddtavyfctrgkncdynwdf	NO: 33
A	ehwgrgtpvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswns
	galtsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep
	kscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpe
	vkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsn
	kalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiavew
	esngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvmhealhnh
	ytqkslslspg
Light	Eivltqspgtlslspgetaiiscrtsqygslawyqqrpgqaprlviysgstraagipdr	SEQ ID
chain	fsgsrwgpdynltisnlesgdfgvyycqqyeffgqgtkvqvdikrtvaapsvfifp	NO: 34
A	psdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewv	SEQ ID
chain	gritgpgegwsvdyaesykgrftisrdntkntlylemnnvrtedtgyyfcar	NO: 35
B	tgkyydfwwgyppgeeyfqdwgqgtlvivssdkthtqmqlqesgpglv
	kpsetlsltcsvsgasisdsywswirrspgkglewigyvhksgdtnyspsl
	ksrvnlsldtsknqvslslvaataadsgkyycartlhgrriygivafnewfty
	fymdvwgngtqvtvssdkthtastkgpsvfplapsskstsggtaalgclvk
	dyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyic
	nvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkd
	tlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqyns
	tyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqv
	ytlppcrdeltknqvslwclykgfypsdiavewesngqpennykttppvl
	dsdgsfflyskltvdksrwqqgnyfscsvmhealhnhytqkslslspg
Light	Sdisvapgetariscgekslgsravqwyqhragqapsliiynnqdrpsgiperfsg	SEQ ID
chain	spdspfgttatltitsveagdeadyychiwdsrvptkwvfgggttltvldkthtaselt	NO: 36
B	qdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsgipdrf
	sgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldkthtrtvaap
	svfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqds
	kdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 5 Nucleotide Sequences
Heavy	Caggtgcagctggtgcagtctggcggccagatgaagaaacccggcgagagcatg	SEQ ID
chain	cggatcagctgcagagccagcggctacgagttcatcgactgcaccctgaactggat	NO: 37
A	cagactggcccctggcaagcggcctgagtggatgggatggctgaagcctagaggc
	ggagccgtgaactacgccagacctctgcagggcagagtgaccatgacccgggac
	gtgtacagcgataccgccttcctggaactgcggagcctgaccgtggatgataccgcc
	gtgtacttctgcacccggggcaagaactgcgactacaactgggacttcgagcactgg
	ggcagaggcacccctgtgatcgtgtcaagc
	gcgtcgaccaagggccccagcgtgttccctctggcccctagcagcaagagcacatc
	tggcggaacagccgccctgggctgcctcgtgaaggactactttcccgagcccgtga
	ccgtgtcctggaattctggcgccctgaccagcggcgtgcacacctttccagctgtgct
	gcagtccagcggcctgtacagcctgagcagcgtcgtgacagtgcccagcagctctc
	tgggcacccagacctacatctgcaacgtgaaccacaagcccagcaacaccaaggt
	ggacaagaaggtggaacccaagagctgcgacaagacccacacctgtcccccttgt
	cctgcccccgaactgctgggaggcccttccgtgttcctgttccccccaaagcccaag
	gacaccctgatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtc
	ccacgaggaccctgaagtgaagttcaattggtacgtggacggcgtggaagtgcaca
	acgccaagaccaagccaagagaggaacagtacaacagcacctaccgggtggtgtc
	cgtgctgaccgtgctgcaccaggactggctgaacggcaaagagtacaagtgcaag
	gtgtccaacaaggccctgcctgcccccatcgagaaaaccatcagcaaggccaagg
	gccagccccgcgaaccccaggtgtgcacactgcccccaagcagggacgagctga
	ccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctacccctccgatatcg
	ccgtggaatgggagagcaacggccagcccgagaacaactacaagaccacccccc
	ctgtgctggacagcgacggctcattcttcctggtgtccaagctgacagtggacaagtc
	ccggtggcagcagggcaacgtgttcagctgctccgtgatgcacgaggccctgcaca
	accactacacccagaagtccctgagcctgagccccggc
Light	Gagatcgtgctgacacagagccctggcaccctgagcctgtctccaggcgagacag	SEQ ID
chain	ccatcatcagctgccggacaagccagtacggcagcctggcctggtatcagcagag	NO: 38
A	gcctggacaggcccccagactcgtgatctacagcggcagcacaagagccgccgg
	aatccccgatagattcagcggctccagatggggccctgactacaacctgaccatcag
	caacctggaaagcggcgacttcggcgtgtactactgccagcagtacgagttcttcgg
	ccagggcaccaaggtgcaggtggacatcaagcgtacggtggccgctcccagcgtg
	ttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcc
	tgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgcc
	ctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactc
	cacctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcac
	aaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaaga
	gcttcaaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgactgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 39
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtggggctatccccctgg
	cgaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaa
	acccatacccagatgcagctgcaggagagcggccctggactcgtgaagcccagcg
	agaccctgagcctgacatgcagcgtgagcggcgccagcatcagcgacagctactg
	gagctggatcaggaggagccctggcaagggcctggagtggatcggctacgtgcac
	aagagcggcgacaccaactacagcccctccctgaagtccagggtgaacctgtccct
	ggacaccagcaagaaccaggtgagcctgtccctggtggctgccacagctgctgac
	agcggcaagtactactgtgccaggaccctgcacggcaggaggatctacggcatcgt
	ggccttcaacgagtggttcacctacttctacatggacgtgtggggcaacggcaccca
	ggtgaccgtgagctccgataagacccacaccgcttccaccaagggcccatcggtctt
	ccccctggcaccctcctccaagagcacctctgggggcacagcggccctgggctgc
	ctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcgccct
	gaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactctactccctc
	agcagcgtggtgaccgtgccctccagcagcttgggcacccagacctacatctgcaa
	cgtgaatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatctt
	gtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggacc
	gtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccct
	gaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaa
	ctggtatgttgacggcgtggaggtgcataatgccaagacaaagccgcgggaggag
	cagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactg
	gctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagccccca
	tcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacac
	cctgcccccatgccgggatgagctgaccaagaatcaagtcagcctgtggtgcctggt
	aaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccg
	gagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctct
	actcaaaactcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgc
	tccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctc
	cgggt
Light	tccgacatcagcgtggcccccggagagacagccaggatctcctgcggcgagaaga	SEQ ID
chain	gcctgggaagcagggctgtgcagtggtaccaacacagggccggacaggctccca	NO: 40
B	gcctgatcatctacaacaaccaggacaggcccagcggcatccctgagaggttcagc
	ggaagccccgacagccccttcggaaccacagccaccctgaccatcacaagcgtgg
	aagccggcgacgaggccgactactactgccacatctgggacagcagggtgcccac
	caagtgggtgtttggcggcggcaccaccctgaccgtgctggacaaaacccataccg
	catccgaactgactcaggaccctgccgtctctgtggcactgaagcagactgtgactat
	tacttgccgaggcgactcactgcggagccactacgcttcctggtatcagaagaaacc
	cggccaggcacctgtgctgctgttctacggaaagaacaataggccatctggcatccc
	cgaccgcttttctggcagtgcatcagggaaccgagccagtctgaccattaccggcgc
	ccaggctgaggacgaagccgattactattgcagctcccgggataagagcggctcca
	gactgagcgtgttcggaggaggaactaaactgaccgtcctcgataagacccatacc
	cgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagctgaag
	tccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggccaaa
	gtgcagtggaaggtggacaacgccctgcagagcggcaacagccaggaaagcgtg
	accgagcaggacagcaaggactccacctacagcctgagcagcaccctgacactga
	gcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccagg
	gcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 6 Amino Acid Sequences
Heavy	Qvqlvqsggqmkkpgesmriscrasgyefidctlnwirlapgkrpewmgwlk	SEQ ID
chain	prggavnyarplqgrvtmtrdvysdtafleirsltvddtavyfctrgkncdynwdf	NO: 41
A	ehwgrgtpvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswns
	galtsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep
	kscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpe
	vkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsn
	kalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiavew
	esngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvmhealhnh
	ytqkslslspg
Light	Eivltqspgtlslspgetaiiscrtsqygslawyqqrpgqaprlviysgstraagipdr	SEQ ID
chain	fsgsrwgpdynltisnlesgdfgvyycqqyeffgqgtkvqvdikrtvaapsvfifp	NO: 42
A	psdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwm	SEQ ID
chain	gwishegdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakg	NO: 43
B	skhrlrdyalydddgalnwavdvdylsnlefwgqgtavtvssdkthtevrl
	vesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewvgritg
	pgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcartgky
	ydfwwgyppgeeyfqdwgqgtlvivssdkthtastkgpsvfplapsskst
	sggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvt
	vpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellgg
	psvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhn
	aktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektis
	kakgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewesngq
	pennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhy
	tqkslslspg
Light	Aseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrps	SEQ ID
chain	gipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldktht	NO: 44
B	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylass
	rasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikd
	kthtrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgns
	qesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 6 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcggccagatgaagaaacccggcgagagcatgc	SEQ ID
chain	ggatcagctgcagagccagcggctacgagttcatcgactgcaccctgaactggatc	NO: 45
A	agactggcccctggcaagcggcctgagtggatgggatggctgaagcctagaggcg
	gagccgtgaactacgccagacctctgcagggcagagtgaccatgacccgggacgt
	gtacagcgataccgccttcctggaactgcggagcctgaccgtggatgataccgccgt
	gtacttctgcacccggggcaagaactgcgactacaactgggacttcgagcactggg
	gcagaggcacccctgtgatcgtgtcaagcgcgtcgaccaagggccccagcgtgttc
	cctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctgcct
	cgtgaaggactactacccgagcccgtgaccgtgtcctggaattctggcgccctgac
	cagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctgag
	cagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaacgt
	gaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagagctg
	cgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcccttc
	cgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccg
	aagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttcaatt
	ggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagaggaac
	agtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggactgg
	ctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccccat
	cgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtgcac
	actgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgtgcc
	gtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggccagcc
	cgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttcct
	ggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgttcagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgagcctg
	agccccggc
Light	gagatcgtgctgacacagagccctggcaccctgagcctgtctccaggcgagacag	SEQ ID
chain	ccatcatcagctgccggacaagccagtacggcagcctggcctggtatcagcagag	NO: 46
A	gcctggacaggcccccagactcgtgatctacagcggcagcacaagagccgccgg
	aatccccgatagattcagcggctccagatggggccctgactacaacctgaccatcag
	caacctggaaagcggcgacttcggcgtgtactactgccagcagtacgagttcttcgg
	ccagggcaccaaggtgcaggtggacatcaagcgtacggtggccgctcccagcgtg
	ttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcc
	tgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgcc
	ctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactc
	cacctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcac
	aaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaaga
	gcttcaaccggggcgagtgt
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctctgtga	SEQ ID
chain	aggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgcactgggtg	NO: 47
B	cgcagcgtgccaggacagggactgcagtggatgggctggatcagccacgagggc
	gacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcgactgggaca
	gaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcgataccgc
	cgtgtactactgcgccaagggcagcaagcaccggctgagagactacgccctgtac
	gacgatgacggcgccctgaactgggccgtggatgtggactacctgagcaacctgg
	aattctggggccagggcacagccgtgaccgtgtcatctgacaaaacccataccgag
	gttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccgcct
	gagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggcag
	cctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagggct
	ggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggacaata
	ccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggatatta
	cttctgtgccagaacaggcaaatactacgacttctggtggggctatccccctggcga
	ggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgataagaccc
	acaccgcttccaccaagggcccatcggtcttccccctggcaccctcctccaagagca
	cctctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccg
	gtgacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggc
	tgtcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagc
	agcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaa
	ggtggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtg
	cccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaa
	ggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtga
	gccacgaagaccctgaggtcaaghcaactggtatgttgacggcgtggaggtgcata
	atgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcag
	cgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaagg
	tctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaaggg
	cagccccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgacca
	agaatcaagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgccgt
	ggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgt
	gctggactccgacggctccttcttcctctactcaaaactcaccgtggacaagagcag
	gtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaacca
	ctacacgcagaagagcctctccctgtctccgggt
Light	Gcatccgaactgactcaggaccctgccgtctctgtggcactgaagcagact	SEQ ID
chain	gtgactattacttgccgaggcgactcactgcggagccactacgcttcctggta	NO: 48
B	tcagaagaaacccggccaggcacctgtgctgctgttctacggaaagaacaat
	aggccatctggcatccccgaccgcttttctggcagtgcatcagggaaccgag
	ccagtctgaccattaccggcgcccaggctgaggacgaagccgattactattg
	cagctcccgggataagagcggctccagactgagcgtgttcggaggaggaa
	ctaaactgaccgtcctcgacaaaacccataccgacttcgtgctgacccagag
	ccctcacagcctgagcgtgacacctggcgagagcgccagcatcagctgca
	agagcagccactccctgatccacggcgaccggaacaactacctggcttggt
	acgtgcagaagcccggcagatccccccagctgctgatctacctggccagca
	gcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaag
	gacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctac
	tactgtatgcagggcagagagagcccctggacctttggccagggcaccaag
	gtggacatcaaggataagacccatacccgtacggtggccgctcccagcgtg
	ttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgt
	gtgcctgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggt
	ggacaacgccctgcagagcggcaacagccaggaaagcgtgaccgagcag
	gacagcaaggactccacctacagcctgagcagcaccctgacactgagcaa
	ggccgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccagg
	gcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 7 Amino Acid Sequences
Heavy	Qvqlvqsggqmkkpgesmriscrasgyefidctlnwirlapgkrpewmgwlk	SEQ ID
chain	prggavnyarplqgrvtmtrdvysdtaflelrsltvddtavyfctrgkncdynwdf	NO: 49
A	ehwgrgtpvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswns
	galtsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep
	kscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpe
	vkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsn
	kalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiavew
	esngqpennykttppvldsdgsfflvskitvdksrwqqgnvfscsvmhealhnh
	ytqkslslspg
Light	Eivltqspgtlslspgetaiiscrtsqygslawyqqrpgqaprlviysgstraagipdr	SEQ ID
chain	fsgsrwgpdynltisnlesgdfgvyycqgyeffgqgtkvqvdikrtvaapsvfifp	NO: 50
A	psdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	qmqlqesgpglvkpsetlsltcsvsgasisdsywswirrspgkglewigy	SEQ ID
chain	vhksgdtnyspslksrvnlsldtsknqvslslvaataadsgkyycartlhgrr	NO: 51
B	iygivafnewftyfymdvwgngtqvtvssdkthtQvhltqsgpevrkpg
	tsvkvsckapgntlktydlhwvrsvpgqglqwmgwishegdkkviver
	fkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyalydddga
	lnwavdvdylsnlefwgqgtavtvssdkthtastkgpsvfplapsskstsg
	gtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvp
	ssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggps
	vflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhna
	ktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektisk
	akgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewesngqp
	ennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhyt
	qkslslspg
Light	Dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylas	SEQ ID
chain	srasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdik	NO: 52
B	dkthtsdisvapgetariscgekslgsravqwyqhragqapsliiynnqdrpsgip
	erfsgspdspfgttatltitsveagdeadyychiwdsrvptkwvfgggaltvldkth
	trtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqes
	vteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 7 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcggccagatgaagaaacccggcgagagcatgc	SEQ ID
chain	ggatcagctgcagagccagcggctacgagttcatcgactgcaccctgaactggatc	NO: 53
A	agactggcccctggcaagcggcctgagtggatgggatggctgaagcctagaggcg
	gagccgtgaactacgccagacctctgcagggcagagtgaccatgacccgggacgt
	gtacagcgataccgccttcctggaactgcggagcctgaccgtggatgataccgccgt
	gtacttctgcacccggggcaagaactgcgactacaactgggacttcgagcactggg
	gcagaggcacccctgtgatcgtgtcaagcgcgtcgaccaagggccccagcgtgttc
	cctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctgcct
	cgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctgac
	cagcggcgtgcacacccttccagctgtgctgcagtccagcggcctgtacagcctgag
	cagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaacgt
	gaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagagctg
	cgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcccttc
	cgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccg
	aagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttcaatt
	ggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagaggaac
	agtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggactgg
	ctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccccat
	cgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtgcac
	actgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgtgcc
	gtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggccagcc
	cgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttcct
	ggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgttcagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgagcctg
	agccccggc
Light	gagatcgtgctgacacagagccctggcaccctgagcctgtctccaggcgagacag	SEQ ID
chain	ccatcatcagctgccggacaagccagtacggcagcctggcctggtatcagcagag	NO: 54
A	gcctggacaggcccccagactcgtgatctacagcggcagcacaagagccgccgg
	aatccccgatagattcagcggctccagatggggccctgactacaacctgaccatcag
	caacctggaaagcggcgacttcggcgtgtactactgccagcagtacgagttcttcgg
	ccagggcaccaaggtgcaggtggacatcaagcgtacggtggccgctcccagcgtg
	ttcatcacccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcc
	tgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgcc
	ctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactc
	cacctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcac
	aaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaaga
	gcttcaaccggggcgagtgt
Heavy	cagatgcagctgcaggagagcggccctggactcgtgaagcccagcgagaccctg	SEQ ID
chain	agcctgacatgcagcgtgagcggcgccagcatcagcgacagctactggagctgga	NO: 55
B	tcaggaggagccctggcaagggcctggagtggatcggctacgtgcacaagagcg
	gcgacaccaactacagcccctccctgaagtccagggtgaacctgtccctggacacc
	agcaagaaccaggtgagcctgtccctggtggctgccacagctgctgacagcggca
	agtactactgtgccaggaccctgcacggcaggaggatctacggcatcgtggccttca
	acgagtggttcacctacttctacatggacgtgtggggcaacggcacccaggtgacc
	gtgagctccgacaaaacccatacccaggtgcacctgacacagagcggacccgaag
	tgcggaagcctggcacctctgtgaaggtgtcctgcaaggcccctggcaacaccctg
	aaaacctacgacctgcactgggtgcgcagcgtgccaggacagggactgcagtgga
	tgggctggatcagccacgagggcgacaagaaagtgatcgtggaacggttcaaggc
	caaagtgaccatcgactgggacagaagcaccaacaccgcctacctgcagctgagc
	ggcctgacctctggcgataccgccgtgtactactgcgccaagggcagcaagcacc
	ggctgagagactacgccctgtacgacgatgacggcgccctgaactgggccgtgga
	tgtggactacctgagcaacctggaattctggggccagggcacagccgtgaccgtgt
	catctgataagacccacaccgcttccaccaagggcccatcggtcttccccctggcac
	cctcctccaagagcacctctgggggcacagcggccctgggctgcctggtcaagga
	ctacttccccgaaccggtgacggtgtcgtggaactcaggcgccctgaccagcggcg
	tgcacaccttcccggctgtcctacagtcctcaggactctactccctcagcagcgtggt
	gaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtgaatcaca
	agcccagcaacaccaaggtggacaagaaagttgagcccaaatcttgtgacaaaact
	cacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctc
	ttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgc
	gtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtatgttgac
	ggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagc
	acgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaag
	gagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccat
	ctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatgc
	cgggatgagctgaccaagaatcaagtcagcctgtggtgcctggtaaaaggcttctat
	cccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactac
	aagaccacgcctcccgtgctggactccgacggctccttcttcctctactcaaaactca
	ccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcat
	gaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggt
Light	Gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgag	SEQ ID
chain	agcgccagcatcagctgcaagagcagccactccctgatccacggcgaccg	NO: 56
B	gaacaactacctggcttggtacgtgcagaagcccggcagatccccccagct
	gctgatctacctggccagcagcagagccagcggcgtgcccgatagattttct
	ggcagcggcagcgacaaggacttcaccctgaagatcagccgggtggaaac
	cgaggacgtgggcacctactactgtatgcagggcagagagagcccctgga
	cctttggccagggcaccaaggtggacatcaaggacaaaacccatacctccg
	acatcagcgtggcccccggagagacagccaggatctcctgcggcgagaag
	agcctgggaagcagggctgtgcagtggtaccaacacagggccggacagg
	ctcccagcctgatcatctacaacaaccaggacaggcccagcggcatccctg
	agaggttcagcggaagccccgacagccccttcggaaccacagccaccctg
	accatcacaagcgtggaagccggcgacgaggccgactactactgccacatc
	tgggacagcagggtgcccaccaagtgggtgtttggcggcggcaccaccct
	gaccgtgctggataagacccatacccgtacggtggccgctcccagcgtgttc
	atcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgt
	gcctgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtgg
	acaacgccctgcagagcggcaacagccaggaaagcgtgaccgagcagga
	cagcaaggactccacctacagcctgagcagcaccctgacactgagcaagg
	ccgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccagggc
	ctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 8 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwikpq	SEQ ID
chain	ygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsygdsswal	NO: 57
A	dawgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswn
	sgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve
	pkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedp
	evkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvs
	nkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiave
	wesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvlhealhsh
	ytqkslslspg
Light	Yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved	SEQ ID
chain	gvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifpp	NO: 58
A	sdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstysl
	sstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewv	SEQ ID
chain	gritgpgegwsvdyaesykgrftisrdntkntlylemnnvrtedtgyyfcar	NO: 59
B	tgkyydfwwgyppgeeyfqdwgqgtlvivssdkthtqvqlvesgggvv
	qpgtslrlscaasqfrfdgygmhwvrqapgkglewvasishdgikkyha
	ekvwgrftisrdnskntlylqmnslrpedtalyycakdlredeceewwsd
	yydfgkqlpcaksrgglygiadnwgqgtmvtvssdkthtastkgpsvfpl
	apsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssgly
	slssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpa
	pellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvd
	gvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalp
	apiektiskakgqprepqvytlppcrdeltknqvslwclvkgfypsdiave
	wesngqpennykttppvldsdgsfflyskltvdksrwqqgnyfscsvmh
	ealhnhytqkslslspg
Light	Qsvltqppsvsaapgqkvtiscsgntsnignnfvswyqqrpgrapqlliyetdkr	SEQ ID
chain	psgipdrfsasksgtsgtlaitglqtgdeadyycatwaaslssarvfgtgtkvivldkt	NO: 60
B	htaseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrp
	sgipdrfsgsasgnrasititgaqaedeadyycssrdksgsrlsvfgggtkltvldkt
	htrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqe
	svteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 8 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggaccg	NO: 61
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgt
	accgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgt
	gtactactgcgccagagacagaagctacggcgacagcagctgggctctggatgctt
	ggggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgt
	gttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggct
	gcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccct
	gaccagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcc
	tgagcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgc
	aacgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaag
	agctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggagg
	cccttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggac
	ccccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagt
	tcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagaga
	ggaacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccag
	gactggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctg
	cccccatcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccag
	gtgtgcacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctga
	gctgtgccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaac
	ggccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggc
	tcattcttcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaac
	gtgttcagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtc
	cctgagcctgagccccggcaag
Light	Tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgac	SEQ ID
chain	agagtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcac	NO: 62
A	tggtatcagcacaagcctggcagagcccccaagctgctgatccaccacaca
	agcagcgtggaagatggcgtgcccagcagattttccggcagcggcttccac
	accagcttcaacctgaccatcagcgatctgcaggccgacgacattgccacct
	actattgtcaggtgctgcagttcttcggcagaggcagcagactgcacatcaa
	gcgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcag
	ctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccg
	cgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaac
	agccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcct
	gagcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgt
	acgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagct
	tcaaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 63
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtggggctatccccctgg
	cgaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaa
	acccatacccaggtgcagttggtggagtctgggggaggcgtggtccagcctggga
	cgtccctgagactctcctgtgcagcctctcaattcaggtttgatggttatggcatgcact
	gggtccgccaggccccaggcaaggggctggagtgggtggcatctatatcacatga
	tggaattaaaaagtatcacgcagaaaaagtgtggggccgcttcaccatctccagaga
	caattccaagaacacactgtatctacaaatgaacagcctgcgacctgaggacacgg
	ctctctactactgtgcgaaagatttgcgagaagacgaatgtgaagagtggtggtcgg
	attattacgattttgggaaacaactcccttgcgcaaagtcacgcggcggcttggttgg
	aattgctgataactggggccaagggacaatggtcaccgtctcttcagataagaccca
	caccgcttccaccaagggcccatcggtcttccccctggcaccctcctccaagagca
	cctctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaacc
	ggtgacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccg
	gctgtcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctcca
	gcagcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacacc
	aaggtggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccacc
	gtgcccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacc
	caaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacg
	tgagccacgaagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtg
	cataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtg
	gtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtg
	caaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagcca
	aagggcagccccgagaaccacaggtgtacaccctgcccccatgccgggatgagct
	gaccaagaatcaagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacat
	cgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgc
	ctcccgtgctggactccgacggctccttcttcctctactcaaaactcaccgtggacaa
	gagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgc
	acaaccactacacgcagaagagcctctccctgtctccgggt
Light	Cagtctgtgctgacgcagccgccctcagtgtctgcggccccaggacagaa	SEQ ID
chain	ggtcaccatctcctgctctggaaacacctccaacattggcaataattttgtgtcc	NO: 64
B	tggtatcaacagcgccccggcagagccccccaactcctcatttatgaaactg
	acaagcgaccctcagggattcctgaccgattctctgcttccaagtctggtacgt
	caggcaccctggccatcaccgggctgcagactggggacgaggccgattatt
	actgcgccacatgggctgccagcctgagttccgcgcgtgtcttcggaactgg
	gaccaaggtcatcgtcctggacaaaacccataccgcatccgaactgactcag
	gaccctgccgtctctgtggcactgaagcagactgtgactattacttgccgagg
	cgactcactgcggagccactacgcttcctggtatcagaagaaacccggcca
	ggcacctgtgctgctgttctacggaaagaacaataggccatctggcatcccc
	gaccgcttttctggcagtgcatcagggaaccgagccagtctgaccattaccg
	gcgcccaggctgaggacgaagccgattactattgcagctcccgggataaga
	gcggctccagactgagcgtgttcggaggaggaactaaactgaccgtcctcg
	ataagacccatacccgtacggtggccgctcccagcgtgttcatcttcccacct
	agcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaac
	aacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctg
	cagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggac
	tccacctacagcctgagcagcaccctgacactgagcaaggccgactacgag
	aagcacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagcccc
	gtgaccaagagcttcaaccggggcgagtgt
Binding Protein 9 Amino Acid Sequences
Heavy	Qvqlvqsggqmkkpgesmriscrasgyefidctlnwirlapgkrpewmgwlk	SEQ ID
chain	prggavnyarplqgrvtmtrdvysdtaflelrsltvddtavyfctrgkncdynwdf	NO: 65
A	ehwgrgtpvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswns
	galtsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep
	kscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpe
	vkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsn
	kalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiavew
	esngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvmhealhnh
	ytqkslslspg
Light	Eivltqspgtlslspgetaiiscrtsqygslawyqqrpgqaprlviysgstraagipdr	SEQ ID
chain	fsgsrwgpdynltisnlesgdfgvyycqqyeffgqgtkvqvdikrtvaapsvfifp	NO: 66
A	psdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewv	SEQ ID
chain	gritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcar	NO: 67
B	tgkyydfwwgyppgeeyfqdwgqgtlvivssdkthtqvqlvesgggvv
	qpgtslrlscaasqfrfdgygmhwvrqapgkglewvasishdgikkyha
	ekvwgrftisrdnskntlylqmnslrpedtalyycakdlredeceewwsd
	yydfgkqlpcaksrgglvgiadnwgqgtmvtvssdkthtastkgpsvfpl
	apsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssgly
	slssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpa
	pellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvd
	gvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalp
	apiektiskakgqprepqvytlppcrdeltknqvslwclvkgfypsdiave
	wesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmh
	ealhnhytqkslslspg
Light	qsvltqppsysaapgqkvtiscsgntsnignnfvswyqqrpgrapqlliyetdkrp	SEQ ID
chain	sgipdrfsasksgtsgtlaitglqtgdeadyycatwaaslssarvfgtgtkvivldkth	NO: 68
B	taseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrps
	gipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldktht
	rtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqes
	vteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 9 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcggccagatgaagaaacccggcgagagcatgc	SEQ ID
chain	ggatcagctgcagagccagcggctacgagttcatcgactgcaccctgaactggatc	NO: 69
A	agactggcccctggcaagcggcctgagtggatgggatggctgaagcctagaggcg
	gagccgtgaactacgccagacctctgcagggcagagtgaccatgacccgggacgt
	gtacagcgataccgccttcctggaactgcggagcctgaccgtggatgataccgccgt
	gtacttctgcacccggggcaagaactgcgactacaactgggacttcgagcactggg
	gcagaggcacccctgtgatcgtgtcaagcgcgtcgaccaagggccccagcgtgttc
	cctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctgcct
	cgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctgac
	cagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctgag
	cagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaacgt
	gaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagagctg
	cgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcccttc
	cgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccg
	aagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttcaatt
	ggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagaggaac
	agtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggactgg
	ctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccccat
	cgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtgcac
	actgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgtgcc
	gtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggccagcc
	cgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttcct
	ggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgttcagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgagcctg
	agccccggc
Light	gagatcgtgctgacacagagccctggcaccctgagcctgtctccaggcgagacag	SEQ ID
chain	ccatcatcagctgccggacaagccagtacggcagcctggcctggtatcagcagag	NO: 70
A	gcctggacaggcccccagactcgtgatctacagcggcagcacaagagccgccgg
	aatccccgatagattcagcggctccagatggggccctgactacaacctgaccatcag
	caacctggaaagcggcgacttcggcgtgtactactgccagcagtacgagttcttcgg
	ccagggcaccaaggtgcaggtggacatcaagcgtacggtggccgctcccagcgtg
	ttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcc
	tgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgcc
	ctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactc
	cacctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcac
	aaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaaga
	gcttcaaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 71
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtggggctatccccctgg
	cgaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaa
	acccatacccaggtgcagttggtggagtctgggggaggcgtggtccagcctggga
	cgtccctgagactctcctgtgcagcctctcaattcaggtttgatggttatggcatgcact
	gggtccgccaggccccaggcaaggggctggagtgggtggcatctatatcacatgat
	ggaattaaaaagtatcacgcagaaaaagtgtggggccgcttcaccatctccagagac
	aattccaagaacacactgtatctacaaatgaacagcctgcgacctgaggacacggct
	ctctactactgtgcgaaagatttgcgagaagacgaatgtgaagagtggtggtcggatt
	attacgattttgggaaacaactcccttgcgcaaagtcacgcggcggcttggttggaatt
	gctgataactggggccaagggacaatggtcaccgtctcttcagataagacccacacc
	gcttccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacctct
	gggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggtga
	cggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctgtc
	ctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagcagc
	ttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaaggt
	ggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgccc
	agcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaagga
	caccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagcca
	cgaagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtgcataatgc
	caagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtc
	ctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctc
	caacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcag
	ccccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgaccaaga
	atcaagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgccgtgg
	agtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgct
	ggactccgacggctccttcttcctctactcaaaactcaccgtggacaagagcaggtg
	gcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccacta
	cacgcagaagagcctctccctgtctccgggt
Light	cagtctgtgctgacgcagccgccctcagtgtctgcggccccaggacagaaggtcac	SEQ ID
chain	catctcctgctctggaaacacctccaacattggcaataattttgtgtcctggtatcaaca	NO: 72
B	gcgccccggcagagccccccaactcctcatttatgaaactgacaagcgaccctcag
	ggattcctgaccgattctctgcttccaagtctggtacgtcaggcaccctggccatcacc
	gggctgcagactggggacgaggccgattattactgcgccacatgggctgccagcct
	gagttccgcgcgtgtcttcggaactgggaccaaggtcatcgtcctg
	gacaaaacccataccgcatccgaactgactcaggaccctgccgtctctgtggcactg
	aagcagactgtgactattacttgccgaggcgactcactgcggagccactacgcttcct
	ggtatcagaagaaacccggccaggcacctgtgctgctgttctacggaaagaacaat
	aggccatctggcatccccgaccgcttttctggcagtgcatcagggaaccgagccagt
	ctgaccattaccggcgcccaggctgaggacgaagccgattactattgcagctcccg
	ggataagagcggctccagactgagcgtgttcggaggaggaactaaactgaccgtcc
	tcgataagacccatacccgtacggtggccgctcccagcgtgttcatcttcccacctag
	cgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttcta
	cccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaa
	cagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctgag
	cagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgcctgc
	gaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccggggcg
	agtgt
Binding Protein 10 Amino Acid Sequences
Heavy	Qvqlvqsggqmkkpgesmriscrasgyefidctlnwirlapgkrpewmgwlk	SEQ ID
chain	prggavnyarplqgrvtmtrdvysdtaflelrsltvddtavyfctrgkncdynwdf	NO: 73
A	ehwgrgtpvivssastkgpsvfplapsskstsggtaalgclykdyfpepvtvswns
	galtsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep
	kscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpe
	vkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsn
	kalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiavew
	esngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvmhealhnh
	ytqkslslspg
Light	Eivltqspgtlslspgetaiiscrtsqygslawyqqrpgqaprlviysgstraagipdr	SEQ ID
chain	fsgsrwgpdynltisnlesgdfgvyycqqyeffgqgtkvqvdikrtvaapsvfifp	NO: 74
A	psdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	qvqlvesgggvvqpgtslrlscaasqfrfdgygmhwvrqapgkglewv	SEQ ID
chain	asishdgikkyhaekvwgrftisrdnskntlylqmnslrpedtalyycakd	NO: 75
B	lredeceewwsdyydfgkqlpcaksrgglvgiadnwgqgtmvtvssdk
	thtevrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkgle
	wvgritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyf
	cartgkyydfwwgyppgeeyfqdwgqgtlvivssdkthtastkgpsvfp
	lapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssgl
	yslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcp
	apellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvd
	gvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalp
	apiektiskakgqprepqvytlppcrdeltknqvslwclvkgfypsdiave
	wesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmh
	ealhnhytqkslslspg
Light	aseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsg	SEQ ID
chain	ipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldkthtq	NO: 76
B	svltqppsvsaapgqkvtiscsgntsnignnfvswyqqrpgrapqlliyetdkrps
	gipdrfsasksgtsgtlaitglqtgdeadyycatwaaslssarvfgtgtkvivldktht
	rtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqes
	vteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 10 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcggccagatgaagaaacccggcgagagcatg	SEQ ID
chain	cggatcagctgcagagccagcggctacgagttcatcgactgcaccctgaactggat	NO: 77
A	cagactggcccctggcaagcggcctgagtggatgggatggctgaagcctagaggc
	ggagccgtgaactacgccagacctctgcagggcagagtgaccatgacccgggac
	gtgtacagcgataccgccttcctggaactgcggagcctgaccgtggatgataccgc
	cgtgtacttctgcacccggggcaagaactgcgactacaactgggacttcgagcact
	ggggcagaggcacccctgtgatcgtgtcaagcgcgtcgaccaagggccccagcg
	tgttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggc
	tgcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccc
	tgaccagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagc
	ctgagcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctg
	caacgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaa
	gagctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggag
	gcccttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccgga
	cccccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaag
	ttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagag
	aggaacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccag
	gactggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctg
	cccccatcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccag
	gtgtgcacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctga
	gctgtgccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaac
	ggccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggc
	tcattcttcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaac
	gtgttcagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtc
	cctgagcctgagccccggc
Light	gagatcgtgctgacacagagccctggcaccctgagcctgtctccaggcgagacag	SEQ ID
chain	ccatcatcagctgccggacaagccagtacggcagcctggcctggtatcagcagag	NO: 78
A	gcctggacaggcccccagactcgtgatctacagcggcagcacaagagccgccgg
	aatccccgatagattcagcggctccagatggggccctgactacaacctgaccatca
	gcaacctggaaagcggcgacttcggcgtgtactactgccagcagtacgagttcttcg
	gccagggcaccaaggtgcaggtggacatcaagcgtacggtggccgctcccagcg
	tgttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtg
	cctgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaac
	gccctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaagga
	ctccacctacagcctgagcagcaccctgacactgagcaaggccgactacgagaag
	cacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgacca
	agagcttcaaccggggcgagtgt
Heavy	caggtgcagttggtggagtctgggggaggcgtggtccagcctgggacgtccctga	SEQ ID
chain	gactctcctgtgcagcctctcaattcaggtttgatggttatggcatgcactgggtccgc	NO: 79
B	caggccccaggcaaggggctggagtgggtggcatctatatcacatgatggaattaa
	aaagtatcacgcagaaaaagtgtggggccgcttcaccatctccagagacaattccaa
	gaacacactgtatctacaaatgaacagcctgcgacctgaggacacggctctctacta
	ctgtgcgaaagatttgcgagaagacgaatgtgaagagtggtggtcggattattacga
	ttttgggaaacaactcccttgcgcaaagtcacgcggcggcttggttggaattgctgat
	aactggggccaagggacaatggtcaccgtctcttcagacaaaacccataccgaggt
	tagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccgcctga
	gctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggcagcct
	ccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagggctgg
	tccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggacaatacc
	aagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggatattact
	tctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggcgagg
	aatattttcaagactggggtcagggaacccttgttatcgtgtcctccgataagacccac
	accgcttccaccaagggcccatcggtcttccccctggcaccctcctccaagagcac
	ctctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccg
	gtgacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccgg
	ctgtcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccag
	cagcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacacca
	aggtggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgt
	gcccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaaccca
	aggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtg
	agccacgaagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtgca
	taatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtc
	agcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaa
	ggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaag
	ggcagccccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgac
	caagaatcaagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgc
	cgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcc
	cgtgctggactccgacggctccttcttcctctactcaaaactcaccgtggacaagagc
	aggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaac
	cactacacgcagaagagcctctccctgtctccgggt
Light	gcatccgaactgactcaggaccctgccgtctctgtggcactgaagcagactg	SEQ ID
chain	tgactattacttgccgaggcgactcactgcggagccactacgcttcctggtat	NO: 80
B	cagaagaaacccggccaggcacctgtgctgctgttctacggaaagaacaat
	aggccatctggcatccccgaccgcttttctggcagtgcatcagggaaccgag
	ccagtctgaccattaccggcgcccaggctgaggacgaagccgattactattg
	cagctcccgggataagagcggctccagactgagcgtgttcggaggaggaa
	ctaaactgaccgtcctcgacaaaacccatacc
	cagtctgtgctgacgcagccgccctcagtgtctgcggccccaggacagaag
	gtcaccatctcctgctctggaaacacctccaacattggcaataattttgtgtcct
	ggtatcaacagcgccccggcagagccccccaactcctcatttatgaaactga
	caagcgaccctcagggattcctgaccgattctctgcttccaagtctggtacgtc
	aggcaccctggccatcaccgggctgcagactggggacgaggccgattatta
	ctgcgccacatgggctgccagcctgagttccgcgcgtgtcttcggaactggg
	accaaggtcatcgtcctg
	gataagacccatacccgtacggtggccgctcccagcgtgttcatcttcccacc
	tagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaac
	aacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctg
	cagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggac
	tccacctacagcctgagcagcaccctgacactgagcaaggccgactacgag
	aagcacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagcccc
	gtgaccaagagcttcaaccggggcgagtgt
Binding Protein 11 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwikpq	SEQ ID
chain	ygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsygdsswal	NO: 81
A	dawgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswn
	sgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve
	pkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedp
	evkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvs
	nkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiave
	wesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvmhealhn
	hytqkslslspg
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved	SEQ ID
chain	gvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifpp	NO: 82
A	sdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstysl
	sstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewvg	SEQ ID
chain	ritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcart	NO: 83
B	gkyydfwwgyppgeeyfqdwgqgtlvivssdkthtqvhltqsgpevrk
	pgtsvkvsckapgntlktydlhwvrsvpgqglqwmgwishegdkkviv
	erfkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyalyddd
	galnwavdvdylsnlefwgqgtavtvssdkthtastkgpsvfplapsskst
	sggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvt
	vpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellgg
	psvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhn
	aktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektis
	kakgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewesngq
	pennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhy
	tqkslslspg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylass	SEQ ID
chain	rasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikd	NO: 84
B	kthtaseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnr
	psgipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldk
	thtrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsq
	esvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 11 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggttccg	NO: 85
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtg
	ttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctg
	cctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctg
	accagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctg
	agcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaa
	cgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagag
	ctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcc
	cttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggaccc
	ccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttca
	attggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagagg
	aacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggac
	tggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccc
	catcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtg
	cacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgt
	gccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattct
	tcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgttc
	agctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgag
	cctgagccccggcaag
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgac	SEQ ID
chain	agagtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcac	NO: 86
A	tggtatcagcacaagcctggcagagcccccaagctgctgatccaccacaca
	agcagcgtggaagatggcgtgcccagcagattttccggcagcggcttccac
	accagcttcaacctgaccatcagcgatctgcaggccgacgacattgccacct
	actattgtcaggtgctgcagttcttcggcagaggcagcagactgcacatcaag
	cgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagc
	tgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgc
	gaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaaca
	gccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctg
	agcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgta
	cgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagctt
	caaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 87
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtggggctatccccctgg
	cgaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaa
	acccatacccaggtgcacctgacacagagcggacccgaagtgcggaagcctggc
	acctctgtgaaggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctg
	cactgggtgcgcagcgtgccaggacagggactgcagtggatgggctggatcagcc
	acgagggcgacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcga
	ctgggacagaagcaccaacaccgcctacctgcagctgagcggcctgacctctggc
	gataccgccgtgtactactgcgccaagggcagcaagcaccggctgagagactacg
	ccctgtacgacgatgacggcgccctgaactgggccgtggatgtggactacctgagc
	aacctggaattctggggccagggcacagccgtgaccgtgtcatctgataagaccca
	caccgcttccaccaagggcccatcggtcttccccctggcaccctcctccaagagcac
	ctctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccgg
	tgacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggct
	gtcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagc
	agcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaa
	ggtggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtg
	cccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaa
	ggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtga
	gccacgaagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtgcata
	atgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcag
	cgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaagg
	tctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaaggg
	cagccccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgacca
	agaatcaagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgccgt
	ggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgt
	gctggactccgacggctccttcttcctctactcaaaactcaccgtggacaagagcag
	gtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaacca
	ctacacgcagaagagcctctccctgtctccgggt
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgag	SEQ ID
chain	agcgccagcatcagctgcaagagcagccactccctgatccacggcgaccg	NO: 88
B	gaacaactacctggcttggtacgtgcagaagcccggcagatccccccagct
	gctgatctacctggccagcagcagagccagcggcgtgcccgatagattttct
	ggcagcggcagcgacaaggacttcaccctgaagatcagccgggtggaaac
	cgaggacgtgggcacctactactgtatgcagggcagagagagcccctgga
	cctttggccagggcaccaaggtggacatcaaggacaaaacccataccgcat
	ccgaactgactcaggaccctgccgtctctgtggcactgaagcagactgtgac
	tattacttgccgaggcgactcactgcggagccactacgcttcctggtatcaga
	agaaacccggccaggcacctgtgctgctgttctacggaaagaacaataggc
	catctggcatccccgaccgcttttctggcagtgcatcagggaaccgagccag
	tctgaccattaccggcgcccaggctgaggacgaagccgattactattgcagc
	tcccgggataagagcggctccagactgagcgtgttcggaggaggaactaaa
	ctgaccgtcctcgataagacccatacccgtacggtggccgctcccagcgtgt
	tcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgt
	gtgcctgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggt
	ggacaacgccctgcagagcggcaacagccaggaaagcgtgaccgagcag
	gacagcaaggactccacctacagcctgagcagcaccctgacactgagcaa
	ggccgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccagg
	gcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 12 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwikpq	SEQ ID
chain	ygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsygdsswal	NO: 89
A	dawgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswn
	sgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve
	pkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedp
	evkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvs
	nkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiave
	wesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvmhealhn
	hytqkslslspg
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved	SEQ ID
chain	gvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifpp	NO: 90
A	sdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstysl
	sstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewvg	SEQ ID
chain	ritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcart	NO: 91
B	gkyydfwwgyppgeeyfqdwgqgftvivssdkthtqmqlqesgpglv
	kpsetlsltcsvsgasisdsywswirrspgkglewigyvhksgdtnyspsl
	ksrvnlsldtsknqvslslvaataadsgkyycartlhgrriygivafnewfty
	fymdvwgngtqvtvssdkthtastkgpsvfplapsskstsggtaalgclvk
	dyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyic
	nvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkd
	tlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqyns
	tyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqv
	ytlppcrdeltknqvslwclvkgfypsdiavewesngqpennykttppvl
	dsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg
Light	sdisvapgetariscgekslgsravqwyqhragqapsliiynnqdrpsgiperfsgs	SEQ ID
chain	pdspfgttatltitsveagdeadyychiwdsrvptkwvfgggttltvldkthtaselt	NO: 92
B	qdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsgipdrf
	sgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldkthtrtvaap
	svfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqds
	kdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 12 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggttccg	NO: 93
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtg
	ttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctg
	cctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctg
	accagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctg
	agcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaa
	cgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagag
	ctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcc
	cttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggaccc
	ccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttca
	attggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagagg
	aacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggac
	tggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccc
	catcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtg
	cacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgt
	gccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattct
	tcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgttc
	agctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgag
	cctgagccccggcaag
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgac	SEQ ID
chain	agagtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcac	NO: 94
A	tggtatcagcacaagcctggcagagcccccaagctgctgatccaccacaca
	agcagcgtggaagatggcgtgcccagcagattttccggcagcggcttccac
	accagcttcaacctgaccatcagcgatctgcaggccgacgacattgccacct
	actattgtcaggtgctgcagttcttcggcagaggcagcagactgcacatcaag
	cgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagc
	tgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgc
	gaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaaca
	gccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctg
	agcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgta
	cgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagctt
	caaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 95
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtggggctatccccctgg
	cgaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaa
	acccatacccagatgcagctgcaggagagcggccctggactcgtgaagcccagcg
	agaccctgagcctgacatgcagcgtgagcggcgccagcatcagcgacagctactg
	gagctggatcaggaggagccctggcaagggcctggagtggatcggctacgtgcac
	aagagcggcgacaccaactacagcccctccctgaagtccagggtgaacctgtccct
	ggacaccagcaagaaccaggtgagcctgtccctggtggctgccacagctgctgac
	agcggcaagtactactgtgccaggaccctgcacggcaggaggatctacggcatcgt
	ggccttcaacgagtggttcacctacttctacatggacgtgtggggcaacggcaccca
	ggtgaccgtgagctccgataagacccacaccgcttccaccaagggcccatcggtctt
	ccccctggcaccctcctccaagagcacctctgggggcacagcggccctgggctgc
	ctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcgccct
	gaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactctactccctc
	agcagcgtggtgaccgtgccctccagcagcttgggcacccagacctacatctgcaa
	cgtgaatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatctt
	gtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggacc
	gtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccct
	gaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaa
	ctggtatgttgacggcgtggaggtgcataatgccaagacaaagccgcgggaggag
	cagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactg
	gctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagccccca
	tcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacac
	cctgcccccatgccgggatgagctgaccaagaatcaagtcagcctgtggtgcctggt
	aaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccg
	gagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctct
	actcaaaactcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgc
	tccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctc
	cgggt
Light	tccgacatcagcgtggcccccggagagacagccaggatctcctgcggcga	SEQ ID
chain	gaagagcctgggaagcagggctgtgcagtggtaccaacacagggccgga	NO: 96
B	caggctcccagcctgatcatctacaacaaccaggacaggcccagcggcatc
	cctgagaggttcagcggaagccccgacagccccttcggaaccacagccac
	cctgaccatcacaagcgtggaagccggcgacgaggccgactactactgcc
	acatctgggacagcagggtgcccaccaagtgggtgtttggcggcggcacca
	ccctgaccgtgctggacaaaacccataccgcatccgaactgactcaggacc
	ctgccgtctctgtggcactgaagcagactgtgactattacttgccgaggcgac
	tcactgcggagccactacgcttcctggtatcagaagaaacccggccaggca
	cctgtgctgctgttctacggaaagaacaataggccatctggcatccccgacc
	gcttttctggcagtgcatcagggaaccgagccagtctgaccattaccggcgc
	ccaggctgaggacgaagccgattactattgcagctcccgggataagagcgg
	ctccagactgagcgtgttcggaggaggaactaaactgaccgtcctcgataag
	acccatacccgtacggtggccgctcccagcgtgttcatcttcccacctagcga
	cgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttct
	acccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagag
	cggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacc
	tacagcctgagcagcaccctgacactgagcaaggccgactacgagaagca
	caaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgac
	caagagcttcaaccggggcgagtgt
Binding Protein 13 Amino Acid Sequences
Heavy	qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwmgwis	SEQ ID
chain	hegdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyal	NO: 97
A	ydddgalnwavdvdylsnlefwgqgtavtvssastkgpsvfplapsskstsggta
	algclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqt
	vicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtl
	misrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreegynstyrvvs
	vltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvctlppsrdelt
	knqvslscavkgfypsdiavewesngqpennykttppvldsdgsfflvskltvdk
	srwqqgnvfscsvmhealhnhytqkslslspg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylas	SEQ ID
chain	srasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikr	NO: 98
A	tvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesv
	teqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewv	SEQ ID
chain	gritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfca	NO: 99
B	rtgkyydfwwgyppgeeyfqdwgqgtlvivssdkthtqmqlqesgpgl
	vkpsetlsltcsvsgasisdsywswirrspgkglewigyvhksgdtnysps
	lksrvnlsldtsknqvslslvaataadsgkyycartlhgrriygivafnewft
	yfymdvwgngtqvtvssdkthtastkgpsvfplapsskstsggtaalgclv
	kdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqty
	icnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkp
	kdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeq
	ynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqpre
	pqvytlppcrdeltknqvslwclvkgfypsdiavewesngqpennyktt
	ppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslsls
	pg
Light	sdisvapgetariscgekslgsravqwyqhragqapsliiynnqdrpsgiperfsg	SEQ ID
chain	spdspfgttatltitsveagdeadyychiwdsrvptkwvfgggttltvldkthtasel	NO: 100
B	tqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsgipdr
	fsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldkthtrtvaa
	psvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqd
	skdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 13 Nucleotide Sequences
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctctgtga	SEQ ID
chain	aggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgcactgggtg	NO: 101
A	cgcagcgtgccaggacagggactgcagtggatgggctggatcagccacgagggc
	gacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcgactgggaca
	gaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcgataccgc
	cgtgtactactgcgccaagggcagcaagcaccggctgagagactacgccctgtac
	gacgatgacggcgccctgaactgggccgtggatgtggactacctgagcaacctgg
	aattctggggccagggcacagccgtgaccgtgtcatctgcttcgaccaagggcccc
	agcgtgttccctctggcccctagcagcaagagcacatctggcggaacagccgccct
	gggctgcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctgg
	cgccctgaccagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgt
	acagcctgagcagcgtcgtgacagtgcccagcagctctctgggcacccagaccta
	catctgcaacgtgaaccacaagcccagcaacaccaaggtggacaagaaggtgga
	acccaagagctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgc
	tgggaggcccttccgtgttcctgttccccccaaagcccaaggacaccctgatgatca
	gccggacccccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctga
	agtgaagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaag
	ccaagagaggaacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgct
	gcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggc
	cctgcctgcccccatcgagaaaaccatcagcaaggccaagggccagccccgcga
	accccaggtgtgcacactgcccccaagcagggacgagctgaccaagaaccaggt
	gtccctgagctgtgccgtgaaaggcttctacccctccgatatcgccgtggaatggga
	gagcaacggccagcccgagaacaactacaagaccaccccccctgtgctggacag
	cgacggctcattcttcctggtgtccaagctgacagtggacaagtcccggtggcagca
	gggcaacgtgttcagctgctccgtgatgcacgaggccctgcacaaccactacaccc
	agaagtccctgagcctgagccccggcaag
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcg	SEQ ID
chain	ccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta	NO: 102
A	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctgg
	ccagcagcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaa
	ggacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactact
	gtatgcagggcagagagagcccctggacctttggccagggcaccaaggtggacat
	caagcgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagct
	gaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggc
	caaagtgcagtggaaggtggacaacgccctgcagagcggcaacagccaggaaa
	gcgtgaccgagcaggacagcaaggactccacctacagcctgagcagcaccctga
	cactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgaccca
	ccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 103
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtggggctatccccctgg
	cgaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaa
	acccatacccagatgcagctgcaggagagcggccctggactcgtgaagcccagc
	gagaccctgagcctgacatgcagcgtgagcggcgccagcatcagcgacagctact
	ggagctggatcaggaggagccctggcaagggcctggagtggatcggctacgtgc
	acaagagcggcgacaccaactacagcccctccctgaagtccagggtgaacctgtc
	cctggacaccagcaagaaccaggtgagcctgtccctggtggctgccacagctgctg
	acagcggcaagtactactgtgccaggaccctgcacggcaggaggatctacggcat
	cgtggccttcaacgagtggttcacctacttctacatggacgtgtggggcaacggcac
	ccaggtgaccgtgagctccgataagacccacaccgcttccaccaagggcccatcg
	gtcttccccctggcaccctcctccaagagcacctctgggggcacagcggccctggg
	ctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcg
	ccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactctact
	ccctcagcagcgtggtgaccgtgccctccagcagcttgggcacccagacctacatc
	tgcaacgtgaatcacaagcccagcaacaccaaggtggacaagaaagttgagccca
	aatcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggg
	gaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccgga
	cccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaa
	gttcaactggtatgttgacggcgtggaggtgcataatgccaagacaaagccgcggg
	aggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccag
	gactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccag
	cccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacagg
	tgtacaccctgcccccatgccgggatgagctgaccaagaatcaagtcagcctgtggt
	gcctggtaaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatggg
	cagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctcctt
	cttcctctactcaaaactcaccgtggacaagagcaggtggcagcaggggaacgtctt
	ctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctc
	cctgtctccgggt
Light	tccgacatcagcgtggcccccggagagacagccaggatctcctgcggcga	SEQ ID
chain	gaagagcctgggaagcagggctgtgcagtggtaccaacacagggccgga	NO: 104
B	caggctcccagcctgatcatctacaacaaccaggacaggcccagcggcatc
	cctgagaggttcagcggaagccccgacagccccttcggaaccacagccac
	cctgaccatcacaagcgtggaagccggcgacgaggccgactactactgcc
	acatctgggttcagcagggtgcccaccaagtgggtgtttggcggcggcacc
	accctgaccgtgctggacaaaacccataccgcatccgaactgactcaggac
	cctgccgtctctgtggcactgaagcagactgtgactattacttgccgaggcga
	ctcactgcggagccactacgcttcctggtatcagaagaaacccggccaggc
	acctgtgctgctgttctacggaaagaacaataggccatctggcatccccgac
	cgcttttctggcagtgcatcagggaaccgagccagtctgaccattaccggcg
	cccaggctgaggacgaagccgattactattgcagctcccgggataagagcg
	gctccagactgagcgtgttcggaggaggaactaaactgaccgtcctcgataa
	gacccatacccgtacggtggccgctcccagcgtgttcatcttcccacctagc
	gacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaact
	tctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcag
	agcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactcca
	cctacagcctgagcagcaccctgacactgagcaaggccgactacgagaag
	cacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtg
	accaagagcttcaaccggggcgagtgt
Binding Protein 14 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwikpq	SEQ ID
chain	ygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsygdsswal	NO: 105
A	dawgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswn
	sgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve
	pkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedp
	evkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckv
	snkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiav
	ewesngqpennykttppvldsdgsfflvskftvdksrwqqgnvfscsvmheal
	hnhytqkslslspg
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved	SEQ ID
chain	gvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifp	NO: 106
A	psdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdsty
	slsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwm	SEQ ID
chain	gwishegdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakg	NO: 107
B	skhrlrdyalydddgalnwavdvdylsnlefwgqgtavtvssdkthtevrl
	vesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewvgritg
	pgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcartgky
	ydfwwgyppgeeyfqdwgqgtlvivssdkthtastkgpsvfplapssks
	tsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvv
	tvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellg
	gpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvev
	hnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiek
	tiskakgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewesn
	gqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealh
	nhytqkslslspg
Light	aseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsg	SEQ ID
chain	ipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldktht	NO: 108
B	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylas
	srasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdik
	dkthtrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsg
	nsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 14 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggttccg	NO: 109
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgt
	accgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgt
	gtactactgcgccagagacagaagctacggcgacagcagctgggctctggatgctt
	ggggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgt
	gttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggct
	gcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccct
	gaccagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcc
	tgagcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgc
	aacgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaag
	agctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggagg
	cccttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggac
	ccccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagt
	tcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagaga
	ggaacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccag
	gactggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctg
	cccccatcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccag
	gtgtgcacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctga
	gctgtgccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaac
	ggccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggc
	tcattcttcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaac
	gtgttcagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtc
	cctgagcctgagccccggcaag
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgac	SEQ ID
chain	agagtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcac	NO: 110
A	tggtatcagcacaagcctggcagagcccccaagctgctgatccaccacaca
	agcagcgtggaagatggcgtgcccagcagattttccggcagcggcttccac
	accagcttcaacctgaccatcagcgatctgcaggccgacgacattgccacct
	actattgtcaggtgctgcagttcttcggcagaggcagcagactgcacatcaa
	gcgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcag
	ctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccg
	cgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaac
	agccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcct
	gagcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgt
	acgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagct
	tcaaccggggcgagtgt
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctctgtga	SEQ ID
chain	aggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgcactgggtg	NO: 111
B	cgcagcgtgccaggacagggactgcagtggatgggctggatcagccacgagggc
	gacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcgactgggaca
	gaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcgataccgc
	cgtgtactactgcgccaagggcagcaagcaccggctgagagactacgccctgtac
	gacgatgacggcgccctgaactgggccgtggatgtggactacctgagcaacctgg
	aattctggggccagggcacagccgtgaccgtgtcatctgacaaaacccataccgag
	gttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccgcct
	gagctgactgcctccggctttgatttcgataacgcctggatgacctgggtcaggcag
	cctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagggc
	tggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggacaat
	accaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggatatt
	acttctgtgccagaacaggcaaatactacgacttctggtggggctatccccctggcg
	aggaatattttaagactggggtcagggaacccttgttatcgtgtcctccgataagac
	ccacaccgcttccaccaagggcccatcggtcttccccctggcaccctcctccaaga
	gcacctctgggggcacagcggccctgggctgcctggtcaaggactacttccccga
	accggtgacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttc
	ccggctgtcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccc
	tccagcagcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaa
	caccaaggtggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcc
	caccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaa
	aacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtg
	gacgtgagccacgaagaccctgaggtcaagttcaactggtatgttgacggcgtgga
	ggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccg
	tgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtaca
	agtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaa
	gccaaagggcagccccgagaaccacaggtgtacaccctgcccccatgccgggat
	gagctgaccaagaatcaagtcagcctgtggtgcctggtaaaaggcttctatcccagc
	gacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagacc
	acgcctcccgtgctggactccgacggctccttcttcctctactcaaaactcaccgtgg
	acaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggct
	ctgcacaaccactacacgcagaagagcctctccctgtctccgggt
Light	gcatccgaactgactcaggaccctgccgtctctgtggcactgaagcagactg	SEQ ID
chain	tgactattacttgccgaggcgactcactgcggagccactacgcttcctggtat	NO: 112
B	cagaagaaacccggccaggcacctgtgctgctgttctacggaaagaacaat
	aggccatctggcatccccgaccgcttttctggcagtgcatcagggaaccgag
	ccagtctgaccattaccggcgcccaggctgaggacgaagccgattactattg
	cagctcccgggataagagcggctccagactgagcgtgttcggaggaggaa
	ctaaactgaccgtcctcgacaaaacccataccgacttcgtgctgacccagag
	ccctcacagcctgagcgtgacacctggcgagagcgccagcatcagctgca
	agagcagccactccctgatccacggcgaccggaacaactacctggcttggt
	acgtgcagaagcccggcagatccccccagctgctgatctacctggccagca
	gcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaag
	gacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcaccta
	ctactgtatgcagggcagagagagcccctggacctttggccagggcaccaa
	ggtggacatcaaggataagacccatacccgtacggtggccgctcccagcgt
	gttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtc
	gtgtgcctgctgaacaacttctacccccgcgaggccaaagtgcagtggaag
	gtggacaacgccctgcagagcggcaacagccaggaaagcgtgaccgagc
	aggacagcaaggactccacctacagcctgagcagcaccctgacactgagc
	aaggccgactacgagaagcacaaggtgtacgcctgcgaagtgacccacca
	gggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 15 Amino Acid Sequences
Heavy	qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwmgwish	SEQ ID
chain	egdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyaly	NO: 113
A	dddgalnwavdvdylsnlefwgqgtavtvssastkgpsvfplapsskstsggtaal
	gclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyi
	cnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmi
	srtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvlt
	vlhqdwlngkeykckvsnkalpapiektiskakgqprepqvctlppsrdeltknq
	vslscavkgfypsdiavewesngqpennykttppvldsdgsfflvskltvdksrw
	qqgnvfscsvmhealhnhytqkslslspg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylass	SEQ ID
chain	rasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikrt	NO: 114
A	vaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvt
	eqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewv	SEQ ID
chain	gritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcar	NO: 115
B	tgkyydfwsgyppgeeyfqdwgqgtlvivssdkthtqmqlqesgpglv
	kpsetlsltcsvsgasisdsywswirrspgkglewigyvhksgdtnyspsl
	ksrvnlsldtsknqvslslvaataadsgkyycartlhgrriygivafnewfty
	fymdvwgngtqvtvssdkthtastkgpsvfplapsskstsggtaalgclvk
	dyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyic
	nvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkd
	tlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqyns
	tyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqv
	ytlppcrdeltknqvslwclvkgfypsdiavewesngqpennykttppvl
	dsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg
Light	sdisvapgetariscgekslgsravqwyqhragqapsliiynnqdrpsgiperfsgs	SEQ ID
chain	pdspfgttatltitsveagdeadyychiwdsrvptkwvfgggttltvldkthtaselt	NO: 116
B	qdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsgipdrf
	sgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldkthtrtvaap
	svfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqds
	kdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 15 Nucleotide Sequences
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctctgtga	SEQ ID
chain	aggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgcactgggtg	NO: 117
A	cgcagcgtgccaggacagggactgcagtggatgggctggatcagccacgagggc
	gacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcgactgggaca
	gaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcgataccgc
	cgtgtactactgcgccaagggcagcaagcaccggctgagagactacgccctgtac
	gacgatgacggcgccctgaactgggccgtggatgtggactacctgagcaacctgg
	aattctggggccagggcacagccgtgaccgtgtcatctgcttcgaccaagggcccc
	agcgtgttccctctggcccctagcagcaagagcacatctggcggaacagccgccct
	gggctgcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggc
	gccctgaccagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtac
	agcctgagcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacat
	ctgcaacgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacc
	caagagctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgg
	gaggcccttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagcc
	ggacccccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtg
	aagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaa
	gagaggaacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcac
	caggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgc
	ctgcccccatcgagaaaaccatcagcaaggccaagggccagccccgcgaacccc
	aggtgtgcacactgcccccaagcagggacgagctgaccaagaaccaggtgtccct
	gagctgtgccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagca
	acggccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacg
	gctcattcttcctggtgtccaagctgacagtggacaagtcccggtggcagcagggca
	acgtgttcagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagt
	ccctgagcctgagccccggcaag
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcg	SEQ ID
chain	ccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta	NO: 118
A	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggc
	cagcagcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaag
	gacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactg
	tatgcagggcagagagagcccctggacctttggccagggcaccaaggtggacatc
	aagcgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagctg
	aagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggcc
	aaagtgcagtggaaggtggacaacgccctgcagagcggcaacagccaggaaagc
	gtgaccgagcaggacagcaaggactccacctacagcctgagcagcaccctgacac
	tgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgacccacca
	gggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 119
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggc
	gaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaaa
	cccatacccagatgcagctgcaggagagcggccctggactcgtgaagcccagcga
	gaccctgagcctgacatgcagcgtgagcggcgccagcatcagcgacagctactgg
	agctggatcaggaggagccctggcaagggcctggagtggatcggctacgtgcaca
	agagcggcgacaccaactacagcccctccctgaagtccagggtgaacctgtccctg
	gacaccagcaagaaccaggtgagcctgtccctggtggctgccacagctgctgaca
	gcggcaagtactactgtgccaggaccctgcacggcaggaggatctacggcatcgtg
	gccttcaacgagtggttcacctacttctacatggacgtgtggggcaacggcacccag
	gtgaccgtgagctccgataagacccacaccgcttccaccaagggcccatcggtcttc
	cccctggcaccctcctccaagagcacctctgggggcacagcggccctgggctgcct
	ggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcgccctga
	ccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactctactccctcag
	cagcgtggtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacg
	tgaatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatcttgt
	gacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggaccgtc
	agtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgag
	gtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactg
	gtatgttgacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcag
	tacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctg
	aatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcga
	gaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctg
	cccccatgccgggatgagctgaccaagaatcaagtcagcctgtggtgcctggtaaa
	aggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggag
	aacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctact
	caaaactcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctcc
	gtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccg
	ggt
Light	tccgacatcagcgtggcccccggagagacagccaggatctcctgcggcga	SEQ ID
chain	gaagagcctgggaagcagggctgtgcagtggtaccaacacagggccgga	NO: 120
B	caggctcccagcctgatcatctacaacaaccaggacaggcccagcggcatc
	cctgagaggttcagcggaagccccgacagccccttcggaaccacagccac
	cctgaccatcacaagcgtggaagccggcgacgaggccgactactactgcc
	acatctgggacagcagggtgcccaccaagtgggtgtttggcggcggcacca
	ccctgaccgtgctggacaaaacccataccgcatccgaactgactcaggacc
	ctgccgtctctgtggcactgaagcagactgtgactattacttgccgaggcgac
	tcactgcggagccactacgcttcctggtatcagaagaaacccggccaggca
	cctgtgctgctgttctacggaaagaacaataggccatctggcatccccgacc
	gcttttctggcagtgcatcagggaaccgagccagtctgaccattaccggcgc
	ccaggctgaggacgaagccgattactattgcagctcccgggataagagcgg
	ctccagactgagcgtgttcggaggaggaactaaactgaccgtcctcgataag
	acccatacccgtacggtggccgctcccagcgtgttcatcttcccacctagcga
	cgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttct
	acccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagag
	cggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacc
	tacagcctgagcagcaccctgacactgagcaaggccgactacgagaagca
	caaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgac
	caagagcttcaaccggggcgagtgt
Binding Protein 16 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwikpq	SEQ ID
chain	ygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsygdsswal	NO: 121
A	dawgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswn
	sgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve
	pkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedp
	evkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvs
	nkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiave
	wesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvmhealhn
	hytqkslslspg
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved	SEQ ID
chain	gvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifpp	NO: 122
A	sdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstysl
	sstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewv	SEQ ID
chain	gritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcar	NO: 123
B	tgkyydfwsgyppgeeyfqdwgqgtlvivssdkthtqmqlqesgpglv
	kpsetlsltcsvsgasisdsywswirrspgkglewigyvhksgdtnyspsl
	ksrvnlsldtsknqvslslvaataadsgkyycartlhgrriygivafnewfty
	fymdvwgngtqvtvssdkthtastkgpsvfplapsskstsggtaalgclvk
	dyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyic
	nvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkd
	tlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqyns
	tyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqv
	ytlppcrdeltknqvslwclvkgfypsdiavewesngqpennykttppvl
	dsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg
Light	sdisvapgetariscgekslgsravqwyqhragqapsliiynnqdrpsgiperfsgs	SEQ ID
chain	pdspfgttatltitsveagdeadyychiwdsrvptkwvfgggttltvldkthtaselt	NO: 124
B	qdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsgipdrf
	sgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldkthtrtvaap
	svfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqds
	kdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 16 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggttccg	NO: 125
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtg
	ttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctg
	cctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctg
	accagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctg
	agcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaa
	cgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagag
	ctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcc
	cttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggaccc
	ccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttca
	attggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagagg
	aacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggac
	tggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccc
	catcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtg
	cacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgt
	gccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattct
	tcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgttc
	agctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgag
	cctgagccccggcaag
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgac	SEQ ID
chain	agagtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcac	NO: 126
A	tggtatcagcacaagcctggcagagcccccaagctgctgatccaccacaca
	agcagcgtggaagatggcgtgcccagcagattttccggcagcggcttccac
	accagcttcaacctgaccatcagcgatctgcaggccgacgacattgccacct
	actattgtcaggtgctgcagttcttcggcagaggcagcagactgcacatcaag
	cgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagc
	tgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgc
	gaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaaca
	gccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctg
	agcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgta
	cgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagctt
	caaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgactgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 127
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggc
	gaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaaa
	cccatacccagatgcagctgcaggagagcggccctggactcgtgaagcccagcga
	gaccctgagcctgacatgcagcgtgagcggcgccagcatcagcgacagctactgg
	agctggatcaggaggagccctggcaagggcctggagtggatcggctacgtgcaca
	agagcggcgacaccaactacagcccctccctgaagtccagggtgaacctgtccctg
	gacaccagcaagaaccaggtgagcctgtccctggtggctgccacagctgctgaca
	gcggcaagtactactgtgccaggaccctgcacggcaggaggatctacggcatcgtg
	gccttcaacgagtggttcacctacttctacatggacgtgtggggcaacggcacccag
	gtgaccgtgagctccgataagacccacaccgcttccaccaagggcccatcggtcttc
	cccctggcaccctcctccaagagcacctctgggggcacagcggccctgggctgcct
	ggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcgccctga
	ccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactctactccctcag
	cagcgtggtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacg
	tgaatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatcttgt
	gacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggaccgtc
	agtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgag
	gtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactg
	gtatgttgacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcag
	tacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctg
	aatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcga
	gaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctg
	cccccatgccgggatgagctgaccaagaatcaagtcagcctgtggtgcctggtaaa
	aggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggag
	aacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctact
	caaaactcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctcc
	gtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccg
	ggt
Light	tccgacatcagcgtggcccccggagagacagccaggatctcctgcggcga	SEQ ID
chain	gaagagcctgggaagcagggctgtgcagtggtaccaacacagggccgga	NO: 128
B	caggctcccagcctgatcatctacaacaaccaggacaggcccagcggcatc
	cctgagaggttcagcggaagccccgacagccccttcggaaccacagccac
	cctgaccatcacaagcgtggaagccggcgacgaggccgactactactgcc
	acatctgggacagcagggtgcccaccaagtgggtgtttggcggcggcacca
	ccctgaccgtgctggacaaaacccataccgcatccgaactgactcaggacc
	ctgccgtctctgtggcactgaagcagactgtgactattacttgccgaggcgac
	tcactgcggagccactacgcttcctggtatcagaagaaacccggccaggca
	cctgtgctgctgttctacggaaagaacaataggccatctggcatccccgacc
	gcttttctggcagtgcatcagggaaccgagccagtctgaccattaccggcgc
	ccaggctgaggacgaagccgattactattgcagctcccgggataagagcgg
	ctccagactgagcgtgttcggaggaggaactaaactgaccgtcctcgataag
	acccatacccgtacggtggccgctcccagcgtgttcatcttcccacctagcga
	cgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttct
	acccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagag
	cggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacc
	tacagcctgagcagcaccctgacactgagcaaggccgactacgagaagca
	caaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgac
	caagagcttcaaccggggcgagtgt
Binding Protein 17 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwikpq	SEQ ID
chain	ygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsygdsswal	NO: 129
A	dawgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswn
	sgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve
	pkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedp
	evkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvs
	nkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiave
	wesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvmhealhn
	hytqkslslspg
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved	SEQ ID
chain	gvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifpp	NO: 130
A	sdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstysl
	sstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	qvhltqsgpevrkpgtsykysckapgntlktydlhwvrsvpgqglqwm	SEQ ID
chain	gwishegdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakg	NO: 131
B	skhrlrdyalydddgalnwavdvdylsnlefwgqgtavtvssdkthtqm
	qlqesgpglykpsetlsltcsvsgasisdsywswirrspgkglewigyvhk
	sgdtnyspslksrvnlsldtsknqvslslvaataadsgkyycartlhgrriygi
	vafnewftyfymdvwgngtqvtvssdkthtastkgpsvfplapsskstsg
	gtaalgclykdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvp
	ssslgtqtyicnynhkpsntkvdkkvepkscdkthtcppcpapellggps
	vflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhna
	ktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektisk
	akgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewesngqp
	ennykttppvldsdgsfflyskltvdksrwqqgnyfscsvmhealhnhyt
	qkslslspg
Light	sdisvapgetariscgekslgsravqwyqhragqapsliiynnqdrpsgiperfsgs	SEQ ID
chain	pdspfgttatltitsveagdeadyychiwdsrvptkwvfgggttltvldkthtdfvlt	NO: 132
B	qsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylassrasg
	vpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikdkthtr
	tvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesv
	teqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 17 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggttccg	NO: 133
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtg
	ttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctg
	cctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctg
	accagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctg
	agcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaa
	cgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagag
	ctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcc
	cttccgtgttcctgaccccccaaagcccaaggacaccctgatgatcagccggaccc
	ccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttca
	attggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagagg
	aacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggac
	tggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccc
	catcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtg
	cacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgt
	gccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattct
	tcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgttc
	agctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgag
	cctgagccccggcaag
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgac	SEQ ID
chain	agagtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcac	NO: 134
A	tggtatcagcacaagcctggcagagcccccaagctgctgatccaccacaca
	agcagcgtggaagatggcgtgcccagcagattttccggcagcggcttccac
	accagcttcaacctgaccatcagcgatctgcaggccgacgacattgccacct
	actattgtcaggtgctgcagttcttcggcagaggcagcagactgcacatcaag
	cgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagc
	tgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgc
	gaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaaca
	gccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctg
	agcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgta
	cgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagctt
	caaccggggcgagtgt
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctctgtga	SEQ ID
chain	aggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgcactgggtg	NO: 135
B	cgcagcgtgccaggacagggactgcagtggatgggctggatcagccacgagggc
	gacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcgactgggaca
	gaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcgataccgc
	cgtgtactactgcgccaagggcagcaagcaccggctgagagactacgccctgtac
	gacgatgacggcgccctgaactgggccgtggatgtggactacctgagcaacctgg
	aattctggggccagggcacagccgtgaccgtgtcatctgacaaaacccatacccag
	atgcagctgcaggagagcggccctggactcgtgaagcccagcgagaccctgagc
	ctgacatgcagcgtgagcggcgccagcatcagcgacagctactggagctggatca
	ggaggagccctggcaagggcctggagtggatcggctacgtgcacaagagcggcg
	acaccaactacagcccctccctgaagtccagggtgaacctgtccctggacaccagc
	aagaaccaggtgagcctgtccctggtggctgccacagctgctgacagcggcaagta
	ctactgtgccaggaccctgcacggcaggaggatctacggcatcgtggccttcaacg
	agtggttcacctacttctacatggacgtgtggggcaacggcacccaggtgaccgtga
	gctccgataagacccacaccgcttccaccaagggcccatcggtcttccccctggcac
	cctcctccaagagcacctctgggggcacagcggccctgggctgcctggtcaagga
	ctacttccccgaaccggtgacggtgtcgtggaactcaggcgccctgaccagcggcg
	tgcacaccttcccggctgtcctacagtcctcaggactctactccctcagcagcgtggt
	gaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtgaatcaca
	agcccagcaacaccaaggtggacaagaaagttgagcccaaatcttgtgacaaaact
	cacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctc
	ttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgc
	gtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtatgttgac
	ggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagc
	acgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaag
	gagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccat
	ctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatgc
	cgggatgagctgaccaagaatcaagtcagcctgtggtgcctggtaaaaggcttctat
	cccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactac
	aagaccacgcctcccgtgctggactccgacggctccttcttcctctactcaaaactca
	ccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcat
	gaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggt
Light	tccgacatcagcgtggcccccggagagacagccaggatctcctgcggcga	SEQ ID
chain	gaagagcctgggaagcagggctgtgcagtggtaccaacacagggccgga	NO: 136
B	caggctcccagcctgatcatctacaacaaccaggacaggcccagcggcatc
	cctgagaggttcagcggaagccccgacagccccttcggaaccacagccac
	cctgaccatcacaagcgtggaagccggcgacgaggccgactactactgcc
	acatctgggacagcagggtgcccaccaagtgggtgtttggcggcggcacca
	ccctgaccgtgctggacaaaacccataccgacttcgtgctgacccagagccc
	tcacagcctgagcgtgacacctggcgagagcgccagcatcagctgcaaga
	gcagccactccctgatccacggcgaccggaacaactacctggcttggtacgt
	gcagaagcccggcagatccccccagctgctgatctacctggccagcagca
	gagccagcggcgtgcccgatagattttctggcagcggcagcgacaaggact
	tcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactact
	gtatgcagggcagagagagcccctggacattggccagggcaccaaggtg
	gacatcaaggataagacccatacccgtacggtggccgctcccagcgtgttca
	tcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtg
	cctgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtgga
	caacgccctgcagagcggcaacagccaggaaagcgtgaccgagcaggac
	agcaaggactccacctacagcctgagcagcaccctgacactgagcaaggc
	cgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccagggcc
	tgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 18 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwikpq	SEQ ID
chain	ygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsygdsswal	NO: 137
A	dawgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswn
	sgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve
	pkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedp
	evkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvs
	nkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiave
	wesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvmhealh
	nhytqkslslspg
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved	SEQ ID
chain	gvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifp	NO: 138
A	psdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	qmqlqesgpglvkpsetlsltcsvsgasisdsywswirrspgkglewigy	SEQ ID
chain	vhksgdtnyspslksrvnlsldtsknqvslslvaataadsgkyycartlhgrr	NO: 139
B	iygivafnewftyfymdvwgngtqvtvssdkthtevrlvesggglvkpg
	gsltlscsasgfdfdnawmtwvrqppgkglewvgritgpgegwsvdya
	esvkgrftisrdntkntlylemnnvrtedtgyyfcartgkyydfwsgyppg
	eeyfqdwgqgtlvivssdkthtastkgpsvfplapsskstsggtaalgclvk
	dyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyic
	nvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkd
	tlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqyn
	styrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepq
	vytlppcrdeltknqvslwclvkgfypsdiavewesngqpennykttpp
	vldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg
Light	aseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsg	SEQ ID
chain	ipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkitvldkthts	NO: 140
B	disvapgetariscgekslgsravqwyqhragqapsliiynnqdrpsgiperfsgs
	pdspfgttatltitsveagdeadyychiwdsrvptkwvfgggttltvldkthtrtvaa
	psvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqd
	skdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 18 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggttccg	NO: 141
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtg
	ttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctg
	cctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctg
	accagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctg
	agcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaa
	cgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagag
	ctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcc
	cttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggaccc
	ccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttca
	attggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagagg
	aacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggac
	tggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccc
	catcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtg
	cacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgt
	gccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattct
	tcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgttc
	agctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgag
	cctgagccccggcaag
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgac	SEQ ID
chain	agagtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcac	NO: 142
A	tggtatcagcacaagcctggcagagcccccaagctgctgatccaccacaca
	agcagcgtggaagatggcgtgcccagcagattttccggcagcggcttccac
	accagcttcaacctgaccatcagcgatctgcaggccgacgacattgccacct
	actattgtcaggtgctgcagttcttcggcagaggcagcagactgcacatcaag
	cgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagc
	tgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgc
	gaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaaca
	gccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctg
	agcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgta
	cgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagctt
	caaccggggcgagtgt
Heavy	cagatgcagctgcaggagagcggccctggactcgtgaagcccagcgagaccctg	SEQ ID
chain	agcctgacatgcagcgtgagcggcgccagcatcagcgacagctactggagctgga	NO: 143
B	tcaggaggagccctggcaagggcctggagtggatcggctacgtgcacaagagcg
	gcgacaccaactacagcccctccctgaagtccagggtgaacctgtccctggacacc
	agcaagaaccaggtgagcctgtccctggtggctgccacagctgctgacagcggca
	agtactactgtgccaggaccctgcacggcaggaggatctacggcatcgtggccttca
	acgagtggttcacctacttctacatggacgtgtggggcaacggcacccaggtgacc
	gtgagctccgacaaaacccataccgaggttagactggtggagtcaggaggggggc
	ttgtgaagcccggtgggtctctccgcctgagctgttctgcctccggctttgatttcgata
	acgcctggatgacctgggtcaggcagcctccaggtaagggactggagtgggtggg
	aagaatcacaggtccaggcgagggctggtccgtggactacgcggaatctgttaaag
	ggcggtttacaatctcaagggacaataccaagaataccttgtataggagatgaacaa
	cgtgagaactgaagacaccggatattacttctgtgccagaacaggcaaatactacga
	cttctggtccggctatccccctggcgaggaatattacaagactggggtcagggaacc
	cttgttatcgtgtcctccgataagacccacaccgcttccaccaagggcccatcggtctt
	ccccctggcaccctcctccaagagcacctctgggggcacagcggccctgggctgc
	ctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcgccct
	gaccagcggcgtgcacaccacccggctgtcctacagtcctcaggactctactccctc
	agcagcgtggtgaccgtgccctccagcagcttgggcacccagacctacatctgcaa
	cgtgaatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatat
	gtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggacc
	gtcagtatcctcttccccccaaaacccaaggacaccctcatgatctcccggacccct
	gaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaa
	ctggtatgagacggcgtggaggtgcataatgccaagacaaagccgcgggaggag
	cagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactg
	gctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagccccca
	tcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacac
	cctgcccccatgccgggatgagctgaccaagaatcaagtcagcctgtggtgcctggt
	aaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccg
	gagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctct
	actcaaaactcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgc
	tccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctc
	cgggt
Light	gcatccgaactgactcaggaccctgccgtctctgtggcactgaagcagactg	SEQ ID
chain	tgactattacttgccgaggcgactcactgcggagccactacgcttcctggtatc	NO: 144
B	agaagaaacccggccaggcacctgtgctgctgttctacggaaagaacaata
	ggccatctggcatccccgaccgcttttctggcagtgcatcagggaaccgagc
	cagtctgaccattaccggcgcccaggctgaggacgaagccgattactattgc
	agctcccgggataagagcggctccagactgagcgtgttcggaggaggaact
	aaactgaccgtcctcgacaaaacccatacctccgacatcagcgtggccccc
	ggagagacagccaggatctcctgcggcgagaagagcctgggaagcaggg
	ctgtgcagtggtaccaacacagggccggacaggctcccagcctgatcatcta
	caacaaccaggacaggcccagcggcatccctgagaggttcagcggaagcc
	ccgacagccccttcggaaccacagccaccctgaccatcacaagcgtggaa
	gccggcgacgaggccgactactactgccacatctgggacagcagggtgcc
	caccaagtgggtgtttggcggcggcaccaccctgaccgtgctggataagac
	ccatacccgtacggtggccgctcccagcgtgttcatcttcccacctagcgacg
	agcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctac
	ccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcg
	gcaacagccaggaaagcgtgaccgagcaggacagcaaggactccaccta
	cagcctgagcagcaccctgacactgagcaaggccgactacgagaagcaca
	aggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgacca
	agagcttcaaccggggcgagtgt
Binding Protein 19 Amino Acid Sequences
Heavy	evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewvgritgp	SEQ ID
chain	gegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcartgkyydfws	NO: 145
A	gyppgeeyfqdwgqgtlvivssastkgpsvfplapsskstsggtaalgclvkdyfp
	epvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsn
	tkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvv
	vdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlng
	keykckvsnkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgf
	vpsdiavewesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscs
	vmhealhnhytqkslslspg
Light	aseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsg	SEQ ID
chain	ipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvlsqpka	NO: 146
A	apsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvettlpskqs
	nnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs
Heavy	qmqlqesgpglvkpsetlsltcsvsgasisdsywswirrspgkglewigy	SEQ ID
chain	vhksgdtnyspslksrvnlsldtsknqvslslvaataadsgkyycartlhgrr	NO: 147
B	iygivafnewftyfymdvwgngtqvtvssdkthtQvhltqsgpevrkpg
	tsvkvsckapgntlktydlhwvrsvpgqglqwmgwishegdkkviver
	fkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyalydddga
	lnwavdvdylsnlefwgqgtavtvssdkthtastkgpsvfplapsskstsg
	gtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvp
	ssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggps
	vflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhna
	ktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektisk
	akgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewesngqp
	ennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhyt
	qkslslspg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylass	SEQ ID
chain	rasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikd	NO: 148
B	kthtsdisvapgetariscgekslgsravqwyqhragqapsliiynnqdrpsgiper
	fsgspdspfgttatltitsveagdeadyychiwdsrvptkwvfgggttltvldkthtrt
	vaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvt
	eqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 19 Nucleotide Sequences
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgactgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 149
A	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtataggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggc
	gaggaatattacaagactggggtcagggaacccttgttatcgtgtcctccgcgtcga
	ccaagggccccagcgtgttccctctggcccctagcagcaagagcacatctggcgga
	acagccgccctgggctgcctcgtgaaggactactacccgagcccgtgaccgtgtcc
	tggaattctggcgccctgaccagcggcgtgcacacctaccagctgtgctgcagtcc
	agcggcctgtacagcctgagcagcgtcgtgacagtgcccagcagctctctgggcac
	ccagacctacatctgcaacgtgaaccacaagcccagcaacaccaaggtggacaag
	aaggtggaacccaagagctgcgacaagacccacacctgtcccccttgtcctgcccc
	cgaactgctgggaggcccttccgtgttcctgaccccccaaagcccaaggacaccct
	gatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccacgagg
	accctgaagtgaagttcaattggtacgtggacggcgtggaagtgcacaacgccaag
	accaagccaagagaggaacagtacaacagcacctaccgggtggtgtccgtgctga
	ccgtgctgcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaa
	caaggccctgcctgcccccatcgagaaaaccatcagcaaggccaagggccagcc
	ccgcgaaccccaggtgtgcacactgcccccaagcagggacgagctgaccaagaa
	ccaggtgtccctgagctgtgccgtgaaaggcttctacccctccgatatcgccgtgga
	atgggagagcaacggccagcccgagaacaactacaagaccaccccccctgtgctg
	gacagcgacggctcattcttcctggtgtccaagctgacagtggacaagtcccggtgg
	cagcagggcaacgtgttcagctgctccgtgatgcacgaggccctgcacaaccacta
	cacccagaagtccctgagcctgagccccggcaag
Light	gcatccgaactgactcaggaccctgccgtctctgtggcactgaagcagactg	SEQ ID
chain	tgactattacttgccgaggcgactcactgcggagccactacgcttcctggtatc	NO: 150
A	agaagaaacccggccaggcacctgtgctgctgttctacggaaagaacaata
	ggccatctggcatccccgaccgcttttctggcagtgcatcagggaaccgagc
	cagtctgaccattaccggcgcccaggctgaggacgaagccgattactattgc
	agctcccgggataagagcggctccagactgagcgtgttcggaggaggaact
	aaactgaccgtcctcagtcagcccaaggctgccccctcggtcactctgttccc
	gccctcgagtgaggagcttcaagccaacaaggccacactggtgtgtctcata
	agtgacttctacccgggagccgtgacagtggcctggaaggcagatagcagc
	cccgtcaaggcgggagtggagaccaccacaccctccaaacaaagcaacaa
	caagtacgcggccagcagctacctgagcctgacgcctgagcagtggaagtc
	ccacagaagctacagctgccaggtcacgcatgaagggagcaccgtggaga
	agacagtggcccctacagaatgttca
Heavy	cagatgcagctgcaggagagcggccctggactcgtgaagcccagcgagaccctg	SEQ ID
chain	agcctgacatgcagcgtgagcggcgccagcatcagcgacagctactggagctgga	NO: 151
B	tcaggaggagccctggcaagggcctggagtggatcggctacgtgcacaagagcg
	gcgacaccaactacagcccctccctgaagtccagggtgaacctgtccctggacacc
	agcaagaaccaggtgagcctgtccctggtggctgccacagctgctgacagcggca
	agtactactgtgccaggaccctgcacggcaggaggatctacggcatcgtggccttca
	acgagtggttcacctacttctacatggacgtgtggggcaacggcacccaggtgacc
	gtgagctccgacaaaacccatacccaggtgcacctgacacagagcggacccgaag
	tgcggaagcctggcacctctgtgaaggtgtcctgcaaggcccctggcaacaccctg
	aaaacctacgacctgcactgggtgcgcagcgtgccaggacagggactgcagtgga
	tgggctggatcagccacgagggcgacaagaaagtgatcgtggaacggttcaaggc
	caaagtgaccatcgactgggacagaagcaccaacaccgcctacctgcagctgagc
	ggcctgacctctggcgataccgccgtgtactactgcgccaagggcagcaagcacc
	ggctgagagactacgccctgtacgacgatgacggcgccctgaactgggccgtgga
	tgtggactacctgagcaacctggaattctggggccagggcacagccgtgaccgtgt
	catctgataagacccacaccgcttccaccaagggcccatcggtcttccccctggcac
	cctcctccaagagcacctctgggggcacagcggccctgggctgcctggtcaagga
	ctacttccccgaaccggtgacggtgtcgtggaactcaggcgccctgaccagcggcg
	tgcacaccttcccggctgtcctacagtcctcaggactctactccctcagcagcgtggt
	gaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtgaatcaca
	agcccagcaacaccaaggtggacaagaaagttgagcccaaatcttgtgacaaaact
	cacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctc
	ttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgc
	gtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtatgttgac
	ggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagc
	acgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaag
	gagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccat
	ctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatgc
	cgggatgagctgaccaagaatcaagtcagcctgtggtgcctggtaaaaggcttctat
	cccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactac
	aagaccacgcctcccgtgctggactccgacggctccttcttcctctactcaaaactca
	ccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcat
	gaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggt
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgag	SEQ ID
chain	agcgccagcatcagctgcaagagcagccactccctgatccacggcgaccg	NO: 152
B	gaacaactacctggcttggtacgtgcagaagcccggcagatccccccagct
	gctgatctacctggccagcagcagagccagcggcgtgcccgatagattttct
	ggcagcggcagcgacaaggacttcaccctgaagatcagccgggtggaaac
	cgaggacgtgggcacctactactgtatgcagggcagagagagcccctgga
	cctttggccagggcaccaaggtggacatcaaggacaaaacccatacctccg
	acatcagcgtggcccccggagagacagccaggatctcctgcggcgagaag
	agcctgggaagcagggctgtgcagtggtaccaacacagggccggacagg
	ctcccagcctgatcatctacaacaaccaggacaggcccagcggcatccctg
	agaggttcagcggaagccccgacagccccttcggaaccacagccaccctg
	accatcacaagcgtggaagccggcgacgaggccgactactactgccacatc
	tgggacagcagggtgcccaccaagtgggtgtaggcggcggcaccaccct
	gaccgtgctggataagacccatacccgtacggtggccgctcccagcgtgttc
	atcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgt
	gcctgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtgg
	acaacgccctgcagagcggcaacagccaggaaagcgtgaccgagcagga
	cagcaaggactccacctacagcctgagcagcaccctgacactgagcaagg
	ccgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccagggc
	ctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 20 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwikpq	SEQ ID
chain	ygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsygdsswal	NO: 153
A	dawgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswn
	sgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve
	pkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedp
	evkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvs
	nkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiave
	wesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvmhealhn
	hytqkslslspg
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved	SEQ ID
chain	gvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifpp	NO: 154
A	sdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstysl
	sstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	qmqlqesgpglvkpsetlsltcsvsgasisdsywswirrspgkglewigy	SEQ ID
chain	vhksgdtnyspslksrvnlsldtsknqvslslvaataadsgkyycartlhgrr	NO: 155
B	iygivafnewftyfymdvwgngtqvtvssdkthtQvhltqsgpevrkpg
	tsvkvsckapgntlktydlhwvrsvpgqglqwmgwishegdkkviver
	fkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyalydddga
	lnwavdvdylsnlefwgqgtavtvssdkthtastkgpsvfplapsskstsg
	gtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvp
	ssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggps
	vflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhna
	ktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektisk
	akgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewesngqp
	ennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhyt
	qkslslspg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylass	SEQ ID
chain	rasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikd	NO: 156
B	kthtsdisvapgetariscgekslgsravqwyqhragqapsliiynnqdrpsgiper
	fsgspdspfgttatltitsveagdeadyychiwdsrvptkwvfgggttltvldkthtrt
	vaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvt
	eqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 20 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggttccg	NO: 157
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtg
	ttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctg
	cctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctg
	accagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctg
	agcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaa
	cgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagag
	ctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcc
	cttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggaccc
	ccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttc
	aattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagag
	gaacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccagga
	ctggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcc
	cccatcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtg
	tgcacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagct
	gtgccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggc
	cagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcatt
	cttcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgtt
	cagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctga
	gcctgagccccggcaag
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgac	SEQ ID
chain	agagtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcac	NO: 158
A	tggtatcagcacaagcctggcagagcccccaagctgctgatccaccacaca
	agcagcgtggaagatggcgtgcccagcagattttccggcagcggcttccac
	accagcttcaacctgaccatcagcgatctgcaggccgacgacattgccacct
	actattgtcaggtgctgcagttcttcggcagaggcagcagactgcacatcaag
	cgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagc
	tgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgc
	gaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaaca
	gccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctg
	agcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgta
	cgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagctt
	caaccggggcgagtgt
Heavy	cagatgcagctgcaggagagcggccctggactcgtgaagcccagcgagaccctg	SEQ ID
chain	agcctgacatgcagcgtgagcggcgccagcatcagcgacagctactggagctgga	NO: 159
B	tcaggaggagccctggcaagggcctggagtggatcggctacgtgcacaagagcg
	gcgacaccaactacagcccctccctgaagtccagggtgaacctgtccctggacacc
	agcaagaaccaggtgagcctgtccctggtggctgccacagctgctgacagcggca
	agtactactgtgccaggaccctgcacggcaggaggatctacggcatcgtggccttc
	aacgagtggttcacctacttctacatggacgtgtggggcaacggcacccaggtgac
	cgtgagctccgacaaaacccatacccaggtgcacctgacacagagcggacccgaa
	gtgcggaagcctggcacctctgtgaaggtgtcctgcaaggcccctggcaacaccct
	gaaaacctacgacctgcactgggtgcgcagcgtgccaggacagggactgcagtgg
	atgggctggatcagccacgagggcgacaagaaagtgatcgtggaacggttcaagg
	ccaaagtgaccatcgactgggacagaagcaccaacaccgcctacctgcagctgag
	cggcctgacctctggcgataccgccgtgtactactgcgccaagggcagcaagcac
	cggctgagagactacgccctgtacgacgatgacggcgccctgaactgggccgtgg
	atgtggactacctgagcaacctggaattctggggccagggcacagccgtgaccgtg
	tcatctgataagacccacaccgcttccaccaagggcccatcggtcttccccctggca
	ccctcctccaagagcacctctgggggcacagcggccctgggctgcctggtcaagg
	actacttccccgaaccggtgacggtgtcgtggaactcaggcgccctgaccagcggc
	gtgcacaccttcccggctgtcctacagtcctcaggactctactccctcagcagcgtgg
	tgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtgaatcaca
	agcccagcaacaccaaggtggacaagaaagttgagcccaaatcttgtgacaaaact
	cacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctc
	ttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgc
	gtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtatgttgac
	ggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagc
	acgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaa
	ggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacc
	atctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccat
	gccgggatgagctgaccaagaatcaagtcagcctgtggtgcctggtaaaaggcttct
	atcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaact
	acaagaccacgcctcccgtgctggactccgacggctccttcttcctctactcaaaact
	caccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgc
	atgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggt
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgag	SEQ ID
chain	agcgccagcatcagctgcaagagcagccactccctgatccacggcgaccg	NO: 160
B	gaacaactacctggcttggtacgtgcagaagcccggcagatccccccagct
	gctgatctacctggccagcagcagagccagcggcgtgcccgatagattttct
	ggcagcggcagcgacaaggacttcaccctgaagatcagccgggtggaaac
	cgaggacgtgggcacctactactgtatgcagggcagagagagcccctgga
	cctttggccagggcaccaaggtggacatcaaggacaaaacccatacctccg
	acatcagcgtggcccccggagagacagccaggatctcctgcggcgagaag
	agcctgggaagcagggctgtgcagtggtaccaacacagggccggacagg
	ctcccagcctgatcatctacaacaaccaggacaggcccagcggcatccctg
	agaggttcagcggaagccccgacagccccttcggaaccacagccaccctg
	accatcacaagcgtggaagccggcgacgaggccgactactactgccacatc
	tgggacagcagggtgcccaccaagtgggtgtttggcggcggcaccaccct
	gaccgtgctggataagacccatacccgtacggtggccgctcccagcgtgttc
	atcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgt
	gcctgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtgg
	acaacgccctgcagagcggcaacagccaggaaagcgtgaccgagcagga
	cagcaaggactccacctacagcctgagcagcaccctgacactgagcaagg
	ccgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccagggc
	ctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 21 Amino Acid Sequences
Heavy	qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwmgwish	SEQ ID
chain	egdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyaly	NO: 161
A	dddgalnwavdvdylsnlefwgqgtavtvssastkgpsvfplapsskstsggtaal
	gclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyi
	cnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmi
	srtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreegynstyrvvsvlt
	vlhqdwlngkeykckvsnkalpapiektiskakgqprepqvctlppsrdeltknq
	vslscavkgfypsdiavewesngqpennykttppvldsdgsfflvskltvdksrw
	qqgnvfscsvmhealhnhytqkslslspg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylass	SEQ ID
chain	rasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikrt	NO: 162
A	vaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvt
	eqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewv	SEQ ID
chain	gritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcar	NO: 163
B	tgkyydfwsgyppgeeyfqdwgqgtlvivssdktht
	rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgw
	ikpqygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrs
	ygdsswaldawgqgttvvvsadkthtastkgpsvfplapsskstsggtaal
	gclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslg
	tqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfp
	pkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpr
	eeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgq
	prepqvytlppcrdeltknqvslwclvkgfypsdiavewesngqpenny
	kttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqksls
	lspg
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved	SEQ ID
chain	gvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikdkthtaseltqd	NO: 164
B	pavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsgipdrfsg
	sasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldkthtrtvaapsv
	fifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskd
	styslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 21 Nucleotide Sequences
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctctgtga	SEQ ID
chain	aggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgcactgggtg	NO: 165
A	cgcagcgtgccaggacagggactgcagtggatgggctggatcagccacgagggc
	gacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcgactgggaca
	gaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcgataccgc
	cgtgtactactgcgccaagggcagcaagcaccggctgagagactacgccctgtac
	gacgatgacggcgccctgaactgggccgtggatgtggactacctgagcaacctgg
	aattctggggccagggcacagccgtgaccgtgtcatctgcttcgaccaagggcccc
	agcgtgttccctctggcccctagcagcaagagcacatctggcggaacagccgccct
	gggctgcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggc
	gccctgaccagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtac
	agcctgagcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacat
	ctgcaacgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacc
	caagagctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgg
	gaggcccttccgtgacctgaccccccaaagcccaaggacaccctgatgatcagcc
	ggacccccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtg
	aagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaa
	gagaggaacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcac
	caggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgc
	ctgcccccatcgagaaaaccatcagcaaggccaagggccagccccgcgaacccc
	aggtgtgcacactgcccccaagcagggacgagctgaccaagaaccaggtgtccct
	gagctgtgccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagca
	acggccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacg
	gctcattcttcctggtgtccaagctgacagtggacaagtcccggtggcagcagggca
	acgtgacagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagt
	ccctgagcctgagccccggcaag
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcg	SEQ ID
chain	ccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta	NO: 166
A	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggc
	cagcagcagagccagcggcgtgcccgatagattactggcagcggcagcgacaag
	gacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactg
	tatgcagggcagagagagcccctggacctttggccagggcaccaaggtggacatc
	aagcgtacggtggccgctcccagcgtgacatcttcccacctagcgacgagcagctg
	aagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggcc
	aaagtgcagtggaaggtggacaacgccctgcagagcggcaacagccaggaaagc
	gtgaccgagcaggacagcaaggactccacctacagcctgagcagcaccctgacac
	tgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgacccacca
	gggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgactgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 167
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtataggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggc
	gaggaatattacaagactggggtcagggaacccttgttatcgtgtcctccgacaaaa
	cccataccagagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgc
	ctctgtgcgggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgact
	ggttccggcaggcccctggcagaggactggaatgggtgggatggatcaagcccca
	gtatggcgccgtgaacttcggcggaggcttccgggatagagtgaccctgacccggg
	acgtgtaccgcgagatcgcctacatggacatccggggcctgaagcccgatgacacc
	gccgtgtactactgcgccagagacagaagctacggcgacagcagctgggctctgg
	atgcttggggccagggcacaaccgtggtggtgtctgccgataagacccacaccgct
	tccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacctctggg
	ggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggtgacggt
	gtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctgtcctac
	agtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagcagcttgg
	gcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaaggtgga
	caagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagc
	acctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacac
	cctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacg
	aagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtgcataatgcca
	agacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcct
	caccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctcca
	acaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagcc
	ccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgaccaagaat
	caagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgccgtggag
	tgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctgg
	actccgacggctccttcttcctctactcaaaactcaccgtggacaagagcaggtggca
	gcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacac
	gcagaagagcctctccctgtctccgggt
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagt	SEQ ID
chain	gaccatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagc	NO: 168
B	acaagcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaaga
	tggcgtgcccagcagattaccggcagcggcttccacaccagcttcaacctgaccat
	cagcgatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttc
	ggcagaggcagcagactgcacatcaaggacaaaacccataccgcatccgaactga
	ctcaggaccctgccgtctctgtggcactgaagcagactgtgactattacttgccgagg
	cgactcactgcggagccactacgcttcctggtatcagaagaaacccggccaggcac
	ctgtgctgctgttctacggaaagaacaataggccatctggcatccccgaccgcttact
	ggcagtgcatcagggaaccgagccagtctgaccattaccggcgcccaggctgagg
	acgaagccgattactattgcagctcccgggataagagcggctccagactgagcgtgt
	tcggaggaggaactaaactgaccgtcctcgataagacccatacccgtacggtggcc
	gctcccagcgtgacatcttcccacctagcgacgagcagctgaagtccggcacagcc
	tctgtcgtgtgcctgctgaacaacttctacccccgcgaggccaaagtgcagtggaag
	gtggacaacgccctgcagagcggcaacagccaggaaagcgtgaccgagcagga
	cagcaaggactccacctacagcctgagcagcaccctgacactgagcaaggccgac
	tacgagaagcacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccc
	cgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 22 Amino Acid Sequences
Heavy	qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwmgwish	SEQ ID
chain	egdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyaly	NO: 169
A	dddgalnwavdvdylsnlefwgqgtavtvssastkgpsvfplapsskstsggtaal
	gclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyi
	cnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmi
	srtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreegynstyrvvsvlt
	vlhqdwlngkeykckvsnkalpapiektiskakgqprepqvctlppsrdeltknq
	vslscavkgfypsdiavewesngqpennykttppvldsdgsfflvskltvdksrw
	qqgnvfscsvmhealhnhytqkslslspg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylass	SEQ ID
chain	rasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikrt	NO: 170
A	vaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvt
	eqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	rahlyqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgw	SEQ ID
chain	ikpqygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrs	NO: 171
B	ygdsswaldawgqgttvvvsadkthtevrlvesggglvkpggslrlscsas
	gfdfdnawmtwvrqppgkglewvgritgpgegwsvdyaesykgrftis
	rdntkntlylemnnvrtedtgyyfcartgkyydfwsgyppgeeyfqdwg
	qgtlvivssdkthtastkgpsvfplapsskstsggtaalgclvkdyfpepvtv
	swnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnynhkpsnt
	kvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevt
	cvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvl
	hqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppcrdelt
	knqvslwclykgfypsdiavewesngqpennykttppvldsdgsf
Light	aseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsg	SEQ ID
chain	ipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldktht	NO: 172
B	Yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved
	gvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhik
	dkthtrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgn
	sqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 22 Nucleotide Sequences
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctctgtga	SEQ ID
chain	aggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgcactgggtg	NO: 173
A	cgcagcgtgccaggacagggactgcagtggatgggctggatcagccacgagggc
	gacaagaaagtgatcgtggaacggacaaggccaaagtgaccatcgactgggaca
	gaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcgataccgc
	cgtgtactactgcgccaagggcagcaagcaccggctgagagactacgccctgtac
	gacgatgacggcgccctgaactgggccgtggatgtggactacctgagcaacctgg
	aattctggggccagggcacagccgtgaccgtgtcatctgcttcgaccaagggcccc
	agcgtgaccctctggcccctagcagcaagagcacatctggcggaacagccgccct
	gggctgcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggc
	gccctgaccagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtac
	agcctgagcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacat
	ctgcaacgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacc
	caagagctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgg
	gaggcccttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagcc
	ggacccccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtg
	aagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaa
	gagaggaacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcac
	caggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgc
	ctgcccccatcgagaaaaccatcagcaaggccaagggccagccccgcgaacccc
	aggtgtgcacactgcccccaagcagggacgagctgaccaagaaccaggtgtccct
	gagctgtgccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagca
	acggccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacg
	gctcattcttcctggtgtccaagctgacagtggacaagtcccggtggcagcagggca
	acgtgttcagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagt
	ccctgagcctgagccccggcaag
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcg	SEQ ID
chain	ccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta	NO: 174
A	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggc
	cagcagcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaag
	gacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactg
	tatgcagggcagagagagcccctggacctttggccagggcaccaaggtggacatc
	aagcgtacggtggccgctcccagcgtgacatcttcccacctagcgacgagcagctg
	aagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggcc
	aaagtgcagtggaaggtggacaacgccctgcagagcggcaacagccaggaaagc
	gtgaccgagcaggacagcaaggactccacctacagcctgagcagcaccctgacac
	tgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgacccacca
	gggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggttccg	NO: 175
B	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgacaaaacccataccgaggttaga
	ctggtggagtcaggaggggggcttgtgaagcccggtgggtctctccgcctgagctg
	ttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggcagcctccag
	gtaagggactggagtgggtgggaagaatcacaggtccaggcgagggctggtccgt
	ggactacgcggaatctgttaaagggcggtttacaatctcaagggacaataccaagaa
	taccttgtatttggagatgaacaacgtgagaactgaagacaccggatattacttctgtg
	ccagaacaggcaaatactacgacttctggtccggctatccccctggcgaggaatattt
	tcaagactggggtcagggaacccttgttatcgtgtcctccgataagacccacaccgct
	tccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacctctggg
	ggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggtgacggt
	gtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctgtcctac
	agtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagcagcttgg
	gcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaaggtgga
	caagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagc
	acctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacac
	cctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacg
	aagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtgcataatgcca
	agacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcct
	caccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctcca
	acaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagcc
	ccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgaccaagaat
	caagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgccgtggag
	tgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctgg
	actccgacggctccttcttcctctactcaaaactcaccgtggacaagagcaggtggca
	gcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacac
	gcagaagagcctctccctgtctccgggt
Light	gcatccgaactgactcaggaccctgccgtctctgtggcactgaagcagactg	SEQ ID
chain	tgactattacttgccgaggcgactcactgcggagccactacgcttcctggtatc	NO: 176
B	agaagaaacccggccaggcacctgtgctgctgttctacggaaagaacaata
	ggccatctggcatccccgaccgcttttctggcagtgcatcagggaaccgagc
	cagtctgaccattaccggcgcccaggctgaggacgaagccgattactattgc
	agctcccgggataagagcggctccagactgagcgtgttcggaggaggaact
	aaactgaccgtcctcgacaaaacccatacctacatccacgtgacccagagcc
	ccagcagcctgtccgtgtccatcggcgacagagtgaccatcaactgccaga
	cctctcagggcgtgggcagcgacctgcactggtatcagcacaagcctggca
	gagcccccaagctgctgatccaccacacaagcagcgtggaagatggcgtg
	cccagcagattttccggcagcggcttccacaccagcttgcaacctgaccatca
	gcgatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttc
	ttcggcagaggcagcagactgcacatcaaggataagacccatacccgtacg
	gtggccgctcccagcgtgttcatcttcccacctagcgacgagcagctgaagt
	ccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggc
	caaagtgcagtggaaggtggacaacgccctgcagagcggcaacagccag
	gaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagcag
	caccctgacactgagcaaggccgactacgagaagcacaaggtgtacgcct
	gcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaacc
	ggggcgagtgt
Binding Protein 23 Amino Acid Sequences
Heavy	evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewvgritgp	SEQ ID
chain	gegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcartgkyydfws	NO: 177
A	gyppgeeyfqdwgqgtlvivssastkgpsvfplapsskstsggtaalgclvkdyfp
	epvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsn
	tkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvv
	vdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlng
	keykckvsnkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgf
	ypsdiavewesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscs
	vmhealhnhytqkslslspg
Light	Aseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrps	SEQ ID
chain	gipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvlsqpk	NO: 178
A	aapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpsk
	qsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs
Heavy	rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgw	SEQ ID
chain	ikpqygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrs	NO: 179
B	ygdsswaldawgqgttvvvsadkthtQvhltqsgpevrkpgtsvkvsck
	apgntlktydlhwvrsvpgqglqwmgwishegdkkviverfkakvtid
	wdrstntaylqlsgltsgdtavyycakgskhrlrdyalydddgalnwavd
	vdylsnlefwgqgtaytvssdkthtastkgpsvfplapsskstsggtaalgcl
	vkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqt
	yicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppk
	pkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpree
	qynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqpr
	epqvytlppcrdeltknqvslwclvkgfypsdiavewesngqpennyktt
	ppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslsls
	pg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylas	SEQ ID
chain	srasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdik	NO: 180
B	dktht
	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved
	gvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikdkthtrtvaaps
	vfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdsk
	dstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 23 Nucleotide Sequences
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgactgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 181
A	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggc
	gaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgcgtcga
	ccaagggccccagcgtgttccctctggcccctagcagcaagagcacatctggcgga
	acagccgccctgggctgcctcgtgaaggactactttcccgagcccgtgaccgtgtcc
	tggaattctggcgccctgaccagcggcgtgcacacctttccagctgtgctgcagtcc
	agcggcctgtacagcctgagcagcgtcgtgacagtgcccagcagctctctgggcac
	ccagacctacatctgcaacgtgaaccacaagcccagcaacaccaaggtggacaag
	aaggtggaacccaagagctgcgacaagacccacacctgtcccccttgtcctgcccc
	cgaactgctgggaggcccttccgtgttcctgaccccccaaagcccaaggacaccct
	gatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccacgagg
	accctgaagtgaagttcaattggtacgtggacggcgtggaagtgcacaacgccaag
	accaagccaagagaggaacagtacaacagcacctaccgggtggtgtccgtgctga
	ccgtgctgcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaa
	caaggccctgcctgcccccatcgagaaaaccatcagcaaggccaagggccagcc
	ccgcgaaccccaggtgtgcacactgcccccaagcagggacgagctgaccaagaa
	ccaggtgtccctgagctgtgccgtgaaaggcttctacccctccgatatcgccgtgga
	atgggagagcaacggccagcccgagaacaactacaagaccaccccccctgtgctg
	gacagcgacggctcattcttcctggtgtccaagctgacagtggacaagtcccggtgg
	cagcagggcaacgtgttcagctgctccgtgatgcacgaggccctgcacaaccacta
	cacccagaagtccctgagcctgagccccggcaag
Light	gcatccgaactgactcaggaccctgccgtctctgtggcactgaagcagactg	SEQ ID
chain	tgactattacttgccgaggcgactcactgcggagccactacgcttcctggtatc	NO: 182
A	agaagaaacccggccaggcacctgtgctgctgttctacggaaagaacaata
	ggccatctggcatccccgaccgcttttctggcagtgcatcagggaaccgagc
	cagtctgaccattaccggcgcccaggctgaggacgaagccgattactattgc
	agctcccgggataagagcggctccagactgagcgtgttcggaggaggaact
	aaactgaccgtcctcagtcagcccaaggctgccccctcggtcactctgttccc
	gccctcgagtgaggagcttcaagccaacaaggccacactggtgtgtctcata
	agtgacttctacccgggagccgtgacagtggcctggaaggcagatagcagc
	cccgtcaaggcgggagtggagaccaccacaccctccaaacaaagcaacaa
	caagtacgcggccagcagctacctgagcctgacgcctgagcagtggaagtc
	ccacagaagctacagctgccaggtcacgcatgaagggagcaccgtggaga
	agacagtggcccctacagaatgttca
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggaccg	NO: 183
B	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgacaaaacccatacccaggtgcac
	ctgacacagagcggacccgaagtgcggaagcctggcacctctgtgaaggtgtcctg
	caaggcccctggcaacaccctgaaaacctacgacctgcactgggtgcgcagcgtg
	ccaggacagggactgcagtggatgggctggatcagccacgagggcgacaagaaa
	gtgatcgtggaacggacaaggccaaagtgaccatcgactgggacagaagcacca
	acaccgcctacctgcagctgagcggcctgacctctggcgataccgccgtgtactact
	gcgccaagggcagcaagcaccggctgagagactacgccctgtacgacgatgacg
	gcgccctgaactgggccgtggatgtggactacctgagcaacctggaattctggggc
	cagggcacagccgtgaccgtgtcatctgataagacccacaccgcttccaccaaggg
	cccatcggtcttccccctggcaccctcctccaagagcacctctgggggcacagcgg
	ccctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaact
	caggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcagga
	ctctactccctcagcagcgtggtgaccgtgccctccagcagcttgggcacccagacc
	tacatctgcaacgtgaatcacaagcccagcaacaccaaggtggacaagaaagttga
	gcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcct
	ggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctc
	ccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgag
	gtcaagttcaactggtatgttgacggcgtggaggtgcataatgccaagacaaagccg
	cgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgca
	ccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcc
	cagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccac
	aggtgtacaccctgcccccatgccgggatgagctgaccaagaatcaagtcagcctg
	tggtgcctggtaaaaggcttctatcccagcgacatcgccgtggagtgggagagcaat
	gggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggct
	ccttcttcctctactcaaaactcaccgtggacaagagcaggtggcagcaggggaac
	gtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagc
	ctctccctgtctccgggt
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgag	SEQ ID
chain	agcgccagcatcagctgcaagagcagccactccctgatccacggcgaccg	NO: 184
B	gaacaactacctggcttggtacgtgcagaagcccggcagatccccccagct
	gctgatctacctggccagcagcagagccagcggcgtgcccgatagattttct
	ggcagcggcagcgacaaggacttcaccctgaagatcagccgggtggaaac
	cgaggacgtgggcacctactactgtatgcagggcagagagagcccctgga
	cctttggccagggcaccaaggtggacatcaaggacaaaacccatacctacat
	ccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagt
	gaccatcaactgccagacctctcagggcgtgggcagcgacctgcactggta
	tcagcacaagcctggcagagcccccaagctgctgatccaccacacaagca
	gcgtggaagatggcgtgcccagcagattttccggcagcggcttccacacca
	gcttcaacctgaccatcagcgatctgcaggccgacgacattgccacctactat
	tgtcaggtgctgcagttcttcggcagaggcagcagactgcacatcaaggata
	agacccatacccgtacggtggccgctcccagcgtgttcatcttcccacctagc
	gacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaact
	tctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcag
	agcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactcca
	cctacagcctgagcagcaccctgacactgagcaaggccgactacgagaag
	cacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtg
	accaagagcttcaaccggggcgagtgt
Binding Protein 24 Amino Acid Sequences
Heavy	evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewvgritgpg	SEQ ID
chain	egwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcartgkyydfwsgy	NO: 185
A	ppgeeyfqdwgqgtlvivssastkgpsvfplapsskstsggtaalgclvkdyfpep
	vtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkv
	dkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvs
	hedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeyk
	ckvsnkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdi
	avewesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvmhea
	lhnhytqkslslspg
Light	aseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsgi	SEQ ID
chain	pdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvlsqpkaa	NO: 186
A	psvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsn
	nkyaassylsltpeqwkshrsyscqvthegstvektvaptecs
Heavy	Qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwmg	SEQ ID
chain	wishegdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakgsk	NO: 187
B	hrlrdyalydddgalnwavdvdylsnlefwgqgtavtvss
	dkthtrahlyqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglew
	vgwikpqygavnfgggfrdrvtltrdyyreiaymdirglkpddtavyycar
	drsygdsswaldawgqgttvvvsadkthtastkgpsvfplapsskstsggta
	algclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpsssl
	gtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfp
	pkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpre
	eqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqpr
	epqvytlppcrdeltknqvslwclykgfypsdiavewesngqpennyktt
	ppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslsp
	g
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssvedg	SEQ ID
chain	vpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikdkthtdfvltqsph	NO: 188
B	slsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylassrasgvpdrf
	sgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikdkthtrtvaaps
	vfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskd
	styslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 24 Nucleotide Sequences
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccgc	SEQ ID
chain	ctgagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggca	NO: 189
A	gcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagggc
	tggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggacaata
	ccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggatattac
	ttctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggcgagg
	aatattttcaagactggggtcagggaacccttgttatcgtgtcctccgcgtcgaccaag
	ggccccagcgtgttccctctggcccctagcagcaagagcacatctggcggaacagc
	cgccctgggctgcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaat
	tctggcgccctgaccagcggcgtgcacacctttccagctgtgctgcagtccagcggc
	ctgtacagcctgagcagcgtcgtgacagtgcccagcagctctctgggcacccagacc
	tacatctgcaacgtgaaccacaagcccagcaacaccaaggtggacaagaaggtgga
	acccaagagctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgct
	gggaggcccttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagc
	cggacccccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagt
	gaagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaa
	gagaggaacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcac
	caggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcc
	tgcccccatcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccag
	gtgtgcacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgag
	ctgtgccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacgg
	ccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcat
	tcttcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtga
	cagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgag
	cctgagccccggcaag
Light	gcatccgaactgactcaggaccctgccgtctctgtggcactgaagcagactgt	SEQ ID
chain	gactattacttgccgaggcgactcactgcggagccactacgcttcctggtatca	NO: 190
A	gaagaaacccggccaggcacctgtgctgctgttctacggaaagaacaatagg
	ccatctggcatccccgaccgcttactggcagtgcatcagggaaccgagccag
	tctgaccattaccggcgcccaggctgaggacgaagccgattactattgcagct
	cccgggataagagcggctccagactgagcgtgttcggaggaggaactaaac
	tgaccgtcctcagtcagcccaaggctgccccctcggtcactctgttcccgccct
	cgagtgaggagcttcaagccaacaaggccacactggtgtgtctcataagtgac
	ttctacccgggagccgtgacagtggcctggaaggcagatagcagccccgtca
	aggcgggagtggagaccaccacaccctccaaacaaagcaacaacaagtac
	gcggccagcagctacctgagcctgacgcctgagcagtggaagtcccacaga
	agctacagctgccaggtcacgcatgaagggagcaccgtggagaagacagtg
	gcccctacagaatgttca
Heavy	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagtg	SEQ ID
chain	accatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagcac	NO: 191
B	aagcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaagatgg
	cgtgcccagcagattaccggcagcggcttccacaccagcttcaacctgaccatcagc
	gatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttcggcag
	aggcagcagactgcacatcaaggacaaaacccataccgacttcgtgctgacccaga
	gccctcacagcctgagcgtgacacctggcgagagcgccagcatcagctgcaagag
	cagccactccctgatccacggcgaccggaacaactacctggcttggtacgtgcagaa
	gcccggcagatccccccagctgctgatctacctggccagcagcagagccagcggc
	gtgcccgatagattactggcagcggcagcgacaaggacttcaccctgaagatcagc
	cgggtggaaaccgaggacgtgggcacctactactgtatgcagggcagagagagcc
	cctggacctaggccagggcaccaaggtggacatcaaggataagacccatacccgta
	cggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagctgaagtccg
	gcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggccaaagtgca
	gtggaaggtggacaacgccctgcagagcggcaacagccaggaaagcgtgaccga
	gcaggacagcaaggactccacctacagcctgagcagcaccctgacactgagcaag
	gccgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccagggcctgtc
	tagccccgtgaccaagagcttcaaccggggcgagtgt
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgaca	SEQ ID
chain	gagtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcactg	NO: 192
B	gtatcagcacaagcctggcagagcccccaagctgctgatccaccacacaagc
	agcgtggaagatggcgtgcccagcagattttccggcagcggcttccacacca
	gcttcaacctgaccatcagcgatctgcaggccgacgacattgccacctactatt
	gtcaggtgctgcagttcttcggcagaggcagcagactgcacatcaaggacaa
	aacccataccgacttcgtgctgacccagagccctcacagcctgagcgtgaca
	cctggcgagagcgccagcatcagctgcaagagcagccactccctgatccac
	ggcgaccggaacaactacctggcttggtacgtgcagaagcccggcagatcc
	ccccagctgctgatctacctggccagcagcagagccagcggcgtgcccgat
	agattttctggcagcggcagcgacaaggacttcaccctgaagatcagccggg
	tggaaaccgaggacgtgggcacctactactgtatgcagggcagagagagcc
	cctggacctttggccagggcaccaaggtggacatcaaggataagacccatac
	ccgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagc
	tgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcg
	aggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaacagc
	caggaaagcgtgaccgagcaggacagcaaggactccacctacagcctgag
	cagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgc
	ctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaac
	cggggcgagtgt
Binding Protein 25 Amino Acid Sequences
Heavy	qvqlvqsggqmkkpgesmriscrasgyef wirlapgkrpewmg	SEQ ID
chain	vtmtrdvysdtaflelrsltvddtavyfctr	NO: 193
A	wgrgtpvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgal
	tsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc
	dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfn
	wyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpa
	piektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiavewesngq
	pennykttppvldsdgsfflvskltvdksrwqqgnvfscsvlhealhshytqkslsls
	pg
Light	eivltqspgtlslspgetaiisc wyqqrpgqaprlviy gipdrf	SEQ ID
chain	sgsrwgpdynltisnlesgdfgvyyc gqgtkvqvdikrtvaapsvfifpps	NO: 194
A	deqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsst
	ltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewvgr	SEQ ID
chain	itgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcartg	NO: 195
B	kyydfwsgyppgeeyfqdwgqgtlvivssdkthtqvqlvesgggvvqpg
	tslrlscaasqfrfdgygmhwvrqapgkglewvasishdgikkyhaekvw
	grftisrdnskntlylqmnslrpedtalyycakdlredeceewwsdyydfgk
	qlpcaksrgglvgiadnwgqgtmvtvssdkthtastkgpsvfplapssksts
	ggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvp
	ssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsv
	flfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktk
	preeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakg
	qprepqvytlppcrdeltknqvslwclvkgfypsdiavewesngqpenny
	kttppvldsdgsfflyskltvdksrwqqgnvfscsvlhealhshytqkslsls
	pg
Light	qsvltqppsvsaapgqkvtiscsgntsnignnfvswyqqrpgrapqlliyetdkrps	SEQ ID
chain	gipdrfsasksgtsgtlaitglqtgdeadyycatwaaslssarvfgtgtkvivldkthta	NO: 196
B	seltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsgip
	drfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldkthtrtva
	apsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqd
	skdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 25 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcggccagatgaagaaacccggcgagagcatgc	SEQ ID
chain	ggatcagctgcagagccagcggctacgagttcatcgactgcaccctgaactggatca	NO: 197
A	gactggcccctggcaagcggcctgagtggatgggatggctgaagcctagaggcgg
	agccgtgaactacgccagacctctgcagggcagagtgaccatgacccgggacgtgt
	acagcgataccgccttcctggaactgcggagcctgaccgtggatgataccgccgtgt
	acttctgcacccggggcaagaactgcgactacaactgggacttcgagcactggggca
	gaggcacccctgtgatcgtgtcaagcgcgtcgaccaagggccccagcgtgttccctc
	tggcccctagcagcaagagcacatctggcggaacagccgccctgggctgcctcgtg
	aaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctgaccagcg
	gcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctgagcagcgt
	cgtgacagtgcccagcagctctctgggcacccagacctacatctgcaacgtgaacca
	caagcccagcaacaccaaggtggacaagaaggtggaacccaagagctgcgacaag
	acccacacctgtcccccttgtcctgcccccgaactgctgggaggcccttccgtgttcct
	gttccccccaaagcccaaggacaccctgatgatcagccggacccccgaagtgacct
	gcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttcaattggtacgtgga
	cggcgtggaagtgcacaacgccaagaccaagccaagagaggaacagtacaacagc
	acctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacggcaaa
	gagtacaagtgcaaggtgtccaacaaggccctgcctgcccccatcgagaaaaccatc
	agcaaggccaagggccagccccgcgaaccccaggtgtgcacactgcccccaagca
	gggacgagctgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctacc
	cctccgatatcgccgtggaatgggagagcaacggccagcccgagaacaactacaag
	accaccccccctgtgctggacagcgacggctcattcttcctggtgtccaagctgacagt
	ggacaagtcccggtggcagcagggcaacgtgttcagctgctccgtgctgcatgaggc
	tctgcacagccactacacgcagaagagcctctccctgtctccgggt
Light	Gagatcgtgctgacacagagccctggcaccctgagcctgtctccaggcgagacagc	SEQ ID
chain	catcatcagctgccggacaagccagtacggcagcctggcctggtatcagcagaggc	NO: 198
A	ctggacaggcccccagactcgtgatctacagcggcagcacaagagccgccggaatc
	cccgatagattcagcggctccagatggggccctgactacaacctgaccatcagcaac
	ctggaaagcggcgacttcggcgtgtactactgccagcagtacgagttcttcggccagg
	gcaccaaggtgcaggtggacatcaagcgtacggtggccgctcccagcgtgttcatctt
	cccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaa
	caacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcaga
	gcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctaca
	gcctgagcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtac
	gcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccg
	gggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccgc	SEQ ID
chain	ctgagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggcag	NO: 199
B	cctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagggct
	ggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggacaatac
	caagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggatattact
	tctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggcgagga
	atattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaaacccatac
	ccaggtgcagttggtggagtctgggggaggcgtggtccagcctgggacgtccctga
	gactctcctgtgcagcctctcaattcaggtttgatggttatggcatgcactgggtccgcc
	aggccccaggcaaggggctggagtgggtggcatctatatcacatgatggaattaaaa
	agtatcacgcagaaaaagtgtggggccgcttcaccatctccagagacaattccaagaa
	cacactgtatctacaaatgaacagcctgcgacctgaggacacggctctctactactgtg
	cgaaagatttgcgagaagacgaatgtgaagagtggtggtcggattattacgattttggg
	aaacaactcccttgcgcaaagtcacgcggcggcttggttggaattgctgataactggg
	gccaagggacaatggtcaccgtctcttcagataagacccacaccgcttccaccaagg
	gcccatcggtcttccccctggcaccctcctccaagagcacctctgggggcacagcgg
	ccctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactc
	aggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggact
	ctactccctcagcagcgtggtgaccgtgccctccagcagcttgggcacccagaccta
	catctgcaacgtgaatcacaagcccagcaacaccaaggtggacaagaaagttgagc
	ccaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggg
	gggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccgg
	acccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaa
	gttcaactggtatgttgacggcgtggaggtgcataatgccaagacaaagccgcggga
	ggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccagga
	ctggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccc
	catcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtaca
	ccctgcccccatgccgggatgagctgaccaagaatcaagtcagcctgtggtgcctgg
	taaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccg
	gagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctcta
	ctcaaaactcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctc
	cgtgctgcatgaggctctgcacagccactacacgcagaagagcctctccctgtctccg
	ggt
Light	cagtctgtgctgacgcagccgccctcagtgtctgcggccccaggacagaagg	SEQ ID
chain	tcaccatctcctgctctggaaacacctccaacattggcaataattagtgtcctgg	NO: 200
B	tatcaacagcgccccggcagagccccccaactcctcatttatgaaactgacaa
	gcgaccctcagggattcctgaccgattctctgcttccaagtctggtacgtcagg
	caccctggccatcaccgggctgcagactggggacgaggccgattattactgc
	gccacatgggctgccagcctgagttccgcgcgtgtcttcggaactgggacca
	aggtcatcgtcctggacaaaacccataccgcatccgaactgactcaggaccct
	gccgtctctgtggcactgaagcagactgtgactattacttgccgaggcgactca
	ctgcggagccactacgcttcctggtatcagaagaaacccggccaggcacctg
	tgctgctgttctacggaaagaacaataggccatctggcatccccgaccgcltttc
	tggcagtgcatcagggaaccgagccagtctgaccattaccggcgcccaggct
	gaggacgaagccgattactattgcagctcccgggataagagcggctccagac
	tgagcgtgttcggaggaggaactaaactgaccgtcctcgataagacccatacc
	cgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagct
	gaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcg
	aggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaacagc
	caggaaagcgtgaccgagcaggacagcaaggactccacctacagcctgag
	cagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgc
	ctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaac
	cggggcgagtgt
Binding Protein 26 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqts fwfrqapgrglewvgw	SEQ ID
chain	nfgggfrdrvtltrdvyreiaymdirglkpddtavyycar	NO: 201
A	wgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsga
	ltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc
	dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfn
	wyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpa
	piektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiavewesngq
	pennykttppvldsdgsfflvskltvdksrwqqgnvfscsvlhealhshytqkslsls
	pg
Light	yihvtqspsslsvsigdrvtincqts hwyqhkpgrapkllihhtssvedg	SEQ ID
chain	vpsrfsgsgf fnltisdlqaddiatyyc grgsrlhikrtvaapsvfifppsd	NO: 202
A	eqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstl
	tlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewvgr	SEQ ID
chain	itgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcartg	NO: 203
B	kyydfwsgyppgeeyfqdwgqgtlvivssdkthtqvqlvesgggvvqpg
	tslrlscaasqfrfdgygmhwvrqapgkglewvasishdgikkyhaekvw
	grftisrdnskntlylqmnslrpedtalyycakdlredeceewwsdyydfgk
	glpcaksrgglvgiadnwgqgtmvtvssdkthtastkgpsvfplapssksts
	ggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvp
	ssslgtqtvicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsv
	flfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktk
	preeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakg
	qprepqvytlppcrdeltknqvslwclvkgfypsdiavewesngqpenny
	kttppvldsdgsfflyskltvdksrwqqgnvfscsvlhealhshytqkslsls
	pg
Light	qsvltqppsvsaapgqkvtiscsgntsnignnfvswyqqrpgrapqlliyetdkrps	SEQ ID
chain	gipdrfsasksgtsgtlaitglqtgdeadyycatwaaslssarvfgtgtkvivldkthta	NO: 204
B	seltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnrpsgip
	drfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldkthtrtva
	apsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqd
	skdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 26 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgcg	SEQ ID
chain	ggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgactggaccggc	NO: 205
A	aggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggcgcc
	gtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgtaccgc
	gagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtgtactac
	tgcgccagagacagaagctacggcgacagcagctgggctctggatgcttggggcca
	gggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtgaccctctg
	gcccctagcagcaagagcacatctggcggaacagccgccctgggctgcctcgtgaa
	ggactactacccgagcccgtgaccgtgtcctggaattctggcgccctgaccagcggc
	gtgcacacctaccagctgtgctgcagtccagcggcctgtacagcctgagcagcgtcg
	tgacagtgcccagcagctctctgggcacccagacctacatctgcaacgtgaaccaca
	agcccagcaacaccaaggtggacaagaaggtggaacccaagagctgcgacaagac
	ccacacctgtcccccttgtcctgcccccgaactgctgggaggcccttccgtgttcctgtt
	ccccccaaagcccaaggacaccctgatgatcagccggacccccgaagtgacctgcg
	tggtggtggatgtgtcccacgaggaccctgaagtgaagttcaattggtacgtggacgg
	cgtggaagtgcacaacgccaagaccaagccaagagaggaacagtacaacagcacc
	taccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacggcaaagag
	tacaagtgcaaggtgtccaacaaggccctgcctgcccccatcgagaaaaccatcagc
	aaggccaagggccagccccgcgaaccccaggtgtgcacactgcccccaagcagg
	gacgagctgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctacccct
	ccgatatcgccgtggaatgggagagcaacggccagcccgagaacaactacaagac
	caccccccctgtgctggacagcgacggctcattcttcctggtgtccaagctgacagtg
	gacaagtcccggtggcagcagggcaacgtgttcagctgctccgtgctgcatgaggct
	ctgcacagccactacacgcagaagagcctctccctgtctccgggt
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagtg	SEQ ID
chain	accatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagcac	NO: 206
A	aagcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaagatgg
	cgtgcccagcagattaccggcagcggcttccacaccagcttcaacctgaccatcagc
	gatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttcggcag
	aggcagcagactgcacatcaagcgtacggtggccgctcccagcgtgttcatcttccca
	cctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaact
	tctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcgg
	caacagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctg
	agcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgcctg
	cgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccggggcg
	agtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccgc	SEQ ID
chain	ctgagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggcag	NO: 207
B	cctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagggct
	ggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggacaatac
	caagaataccttgtataggagatgaacaacgtgagaactgaagacaccggatattact
	tctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggcgagga
	atattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaaacccatac
	ccaggtgcagttggtggagtctgggggaggcgtggtccagcctgggacgtccctga
	gactctcctgtgcagcctctcaattcaggtttgatggttatggcatgcactgggtccgcc
	aggccccaggcaaggggctggagtgggtggcatctatatcacatgatggaattaaaa
	agtatcacgcagaaaaagtgtggggccgcttcaccatctccagagacaattccaagaa
	cacactgtatctacaaatgaacagcctgcgacctgaggacacggctctctactactgtg
	cgaaagatttgcgagaagacgaatgtgaagagtggtggtcggattattacgattttggg
	aaacaactcccttgcgcaaagtcacgcggcggcttggttggaattgctgataactggg
	gccaagggacaatggtcaccgtctcttcagataagacccacaccgcttccaccaagg
	gcccatcggtcttccccctggcaccctcctccaagagcacctctgggggcacagcgg
	ccctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactc
	aggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggact
	ctactccctcagcagcgtggtgaccgtgccctccagcagcttgggcacccagaccta
	catctgcaacgtgaatcacaagcccagcaacaccaaggtggacaagaaagttgagc
	ccaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggg
	gggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccgg
	acccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaa
	gttcaactggtatgttgacggcgtggaggtgcataatgccaagacaaagccgcggga
	ggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccagga
	ctggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccc
	catcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtaca
	ccctgcccccatgccgggatgagctgaccaagaatcaagtcagcctgtggtgcctgg
	taaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccg
	gagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctcta
	ctcaaaactcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctc
	cgtgctgcatgaggctctgcacagccactacacgcagaagagcctctccctgtctccg
	ggt
Light	cagtctgtgctgacgcagccgccctcagtgtctgcggccccaggacagaaggtcacc	SEQ ID
chain	atctcctgctctggaaacacctccaacattggcaataattttgtgtcctggtatcaacagc	NO: 208
B	gccccggcagagccccccaactcctcatttatgaaactgacaagcgaccctcaggga
	ttcctgaccgattctctgcttccaagtctggtacgtcaggcaccctggccatcaccggg
	ctgcagactggggacgaggccgattattactgcgccacatgggctgccagcctgagtt
	ccgcgcgtgtcttcggaactgggaccaaggtcatcgtcctggacaaaacccataccg
	catccgaactgactcaggaccctgccgtctctgtggcactgaagcagactgtgactatt
	acttgccgaggcgactcactgcggagccactacgcttcctggtatcagaagaaaccc
	ggccaggcacctgtgctgctgttctacggaaagaacaataggccatctggcatccccg
	accgcttttctggcagtgcatcagggaaccgagccagtctgaccattaccggcgccca
	ggctgaggacgaagccgattactattgcagctcccgggataagagcggctccagact
	gagcgtgttcggaggaggaactaaactgaccgtcctcgataagacccatacccgtac
	ggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagctgaagtccgg
	cacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggccaaagtgcag
	tggaaggtggacaacgccctgcagagcggcaacagccaggaaagcgtgaccgag
	caggacagcaaggactccacctacagcctgagcagcaccctgacactgagcaaggc
	cgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccagggcctgtcta
	gccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 27 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqts fwfrqapgrglewvgw	SEQ ID
chain	nfgggfrdrvtltrdvyreiaymdirglkpddtavyycar	NO: 209
A	wgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsga
	ltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc
	dkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfn
	wyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpa
	piektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiavewesngq
	pennykttppvldsdgsfflvskltvdksrwqqgnvfscsvlhealhshytqkslsls
	pg
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssvedg	SEQ ID
chain	vpsrfsgsgfhtsfqltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifppsd	NO: 210
A	eqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstl
	tlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewvg	SEQ ID
chain	ritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcartg	NO: 211
B	kyydfwsgyppgeeyfqdwgqgtlvivssdkthtqvhltqsgpevrkpgt
	svkvsckapgntlktydlhwvrsvpgqglqwmgwishegdkkviverfk
	akvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyalydddgaln
	wavdvdylsnlefwgqgtavtvssdkthtastkgpsvfplapsskstsggta
	algclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpsssl
	gtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfp
	pkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpre
	eqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqpr
	epqvytlppcrdeltknqvslwclvkgfypsdiavewesngqpennyktt
	ppvldsdgsfflyskltvdksrwqqgnyfscsvlhealhshytqkslstspg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylassr	SEQ ID
chain	asgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikdkt	NO: 212
B	htaseltqdpavsvalkqtvtitcrgdskrshyaswyqkkpgqapvllfygknnrps
	gipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldkthtr
	tvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvt
	eqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 27 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggaccg	NO: 213
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtg
	ttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctg
	cctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctg
	accagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctg
	agcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaa
	cgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagag
	ctgcgacaagacccacacctgtcccctttgtcctgcccccgaactgctgggaggcc
	cttccgtgacctgaccccccaaagcccaaggacaccctgatgatcagccggaccc
	ccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttc
	aattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagag
	gaacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccagga
	ctggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcc
	cccatcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtg
	tgcacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagct
	gtgccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggc
	cagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcatt
	cttcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgtt
	cagctgctccgtgctgcacgaggccctgcacagccactacacccagaagtccctga
	gcctgagccccggc
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagt	SEQ ID
chain	gaccatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagc	NO: 214
A	acaagcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaaga
	tggcgtgcccagcagattaccggcagcggcttccacaccagcttccagctgaccat
	cagcgatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttc
	ggcagaggcagcagactgcacatcaagcgtacggtggccgctcccagcgtgttcat
	cttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgct
	gaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctg
	cagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccac
	ctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcacaag
	gtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagctt
	caaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgttctgcctccggctagatttcgataacgcctggatgacctgggtcaggc	NO: 215
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtataggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggc
	gaggaatattacaagactggggtcagggaacccttgttatcgtgtcctccgacaaaa
	cccatacccaggtgcacctgacacagagcggacccgaagtgcggaagcctggca
	cctctgtgaaggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgc
	actgggtgcgcagcgtgccaggacagggactgcagtggatgggctggatcagcca
	cgagggcgacaagaaagtgatcgtggaacggacaaggccaaagtgaccatcgac
	tgggacagaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcg
	ataccgccgtgtactactgcgccaagggcagcaagcaccggctgagagactacgc
	cctgtacgacgatgacggcgccctgaactgggccgtggatgtggactacctgagca
	acctggaattctggggccagggcacagccgtgaccgtgtcatctgataagacccac
	accgcttccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacc
	tctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggt
	gacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggct
	gtcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagc
	agcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaa
	ggtggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtg
	cccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaa
	ggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtga
	gccacgaagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtgcata
	atgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtca
	gcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaag
	gtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagg
	gcagccccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgacc
	aagaatcaagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgcc
	gtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctccc
	gtgctggactccgacggctccttcttcctctactcaaaactcaccgtggacaagagca
	ggtggcagcaggggaacgtcttctcatgctccgtgctgcatgaggctctgcacagcc
	actacacgcagaagagcctctccctgtctccgggt
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcg	SEQ ID
chain	ccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta	NO: 216
B	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggc
	cagcagcagagccagcggcgtgcccgatagattactggcagcggcagcgacaag
	gacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactg
	tatgcagggcagagagagcccctggacctttggccagggcaccaaggtggacatc
	aaggacaaaacccataccgcatccgaactgactcaggaccctgccgtctctgtggc
	actgaagcagactgtgactattacttgccgaggcgactcactgcggagccactacgc
	ttcctggtatcagaagaaacccggccaggcacctgtgctgctgactacggaaagaa
	caataggccatctggcatccccgaccgcttttctggcagtgcatcagggaaccgagc
	cagtctgaccattaccggcgcccaggctgaggacgaagccgattactattgcagctc
	ccgggataagagcggctccagactgagcgtgttcggaggaggaactaaactgacc
	gtcctcgataagacccatacccgtacggtggccgctcccagcgtgttcatcttcccac
	ctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaact
	tctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcg
	gcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcc
	tgagcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgc
	ctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccgg
	ggcgagtgt
Binding Protein 28 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqts fwfrqapgrglewvgw	SEQ ID
chain	nfgggfrdrvtltrdvyreiaymdirglkpddtavyycar	NO: 217
A	--wgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswn
	sgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve
	pkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedp
	evkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvs
	nkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiave
	wesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvlhealhsh
	ytqkslslspg
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssvee	SEQ ID
chain	gvpsrfsgsgfhtsfqltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifp	NO: 218
A	psdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewv	SEQ ID
chain	gritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfca	NO: 219
B	rtgkyydfwsgyppgeeyfqdwgqgtlvivssdkthtqvhltqsgpevr
	kpgtsvkvsckapgntlktydlhwvrsvpgqglqwmgwishegdkkv
	iverfkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyalyd
	ddgalnwavdvdylsnlefwgqgtavtvssdkthtastkgpsvfplapss
	kstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslss
	vvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapell
	ggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgve
	vhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapie
	ktiskakgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewes
	ngqpennykttppvldsdgsfflyskltvdksrwqqgnyfscsvlhealhs
	hytqkslstspg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylas	SEQ ID
chain	srasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdik	NO: 220
B	dkthtaseltqdpavsvalkqtvtitcrgdskrshyaswyqkkpgqapvllfygkn
	nrpsgipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvl
	dkthtrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgn
	sqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 28 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggttccg	NO: 221
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtg
	ttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctg
	cctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctg
	accagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctg
	agcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaa
	cgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagag
	ctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcc
	cttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggaccc
	ccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttc
	aattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagag
	gaacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccagga
	ctggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcc
	cccatcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtg
	tgcacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagct
	gtgccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggc
	cagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcatt
	cttcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgtt
	cagctgctccgtgctgcacgaggccctgcacagccactacacccagaagtccctga
	gcctgagccccggc
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagt	SEQ ID
chain	gaccatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagc	NO: 222
A	acaagcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaaga
	aggcgtgcccagcagattttccggcagcggcttccacaccagcttcaacctgaccat
	cagcgatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttc
	ggcagaggcagcagactgcacatcaagcgtacggtggccgctcccagcgtgttcat
	cttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgct
	gaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctg
	cagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccac
	ctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcacaag
	gtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagctt
	caaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 223
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggc
	gaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaaa
	cccatacccaggtgcacctgacacagagcggacccgaagtgcggaagcctggca
	cctctgtgaaggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgc
	actgggtgcgcagcgtgccaggacagggactgcagtggatgggctggatcagcca
	cgagggcgacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcgac
	tgggacagaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcg
	ataccgccgtgtactactgcgccaagggcagcaagcaccggctgagagactacgc
	cctgtacgacgatgacggcgccctgaactgggccgtggatgtggactacctgagca
	acctggaattctggggccagggcacagccgtgaccgtgtcatctgataagacccac
	accgcttccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacc
	tctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggt
	gacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggct
	gtcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagc
	agcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaa
	ggtggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtg
	cccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaa
	ggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtga
	gccacgaagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtgcata
	atgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtca
	gcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaag
	gtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagg
	gcagccccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgacc
	aagaatcaagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgcc
	gtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctccc
	gtgctggactccgacggctccttcttcctctactcaaaactcaccgtggacaagagca
	ggtggcagcaggggaacgtcttctcatgctccgtgctgcatgaggctctgcacagcc
	actacacgcagaagagcctctccctgtctccgggt
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcg	SEQ ID
chain	ccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta	NO: 224
B	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggc
	cagcagcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaag
	gacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactg
	tatgcagggcagagagagcccctggacctaggccagggcaccaaggtggacatc
	aaggacaaaacccataccgcatccgaactgactcaggaccctgccgtctctgtggc
	actgaagcagactgtgactattacttgccgaggcgactcactgcggagccactacgc
	ttcctggtatcagaagaaacccggccaggcacctgtgctgctgttctacggaaagaa
	caataggccatctggcatccccgaccgcttactggcagtgcatcagggaaccgagc
	cagtctgaccattaccggcgcccaggctgaggacgaagccgattactattgcagctc
	ccgggataagagcggctccagactgagcgtgttcggaggaggaactaaactgacc
	gtcctcgataagacccatacccgtacggtggccgctcccagcgtgacatcttcccac
	ctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaact
	tctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcg
	gcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcc
	tgagcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgc
	ctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccgg
	ggcgagtgt
Binding Protein 29 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqts fwfrqapgrglewvgw	SEQ ID
chain	nfgggfrdrvtltrdvyreiaymdirglkpddtavyycar	NO: 225
A	wgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswn
	sgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve
	pkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedp
	evkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvs
	nkalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiave
	wesngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvlhealhsh
	ytqkslslspg
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved	SEQ ID
chain	avpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifpp	NO: 226
A	sdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstysl
	sstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewv	SEQ ID
chain	gritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfca	NO: 227
B	rtgkyydfwsgyppgeeyfqdwgqgtlvivssdkthtqvhltqsgpevr
	kpgtsvkvsckapgntlktydlhwvrsvpgqglqwmgwishegdkkv
	iverfkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyalyd
	ddgalnwavdvdylsnlefwgqgtavtvssdkthtastkgpsvfplapss
	kstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslss
	vvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapell
	ggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgve
	vhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapie
	ktiskakgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewes
	ngqpennykttppvldsdgsfflyskltvdksrwqqgnyfscsvlhealhs
	hytqkslstspg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylas	SEQ ID
chain	srasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdik	NO: 228
B	dkthtaseltqdpavsvalkqtvtitcrgdskrshyaswyqkkpgqapvllfygkn
	nrpsgipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvl
	dkthtrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgn
	sqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 29 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggttccg	NO: 229
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtg
	ttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctg
	cctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctg
	accagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctg
	agcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaa
	cgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagag
	ctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcc
	cttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggaccc
	ccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttca
	attggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagagg
	aacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggac
	tggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccc
	catcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtg
	cacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgt
	gccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattct
	tcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgttc
	agctgctccgtgctgcacgaggccctgcacagccactacacccagaagtccctgag
	cctgagccccggc
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagt	SEQ ID
chain	gaccatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagc	NO: 230
A	acaagcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaaga
	tgccgtgcccagcagattttccggcagcggcttccacaccagcttcaacctgaccatc
	agcgatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttcg
	gcagaggcagcagactgcacatcaagcgtacggtggccgctcccagcgtgttcatc
	ttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctg
	aacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgc
	agagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacct
	acagcctgagcagcaccctgacactgagcaaggccgactacgagaagcacaaggt
	gtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttca
	accggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 231
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtataggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggc
	gaggaatattacaagactggggtcagggaacccttgttatcgtgtcctccgacaaaa
	cccatacccaggtgcacctgacacagagcggacccgaagtgcggaagcctggca
	cctctgtgaaggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgc
	actgggtgcgcagcgtgccaggacagggactgcagtggatgggctggatcagcca
	cgagggcgacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcgac
	tgggacagaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcg
	ataccgccgtgtactactgcgccaagggcagcaagcaccggctgagagactacgc
	cctgtacgacgatgacggcgccctgaactgggccgtggatgtggactacctgagca
	acctggaattctggggccagggcacagccgtgaccgtgtcatctgataagacccac
	accgcttccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacc
	tctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggt
	gacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctg
	tcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagca
	gcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaag
	gtggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgc
	ccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaag
	gacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgag
	ccacgaagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtgcataa
	tgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc
	gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggt
	ctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaaggg
	cagccccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgacca
	agaatcaagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgccgt
	ggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgt
	gctggactccgacggctccttcttcctctactcaaaactcaccgtggacaagagcag
	gtggcagcaggggaacgtcttctcatgctccgtgctgcatgaggctctgcacagcca
	ctacacgcagaagagcctctccctgtctccgggt
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcg	SEQ ID
chain	ccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta	NO: 301
B	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggc
	cagcagcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaag
	gacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactg
	tatgcagggcagagagagcccctggacctaggccagggcaccaaggtggacatc
	aaggacaaaacccataccgcatccgaactgactcaggaccctgccgtctctgtggc
	actgaagcagactgtgactattacttgccgaggcgactcactgcggagccactacgc
	ttcctggtatcagaagaaacccggccaggcacctgtgctgctgttctacggaaagaa
	caataggccatctggcatccccgaccgcttactggcagtgcatcagggaaccgagc
	cagtctgaccattaccggcgcccaggctgaggacgaagccgattactattgcagctc
	ccgggataagagcggctccagactgagcgtgttcggaggaggaactaaactgacc
	gtcctcgataagacccatacccgtacggtggccgctcccagcgtgacatcttcccac
	ctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaact
	tctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcg
	gcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcc
	tgagcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgc
	ctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccggg
	gcgagtgt
Binding Protein 30 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqts fwfrqapgrglewvgw	SEQ ID
chain	nfgggfrdrvtltrdvyreiaymdirglkpddtavyycar	NO: 232
A	wgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswns
	galtsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep
	kscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpe
	vkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsn
	kalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiavew
	esngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvlhealhshyt
	qkslslspg
Light	yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssvee	SEQ ID
chain	gvpsrfsgsgfhtsfqltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifp	NO: 233
A	psdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewv	SEQ ID
chain	gritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfca	NO: 234
B	rtgkyydfwsgyppgeeyfqdwgqgtlvivssdkthtqvhltqsgpevr
	kpgtsvkvsckapgntlktydlhwvrsvpgqglqwmgwishegdkkv
	iverfkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyalyd
	ddgalnwavdvdylsnlefwgqgtavtvssdkthtastkgpsvfplapss
	kstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslss
	vvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapell
	ggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgve
	vhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapie
	ktiskakgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewes
	ngqpennykttppvldsdgsfflyskltvdksrwqqgnyfscsvlhealhs
	hytqkslstspg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylas	SEQ ID
chain	srasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdik	NO: 235
B	dkthtaseltqdpavsvalkqtvtitcrgdskrshyaswyqkkpgqapvllfygkn
	nrpsgipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvl
	dkthtrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgn
	sqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 30 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgactggttccg	NO: 236
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtg
	ttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctg
	cctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctg
	accagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctg
	agcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaa
	cgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagag
	ctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcc
	cttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggaccc
	ccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttca
	attggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagagg
	aacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggac
	tggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcccc
	catcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtgtg
	cacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagctgt
	gccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattct
	tcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgac
	agctgctccgtgctgcacgaggccctgcacagccactacacccagaagtccctgag
	cctgagccccggc
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagt	SEQ ID
chain	gaccatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagc	NO: 237
A	acaagcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaaga
	aggcgtgcccagcagattaccggcagcggcttccacaccagcttccagctgaccat
	cagcgatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttc
	ggcagaggcagcagactgcacatcaagcgtacggtggccgctcccagcgtgttcat
	cttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgct
	gaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctg
	cagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccac
	ctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcacaag
	gtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagctt
	caaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgactgcctccggctagatttcgataacgcctggatgacctgggtcaggc	NO: 238
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtataggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggc
	gaggaatattacaagactggggtcagggaacccttgttatcgtgtcctccgacaaaa
	cccatacccaggtgcacctgacacagagcggacccgaagtgcggaagcctggca
	cctctgtgaaggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgc
	actgggtgcgcagcgtgccaggacagggactgcagtggatgggctggatcagcca
	cgagggcgacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcgac
	tgggacagaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcg
	ataccgccgtgtactactgcgccaagggcagcaagcaccggctgagagactacgc
	cctgtacgacgatgacggcgccctgaactgggccgtggatgtggactacctgagca
	acctggaattctggggccagggcacagccgtgaccgtgtcatctgataagacccac
	accgcttccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacc
	tctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggt
	gacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctg
	tcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagca
	gcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaag
	gtggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgc
	ccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaag
	gacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgag
	ccacgaagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtgcataa
	tgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc
	gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggt
	ctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaaggg
	cagccccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgacca
	agaatcaagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgccgt
	ggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgt
	gctggactccgacggctccttcttcctctactcaaaactcaccgtggacaagagcag
	gtggcagcaggggaacgtcttctcatgctccgtgctgcatgaggctctgcacagcca
	ctacacgcagaagagcctctccctgtctccgggt
Light	Gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcg	SEQ ID
chain	ccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta	NO: 239
B	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggc
	cagcagcagagccagcggcgtgcccgatagattactggcagcggcagcgacaag
	gacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactg
	tatgcagggcagagagagcccctggacctttggccagggcaccaaggtggacatc
	aaggacaaaacccataccgcatccgaactgactcaggaccctgccgtctctgtggc
	actgaagcagactgtgactattacttgccgaggcgactcactgcggagccactacgc
	ttcctggtatcagaagaaacccggccaggcacctgtgctgctgttctacggaaagaa
	caataggccatctggcatccccgaccgcttactggcagtgcatcagggaaccgagc
	cagtctgaccattaccggcgcccaggctgaggacgaagccgattactattgcagctc
	ccgggataagagcggctccagactgagcgtgttcggaggaggaactaaactgacc
	gtcctcgataagacccatacccgtacggtggccgctcccagcgtgacatcttcccac
	ctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaact
	tctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcg
	gcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcc
	tgagcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgc
	ctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccggg
	gcgagtgt
Binding Protein 31 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqts fwfrqapgrglewvgw	SEQ ID
chain	nfgggfrdrvtltrdvyreiaymdirglkpddtavyycar	NO: 240
A	wgqgttvvvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswns
	galtsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep
	kscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpe
	vkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsn
	kalpapiektiskakgqprepqvctlppsrdeltknqvslscavkgfypsdiavew
	esngqpennykttppvldsdgsfflvskltvdksrwqqgnvfscsvlhealhshyt
	qkslslspg
Light	Yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved	SEQ ID
chain	avpsrfsgsgfhtsfqltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifpp	NO: 241
A	sdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstysl
	sstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Evrlvesggglvkpggslrlscsasgfdfdnawmtwvrqppgkglewv	SEQ ID
chain	gritgpgegwsvdyaesvkgrftisrdntkntlylemnnvrtedtgyyfcar	NO: 242
B	tgkyydfwsgyppgeeyfqdwgqgtlvivssdkthtqvhltqsgpevrk
	pgtsvkvsckapgntlktydlhwvrsvpgqglqwmgwishegdkkviv
	erfkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyalyddd
	galnwavdvdylsnlefwgqgtavtvssdkthtastkgpsvfplapsskst
	sggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvt
	vpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellgg
	psvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhn
	aktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektis
	kakgqprepqvytlppcrdeltknqvslwclvkgfypsdiavewesngq
	pennykttppvldsdgsfflyskltvdksrwqqgnyfscsvlhealhshyt
	qkslstspg
Light	dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylass	SEQ ID
chain	rasgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikd	NO: 243
B	kthtaseltqdpavsvalkqtvtitcrgdslrshyaswyqkkpgqapvllfygknnr
	psgipdrfsgsasgnrasltitgaqaedeadyycssrdksgsrlsvfgggtkltvldk
	thtrtvaapsvfifppsedqlksgtasvvcllnnfypreakvqwkvdnalqsgnsq
	esvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 31 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgc	SEQ ID
chain	gggtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgactggaccg	NO: 244
A	gcaggcccctggcagaggactggaatgggtgggatggatcaagccccagtatggc
	gccgtgaacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgta
	ccgcgagatcgcctacatggacatccggggcctgaagcccgatgacaccgccgtg
	tactactgcgccagagacagaagctacggcgacagcagctgggctctggatgcttg
	gggccagggcacaaccgtggtggtgtctgccgcctctacaaagggccccagcgtg
	ttccctctggcccctagcagcaagagcacatctggcggaacagccgccctgggctg
	cctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaattctggcgccctg
	accagcggcgtgcacacctttccagctgtgctgcagtccagcggcctgtacagcctg
	agcagcgtcgtgacagtgcccagcagctctctgggcacccagacctacatctgcaa
	cgtgaaccacaagcccagcaacaccaaggtggacaagaaggtggaacccaagag
	ctgcgacaagacccacacctgtcccccttgtcctgcccccgaactgctgggaggcc
	cttccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggaccc
	ccgaagtgacctgcgtggtggtggatgtgtcccacgaggaccctgaagtgaagttc
	aattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccaagagag
	gaacagtacaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccagga
	ctggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggccctgcctgcc
	cccatcgagaaaaccatcagcaaggccaagggccagccccgcgaaccccaggtg
	tgcacactgcccccaagcagggacgagctgaccaagaaccaggtgtccctgagct
	gtgccgtgaaaggcttctacccctccgatatcgccgtggaatgggagagcaacggc
	cagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcatt
	cttcctggtgtccaagctgacagtggacaagtcccggtggcagcagggcaacgtgtt
	cagctgctccgtgctgcacgaggccctgcacagccactacacccagaagtccctga
	gcctgagccccggc
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagt	SEQ ID
chain	gaccatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagc	NO: 245
A	acaagcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaaga
	tgccgtgcccagcagattttccggcagcggcttccacaccagcttccagctgaccat
	cagcgatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttc
	ggcagaggcagcagactgcacatcaagcgtacggtggccgctcccagcgtgttcat
	cttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgct
	gaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctg
	cagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccac
	ctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcacaag
	gtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagctt
	caaccggggcgagtgt
Heavy	gaggttagactggtggagtcaggaggggggcttgtgaagcccggtgggtctctccg	SEQ ID
chain	cctgagctgttctgcctccggctttgatttcgataacgcctggatgacctgggtcaggc	NO: 246
B	agcctccaggtaagggactggagtgggtgggaagaatcacaggtccaggcgagg
	gctggtccgtggactacgcggaatctgttaaagggcggtttacaatctcaagggaca
	ataccaagaataccttgtatttggagatgaacaacgtgagaactgaagacaccggat
	attacttctgtgccagaacaggcaaatactacgacttctggtccggctatccccctggc
	gaggaatattttcaagactggggtcagggaacccttgttatcgtgtcctccgacaaaa
	cccatacccaggtgcacctgacacagagcggacccgaagtgcggaagcctggca
	cctctgtgaaggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgc
	actgggtgcgcagcgtgccaggacagggactgcagtggatgggctggatcagcca
	cgagggcgacaagaaagtgatcgtggaacggttcaaggccaaagtgaccatcgac
	tgggacagaagcaccaacaccgcctacctgcagctgagcggcctgacctctggcg
	ataccgccgtgtactactgcgccaagggcagcaagcaccggctgagagactacgc
	cctgtacgacgatgacggcgccctgaactgggccgtggatgtggactacctgagca
	acctggaattctggggccagggcacagccgtgaccgtgtcatctgataagacccac
	accgcttccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacc
	tctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggt
	gacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggct
	gtcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagc
	agcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaa
	ggtggacaagaaagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtg
	cccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaa
	ggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtga
	gccacgaagaccctgaggtcaagttcaactggtatgttgacggcgtggaggtgcata
	atgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtca
	gcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaag
	gtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagg
	gcagccccgagaaccacaggtgtacaccctgcccccatgccgggatgagctgacc
	aagaatcaagtcagcctgtggtgcctggtaaaaggcttctatcccagcgacatcgcc
	gtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctccc
	gtgctggactccgacggctccttcttcctctactcaaaactcaccgtggacaagagca
	ggtggcagcaggggaacgtcttctcatgctccgtgctgcatgaggctctgcacagcc
	actacacgcagaagagcctctccctgtctccgggt
Light	Gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcg	SEQ ID
chain	ccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta	NO: 247
B	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggc
	cagcagcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaag
	gacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactg
	tatgcagggcagagagagcccctggacctaggccagggcaccaaggtggacatc
	aaggacaaaacccataccgcatccgaactgactcaggaccctgccgtctctgtggc
	actgaagcagactgtgactattacttgccgaggcgactcactgcggagccactacgc
	ttcctggtatcagaagaaacccggccaggcacctgtgctgctgttctacggaaagaa
	caataggccatctggcatccccgaccgcttactggcagtgcatcagggaaccgagc
	cagtctgaccattaccggcgcccaggctgaggacgaagccgattactattgcagctc
	ccgggataagagcggctccagactgagcgtgttcggaggaggaactaaactgacc
	gtcctcgataagacccatacccgtacggtggccgctcccagcgtgacatcttcccac
	ctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaact
	tctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcg
	gcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcc
	tgagcagcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgc
	ctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccgg
	ggcgagtgt
Binding Protein 32 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwikpq	SEQ ID
chain	ygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsygdsswald	NO: 302
A	awgqgttvvvsaastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsg
	altsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvesky
	gppcppcpapeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfn
	wyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglps
	siektiskakgqprepqvytlppcqeemtknqvslwclvkgfypsdiavewesn
	gqpennykttppvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqk
	slslslgk
Light	Yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved	SEQ ID
chain	avpsrfsgsgfhtsfqltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifpp	NO: 303
A	sdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstysl
	sstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvqlvqsgaevvkpgasvkvsckas hwvrqapgqglewig	SEQ ID
chain	nyaqkfqgratltvdtsistaymelsrlrsddtavyyc	NO: 304
B	wgkgttvtvsssqvqlvesgggvvqpgrslrlscaas
	mhwvrqapgkqlewvaq yatyyadsvkgrflisrddskntlyl
	qmnslraedtavyyc wgqgtlvtvssrtastkgpsvfpla
	pcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglysls
	svvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeflgg
	psvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhn
	aktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektisk
	akgqprepqvctlppsqeemtknqvslscavkgfypsdiavewesngqp
	ennykttppvldsdgsfflvskltvdksrwqegnvfscsvmhealhnhytq
	kslslslgk
Light	Divmtqtplslsvtpgqpasisckss lswylqkpgqspqsliy	SEQ ID
chain	snrfsgvpdrfsgsgsgtdftlkisrveaedvgvyyc ftfgsgtkveikg	NO: 305
B	qpkaapdiqmtqspsslsasvgdrvtitcqas nwyqqkpgkapklliy
	kasnlhtgvpsrfsgsgsgtdftltisslqpediatyyc fgqgtkleiktk
	gpsrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsq
	esvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 32 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgcgg	SEQ ID
chain	gtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgactggttccggcag	NO: 306
A	gcccctggcagaggactggaatgggtgggatggatcaagccccagtatggcgccgtg
	aacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgtaccgcgag
	atcgcctacatggacatccggggcctgaagcccgatgacaccgccgtgtactactgcg
	ccagagacagaagctacggcgacagcagctgggctctggatgcttggggccagggc
	acaaccgtggtggtgtctgccgcctctacaaagggcccctcggtgaccctctggcccc
	ttgcagcagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactac
	tttcccgagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacac
	ctttccagccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgc
	ccagcagcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagca
	acaccaaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgccc
	agcccctgaatactgggcggaccctccgtgacctgaccccccaaagcccaaggaca
	ccctgatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccagga
	agatcccgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaa
	gaccaagcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgac
	cgtgctgcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaa
	gggcctgcccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcg
	agcctcaagtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtc
	cctgtggtgtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagca
	acggccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggc
	tcattcttcctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgt
	gttcagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgt
	ctctgtccctgggcaag
Light	Tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagtg	SEQ ID
chain	accatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagcaca	NO: 307
A	agcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaagatggc
	gtgcccagcagattaccggcagcggcttccacaccagcttcaacctgaccatcagcga
	tctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttcggcagagg
	cagcagactgcacatcaagcgtacggtggccgctcccagcgtgacatcttcccaccta
	gcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctac
	ccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaaca
	gccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagcagc
	accctgacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtg
	acccaccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Heavy	caggtgcagctggtgcagtctggcgccgaggtcgtgaaacctggcgcctctgtgaag	SEQ ID
chain	gtgtcctgcaaggccagcggctacacctttaccagctactacatccactgggtgcgcca	NO: 308
B	ggcccctggacagggactggaatggatcggcagcatctaccccggcaacgtgaacac
	caactacgcccagaagttccagggcagagccaccctgaccgtggacaccagcatcag
	caccgcctacatggaactgagccggctgagaagcgacgacaccgccgtgtactactg
	cacccggtcccactacggcctggattggaacttcgacgtgtggggcaagggcaccac
	cgtgacagtgtctagcagccaggtgcagctggtggaatctggcggcggagtggtgca
	gcctggcagaagcctgagactgagctgtgccgccagcggcttcaccttcaccaaggc
	ctggatgcactgggtgcgccaggcccctggaaagcagctggaatgggtggcccagat
	caaggacaagagcaacagctacgccacctactacgccgacagcgtgaagggccggt
	tcaccatcagccgggacgacagcaagaacaccctgtacctgcagatgaacagcctgc
	gggccgaggacaccgccgtgtactactgtcggggcgtgtactatgccctgagcccat
	cgattactggggccagggaaccctcgtgaccgtgtctagtcggaccgccagcacaaa
	gggcccatcggtgttccctctggccccttgcagcagaagcaccagcgaatctacagcc
	gccctgggctgcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaactc
	tggcgctctgacaagcggcgtgcacacctttccagccgtgctccagagcagcggcctg
	tactctctgagcagcgtcgtgacagtgcccagcagcagcctgggcaccaagacctaca
	cctgtaacgtggaccacaagcccagcaacaccaaggtggacaagcgggtggaatcta
	agtacggccctccctgccctccttgcccagcccctgaatttctgggcggaccctccgtgt
	tcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccgaagtgac
	ctgcgtggtggtggatgtgtcccaggaagatcccgaggtgcagttcaattggtacgtgg
	acggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagttcaacagc
	acctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacggcaaa
	gagtacaagtgcaaggtgtccaacaagggcctgcccagctccatcgagaaaaccatc
	agcaaggccaagggccagccccgcgagcctcaagtgtgtaccctgccccctagcca
	ggaagagatgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctacccc
	agcgacattgccgtggaatgggagagcaacggccagcccgagaacaactacaagac
	caccccccctgtgctggacagcgacggctcattcttcctggtgtccaagctgaccgtgg
	acaagagccggtggcaggaaggcaacgtgttcagctgctccgtgatgcacgaggccc
	tgcacaaccactacacccagaagtccctgtctctgtccctgggcaag
Light	gacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcc	SEQ ID
chain	agcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctg	NO: 309
B	agctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtcca
	acagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcac
	cctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccaggg
	cacccagtaccccttcacctttggcagcggcaccaaggtggaaatcaagggccagcc
	caaggccgcccccgacatccagatgacccagagccccagcagcctgtctgccagcgt
	gggcgacagagtgaccatcacctgtcaggccagccagaacatctacgtgtggctgaa
	ctggtatcagcagaagcccggcaaggcccccaagctgctgatctacaaggccagcaa
	cctgcacaccggcgtgcccagcagattttctggcagcggctccggcaccgacttcacc
	ctgacaatcagctccctgcagcccgaggacattgccacctactactgccagcagggcc
	agacctacccctacacctttggccagggcaccaagctggaaatcaagaccaagggcc
	ccagccgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagct
	gaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggcc
	aaagtgcagtggaaggtggacaacgccctgcagagcggcaacagccaggaaagcgt
	gaccgagcaggacagcaaggactccacctacagcctgagcagcaccctgacactga
	gcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccagggc
	ctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 33 Amino Acid Sequences
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwikpqy	SEQ ID
chain	gavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsygdsswaldaw	NO: 310
A	gqgttvvvsaastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsg
	vhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcp
	pcpapeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgv
	evhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiska
	kgqprepqvytlppcqeemtknqvslwclvkgfypsdiavewesngqpennykt
	tppvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssvedg	SEQ ID
chain	vpsrfsgsgfhtsfqltisdlqaddiatyycqvlqffgrgsrlhikrtvaapsvfifppsd	NO: 311
A	eqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltl
	skadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvqlqesgpglvkpsqtlsltctvsgfslsdygvhwvrqppgkglewlgvi	SEQ ID
chain	wagggtnynpslksrktiskdtsknqvslklssvtaadtavyycardkgysy	NO: 312
B	yysmdywgqgttvtvsssqvqlvesgggvvqpgrslrlscaasgftftkaw
	mhwvrqapgkqlewvaqikdksnsyatyyadsvkgrftisrddskntlylq
	mnslraedtavyycrgvyyalspfdywgqgtlvtvssrtastkgpsvfplapc
	srstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvv
	tvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeflggpsvf
	lfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkp
	reeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqpr
	epqvctlppsqeemtknqvslscavkgfypsdiavewesngqpennyktt
	ppvldsdgsfflvskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Divmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvs	SEQ ID
chain	nrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikgqp	NO: 313
B	kaapdivltqspaslavspgqratitcrasesveyyvtslqwyqqkpgqppkllifa
	asnvesgvparfsgsgsgtdftltinpveandvanyycqqsrkvpytfgqgtkleikt
	kgpsrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsq
	esvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 33 Nucleotide Sequences
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgcgg	SEQ ID
chain	gtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgactggttccggcag	NO: 314
A	gcccctggcagaggactggaatgggtgggatggatcaagccccagtatggcgccgtg
	aacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgtaccgcgag
	atcgcctacatggacatccggggcctgaagcccgatgacaccgccgtgtactactgcg
	ccagagacagaagctacggcgacagcagctgggctctggatgcttggggccagggc
	acaaccgtggtggtgtctgccgcctctacaaagggcccctcggtgaccctctggcccc
	ttgcagcagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactac
	tttcccgagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacac
	ctttccagccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgc
	ccagcagcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagca
	acaccaaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgccc
	agcccctgaatactgggcggaccctccgtgacctgaccccccaaagcccaaggaca
	ccctgatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccagga
	agatcccgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaa
	gaccaagcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgac
	cgtgctgcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaa
	gggcctgcccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcg
	agcctcaagtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtc
	cctgtggtgtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagca
	acggccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggc
	tcattcttcctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgt
	gttcagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgt
	ctctgtccctgggcaag
Light	Tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagtg	SEQ ID
chain	accatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagcaca	NO: 315
A	agcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaagatggc
	gtgcccagcagattaccggcagcggcttccacaccagcttcaacctgaccatcagcga
	tctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttcggcagagg
	cagcagactgcacatcaagcgtacggtggccgctcccagcgtgttcatcttcccaccta
	gcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctac
	ccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaaca
	gccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagcagc
	accctgacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtg
	acccaccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Heavy	caggtgcagctgcaggaatctggccctggcctcgtgaagcctagccagaccctgagc	SEQ ID
chain	ctgacctgtaccgtgtccggcttcagcctgagcgactacggcgtgcactgggtgcgcc	NO: 316
B	agccacctggaaaaggcctggaatggctgggcgtgatctgggctggcggaggcacc
	aactacaaccccagcctgaagtccagaaagaccatcagcaaggacaccagcaagaac
	caggtgtccctgaagctgagcagcgtgacagccgccgataccgccgtgtactactgcg
	ccagagacaagggctacagctactactacagcatggactactggggccagggcacca
	ccgtgaccgtgtcatcctctcaggtgcagctggtggaatctggcggcggagtggtgca
	gcctggcagaagcctgagactgagctgtgccgccagcggcttcaccttcaccaaggc
	ctggatgcactgggtgcgccaggcccctggaaagcagctggaatgggtggcccagat
	caaggacaagagcaacagctacgccacctactacgccgacagcgtgaagggccggt
	tcaccatcagccgggacgacagcaagaacaccctgtacctgcagatgaacagcctgc
	gggccgaggacaccgccgtgtactactgtcggggcgtgtactatgccctgagcccctt
	cgattactggggccagggaaccctcgtgaccgtgtctagtcggaccgcttcgaccaag
	ggcccatcggtgttccctctggccccttgcagcagaagcaccagcgaatctacagccg
	ccctgggctgcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaactct
	ggcgctctgacaagcggcgtgcacacctttccagccgtgctccagagcagcggcctgt
	actctctgagcagcgtcgtgacagtgcccagcagcagcctgggcaccaagacctaca
	cctgtaacgtggaccacaagcccagcaacaccaaggtggacaagcgggtggaatcta
	agtacggccctccctgccctccttgcccagcccctgaatttctgggcggaccctccgtgt
	tcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccgaagtgac
	ctgcgtggtggtggatgtgtcccaggaagatcccgaggtgcagttcaattggtacgtgg
	acggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagttcaacagc
	acctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacggcaaa
	gagtacaagtgcaaggtgtccaacaagggcctgcccagctccatcgagaaaaccatc
	agcaaggccaagggccagccccgcgagcctcaagtgtgtaccctgccccctagcca
	ggaagagatgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctacccc
	agcgacattgccgtggaatgggagagcaacggccagcccgagaacaactacaagac
	caccccccctgtgctggacagcgacggctcattcttcctggtgtccaagctgaccgtgg
	acaagagccggtggcaggaaggcaacgtgttcagctgctccgtgatgcacgaggccc
	tgcacaaccactacacccagaagtccctgtctctgtccctgggcaag
Light	gacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcc	SEQ ID
chain	agcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctg	NO: 317
B	agctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtcca
	acagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcac
	cctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccaggg
	cacccagtaccccttcacctttggcagcggcaccaaggtggaaatcaagggccagcc
	caaggccgcccccgacatcgtgctgacacagagccctgctagcctggccgtgtctcct
	ggacagagggccaccatcacctgtagagccagcgagagcgtggaatattacgtgacc
	agcctgatgcagtggtatcagcagaagcccggccagccccccaagctgctgattttcg
	ccgccagcaacgtggaaagcggcgtgccagccagattttccggcagcggctctggca
	ccgacttcaccctgaccatcaaccccgtggaagccaacgacgtggccaactactactg
	ccagcagagccggaaggtgccctacacctttggccagggcaccaagctggaaatcaa
	gaccaagggccccagccgtacggtggccgctcccagcgtgttcatcttcccacctagc
	gacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctaccc
	ccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaacagc
	caggaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagcagcac
	cctgacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgac
	ccaccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 34 Amino Acid Sequences
Heavy	Qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwmgwishe	SEQ ID
chain	gdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyalydd	NO: 318
A	dgalnwavdvdylsnlefwgqgtavtvssastkgpsvfplapcsrstsestaalgclv
	kdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdh
	kpsntkvdkrveskygppcppcpapeflggpsvflfppkpkdtlmisrtpevtcvv
	vdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngke
	ykckvsnkglpssiektiskakgqprepqvytlppcqeemtknqvslwclvkgfyp
	sdiavewesngqpennykttppvldsdgsfflyskltvdksrwqegnvfscsvmhe
	alhnhytqkslslslgk
Light	Dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylassr	SEQ ID
chain	asgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikrtva	NO: 319
B	apsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqds
	kdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvqlvqsgaevvkpgasvkvsckas ihwvrqapgqglewigs	SEQ ID
chain	nyaqkfqgratltvdtsistaymelsrlrsddtavyyc	NO: 320
B	wgkgttvtvsssqvqlvesgggvvqpgrslrlscaas mh
	wvrqapgkqlewvaq yatyyadsvkgrftisrddskntlylqmn
	slraedtavyy wgqgtlvtvssrtastkgpsvfplapcsrst
	sestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvp
	ssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeflggpsvflfp
	pkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpree
	qfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprep
	qvctlppsqeemtknqvslscavkgfypsdiavewesngqpennykttpp
	vldsdgsfflvskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Divmtqtplslsvtpgqpasisckss swylqkpgqspqsliy	SEQ ID
chain	nrfsgvpdrfsgsgsgtdftlkisrveaedvgvyyc ftfgsgtkveikgqp	NO: 321
B	kaapdiqmtqspsslsasvgdrvtitcqas nwyqqkpgkapklliy
	nlhtgvpsrfsgsgsgtdftltisslqpediatyyc gqgtkleiktkgpsr
	tvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvte
	qdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 34 Nucleotide Sequences
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctctgtgaa	SEQ ID
chain	ggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgcactgggtgcgc	NO: 322
A	agcgtgccaggacagggactgcagtggatgggctggatcagccacgagggcgacaa
	gaaagtgatcgtggaacggttcaaggccaaagtgaccatcgactgggacagaagcac
	caacaccgcctacctgcagctgagcggcctgacctctggcgataccgccgtgtactact
	gcgccaagggcagcaagcaccggctgagagactacgccctgtacgacgatgacggc
	gccctgaactgggccgtggatgtggactacctgagcaacctggaattctggggccagg
	gcacagccgtgaccgtgtcatctgcttcgaccaagggcccctcggtgttccctctggcc
	ccttgcagcagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggact
	actttcccgagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcac
	acctaccagccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagt
	gcccagcagcagcctgggcaccaagacctacacctgtaacgtggaccacaagccca
	gcaacaccaaggtggacaagcgggtggaatctaagtacggccctccctgccctccttg
	cccagcccctgaatactgggcggaccctccgtgacctgttccccccaaagcccaagg
	acaccctgatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtccca
	ggaagatcccgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgc
	caagaccaagcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgct
	gaccgtgctgcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaa
	caagggcctgcccagctccatcgagaaaaccatcagcaaggccaagggccagcccc
	gcgagcctcaagtgtataccctgcccccttgccaggaagagatgaccaagaaccaggt
	gtccctgtggtgtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggaga
	gcaacggccagcccgagaacaactacaagaccaccccccctgtgctggacagcgac
	ggctcattcttcctgtactccaagctgaccgtggacaagagccggtggcaggaaggca
	acgtgttcagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtc
	cctgtctctgtccctgggcaag
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcgcc	SEQ ID
chain	agcatcagctgcaagagcagccactccctgatccacggcgaccggaacaactacctg	NO: 323
A	gcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggccagca
	gcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaaggacttca
	ccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactgtatgcagg
	gcagagagagcccctggacctttggccagggcaccaaggtggacatcaagcgtacg
	gtggccgctcccagcgtgttcatcttcccacctagcgacgagcagctgaagtccggca
	cagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggccaaagtgcagtgg
	aaggtggacaacgccctgcagagcggcaacagccaggaaagcgtgaccgagcagg
	acagcaaggactccacctacagcctgagcagcaccctgacactgagcaaggccgact
	acgagaagcacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccg
	tgaccaagagcttcaaccggggcgagtgt
Heavy	caggtgcagctggtgcagtctggcgccgaggtcgtgaaacctggcgcctctgtgaag	SEQ ID
chain	gtgtcctgcaaggccagcggctacacctttaccagctactacatccactgggtgcgcca	NO: 324
B	ggcccctggacagggactggaatggatcggcagcatctaccccggcaacgtgaacac
	caactacgcccagaagttccagggcagagccaccctgaccgtggacaccagcatcag
	caccgcctacatggaactgagccggctgagaagcgacgacaccgccgtgtactactg
	cacccggtcccactacggcctggattggaacttcgacgtgtggggcaagggcaccac
	cgtgacagtgtctagcagccaggtgcagctggtggaatctggcggcggagtggtgca
	gcctggcagaagcctgagactgagctgtgccgccagcggcttcaccttcaccaaggc
	ctggatgcactgggtgcgccaggcccctggaaagcagctggaatgggtggcccagat
	caaggacaagagcaacagctacgccacctactacgccgacagcgtgaagggccggt
	tcaccatcagccgggacgacagcaagaacaccctgtacctgcagatgaacagcctgc
	gggccgaggacaccgccgtgtactactgtcggggcgtgtactatgccctgagcccctt
	cgattactggggccagggaaccctcgtgaccgtgtctagtcggaccgccagcacaaa
	gggcccatcggtgttccctctggccccttgcagcagaagcaccagcgaatctacagcc
	gccctgggctgcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaactc
	tggcgctctgacaagcggcgtgcacacctttccagccgtgctccagagcagcggcctg
	tactctctgagcagcgtcgtgacagtgcccagcagcagcctgggcaccaagacctaca
	cctgtaacgtggaccacaagcccagcaacaccaaggtggacaagcgggtggaatcta
	agtacggccctccctgccctccttgcccagcccctgaatttctgggcggaccctccgtgt
	tcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccgaagtgac
	ctgcgtggtggtggatgtgtcccaggaagatcccgaggtgcagttcaattggtacgtgg
	acggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagttcaacagc
	acctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacggcaaa
	gagtacaagtgcaaggtgtccaacaagggcctgcccagctccatcgagaaaaccatc
	agcaaggccaagggccagccccgcgagcctcaagtgtgtaccctgccccctagcca
	ggaagagatgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctacccc
	agcgacattgccgtggaatgggagagcaacggccagcccgagaacaactacaagac
	caccccccctgtgctggacagcgacggctcattcttcctggtgtccaagctgaccgtgg
	acaagagccggtggcaggaaggcaacgtgttcagctgctccgtgatgcacgaggccc
	tgcacaaccactacacccagaagtccctgtctctgtccctgggcaag
Light	gacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcc	SEQ ID
chain	agcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctg	NO: 325
B	agctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtcca
	acagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcac
	cctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccaggg
	cacccagtaccccttcacctttggcagcggcaccaaggtggaaatcaagggccagcc
	caaggccgcccccgacatccagatgacccagagccccagcagcctgtctgccagcgt
	gggcgacagagtgaccatcacctgtcaggccagccagaacatctacgtgtggctgaa
	ctggtatcagcagaagcccggcaaggcccccaagctgctgatctacaaggccagcaa
	cctgcacaccggcgtgcccagcagattttctggcagcggctccggcaccgacttcacc
	ctgacaatcagctccctgcagcccgaggacattgccacctactactgccagcagggcc
	agacctacccctacacctttggccagggcaccaagctggaaatcaagaccaagggcc
	ccagccgtacggtggccgctcccagcgtgacatcttcccacctagcgacgagcagct
	gaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggcc
	aaagtgcagtggaaggtggacaacgccctgcagagcggcaacagccaggaaagcgt
	gaccgagcaggacagcaaggactccacctacagcctgagcagcaccctgacactga
	gcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccagggc
	ctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 35 Amino Acid Sequences
Heavy	Qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwmgwishe	SEQ ID
chain	gdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakgskhrlrdyalydd	NO: 326
A	dgalnwavdvdylsnlefwgqgtavtvssastkgpsvfplapcsrstsestaalgclv
	kdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdh
	kpsntkvdkrveskygppcppcpapeflggpsvflfppkpkdtlmisrtpevtcvv
	vdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngke
	ykckvsnkglpssiektiskakgqprepqvytlppcqeemtknqvslwclvkgfyp
	sdiavewesngqpennykttppvldsdgsfflyskltvdksrwqegnvfscsvmhe
	alhnhytqkslslslgk
Light	Dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylassr	SEQ ID
chain	asgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikrtva	NO: 327
B	apsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqds
	kdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvqlqesgpglvkpsqtlsltctvsgfslsdygvhwvrqppgkglewlgvi	SEQ ID
chain	wagggtnynpslksrktiskdtsknqvslklssvtaadtavyycardkgysy	NO: 328
B	yysmdywgqgttvtvsssqvqlvesgggvvqpgrslrlscaasgftftkaw
	mhwvrqapgkqlewvaqikdksnsyatyyadsvkgrftisrddskntlylq
	mnslraedtavyycrgvyyalspfdywgqgtlvtvssrtastkgpsvfplapc
	srstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvv
	tvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeflggpsvf
	lfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkp
	reeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqpr
	epqvctlppsqeemtknqvslscavkgfypsdiavewesngqpennyktt
	ppvldsdgsfflvskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Divmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvs	SEQ ID
chain	nrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikgqp	NO: 329
B	kaapdivltqspaslavspgqratitcrasesveyyvtslqwyqqkpgqppkllifa
	asnvesgvparfsgsgsgtdftltinpveandvanyycqqsrkvpytfgqgtkleikt
	kgpsrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsq
	esvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 35 Nucleotide Sequences
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctctgtgaa	SEQ ID
chain	ggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgcactgggtgcgc	NO: 330
A	agcgtgccaggacagggactgcagtggatgggctggatcagccacgagggcgacaa
	gaaagtgatcgtggaacggttcaaggccaaagtgaccatcgactgggacagaagcac
	caacaccgcctacctgcagctgagcggcctgacctctggcgataccgccgtgtactact
	gcgccaagggcagcaagcaccggctgagagactacgccctgtacgacgatgacggc
	gccctgaactgggccgtggatgtggactacctgagcaacctggaattctggggccagg
	gcacagccgtgaccgtgtcatctgcttcgaccaagggcccctcggtgttccctctggcc
	ccttgcagcagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggact
	actttcccgagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcac
	acctaccagccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagt
	gcccagcagcagcctgggcaccaagacctacacctgtaacgtggaccacaagccca
	gcaacaccaaggtggacaagcgggtggaatctaagtacggccctccctgccctccttg
	cccagcccctgaatactgggcggaccctccgtgacctgttccccccaaagcccaagg
	acaccctgatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtccca
	ggaagatcccgaggtgcagacaattggtacgtggacggcgtggaagtgcacaacgc
	caagaccaagcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgct
	gaccgtgctgcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaa
	caagggcctgcccagctccatcgagaaaaccatcagcaaggccaagggccagcccc
	gcgagcctcaagtgtataccctgcccccagccaggaagagatgaccaagaaccaggt
	gtccctgtggtgtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggaga
	gcaacggccagcccgagaacaactacaagaccaccccccctgtgctggacagcgac
	ggctcattcacctgtactccaagctgaccgtggacaagagccggtggcaggaaggca
	acgtgacagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtc
	cctgtctctgtccctgggcaag
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcgcc	SEQ ID
chain	agcatcagctgcaagagcagccactccctgatccacggcgaccggaacaactacctg	NO: 331
A	gcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggccagca
	gcagagccagcggcgtgcccgatagattactggcagcggcagcgacaaggacttca
	ccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactgtatgcagg
	gcagagagagcccctggacctaggccagggcaccaaggtggacatcaagcgtacg
	gtggccgctcccagcgtgacatcacccacctagcgacgagcagctgaagtccggca
	cagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggccaaagtgcagtgg
	aaggtggacaacgccctgcagagcggcaacagccaggaaagcgtgaccgagcagg
	acagcaaggactccacctacagcctgagcagcaccctgacactgagcaaggccgact
	acgagaagcacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccg
	tgaccaagagcttcaaccggggcgagtgt
Heavy	caggtgcagctgcaggaatctggccctggcctcgtgaagcctagccagaccctgagc	SEQ ID
chain	ctgacctgtaccgtgtccggcttcagcctgagcgactacggcgtgcactgggtgcgcc	NO: 332
B	agccacctggaaaaggcctggaatggctgggcgtgatctgggctggcggaggcacc
	aactacaaccccagcctgaagtccagaaagaccatcagcaaggacaccagcaagaac
	caggtgtccctgaagctgagcagcgtgacagccgccgataccgccgtgtactactgcg
	ccagagacaagggctacagctactactacagcatggactactggggccagggcacca
	ccgtgaccgtgtcatcctctcaggtgcagctggtggaatctggcggcggagtggtgca
	gcctggcagaagcctgagactgagctgtgccgccagcggcttcaccttcaccaaggc
	ctggatgcactgggtgcgccaggcccctggaaagcagctggaatgggtggcccagat
	caaggacaagagcaacagctacgccacctactacgccgacagcgtgaagggccggt
	tcaccatcagccgggacgacagcaagaacaccctgtacctgcagatgaacagcctgc
	gggccgaggacaccgccgtgtactactgtcggggcgtgtactatgccctgagcccat
	cgattactggggccagggaaccctcgtgaccgtgtctagtcggaccgcttcgaccaag
	ggcccatcggtgaccctctggccccttgcagcagaagcaccagcgaatctacagccg
	ccctgggctgcctcgtgaaggactactacccgagcccgtgaccgtgtcctggaactct
	ggcgctctgacaagcggcgtgcacacctaccagccgtgctccagagcagcggcctgt
	actctctgagcagcgtcgtgacagtgcccagcagcagcctgggcaccaagacctaca
	cctgtaacgtggaccacaagcccagcaacaccaaggtggacaagcgggtggaatcta
	agtacggccctccctgccctccttgcccagcccctgaatactgggcggaccctccgtgt
	tcctgaccccccaaagcccaaggacaccctgatgatcagccggacccccgaagtgac
	ctgcgtggtggtggatgtgtcccaggaagatcccgaggtgcagacaattggtacgtgg
	acggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagttcaacagc
	acctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacggcaaa
	gagtacaagtgcaaggtgtccaacaagggcctgcccagctccatcgagaaaaccatc
	agcaaggccaagggccagccccgcgagcctcaagtgtgtaccctgccccctagcca
	ggaagagatgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcactacccc
	agcgacattgccgtggaatgggagagcaacggccagcccgagaacaactacaagac
	caccccccctgtgctggacagcgacggctcattcacctggtgtccaagctgaccgtgg
	acaagagccggtggcaggaaggcaacgtgacagctgctccgtgatgcacgaggccc
	tgcacaaccactacacccagaagtccctgtctctgtccctgggcaag
Light	gacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcc	SEQ ID
chain	agcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctg	NO: 333
B	agctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtcca
	acagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcac
	cctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccaggg
	cacccagtaccccacacctaggcagcggcaccaaggtggaaatcaagggccagcc
	caaggccgcccccgacatcgtgctgacacagagccctgctagcctggccgtgtctcct
	ggacagagggccaccatcacctgtagagccagcgagagcgtggaatattacgtgacc
	agcctgatgcagtggtatcagcagaagcccggccagccccccaagctgctgattacg
	ccgccagcaacgtggaaagcggcgtgccagccagattaccggcagcggctctggca
	ccgacttcaccctgaccatcaaccccgtggaagccaacgacgtggccaactactactg
	ccagcagagccggaaggtgccctacacctaggccagggcaccaagctggaaatcaa
	gaccaagggccccagccgtacggtggccgctcccagcgtgacatcacccacctagc
	gacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctaccc
	ccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaacagc
	caggaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagcagcac
	cctgacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgac
	ccaccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 36 Amino Acid Sequences
Heavy	Qvqlvqsggqmkkpgesmriscrasgyefidctlnwirlapgkrpewmgwlkpr	SEQ ID
chain	ggavnyarplqgrvtmadvysdtaflelrsltvddtavyfctrgkncdynwdfehw	NO: 334
A	grgtpvivssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsg
	vhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcp
	pcpapeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgv
	evhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiska
	kgqprepqvytlppcqeemtknqvslwclvkgfypsdiavewesngqpennykt
	tppvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Eivltqspgtlslspgetaiiscrtsqygslawyqqrpgqaprlviysgstraagipdrfs	SEQ ID
chain	gsrwgpdynltisnlesgdfgvyycqqyeffgqgtkvqvdikrtvaapsvfifppsd	NO: 335
A	eqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltl
	skadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvqlvqsgaevykpgasykysckas hwvrqapgqglewigs	SEQ ID
chain	nyaqkfqgratltvdtsistaymelsrlrsddtavyyc	NO: 336
B	wgkgttvtvsssqvqlvesgggvvqpgrslrlscaas m
	hwvrqapgkqlewvaq yatyyadsvkgrftisrddskntlylqm
	nslraedtavyyc wgqgtlvtvssrtastkgpsvfplapcsr
	stsestaalgclvkdyfpepvtvswnsgailsgvhtfpavlqssglyslssvvt
	vpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeflggpsvfl
	fppkpkdtlmisrtpevtcyvvdvsqedpevqfnwyvdgvevhnaktkpr
	eeqfnstyrvvsvltylhqdwlngkeykckvsnkglpssiektiskakgqpr
	epqvctlppsqeemtknqvslscavkgfypsdiavewesngqpennyktt
	ppvldsdgsfflvskltvdksrwqegnvfscsvmhealhnhytqkslslslg
	k
Light	Divmtqtplslsvtpgqpasisckss swylqkpgqspqsliy	SEQ ID
chain	nrfsgvpdrfsgsgsgtdftlkisrveaedvgvyyc ftfgsgtkveikgqp	NO: 337
B	kaapdiqmtqspsslsasvgdrvtitcqas nwyqqkpgkapklliy
	nlhtgvpsrfsgsgsgtdftltisslqpediatyyc fgqgtkleiktkgpsr
	tvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvte
	qdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 36 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcggccagatgaagaaacccggcgagagcatgcg	SEQ ID
chain	gatcagctgcagagccagcggctacgagacatcgactgcaccctgaactggatcaga	NO: 338
A	ctggcccctggcaagcggcctgagtggatgggatggctgaagcctagaggcggagc
	cgtgaactacgccagacctctgcagggcagagtgaccatgacccgggacgtgtacag
	cgataccgccttcctggaactgcggagcctgaccgtggatgataccgccgtgtacttct
	gcacccggggcaagaactgcgactacaactgggacttcgagcactggggcagaggc
	acccctgtgatcgtgtcaagcgcgtcgaccaagggcccctcggtgaccctctggcccc
	ttgcagcagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactac
	tttcccgagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacac
	ctttccagccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgc
	ccagcagcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagca
	acaccaaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgccc
	agcccctgaatactgggcggaccctccgtgacctgaccccccaaagcccaaggaca
	ccctgatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccagga
	agatcccgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaa
	gaccaagcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgac
	cgtgctgcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaa
	gggcctgcccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcg
	agcctcaagtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtc
	cctgtggtgtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagca
	acggccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggc
	tcattcttcctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgt
	gttcagctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgt
	ctctgtccctgggcaag
Light	Gagatcgtgctgacacagagccctggcaccctgagcctgtctccaggcgagacagcc	SEQ ID
chain	atcatcagctgccggacaagccagtacggcagcctggcctggtatcagcagaggcct	NO: 339
A	ggacaggcccccagactcgtgatctacagcggcagcacaagagccgccggaatccc
	cgatagattcagcggctccagatggggccctgactacaacctgaccatcagcaacctg
	gaaagcggcgacttcggcgtgtactactgccagcagtacgagacttcggccagggca
	ccaaggtgcaggtggacatcaagcgtacggtggccgctcccagcgtgttcatcttccca
	cctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaactt
	ctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggca
	acagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagc
	agcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcga
	agtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtg
	t
Heavy	caggtgcagctggtgcagtctggcgccgaggtcgtgaaacctggcgcctctgtgaag	SEQ ID
chain	gtgtcctgcaaggccagcggctacacctttaccagctactacatccactgggtgcgcca	NO: 340
B	ggcccctggacagggactggaatggatcggcagcatctaccccggcaacgtgaacac
	caactacgcccagaagttccagggcagagccaccctgaccgtggacaccagcatcag
	caccgcctacatggaactgagccggctgagaagcgacgacaccgccgtgtactactg
	cacccggtcccactacggcctggattggaacttcgacgtgtggggcaagggcaccac
	cgtgacagtgtctagcagccaggtgcagctggtggaatctggcggcggagtggtgca
	gcctggcagaagcctgagactgagctgtgccgccagcggcttcaccttcaccaaggc
	ctggatgcactgggtgcgccaggcccctggaaagcagctggaatgggtggcccagat
	caaggacaagagcaacagctacgccacctactacgccgacagcgtgaagggccggt
	tcaccatcagccgggacgacagcaagaacaccctgtacctgcagatgaacagcctgc
	gggccgaggacaccgccgtgtactactgtcggggcgtgtactatgccctgagcccat
	cgattactggggccagggaaccctcgtgaccgtgtctagtcggaccgccagcacaaa
	gggcccatcggtgttccctctggccccttgcagcagaagcaccagcgaatctacagcc
	gccctgggctgcctcgtgaaggactactacccgagcccgtgaccgtgtcctggaactc
	tggcgctctgacaagcggcgtgcacacctaccagccgtgctccagagcagcggcctg
	tactctctgagcagcgtcgtgacagtgcccagcagcagcctgggcaccaagacctaca
	cctgtaacgtggaccacaagcccagcaacaccaaggtggacaagcgggtggaatcta
	agtacggccctccctgccctccttgcccagcccctgaatactgggcggaccctccgtgt
	tcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccgaagtgac
	ctgcgtggtggtggatgtgtcccaggaagatcccgaggtgcagttcaattggtacgtgg
	acggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagttcaacagc
	acctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacggcaaa
	gagtacaagtgcaaggtgtccaacaagggcctgcccagctccatcgagaaaaccatc
	agcaaggccaagggccagccccgcgagcctcaagtgtgtaccctgccccctagcca
	ggaagagatgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctacccc
	agcgacattgccgtggaatgggagagcaacggccagcccgagaacaactacaagac
	caccccccctgtgctggacagcgacggctcattcttcctggtgtccaagctgaccgtgg
	acaagagccggtggcaggaaggcaacgtgacagctgctccgtgatgcacgaggccc
	tgcacaaccactacacccagaagtccctgtctctgtccctgggcaag
Light	gacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcc	SEQ ID
chain	agcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctg	NO: 341
B	agctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtcca
	acagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcac
	cctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccaggg
	cacccagtaccccttcacctaggcagcggcaccaaggtggaaatcaagggccagcc
	caaggccgcccccgacatccagatgacccagagccccagcagcctgtctgccagcgt
	gggcgacagagtgaccatcacctgtcaggccagccagaacatctacgtgtggctgaa
	ctggtatcagcagaagcccggcaaggcccccaagctgctgatctacaaggccagcaa
	cctgcacaccggcgtgcccagcagattactggcagcggctccggcaccgacttcacc
	ctgacaatcagctccctgcagcccgaggacattgccacctactactgccagcagggcc
	agacctacccctacacctaggccagggcaccaagctggaaatcaagaccaagggcc
	ccagccgtacggtggccgctcccagcgtgacatcttcccacctagcgacgagcagct
	gaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggcc
	aaagtgcagtggaaggtggacaacgccctgcagagcggcaacagccaggaaagcgt
	gaccgagcaggacagcaaggactccacctacagcctgagcagcaccctgacactga
	gcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccagggc
	ctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 37 Amino Acid Sequences
Heavy	Qvqlvqsggqmkkpgesmriscrasgyefidctlnwirlapgkrpewmgwlkpr	SEQ ID
chain	ggavnyarplqgrvtmadvysdtaflelrsltvddtavyfctrgkncdynwdfehw	NO: 342
A	grgtpvivssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsg
	vhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcp
	pcpapeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgv
	evhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiska
	kgqprepqvytlppcqeemtknqvslwclvkgfypsdiavewesngqpennykt
	tppvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Eivltqspgtlslspgetaiiscrtsqygslawyqqrpgqaprlviysgstraagipdrfs	SEQ ID
chain	gsrwgpdynltisnlesgdfgvyycqqyeffgqgtkvqvdikrtvaapsvfifppsd	NO: 343
A	eqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltl
	skadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvqlqesgpglvkpsqtlsltctvsgfslsdygvhwvrqppgkglewlgvi	SEQ ID
chain	wagggtnynpslksrktiskdtsknqvslklssvtaadtavyycardkgysy	NO: 344
B	yysmdywgqgttvtvsssqvqlvesgggvvqpgrslrlscaasgftftkaw
	mhwvrqapgkqlewvaqikdksnsyatyyadsvkgrftisrddskntlylq
	mnslraedtavyycrgvyyalspfdywgqgtlvtvssrtastkgpsvfplapc
	srstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvv
	tvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeflggpsvf
	lfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkp
	reeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqpr
	epqvctlppsqeemtknqvslscavkgfypsdiavewesngqpennyktt
	ppvldsdgsfflvskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Divmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvs	SEQ ID
chain	nrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikgqp	NO: 345
B	kaapdivltqspaslavspgqratitcrasesveyyvtslqwyqqkpgqppkllifa
	asnvesgvparfsgsgsgtdftltinpveandvanyycqqsrkvpytfgqgtkleikt
	kgpsrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsq
	esvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 37 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcggccagatgaagaaacccggcgagagcatgcg	SEQ ID
chain	gatcagctgcagagccagcggctacgagttcatcgactgcaccctgaactggatcaga	NO: 346
A	ctggcccctggcaagcggcctgagtggatgggatggctgaagcctagaggcggagc
	cgtgaactacgccagacctctgcagggcagagtgaccatgacccgggacgtgtacag
	cgataccgccttcctggaactgcggagcctgaccgtggatgataccgccgtgtacttctg
	cacccggggcaagaactgcgactacaactgggacttcgagcactggggcagaggca
	cccctgtgatcgtgtcaagcgcgtcgaccaagggcccctcggtgaccctctggcccat
	gcagcagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactt
	tcccgagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacc
	tttccagccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcc
	cagcagcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaa
	caccaaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgccca
	gcccctgaatactgggcggaccctccgtgacctgaccccccaaagcccaaggacac
	cctgatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaa
	gatcccgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaaga
	ccaagcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgt
	gctgcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaaggg
	cctgcccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagc
	ctcaagtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctg
	tggtgtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacg
	gccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcat
	tcttcctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttc
	agctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctct
	gtccctgggcaag
Light	Gagatcgtgctgacacagagccctggcaccctgagcctgtctccaggcgagacagcc	SEQ ID
chain	atcatcagctgccggacaagccagtacggcagcctggcctggtatcagcagaggcctg	NO: 347
A	gacaggcccccagactcgtgatctacagcggcagcacaagagccgccggaatcccc
	gatagattcagcggctccagatggggccctgactacaacctgaccatcagcaacctgg
	aaagcggcgacttcggcgtgtactactgccagcagtacgagttcttcggccagggcac
	caaggtgcaggtggacatcaagcgtacggtggccgctcccagcgtgacatcttcccac
	ctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttc
	tacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaa
	cagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagca
	gcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaag
	tgacccaccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Heavy	caggtgcagctgcaggaatctggccctggcctcgtgaagcctagccagaccctgagcc	SEQ ID
chain	tgacctgtaccgtgtccggcttcagcctgagcgactacggcgtgcactgggtgcgcca	NO: 348
B	gccacctggaaaaggcctggaatggctgggcgtgatctgggctggcggaggcaccaa
	ctacaaccccagcctgaagtccagaaagaccatcagcaaggacaccagcaagaacca
	ggtgtccctgaagctgagcagcgtgacagccgccgataccgccgtgtactactgcgcc
	agagacaagggctacagctactactacagcatggactactggggccagggcaccacc
	gtgaccgtgtcatcctctcaggtgcagctggtggaatctggcggcggagtggtgcagc
	ctggcagaagcctgagactgagctgtgccgccagcggcttcaccttcaccaaggcctg
	gatgcactgggtgcgccaggcccctggaaagcagctggaatgggtggcccagatcaa
	ggacaagagcaacagctacgccacctactacgccgacagcgtgaagggccggttcac
	catcagccgggacgacagcaagaacaccctgtacctgcagatgaacagcctgcgggc
	cgaggacaccgccgtgtactactgtcggggcgtgtactatgccctgagccccttcgatta
	ctggggccagggaaccctcgtgaccgtgtctagtcggaccgcttcgaccaagggccc
	atcggtgttccctctggccccttgcagcagaagcaccagcgaatctacagccgccctgg
	gctgcctcgtgaaggactactacccgagcccgtgaccgtgtcctggaactctggcgctc
	tgacaagcggcgtgcacacctaccagccgtgctccagagcagcggcctgtactctctg
	agcagcgtcgtgacagtgcccagcagcagcctgggcaccaagacctacacctgtaac
	gtggaccacaagcccagcaacaccaaggtggacaagcgggtggaatctaagtacgg
	ccctccctgccctccttgcccagcccctgaatttctgggcggaccctccgtgttcctgttc
	cccccaaagcccaaggacaccctgatgatcagccggacccccgaagtgacctgcgtg
	gtggtggatgtgtcccaggaagatcccgaggtgcagttcaattggtacgtggacggcgt
	ggaagtgcacaacgccaagaccaagcccagagaggaacagttcaacagcacctacc
	gggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacggcaaagagtacaa
	gtgcaaggtgtccaacaagggcctgcccagctccatcgagaaaaccatcagcaaggc
	caagggccagccccgcgagcctcaagtgtgtaccctgccccctagccaggaagagat
	gaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctaccccagcgacattg
	ccgtggaatgggagagcaacggccagcccgagaacaactacaagaccaccccccct
	gtgctggacagcgacggctcattcttcctggtgtccaagctgaccgtggacaagagccg
	gtggcaggaaggcaacgtgttcagctgctccgtgatgcacgaggccctgcacaaccac
	tacacccagaagtccctgtctctgtccctgggcaag
Light	gacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcca	SEQ ID
chain	gcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctga	NO: 349
B	gctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtccaa
	cagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcacc
	ctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccagggc
	acccagtaccccttcacctttggcagcggcaccaaggtggaaatcaagggccagccca
	aggccgcccccgacatcgtgctgacacagagccctgctagcctggccgtgtctcctgg
	acagagggccaccatcacctgtagagccagcgagagcgtggaatattacgtgaccag
	cctgatgcagtggtatcagcagaagcccggccagccccccaagctgctgattttcgccg
	ccagcaacgtggaaagcggcgtgccagccagattttccggcagcggctctggcaccg
	acttcaccctgaccatcaaccccgtggaagccaacgacgtggccaactactactgcca
	gcagagccggaaggtgccctacacctttggccagggcaccaagctggaaatcaagac
	caagggccccagccgtacggtggccgctcccagcgtgttcatcttcccacctagcgac
	gagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccg
	cgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaacagccag
	gaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagcagcaccct
	gacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgaccca
	ccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 38 Amino Acid Sequences
Heavy	Qvqlvqsgaevvkpgasvkvsckasgytftsyyihwvrqapgqglewigsiypgn	SEQ ID
chain	vntnyaqkfqgratltvdtsistaymelsrlrsddtavyyctrshygldwnfdvwgkg	NO: 350
A	ttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtf
	pavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcp
	apeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevh
	naktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgq
	prepqvytlppcqeemtknqvslwclvkgfypsdiavewesngqpennykttpp
	vldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Diqmtqspsslsasvgdrvtltcqasqniyvwlnwyqqkpgkapklliykasnlht	SEQ ID
chain	gvpsrfsgsgsgtdftltisslqpediatyycqqgqtypytfgqgtkleikrtvaapsvfi	NO: 351
A	fppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwi	SEQ ID
chain	kpqygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsyg	NO: 352
B	dsswaldawgqgttvvvsasqvqlvesgggvvqpgrslrlscaasgftftka
	wmhwvrqapgkqlewvaqikdksnsyatyyadsvkgrftisrddskntly
	lqmnslraedtavyycrgvyyalspfdywgqgtlvtvssrtastkgpsvfpla
	pcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslss
	vvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeflggps
	vflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnakt
	kpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakg
	qprepqvctlppsqeemtknqvslscavkgfypsdiavewesngqpenny
	kttppvldsdgsfflvskltvdksrwqegnvfscsvmhealhnhytqkslsls
	lgk
Light	Divmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvs	SEQ ID
chain	nrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikgqp	NO: 353
B	kaapyihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssv
	edgvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhiktkgpsrtvaaps
	vfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskds
	tyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 38 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcgccgaggtcgtgaaacctggcgcctctgtgaagg	SEQ ID
chain	tgtcctgcaaggccagcggctacaccataccagctactacatccactgggtgcgccag	NO: 354
A	gcccctggacagggactggaatggatcggcagcatctaccccggcaacgtgaacacc
	aactacgcccagaagaccagggcagagccaccctgaccgtggacaccagcatcagc
	accgcctacatggaactgagccggctgagaagcgacgacaccgccgtgtactactgc
	acccggtcccactacggcctggattggaacttcgacgtgtggggcaagggcaccacc
	gtgacagtgtctagcgcgtcgaccaagggcccctcggtgaccctctggccccttgcag
	cagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactaccc
	gagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctacc
	agccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagc
	agcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacacc
	aaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagccc
	ctgaatactgggcggaccctccgtgacctgaccccccaaagcccaaggacaccctga
	tgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcc
	cgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaa
	gcccagagaggaacagacaacagcacctaccgggtggtgtccgtgctgaccgtgctg
	caccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctg
	cccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctca
	agtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgtggt
	gtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttc
	ctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgacagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtcc
	ctgggcaag
Light	Gacatccagatgacccagagccccagcagcctgtctgccagcgtgggcgacagagt	SEQ ID
chain	gaccatcacctgtcaggccagccagaacatctacgtgtggctgaactggtatcagcaga	NO: 355
A	agcccggcaaggcccccaagctgctgatctacaaggccagcaacctgcacaccggc
	gtgcccagcagattactggcagcggctccggcaccgacttcaccctgacaatcagctc
	cctgcagcccgaggacattgccacctactactgccagcagggccagacctacccctac
	acctaggccagggcaccaagctggaaatcaagcgtacggtggccgctcccagcgtgt
	tcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctg
	ctgaacaacttctacccccgcgaggccaaggtgcagtggaaggtggacaatgccctgc
	agagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccaccta
	cagcctgagcagcaccctgaccctgagcaaggccgactacgagaagcacaaggtgta
	cgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccg
	gggcgagtgt
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgcgg	SEQ ID
chain	gtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgactggaccggcag	NO: 356
B	gcccctggcagaggactggaatgggtgggatggatcaagccccagtatggcgccgtg
	aacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgtaccgcgag
	atcgcctacatggacatccggggcctgaagcccgatgacaccgccgtgtactactgcg
	ccagagacagaagctacggcgacagcagctgggctctggatgcttggggccagggc
	acaaccgtggtggtgtctgcctctcaggtgcagctggtggaatctggcggcggagtggt
	gcagcctggcagaagcctgagactgagctgtgccgccagcggcttcaccttcaccaag
	gcctggatgcactgggtgcgccaggcccctggaaagcagctggaatgggtggcccag
	atcaaggacaagagcaacagctacgccacctactacgccgacagcgtgaagggccg
	gttcaccatcagccgggacgacagcaagaacaccctgtacctgcagatgaacagcctg
	cgggccgaggacaccgccgtgtactactgtcggggcgtgtactatgccctgagcccctt
	cgattactggggccagggaaccctcgtgaccgtgtctagtcggaccgcttcgaccaag
	ggcccatcggtgttccctctggccccttgcagcagaagcaccagcgaatctacagccg
	ccctgggctgcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaactctg
	gcgctctgacaagcggcgtgcacacctttccagccgtgctccagagcagcggcctgta
	ctctctgagcagcgtcgtgacagtgcccagcagcagcctgggcaccaagacctacacc
	tgtaacgtggaccacaagcccagcaacaccaaggtggacaagcgggtggaatctaag
	tacggccctccctgccctccttgcccagcccctgaatactgggcggaccctccgtgac
	ctgttccccccaaagcccaaggacaccctgatgatcagccggacccccgaagtgacct
	gcgtggtggtggatgtgtcccaggaagatcccgaggtgcagttcaattggtacgtggac
	ggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagttcaacagcac
	ctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacggcaaagag
	tacaagtgcaaggtgtccaacaagggcctgcccagctccatcgagaaaaccatcagca
	aggccaagggccagccccgcgagcctcaagtgtgtaccctgccccctagccaggaag
	agatgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctaccccagcga
	cattgccgtggaatgggagagcaacggccagcccgagaacaactacaagaccaccc
	cccctgtgctggacagcgacggctcattcttcctggtgtccaagctgaccgtggacaag
	agccggtggcaggaaggcaacgtgttcagctgctccgtgatgcacgaggccctgcac
	aaccactacacccagaagtccctgtctctgtccctgggcaag
Light	Gacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcc	SEQ ID
chain	agcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctg	NO: 357
B	agctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtcca
	acagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcac
	cctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccaggg
	cacccagtaccccttcacctttggcagcggcaccaaggtggaaatcaagggccagccc
	aaggccgccccctacatccacgtgacccagagccccagcagcctgtccgtgtccatcg
	gcgacagagtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcact
	ggtatcagcacaagcctggcagagcccccaagctgctgatccaccacacaagcagcg
	tggaagatggcgtgcccagcagattttccggcagcggcttccacaccagcttcaacctg
	accatcagcgatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttc
	ttcggcagaggcagcagactgcacatcaagaccaagggccccagccgtacggtggc
	cgctcccagcgtgttcatcttcccacctagcgacgagcagctgaagtccggcacagcct
	ctgtcgtgtgcctgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtg
	gacaacgccctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagca
	aggactccacctacagcctgagcagcaccctgacactgagcaaggccgactacgaga
	agcacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgacca
	agagcttcaaccggggcgagtgt
Binding Protein 39 Amino Acid Sequences
Heavy	Qvqlvqsgaevvkpgasvkvsckasgytftsyyihwvrqapgqglewigsiypgn	SEQ ID
chain	vntnyaqkfqgratltvdtsistaymelsrlrsddtavyyctrshygldwnfdvwgkg	NO: 358
A	ttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtf
	pavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcp
	apeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevh
	naktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgq
	prepqvytlppcqeemtknqvslwclvkgfypsdiavewesngqpennykttpp
	vldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Diqmtqspsslsasvgdrvtltcqasqniyvwlnwyqqkpgkapklliykasnlht	SEQ ID
chain	gvpsrfsgsgsgtdftltisslqpediatyycqqgqtypytfgqgtkleikrtvaapsvfi	NO: 359
A	fppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwi	SEQ ID
chain	kpqygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsyg	NO: 360
B	dsswaldawgqgttvvvsasqvqlvesgggvvqpgrslrlscaasgftf
	tkawmhwvrqapgkqlewvaqikdksnsyatyyadsvkgrftisrddskn
	tlylqmnslraedtavyycrgvyyalspfdywgqgtlvtvssrtastkgp
	svfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqss
	glyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpap
	eflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgve
	vhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiekti
	skakgqprepqvctlppsqeemtknqvslscavkgfypsdiavewesngq
	pennykttppvldsdgsfflvskltvdksrwqegnvfscsvmhealhnhytq
	kslslslgk
Light	Divmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvs	SEQ ID
chain	nrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikdkth	NO: 361
B	tyihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssvedg
	vpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhiktkgpsrtvaapsvfif
	ppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstysl
	sstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 39 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcgccgaggtcgtgaaacctggcgcctctgtgaagg	SEQ ID
chain	tgtcctgcaaggccagcggctacacctttaccagctactacatccactgggtgcgccag	NO: 362
A	gcccctggacagggactggaatggatcggcagcatctaccccggcaacgtgaacacc
	aactacgcccagaagttccagggcagagccaccctgaccgtggacaccagcatcagc
	accgcctacatggaactgagccggctgagaagcgacgacaccgccgtgtactactgc
	acccggtcccactacggcctggattggaacttcgacgtgtggggcaagggcaccacc
	gtgacagtgtctagcgcgtcgaccaagggcccctcggtgttccctctggccccttgcag
	cagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttccc
	gagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctttcc
	agccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagc
	agcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacacc
	aaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagccc
	ctgaatttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctga
	tgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcc
	cgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaa
	gcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctg
	caccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctg
	cccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctca
	agtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgtggt
	gtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttc
	ctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttcagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtcc
	ctgggcaag
Light	gacatccagatgacccagagccccagcagcctgtctgccagcgtgggcgacagagtg	SEQ ID
chain	accatcacctgtcaggccagccagaacatctacgtgtggctgaactggtatcagcagaa	NO: 363
A	gcccggcaaggcccccaagctgctgatctacaaggccagcaacctgcacaccggcgt
	gcccagcagattttctggcagcggctccggcaccgacttcaccctgacaatcagctccc
	tgcagcccgaggacattgccacctactactgccagcagggccagacctacccctacac
	ctttggccagggcaccaagctggaaatcaagcgtacggtggccgctcccagcgtgttc
	atcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgct
	gaacaacttctacccccgcgaggccaaggtgcagtggaaggtggacaatgccctgca
	gagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctac
	agcctgagcagcaccctgaccctgagcaaggccgactacgagaagcacaaggtgtac
	gcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccgg
	ggcgagtgt
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgcgg	SEQ ID
chain	gtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgactggaccggcag	NO: 364
B	gcccctggcagaggactggaatgggtgggatggatcaagccccagtatggcgccgtg
	aacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgtaccgcgag
	atcgcctacatggacatccggggcctgaagcccgatgacaccgccgtgtactactgcg
	ccagagacagaagctacggcgacagcagctgggctctggatgcttggggccagggc
	acaaccgtggtggtgtctgccgacaaaacccatacccaggtgcagctggtggaatctg
	gcggcggagtggtgcagcctggcagaagcctgagactgagctgtgccgccagcggc
	ttcaccttcaccaaggcctggatgcactgggtgcgccaggcccctggaaagcagctgg
	aatgggtggcccagatcaaggacaagagcaacagctacgccacctactacgccgaca
	gcgtgaagggccggttcaccatcagccgggacgacagcaagaacaccctgtacctgc
	agatgaacagcctgcgggccgaggacaccgccgtgtactactgtcggggcgtgtacta
	tgccctgagccccttcgattactggggccagggaaccctcgtgaccgtgtctagtgataa
	gacccacaccgcttcgaccaagggcccatcggtgttccctctggccccttgcagcaga
	agcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttcccgagc
	ccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctttccagcc
	gtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagcagca
	gcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacaccaagg
	tggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagcccctgaa
	tttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctgatgatc
	agccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcccgag
	gtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccca
	gagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctgcacca
	ggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctgcccag
	ctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctcaagtgtg
	taccctgccccctagccaggaagagatgaccaagaaccaggtgtccctgagctgtgcc
	gtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggccagccc
	gagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttcctggt
	gtccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttcagctgctc
	cgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtccctgg
	gcaag
Light	gacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcca	SEQ ID
chain	gcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctga	NO: 365
B	gctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtccaa
	cagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcacc
	ctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccagggc
	acccagtaccccttcacctttggcagcggcaccaaggtggaaatcaaggacaaaaccc
	atacctacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacag
	agtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcag
	cacaagcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaagat
	ggcgtgcccagcagattttccggcagcggcttccacaccagcttcaacctgaccatcag
	cgatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttcggcag
	aggcagcagactgcacatcaaggataagacccatacccgtacggtggccgctcccag
	cgtgttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtg
	cctgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgc
	cctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactcc
	acctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcacaag
	gtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttca
	accggggcgagtgt
Binding Protein 40 Amino Acid Sequences
Heavy	Qvqlvqsgaevvkpgasvkvsckasgytftsyyihwvrqapgqglewigsiypg	SEQ ID
chain	nvntnyaqkfqgratltvdtsistaymelsrlrsddtavyyctrshygldwnfdvwgk	NO: 366
A	gttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvht
	fpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppc
	papeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvev
	hnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakg
	qprepqvytlppcqeemtknqvslwclvkgfypsdiavewesngqpennykttp
	pvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Diqmtqspsslsasvgdrvtltcqasqniyvwlnwyqqkpgkapklliykasnlht	SEQ ID
chain	gvpsrfsgsgsgtdftltisslqpediatyycqqgqtypytfgqgtkleikrtvaapsvfi	NO: 367
A	fppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdsty
	slsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvqlvesgggyvqpgrslrlscaasgftftkawmhwyrqapgkqlewva	SEQ ID
chain	qikdksnsyatyyadsvkgrftisrddskntlylqmnslraedtavyycrgvy	NO: 368
B	yalspfdywgqgtlytysssrahlyqsgtamkkpgasvrvscqtsgytftahi
	lfwfrqapgrglewygwikpqygavnfgggfrdrytltrdyyreiaymdirg
	lkpddtavyycardrsygdsswaldawgqgttyvvsartastkgpsvfplap
	csrstsestaalgclykdyfpepytyswnsgaltsgyhtfpavlqssglyslssv
	vtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeflggps
	vflfppkpkdtlmisrtpevtcyvvdvsqedpevqfnwyydgvevhnakt
	kpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakg
	qprepqvctlppsqeemtknqvslscavkgfypsdiavewesngqpenny
	kttppvldsdgsfflvskltvdksrwqegnvfscsvmhealhnhytqkslsls
	lgk
Light	Yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssvedg	SEQ ID
chain	vpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikgqpkaapdivmtqt	NO: 369
B	plslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvsnrfsgvpd
	rfsgsgsgdftlkisrveaedvgvyycgqgtqypftfgsgtkveiktkgpsrtvaaps
	vfifppsdeqlksgtaswcllnnfypreakvqwkvdnalqsgnsqesvteqdskds
	tyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 40 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcgccgaggtcgtgaaacctggcgcctctgtgaagg	SEQ ID
chain	tgtcctgcaaggccagcggctacacctttaccagctactacatccactgggtgcgccag	NO: 370
A	gcccctggacagggactggaatggatcggcagcatctaccccggcaacgtgaacacc
	aactacgcccagaagttccagggcagagccaccctgaccgtggacaccagcatcagc
	accgcctacatggaactgagccggctgagaagcgacgacaccgccgtgtactactgc
	acccggtcccactacggcctggattggaacttcgacgtgtggggcaagggcaccacc
	gtgacagtgtctagcgcgtcgaccaagggcccctcggtgttccctctggccccttgcag
	cagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttccc
	gagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctttcc
	agccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagc
	agcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacacc
	aaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagccc
	ctgaatttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctga
	tgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcc
	cgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaa
	gcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctg
	caccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctg
	cccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctca
	agtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgtggt
	gtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttc
	ctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttcagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtcc
	ctgggcaag
Light	gacatccagatgacccagagccccagcagcctgtctgccagcgtgggcgacagagtg	SEQ ID
chain	accatcacctgtcaggccagccagaacatctacgtgtggctgaactggtatcagcagaa	NO: 371
A	gcccggcaaggcccccaagctgctgatctacaaggccagcaacctgcacaccggcgt
	gcccagcagattttctggcagcggctccggcaccgacttcaccctgacaatcagctccc
	tgcagcccgaggacattgccacctactactgccagcagggccagacctacccctacac
	ctttggccagggcaccaagctggaaatcaagcgtacggtggccgctcccagcgtgttc
	atcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgct
	gaacaacttctacccccgcgaggccaaggtgcagtggaaggtggacaatgccctgca
	gagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctac
	agcctgagcagcaccctgaccctgagcaaggccgactacgagaagcacaaggtgtac
	gcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccgg
	ggcgagtgt
Heavy	caggtgcagctggtggaatctggcggcggagtggtgcagcctggcagaagcctgaga	SEQ ID
chain	ctgagctgtgccgccagcggcttcaccttcaccaaggcctggatgcactgggtgcgcc	NO: 372
B	aggcccctggaaagcagctggaatgggtggcccagatcaaggacaagagcaacagc
	tacgccacctactacgccgacagcgtgaagggccggttcaccatcagccgggacgac
	agcaagaacaccctgtacctgcagatgaacagcctgcgggccgaggacaccgccgtg
	tactactgtcggggcgtgtactatgccctgagccccttcgattactggggccagggaac
	cctcgtgaccgtgtctagtagcagagcccacctggtgcagtctggcaccgccatgaag
	aaaccaggcgcctctgtgcgggtgtcctgtcagacaagcggctacaccttcaccgccc
	acatcctgttctggttccggcaggcccctggcagaggactggaatgggtgggatggat
	caagccccagtatggcgccgtgaacttcggcggaggcttccgggatagagtgaccctg
	acccgggacgtgtaccgcgagatcgcctacatggacatccggggcctgaagcccgat
	gacaccgccgtgtactactgcgccagagacagaagctacggcgacagcagctgggct
	ctggatgcttggggccagggcacaaccgtggtggtgtctgcccggaccgccagcaca
	aagggcccatcggtgttccctctggccccttgcagcagaagcaccagcgaatctacag
	ccgccctgggctgcctcgtgaaggactactacccgagcccgtgaccgtgtcctggaac
	tctggcgctctgacaagcggcgtgcacacctttccagccgtgctccagagcagcggcc
	tgtactctctgagcagcgtcgtgacagtgcccagcagcagcctgggcaccaagaccta
	cacctgtaacgtggaccacaagcccagcaacaccaaggtggacaagcgggtggaatc
	taagtacggccctccctgccctccttgcccagcccctgaatactgggcggaccctccgt
	gttcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccgaagtg
	acctgcgtggtggtggatgtgtcccaggaagatcccgaggtgcagttcaattggtacgt
	ggacggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagttcaaca
	gcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacggcaa
	agagtacaagtgcaaggtgtccaacaagggcctgcccagctccatcgagaaaaccatc
	agcaaggccaagggccagccccgcgagcctcaagtgtgtaccctgccccctagccag
	gaagagatgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctacccca
	gcgacattgccgtggaatgggagagcaacggccagcccgagaacaactacaagacc
	accccccctgtgctggacagcgacggctcattcttcctggtgtccaagctgaccgtgga
	caagagccggtggcaggaaggcaacgtgttcagctgctccgtgatgcacgaggccct
	gcacaaccactacacccagaagtccctgtctctgtccctgggcaag
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacag	SEQ ID
chain	agtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcactggt	NO: 373
B	atcagcacaagcctggcagagcccccaagctgctgatccaccacacaagcag
	cgtggaagatggcgtgcccagcagattttccggcagcggcttccacaccagctt
	caacctgaccatcagcgatctgcaggccgacgacattgccacctactattgtca
	ggtgctgcagttcttcggcagaggcagcagactgcacatcaagggccagccca
	aggccgcccccgacatcgtgatgacccagacccccctgagcctgagcgtgac
	acctggacagcctgccagcatcagctgcaagagcagccagagcctggtgcac
	aacaacgccaacacctacctgagctggtatctgcagaagcccggccagagcc
	cccagtccctgatctacaaggtgtccaacagattcagcggcgtgcccgacagat
	tctccggcagcggctctggcaccgacttcaccctgaagatcagccgggtggaa
	gccgaggacgtgggcgtgtactattgtggccagggcacccagtaccccttcac
	ctttggcagcggcaccaaggtggaaatcaagaccaagggccccagccgtacg
	gtggccgctcccagcgtgttcatcttcccacctagcgacgagcagctgaagtcc
	ggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggccaaa
	gtgcagtggaaggtggacaacgccctgcagagcggcaacagccaggaaagc
	gtgaccgagcaggacagcaaggactccacctacagcctgagcagcaccctga
	cactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgac
	ccaccagggcctgtctagccccgtgaccaagagatcaaccggggcgagtgt
Binding Protein 41 Amino Acid Sequences
Heavy	Qvqlvqsgaevvkpgasvkvsckasgytftsyyihwvrqapgqglewigsiypgn	SEQ ID
chain	vntnyaqkfqgratltvdtsistaymelsrlrsddtavyyctrshygldwnfdvwgkg	NO: 374
A	ttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtf
	pavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcp
	apeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevh
	naktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgq
	prepqvytlppcqeemtknqvslwclvkgfypsdiavewesngqpennykttpp
	vldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Diqmtqspsslsasvgdrvtltcqasqniyvwlnwyqqkpgkapklliykasnlht	SEQ ID
chain	gvpsrfsgsgsgtdftltisslqpediatyycqqgqtypytfgqgtkleikrtvaapsvfi	NO: 375
A	fppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvqlvesgggyvqpgrslrlscaasgftftkawmhwyrqapgkqlewvaq	SEQ ID
chain	ikdksnsyatyyadsvkgrftisrddskntlylqmnslraedtavyycrgvyy	NO: 376
B	alspfdywgqgtlytysssrahlyqsgtamkkpgasvrvscqtsgytft
	ahilfwfrqapgrglewygwikpqygavnfgggfrdrvtltrdvyreiaym
	dirglkpddtavyycardrsygdsswaldawgqgttvvvsartastkgp
	svfplapcsrstsestaalgclykdyfpepytyswnsgaltsgyhtfpavlqss
	glyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpap
	eflggpsvflfppkpkdtlmisrtpevtcyvvdvsqedpevqfnwyydgve
	vhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiekti
	skakgqprepqvctlppsqeemtknqvslscavkgfypsdiavewesngq
	pennykttppvldsdgsfflvskltvdksrwqegnvfscsvmhealhnhytq
	kslslslgk
Light	Yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssvedg	SEQ ID
chain	vpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikdkthtdivmtqtplsl	NO: 377
B	svtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvsnrfsgvpdrfs
	gsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikdkthtrtvaapsvfif
	ppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstysl
	sstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 41 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcgccgaggcgtgaaacctggcgcctctgtgaagg	SEQ ID
chain	tgtcctgcaaggccagcggctacacctttaccagctactacatccactgggtgcgccag	NO: 378
A	gcccctggacagggactggaatggatcggcagcatctaccccggcaacgtgaacacc
	aactacgcccagaagttccagggcagagccaccctgaccgtggacaccagcatcagc
	accgcctacatggaactgagccggctgagaagcgacgacaccgccgtgtactactgc
	acccggtcccactacggcctggattggaacttcgacgtgtggggcaagggcaccacc
	gtgacagtgtctagcgcgtcgaccaagggcccctcggtgttccctctggccccttgcag
	cagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttccc
	gagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctttcc
	agccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagc
	agcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacacc
	aaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagccc
	ctgaatttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctga
	tgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcc
	cgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaa
	gcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctg
	caccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctg
	cccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctca
	agtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgtggt
	gtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttc
	ctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttcagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtcc
	ctgggcaag
Light	gacatccagatgacccagagccccagcagcctgtctgccagcgtgggcgacagagtg	SEQ ID
chain	accatcacctgtcaggccagccagaacatctacgtgtggctgaactggtatcagcagaa	NO: 379
A	gcccggcaaggcccccaagctgctgatctacaaggccagcaacctgcacaccggcgt
	gcccagcagattttctggcagcggctccggcaccgacttcaccctgacaatcagctccc
	tgcagcccgaggacattgccacctactactgccagcagggccagacctacccctacac
	ctttggccagggcaccaagctggaaatcaagcgtacggtggccgctcccagcgtgttc
	atcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgct
	gaacaacttctacccccgcgaggccaaggtgcagtggaaggtggacaatgccctgca
	gagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctac
	agcctgagcagcaccctgaccctgagcaaggccgactacgagaagcacaaggtgtac
	gcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccgg
	ggcgagtgt
Heavy	caggtgcagctggtggaatctggcggcggagtggtgcagcctggcagaagcctgaga	SEQ ID
chain	ctgagctgtgccgccagcggcttcaccttcaccaaggcctggatgcactgggtgcgcc	NO: 380
B	aggcccctggaaagcagctggaatgggtggcccagatcaaggacaagagcaacagc
	tacgccacctactacgccgacagcgtgaagggccggttcaccatcagccgggacgac
	agcaagaacaccctgtacctgcagatgaacagcctgcgggccgaggacaccgccgtg
	tactactgtcggggcgtgtactatgccctgagccccttcgattactggggccagggaac
	cctcgtgaccgtgtctagtgacaaaacccataccagagcccacctggtgcagtctggca
	ccgccatgaagaaaccaggcgcctctgtgcgggtgtcctgtcagacaagcggctacac
	cttcaccgcccacatcctgttctggttccggcaggcccctggcagaggactggaatggg
	tgggatggatcaagccccagtatggcgccgtgaacttcggcggaggcttccgggatag
	agtgaccctgacccgggacgtgtaccgcgagatcgcctacatggacatccggggcct
	gaagcccgatgacaccgccgtgtactactgcgccagagacagaagctacggcgacag
	cagctgggctctggatgcttggggccagggcacaaccgtggtggtgtctgccgataag
	acccacaccgccagcacaaagggcccatcggtgaccctctggcccatgcagcagaa
	gcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttcccgagcc
	cgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctttccagccg
	tgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagcagcag
	cctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacaccaaggt
	ggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagcccctgaat
	ttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctgatgatca
	gccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcccgagg
	tgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagcccag
	agaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccag
	gactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctgcccagc
	tccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctcaagtgtgt
	accctgccccctagccaggaagagatgaccaagaaccaggtgtccctgagctgtgcc
	gtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggccagccc
	gagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttcctggt
	gtccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttcagctgctc
	cgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtccctgg
	gcaag
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagtga	SEQ ID
chain	ccatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagcacaa	NO: 381
B	gcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaagatggcgt
	gcccagcagattttccggcagcggcttccacaccagcttcaacctgaccatcagcgatc
	tgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttcggcagaggca
	gcagactgcacatcaaggacaaaacccataccgacatcgtgatgacccagacccccct
	gagcctgagcgtgacacctggacagcctgccagcatcagctgcaagagcagccaga
	gcctggtgcacaacaacgccaacacctacctgagctggtatctgcagaagcccggcca
	gagcccccagtccctgatctacaaggtgtccaacagattcagcggcgtgcccgacaga
	ttctccggcagcggctctggcaccgacttcaccctgaagatcagccgggtggaagccg
	aggacgtgggcgtgtactattgtggccagggcacccagtaccccttcacctttggcagc
	ggcaccaaggtggaaatcaaggataagacccatacccgtacggtggccgctcccagc
	gtgttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgc
	ctgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaacgcc
	ctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactcca
	cctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcacaag
	gtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttca
	accggggcgagtgt
Binding Protein 42 Amino Acid Sequences
Heavy	Qvqlqesgpglvkpsqtlsltctvsgfslsdygvhwvrqppgkglewlgviwaggg	SEQ ID
chain	tnynpslksrktiskdtsknqvslklssvtaadtavyycardkgysyyysmdywgq	NO: 382
A	gttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvht
	fpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppc
	papeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvev
	hnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakg
	qprepqvytippcqeemtknqvslwclvkgfypsdiavewesngqpennykttp
	pvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Divltqspaslavspgqratitcrasesveyyvtslmqwyqqkpgqppkllifaasn	SEQ ID
chain	vesgvparfsgsgsgtdftltinpveandvanyycqqsrkvpytfgqgtkleikrtvaa	NO: 383
A	psvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdsk
	dstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwi	SEQ ID
chain	kpqygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsyg	NO: 384
B	dsswaldawgqgttvvvsasqvqlvesgggvvqpgrslrlscaasgftftka
	wmhwvrqapgkqlewvaqikdksnsyatyyadsvkgrftisrddskntly
	lqmnslraedtavyycrgvyyalspfdywgqgtlvtvssrtastkgpsvfpla
	pcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslss
	vvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeflggps
	vflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnakt
	kpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakg
	qprepqvctlppsqeemtknqvslscavkgfypsdiavewesngqpenny
	kttppvldsdgsfflvskltvdksrwqegnvfscsvmhealhnhytqkslsls
	lgk
Light	Divmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvs	SEQ ID
chain	nrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikgpq	NO: 385
B	kaapyihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssv
	edgvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhiktkgpsrtvaaps
	vfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskds
	tyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 42 Nucleotide Sequences
Heavy	caggtgcagctgcaggaatctggccctggcctcgtgaagcctagccagaccctgagc	SEQ ID
chain	ctgacctgtaccgtgtccggcttcagcctgagcgactacggcgtgcactgggtgcgcc	NO: 386
A	agccacctggaaaaggcctggaatggctgggcgtgatctgggctggcggaggcacc
	aactacaaccccagcctgaagtccagaaagaccatcagcaaggacaccagcaagaac
	caggtgtccctgaagctgagcagcgtgacagccgccgataccgccgtgtactactgcg
	ccagagacaagggctacagctactactacagcatggactactggggccagggcacca
	ccgtgaccgtgtcatccgcgtcgaccaagggcccctcggtgttccctctggccccttgc
	agcagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttc
	ccgagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacaccttt
	ccagccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgccca
	gcagcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaaca
	ccaaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagc
	ccctgaatttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccct
	gatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagat
	cccgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagacc
	aagcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtg
	ctgcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggc
	ctgcccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcc
	tcaagtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgt
	ggtgtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacgg
	ccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcatt
	cttcctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttc
	agctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctct
	gtccctgggcaag
Light	gacatcgtgctgacacagagccctgctagcctggccgtgtctcctggacagagggcca	SEQ ID
chain	ccatcacctgtagagccagcgagagcgtggaatattacgtgaccagcctgatgcagtg	NO: 387
A	gtatcagcagaagcccggccagccccccaagctgctgattttcgccgccagcaacgtg
	gaaagcggcgtgccagccagattttccggcagcggctctggcaccgacttcaccctga
	ccatcaaccccgtggaagccaacgacgtggccaactactactgccagcagagccgga
	aggtgccctacacctttggccagggcaccaagctggaaatcaagcgtacggtggccg
	ctcccagcgtgttcatcttcccacctagcgacgagcagctgaagtccggcacagcctct
	gtcgtgtgcctgctgaacaacttctacccccgcgaggccaaggtgcagtggaaggtgg
	acaatgccctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaa
	ggactccacctacagcctgagcagcaccctgaccctgagcaaggccgactacgagaa
	gcacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaa
	gagcttcaaccggggcgagtgt
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgcgg	SEQ ID
chain	gtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgactggttccggcag	NO: 388
B	gcccctggcagaggactggaatgggtgggatggatcaagccccagtatggcgccgtg
	aacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgtaccgcgag
	atcgcctacatggacatccggggcctgaagcccgatgacaccgccgtgtactactgcg
	ccagagacagaagctacggcgacagcagctgggctctggatgcttggggccagggc
	acaaccgtggtggtgtctgcctctcaggtgcagctggtggaatctggcggcggagtgg
	tgcagcctggcagaagcctgagactgagctgtgccgccagcggcttcaccttcaccaa
	ggcctggatgcactgggtgcgccaggcccctggaaagcagctggaatgggtggccc
	agatcaaggacaagagcaacagctacgccacctactacgccgacagcgtgaagggc
	cggttcaccatcagccgggacgacagcaagaacaccctgtacctgcagatgaacagc
	ctgcgggccgaggacaccgccgtgtactactgtcggggcgtgtactatgccctgagcc
	ccttcgattactggggccagggaaccctcgtgaccgtgtctagtcggaccgcttcgacc
	aagggcccatcggtgttccctctggccccttgcagcagaagcaccagcgaatctacag
	ccgccctgggctgcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaac
	tctggcgctctgacaagcggcgtgcacacctttccagccgtgctccagagcagcggcc
	tgtactctctgagcagcgtcgtgacagtgcccagcagcagcctgggcaccaagaccta
	cacctgtaacgtggaccacaagcccagcaacaccaaggtggacaagcgggtggaat
	ctaagtacggccctccctgccctccttgcccagcccctgaatttctgggcggaccctcc
	gtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccgaag
	tgacctgcgtggtggtggatgtgtcccaggaagatcccgaggtgcagttcaattggtac
	gtggacggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagttcaa
	cagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacgg
	caaagagtacaagtgcaaggtgtccaacaagggcctgcccagctccatcgagaaaac
	catcagcaaggccaagggccagccccgcgagcctcaagtgtgtaccctgccccctag
	ccaggaagagatgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctac
	cccagcgacattgccgtggaatgggagagcaacggccagcccgagaacaactacaa
	gaccaccccccctgtgctggacagcgacggctcattcttcctggtgtccaagctgaccg
	tggacaagagccggtggcaggaaggcaacgtgttcagctgctccgtgatgcacgagg
	ccctgcacaaccactacacccagaagtccctgtctctgtccctgggcaag
Light	gacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcc	SEQ ID
chain	agcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctg	NO: 389
B	agctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtcca
	acagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcac
	cctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccaggg
	cacccagtaccccttcacctttggcagcggcaccaaggtggaaatcaagggccagcc
	caaggccgccccctacatccacgtgacccagagccccagcagcctgtccgtgtccatc
	ggcgacagagtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcac
	tggtatcagcacaagcctggcagagcccccaagctgctgatccaccacacaagcagc
	gtggaagatggcgtgcccagcagattttccggcagcggcttccacaccagcttcaacct
	gaccatcagcgatctgcaggccgacgacattgccacctactattgtcaggtgctgcagtt
	cttcggcagaggcagcagactgcacatcaagaccaagggccccagccgtacggtgg
	ccgctcccagcgtgttcatcttcccacctagcgacgagcagctgaagtccggcacagc
	ctctgtcgtgtgcctgctgaacaacttctacccccgcgaggccaaagtgcagtggaagg
	tggacaacgccctgcagagcggcaacagccaggaaagcgtgaccgagcaggacag
	caaggactccacctacagcctgagcagcaccctgacactgagcaaggccgactacga
	gaagcacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgac
	caagagcttcaaccggggcgagtgt
Binding Protein 43 Amino Acid Sequences
Heavy	Qvqlqesgpglvkpsqtlsltctvsgfslsdygvhwvrqppgkglewlgviwaggg	SEQ ID
chain	tnynpslksrktiskdtsknqvslklssvtaadtavyycardkgysyyysmdywg	NO: 390
A	qgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgv
	htfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcpp
	cpapeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgve
	vhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskak
	gqprepqvytippcqeemtknqvslwclvkgfypsdiavewesngqpennyktt
	ppvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Divltqspaslavspgqratitcrasesveyyvtslmqwyqqkpgqppkllifaasn	SEQ ID
chain	vesgvparfsgsgsgtdftltinpveandvanyycqqsrkvpytfgqgtkleikrtva	NO: 391
A	apsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqds
	kdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Rahlvqsgtamkkpgasvrvscqtsgytftahilfwfrqapgrglewvgwi	SEQ ID
chain	kpqygavnfgggfrdrvtltrdvyreiaymdirglkpddtavyycardrsyg	NO: 392
B	dsswaldawgqgttvvvsasqvqlvesgggvvqpgrslrlscaasgft
	ftkawmhwvrqapgkqlewvaqikdksnsyatyyadsvkgrftisrddsk
	ntlylqmnslraedtavyycrgvyyalspfdywgqgtlvtvssrtastkg
	psvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqs
	sglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpa
	peflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgv
	evhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiek
	tiskakgqprepqvctlppsqeemtknqvslscavkgfypsdiavewesng
	qpennykttppvldsdgsfflvskltvdksrwqegnvfscsvmhealhnhy
	tqkslslslgk
Light	Divmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvs	SEQ ID
chain	nrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikdkt	NO: 393
B	htyihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssved
	gvpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhiktkgpsrtvaapsvfi
	fppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdsty
	slsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 43 Nucleotide Sequences
Heavy	caggtgcagctgcaggaatctggccctggcctcgtgaagcctagccagaccctgagc	SEQ ID
chain	ctgacctgtaccgtgtccggcttcagcctgagcgactacggcgtgcactgggtgcgcc	NO: 394
A	agccacctggaaaaggcctggaatggctgggcgtgatctgggctggcggaggcacc
	aactacaaccccagcctgaagtccagaaagaccatcagcaaggacaccagcaagaac
	caggtgtccctgaagctgagcagcgtgacagccgccgataccgccgtgtactactgcg
	ccagagacaagggctacagctactactacagcatggactactggggccagggcacca
	ccgtgaccgtgtcatccgcgtcgaccaagggcccctcggtgttccctctggccccttgc
	agcagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttc
	ccgagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacaccttt
	ccagccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgccca
	gcagcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaaca
	ccaaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagc
	ccctgaatttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccct
	gatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagat
	cccgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagacc
	aagcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtg
	ctgcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggc
	ctgcccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcc
	tcaagtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgt
	ggtgtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacgg
	ccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcatt
	cttcctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttc
	agctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctct
	gtccctgggcaag
Light	gacatcgtgctgacacagagccctgctagcctggccgtgtctcctggacagagggcca	SEQ ID
chain	ccatcacctgtagagccagcgagagcgtggaatattacgtgaccagcctgatgcagtg	NO: 395
A	gtatcagcagaagcccggccagccccccaagctgctgattttcgccgccagcaacgtg
	gaaagcggcgtgccagccagattttccggcagcggctctggcaccgacttcaccctga
	ccatcaaccccgtggaagccaacgacgtggccaactactactgccagcagagccgga
	aggtgccctacacctttggccagggcaccaagctggaaatcaagcgtacggtggccg
	ctcccagcgtgttcatcttcccacctagcgacgagcagctgaagtccggcacagcctct
	gtcgtgtgcctgctgaacaacttctacccccgcgaggccaaggtgcagtggaaggtgg
	acaatgccctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaa
	ggactccacctacagcctgagcagcaccctgaccctgagcaaggccgactacgagaa
	gcacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaa
	gagcttcaaccggggcgagtgt
Heavy	agagcccacctggtgcagtctggcaccgccatgaagaaaccaggcgcctctgtgcgg	SEQ ID
chain	gtgtcctgtcagacaagcggctacaccttcaccgcccacatcctgttctggttccggcag	NO: 396
B	gcccctggcagaggactggaatgggtgggatggatcaagccccagtatggcgccgtg
	aacttcggcggaggcttccgggatagagtgaccctgacccgggacgtgtaccgcgag
	atcgcctacatggacatccggggcctgaagcccgatgacaccgccgtgtactactgcg
	ccagagacagaagctacggcgacagcagctgggctctggatgcttggggccagggc
	acaaccgtggtggtgtctgccgacaaaacccatacccaggtgcagctggtggaatctg
	gcggcggagtggtgcagcctggcagaagcctgagactgagctgtgccgccagcggc
	ttcaccttcaccaaggcctggatgcactgggtgcgccaggcccctggaaagcagctgg
	aatgggtggcccagatcaaggacaagagcaacagctacgccacctactacgccgaca
	gcgtgaagggccggttcaccatcagccgggacgacagcaagaacaccctgtacctgc
	agatgaacagcctgcgggccgaggacaccgccgtgtactactgtcggggcgtgtact
	atgccctgagccccttcgattactggggccagggaaccctcgtgaccgtgtctagtgat
	aagacccacaccgcttcgaccaagggcccatcggtgttccctctggccccttgcagca
	gaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttcccga
	gcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctttccag
	ccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagcag
	cagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacaccaa
	ggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagcccct
	gaatttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctgat
	gatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcc
	cgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaa
	gcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctg
	caccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctg
	cccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctca
	agtgtgtaccctgccccctagccaggaagagatgaccaagaaccaggtgtccctgagc
	tgtgccgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggcc
	agcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattctt
	cctggtgtccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttcag
	ctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgt
	ccctgggcaag
Light	gacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcc	SEQ ID
chain	agcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctg	NO: 397
B	agctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtcca
	acagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcac
	cctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccaggg
	cacccagtaccccttcacctttggcagcggcaccaaggtggaaatcaaggacaaaacc
	catacctacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgaca
	gagtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatca
	gcacaagcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaag
	atggcgtgcccagcagattttccggcagcggcttccacaccagcttcaacctgaccatc
	agcgatctgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttcggc
	agaggcagcagactgcacatcaaggataagacccatacccgtacggtggccgctccc
	agcgtgttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgt
	gtgcctgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaa
	cgccctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggac
	tccacctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcac
	aaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagc
	ttcaaccggggcgagtgt
Binding Protein 44 Amino Acid Sequences
Heavy	Qvqlqesgpglvkpsqtlsltctvsgfslsdygvhwvrqppgkglewlgviwaggg	SEQ ID
chain	tnynpslksrktiskdtsknqvslklssvtaadtavyycardkgysyyysmdywgq	NO: 398
A	gttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvht
	fpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppc
	papeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvev
	hnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakg
	qprepqvytippcqeemtknqvslwclvkgfypsdiavewesngqpennykttp
	pvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Divltqspaslavspgqratitcrasesveyyvtslmqwyqqkpgqppkllifaasn	SEQ ID
chain	vesgvparfsgsgsgtdftltinpveandvanyycqqsrkvpytfgqgtkleikrtvaa	NO: 399
A	psvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdsk
	dstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvqlvesgggyvqpgrslrlscaasgftftkawmhwyrqapgkqlewvaq	SEQ ID
chain	ikdksnsyatyyadsvkgrftisrddskntlylqmnslraedtavyycrgvyy	NO: 400
B	alspfdywgqgtlytysssrahlyqsgtamkkpgasvrvscqtsgytftahilf
	wfrqapgrglewygwikpqygavnfgggfrdrvtltrdvyreiaymdirgl
	kpddtavyycardrsygdsswaldawgqgttvvvsartastkgpsvfplapc
	srstsestaalgclykdyfpepytyswnsgaltsgyhtfpavlqssglyslssvv
	tvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeflggpsvf
	lfppkpkdtlmisrtpevtcyvvdvsqedpevqfnwyydgvevhnaktkp
	reeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqpr
	epqvctlppsqeemtknqvslscavkgfypsdiavewesngqpennyktt
	ppvldsdgsfflvskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssvedg	SEQ ID
chain	vpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikgqpkaapdivmtqt	NO: 401
B	plslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvsnrfsgvpd
	rfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveiktkgpsrtvaaps
	vfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskds
	tyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 44 Nucleotide Sequences
Heavy	caggtgcagctgcaggaatctggccctggcctcgtgaagcctagccagaccctgagc	SEQ ID
chain	ctgacctgtaccgtgtccggcttcagcctgagcgactacggcgtgcactgggtgcgcc	NO: 402
A	agccacctggaaaaggcctggaatggctgggcgtgatctgggctggcggaggcacc
	aactacaaccccagcctgaagtccagaaagaccatcagcaaggacaccagcaagaac
	caggtgtccctgaagctgagcagcgtgacagccgccgataccgccgtgtactactgcg
	ccagagacaagggctacagctactactacagcatggactactggggccagggcacca
	ccgtgaccgtgtcatccgcgtcgaccaagggcccctcggtgttccctctggccccttgc
	agcagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttc
	ccgagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacaccttt
	ccagccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgccca
	gcagcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaaca
	ccaaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagc
	ccctgaatttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccct
	gatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagat
	cccgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagacc
	aagcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtg
	ctgcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggc
	ctgcccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcc
	tcaagtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgt
	ggtgtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacgg
	ccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcatt
	cttcctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttc
	agctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctct
	gtccctgggcaag
Light	gacatcgtgctgacacagagccctgctagcctggccgtgtctcctggacagagggcca	SEQ ID
chain	ccatcacctgtagagccagcgagagcgtggaatattacgtgaccagcctgatgcagtg	NO: 403
A	gtatcagcagaagcccggccagccccccaagctgctgattttcgccgccagcaacgtg
	gaaagcggcgtgccagccagattttccggcagcggctctggcaccgacttcaccctga
	ccatcaaccccgtggaagccaacgacgtggccaactactactgccagcagagccgga
	aggtgccctacacctttggccagggcaccaagctggaaatcaagcgtacggtggccg
	ctcccagcgtgttcatcttcccacctagcgacgagcagctgaagtccggcacagcctct
	gtcgtgtgcctgctgaacaacttctacccccgcgaggccaaggtgcagtggaaggtgg
	acaatgccctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaa
	ggactccacctacagcctgagcagcaccctgaccctgagcaaggccgactacgagaa
	gcacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaa
	gagcttcaaccggggcgagtgt
Heavy	caggtgcagctggtggaatctggcggcggagtggtgcagcctggcagaagcctgag	SEQ ID
chain	actgagctgtgccgccagcggcttcaccttcaccaaggcctggatgcactgggtgcgc	NO: 404
B	caggcccctggaaagcagctggaatgggtggcccagatcaaggacaagagcaacag
	ctacgccacctactacgccgacagcgtgaagggccggttcaccatcagccgggacga
	cagcaagaacaccctgtacctgcagatgaacagcctgcgggccgaggacaccgccg
	tgtactactgtcggggcgtgtactatgccctgagccccttcgattactggggccaggga
	accctcgtgaccgtgtctagtagcagagcccacctggtgcagtctggcaccgccatga
	agaaaccaggcgcctctgtgcgggtgtcctgtcagacaagcggctacaccttcaccgc
	ccacatcctgttctggttccggcaggcccctggcagaggactggaatgggtgggatgg
	atcaagccccagtatggcgccgtgaacttcggcggaggcttccgggatagagtgaccc
	tgacccgggacgtgtaccgcgagatcgcctacatggacatccggggcctgaagcccg
	atgacaccgccgtgtactactgcgccagagacagaagctacggcgacagcagctggg
	ctctggatgcttggggccagggcacaaccgtggtggtgtctgcccggaccgccagca
	caaagggcccatcggtgttccctctggccccttgcagcagaagcaccagcgaatctac
	agccgccctgggctgcctcgtgaaggactactttcccgagcccgtgaccgtgtcctgg
	aactctggcgctctgacaagcggcgtgcacacctttccagccgtgctccagagcagcg
	gcctgtactctctgagcagcgtcgtgacagtgcccagcagcagcctgggcaccaaga
	cctacacctgtaacgtggaccacaagcccagcaacaccaaggtggacaagcgggtg
	gaatctaagtacggccctccctgccctccttgcccagcccctgaatttctgggcggacc
	ctccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggaccccc
	gaagtgacctgcgtggtggtggatgtgtcccaggaagatcccgaggtgcagttcaattg
	gtacgtggacggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagt
	tcaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaa
	cggcaaagagtacaagtgcaaggtgtccaacaagggcctgcccagctccatcgagaa
	aaccatcagcaaggccaagggccagccccgcgagcctcaagtgtgtaccctgccccc
	tagccaggaagagatgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttc
	taccccagcgacattgccgtggaatgggagagcaacggccagcccgagaacaacta
	caagaccaccccccctgtgctggacagcgacggctcattcttcctggtgtccaagctga
	ccgtggacaagagccggtggcaggaaggcaacgtgttcagctgctccgtgatgcacg
	aggccctgcacaaccactacacccagaagtccctgtctctgtccctgggcaag
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacag	SEQ ID
chain	agtgaccatcaactgccagacctctcagggcgtgggcagcgacctgcactggt	NO: 405
B	atcagcacaagcctggcagagcccccaagctgctgatccaccacacaagcag
	cgtggaagatggcgtgcccagcagattaccggcagcggcttccacaccagctt
	caacctgaccatcagcgatctgcaggccgacgacattgccacctactattgtca
	ggtgctgcagttcttcggcagaggcagcagactgcacatcaagggccagccc
	aaggccgcccccgacatcgtgatgacccagacccccctgagcctgagcgtga
	cacctggacagcctgccagcatcagctgcaagagcagccagagcctggtgca
	caacaacgccaacacctacctgagctggtatctgcagaagcccggccagagc
	ccccagtccctgatctacaaggtgtccaacagattcagcggcgtgcccgacag
	attctccggcagcggctctggcaccgacttcaccctgaagatcagccgggtgg
	aagccgaggacgtgggcgtgtactattgtggccagggcacccagtaccccttc
	acctttggcagcggcaccaaggtggaaatcaagaccaagggccccagccgta
	cggtggccgctcccagcgtgttcatcttcccacctagcgacgagcagctgaagt
	ccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgaggcca
	aagtgcagtggaaggtggacaacgccctgcagagcggcaacagccaggaaa
	gcgtgaccgagcaggacagcaaggactccacctacagcctgagcagcaccct
	gacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtg
	acccaccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagt
	gt
Binding Protein 45 Amino Acid Sequences
Heavy	Qvqlqesgpglvkpsqtlsltctvsgfslsdygvhwvrqppgkglewlgviwagg	SEQ ID
chain	gtnynpslksrktiskdtsknqvslklssvtaadtavyycardkgysyyysmdywg	NO: 406
A	qgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgv
	htfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcpp
	cpapeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgve
	vhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskak
	gqprepqvytippcqeemtknqvslwclvkgfypsdiavewesngqpennyktt
	ppvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Divltqspaslavspgqratitcrasesveyyvtslmqwyqqkpgqppkllifaasn	SEQ ID
chain	vesgvparfsgsgsgtdftltinpveandvanyycqqsrkvpytfgqgtkleikrtva	NO: 407
A	apsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdsk
	kdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	qvqlvesgggyvqpgrslrlscaasgftftkawmhwyrqapgkqlewvaq	SEQ ID
chain	ikdksnsyatyyadsvkgrftisrddskntlylqmnslraedtavyycrgvyy	NO: 408
B	alspfdywgqgtlvtvsssrahlyqsgtamkkpgasvrvscqtsgytft
	ahilfwfrqapgrglewygwikpqygavnfgggfrdrvtltrdvyreiaym
	dirglkpddtavyycardrsygdsswaldawgqgttvvvsartastkgp
	svfplapcsrstsestaalgclykdyfpepytyswnsgaltsgyhtfpavlqss
	glyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpap
	eflggpsvflfppkpkdtlmisrtpevtcyvvdvsqedpevqfnwyydgve
	vhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiekt
	iskakgqprepqvctlppsqeemtknqvslscavkgfypsdiavewesng
	qpennykttppvldsdgsfflvskltvdksrwqegnvfscsvmhealhnhy
	tqkslslslgk
Light	Yihvtqspsslsvsigdrvtincqtsqgvgsdlhwyqhkpgrapkllihhtssvedg	SEQ ID
chain	vpsrfsgsgfhtsfnltisdlqaddiatyycqvlqffgrgsrlhikgqpkaapdivmtqtpls	NO: 409
B	lsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvsnrfsgvpdrfs
	gsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveiktkgpsrtvaapsvfi
	fppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdsty
	slsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 45 Nucleotide Sequences
Heavy	caggtgcagctgcaggaatctggccctggcctcgtgaagcctagccagaccctgagc	SEQ ID
chain	ctgacctgtaccgtgtccggcttcagcctgagcgactacggcgtgcactgggtgcgcc	NO: 410
A	agccacctggaaaaggcctggaatggctgggcgtgatctgggctggcggaggcacc
	aactacaaccccagcctgaagtccagaaagaccatcagcaaggacaccagcaagaac
	caggtgtccctgaagctgagcagcgtgacagccgccgataccgccgtgtactactgcg
	ccagagacaagggctacagctactactacagcatggactactggggccagggcacca
	ccgtgaccgtgtcatccgcgtcgaccaagggcccctcggtgttccctctggccccttgc
	agcagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactac
	ccgagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacaccttt
	ccagccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgccca
	gcagcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaaca
	ccaaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagc
	ccctgaatactgggcggaccctccgtgacctgaccccccaaagcccaaggacaccct
	gatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagat
	cccgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagacc
	aagcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtg
	ctgcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggc
	ctgcccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcc
	tcaagtgtataccctgcccccagccaggaagagatgaccaagaaccaggtgtccctgt
	ggtgtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacgg
	ccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcatt
	cttcctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttc
	agctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctct
	gtccctgggcaag
Light	gacatcgtgctgacacagagccctgctagcctggccgtgtctcctggacagagggcca	SEQ ID
chain	ccatcacctgtagagccagcgagagcgtggaatattacgtgaccagcctgatgcagtg	NO: 411
A	gtatcagcagaagcccggccagccccccaagctgctgattttcgccgccagcaacgtg
	gaaagcggcgtgccagccagattttccggcagcggctctggcaccgacttcaccctga
	ccatcaaccccgtggaagccaacgacgtggccaactactactgccagcagagccgga
	aggtgccctacacctttggccagggcaccaagctggaaatcaagcgtacggtggccg
	ctcccagcgtgacatcacccacctagcgacgagcagctgaagtccggcacagcctct
	gtcgtgtgcctgctgaacaacttctacccccgcgaggccaaggtgcagtggaaggtgg
	acaatgccctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaa
	ggactccacctacagcctgagcagcaccctgaccctgagcaaggccgactacgagaa
	gcacaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaa
	gagcttcaaccggggcgagtgt
Heavy	caggtgcagctggtggaatctggcggcggagtggtgcagcctggcagaagcctgag	SEQ ID
chain	actgagctgtgccgccagcggcttcaccttcaccaaggcctggatgcactgggtgcgc	NO: 412
B	caggcccctggaaagcagctggaatgggtggcccagatcaaggacaagagcaacag
	ctacgccacctactacgccgacagcgtgaagggccggttcaccatcagccgggacga
	cagcaagaacaccctgtacctgcagatgaacagcctgcgggccgaggacaccgccg
	tgtactactgtcggggcgtgtactatgccctgagccccttcgattactggggccaggga
	accctcgtgaccgtgtctagtgacaaaacccataccagagcccacctggtgcagtctgg
	caccgccatgaagaaaccaggcgcctctgtgcgggtgtcctgtcagacaagcggcta
	caccacaccgcccacatcctgactggaccggcaggcccctggcagaggactggaat
	gggtgggatggatcaagccccagtatggcgccgtgaacttcggcggaggcttccggg
	atagagtgaccctgacccgggacgtgtaccgcgagatcgcctacatggacatccggg
	gcctgaagcccgatgacaccgccgtgtactactgcgccagagacagaagctacggcg
	acagcagctgggctctggatgcttggggccagggcacaaccgtggtggtgtctgccg
	ataagacccacaccgccagcacaaagggcccatcggtgttccctctggccccttgcag
	cagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactaccc
	gagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctacc
	agccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagc
	agcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacacc
	aaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagccc
	ctgaatttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctg
	atgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatc
	ccgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagacca
	agcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgct
	gcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcct
	gcccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctc
	aagtgtgtaccctgccccctagccaggaagagatgaccaagaaccaggtgtccctgag
	ctgtgccgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggc
	cagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattct
	tcctggtgtccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttca
	gctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctg
	tccctgggcaag
Light	tacatccacgtgacccagagccccagcagcctgtccgtgtccatcggcgacagagtga	SEQ ID
chain	ccatcaactgccagacctctcagggcgtgggcagcgacctgcactggtatcagcacaa	NO: 413
B	gcctggcagagcccccaagctgctgatccaccacacaagcagcgtggaagatggcgt
	gcccagcagattaccggcagcggcttccacaccagcttcaacctgaccatcagcgatc
	tgcaggccgacgacattgccacctactattgtcaggtgctgcagttcttcggcagaggc
	agcagactgcacatcaaggacaaaacccataccgacatcgtgatgacccagaccccc
	ctgagcctgagcgtgacacctggacagcctgccagcatcagctgcaagagcagccag
	agcctggtgcacaacaacgccaacacctacctgagctggtatctgcagaagcccggc
	cagagcccccagtccctgatctacaaggtgtccaacagattcagcggcgtgcccgaca
	gattctccggcagcggctctggcaccgacttcaccctgaagatcagccgggtggaagc
	cgaggacgtgggcgtgtactattgtggccagggcacccagtaccccttcacctaggca
	gcggcaccaaggtggaaatcaaggataagacccatacccgtacggtggccgctccca
	gcgtgacatcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtg
	tgcctgctgaacaacttctacccccgcgaggccaaagtgcagtggaaggtggacaac
	gccctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggact
	ccacctacagcctgagcagcaccctgacactgagcaaggccgactacgagaagcaca
	aggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagctt
	caaccggggcgagtgt
Binding Protein 46 Amino Acid Sequences
Heavy	Qvqlvqsgaevvkpgasvkvsckasgytftsyyihwvrqapgqglewigsiypg	SEQ ID
chain	nvntnyaqkfqgratltvdtsistaymelsrlrsddtavyyctrshygldwnfdvwgk	NO: 414
A	gttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvht
	fpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppc
	papeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvev
	hnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakg
	qprepqvytlppcqeemtknqvslwclvkgfypsdiavewesngqpennykttp
	pvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Diqmtqspsslsasvgdrvtltcqasqniyvwlnwyqqkpgkapklliykasnlht	SEQ ID
chain	gvpsrfsgsgsgtdftltisslqpediatyycqqgqtypytfgqgtkleikrtvaapsvfi	NO: 415
A	fppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdsty
	slsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwmg	SEQ ID
chain	wishegdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakgskh	NO: 416
B	rlrdyalydddgalnwavdvdylsnlefwgqgtavtvsssqvqlvesgggv
	vqpgrslrlscaasgftftkawmhwvrqapgkqlewvaqikdksnsyatyy
	adsvkgrftisrddskntlylqmnslraedtavyycrgvyyalspfdywgqg
	tlvtvssrtastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgalt
	sgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvesk
	ygppcppcpapeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpe
	vqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykck
	vsnkglpssiektiskakgqprepqvctlppsqeemtknqvslscavkgfyp
	sdiavewesngqpennykttppvldsdgsfflvskltvdksrwqegnvfscs
	vmhealhnhytqkslslslgk
Light	Divmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvs	SEQ ID
chain	nrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikgqp	NO: 417
B	kaapdfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliyl
	assrasgvpdrfsgsgsdkdftlkisretedvgtyycmqgrespwtfgqgtkvdikt
	kgpsrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsq
	evteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 46 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcgccgaggtcgtgaaacctggcgcctctgtgaag	SEQ ID
chain	gtgtcctgcaaggccagcggctacacctttaccagctactacatccactgggtgcgcca	NO: 418
A	ggcccctggacagggactggaatggatcggcagcatctaccccggcaacgtgaacac
	caactacgcccagaagttccagggcagagccaccctgaccgtggacaccagcatcag
	caccgcctacatggaactgagccggctgagaagcgacgacaccgccgtgtactactg
	cacccggtcccactacggcctggattggaacttcgacgtgtggggcaagggcaccac
	cgtgacagtgtctagcgcgtcgaccaagggcccctcggtgaccctctggccccttgca
	gcagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttcc
	cgagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctac
	cagccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccag
	cagcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacac
	caaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagcc
	cctgaatactgggcggaccctccgtgacctgttccccccaaagcccaaggacaccct
	gatgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagat
	cccgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagacc
	aagcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtg
	ctgcaccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggc
	ctgcccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcc
	tcaagtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgt
	ggtgtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacgg
	ccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcatt
	cttcctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttc
	agctgctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctct
	gtccctgggcaag
Light	gacatccagatgacccagagccccagcagcctgtctgccagcgtgggcgacagagtg	SEQ ID
chain	accatcacctgtcaggccagccagaacatctacgtgtggctgaactggtatcagcagaa	NO: 419
A	gcccggcaaggcccccaagctgctgatctacaaggccagcaacctgcacaccggcgt
	gcccagcagattactggcagcggctccggcaccgacttcaccctgacaatcagctccc
	tgcagcccgaggacattgccacctactactgccagcagggccagacctacccctacac
	ctttggccagggcaccaagctggaaatcaagcgtacggtggccgctcccagcgtgttc
	atcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgct
	gaacaacttctacccccgcgaggccaaggtgcagtggaaggtggacaatgccctgca
	gagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctac
	agcctgagcagcaccctgaccctgagcaaggccgactacgagaagcacaaggtgta
	cgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccg
	gggcgagtgt
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctctgtgaa	SEQ ID
chain	ggtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgcactgggtgcgc	NO: 420
B	agcgtgccaggacagggactgcagtggatgggctggatcagccacgagggcgacaa
	gaaagtgatcgtggaacggttcaaggccaaagtgaccatcgactgggacagaagcac
	caacaccgcctacctgcagctgagcggcctgacctctggcgataccgccgtgtactact
	gcgccaagggcagcaagcaccggctgagagactacgccctgtacgacgatgacggc
	gccctgaactgggccgtggatgtggactacctgagcaacctggaattctggggccagg
	gcacagccgtgaccgtgtcatcttctcaggtgcagctggtggaatctggcggcggagt
	ggtgcagcctggcagaagcctgagactgagctgtgccgccagcggcttcaccttcacc
	aaggcctggatgcactgggtgcgccaggcccctggaaagcagctggaatgggtggc
	ccagatcaaggacaagagcaacagctacgccacctactacgccgacagcgtgaagg
	gccggttcaccatcagccgggacgacagcaagaacaccctgtacctgcagatgaaca
	gcctgcgggccgaggacaccgccgtgtactactgtcggggcgtgtactatgccctgag
	ccccttcgattactggggccagggaaccctcgtgaccgtgtctagtcggaccgcttcgc
	ccaagggcccatcggtgaccctctggccccttgcagcagaagcaccagcgaatctac
	agccgccctgggctgcctcgtgaaggactactacccgagcccgtgaccgtgtcctgg
	aactctggcgctctgacaagcggcgtgcacacctttccagccgtgctccagagcagcg
	gcctgtactctctgagcagcgtcgtgacagtgcccagcagcagcctgggcaccaaga
	cctacacctgtaacgtggaccacaagcccagcaacaccaaggtggacaagcgggtg
	gaatctaagtacggccctccctgccctccttgcccagcccctgaatttctgggcggacc
	ctccgtgttcctgttccccccaaagcccaaggacaccctgatgatcagccggaccccc
	gaagtgacctgcgtggtggtggatgtgtcccaggaagatcccgaggtgcagttcaattg
	gtacgtggacggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagt
	tcaacagcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaa
	cggcaaagagtacaagtgcaaggtgtccaacaagggcctgcccagctccatcgagaa
	aaccatcagcaaggccaagggccagccccgcgagcctcaagtgtgtaccctgccccc
	tagccaggaagagatgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttc
	taccccagcgacattgccgtggaatgggagagcaacggccagcccgagaacaacta
	caagaccaccccccctgtgctggacagcgacggctcattcttcctggtgtccaagctga
	ccgtggacaagagccggtggcaggaaggcaacgtgttcagctgctccgtgatgcacg
	aggccctgcacaaccactacacccagaagtccctgtctctgtccctgggcaag
Light	gacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcc	SEQ ID
chain	agcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctg	NO: 421
B	agctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtcca
	acagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcac
	cctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccaggg
	cacccagtaccccttcacctttggcagcggcaccaaggtggaaatcaagggccagcc
	caaggccgcccccgacttcgtgctgacccagagccctcacagcctgagcgtgacacc
	tggcgagagcgccagcatcagctgcaagagcagccactccctgatccacggcgacc
	ggaacaactacctggcttggtacgtgcagaagcccggcagatccccccagctgctgat
	ctacctggccagcagcagagccagcggcgtgcccgatagattactggcagcggcag
	cgacaaggacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcaccta
	ctactgtatgcagggcagagagagcccctggacctaggccagggcaccaaggtgga
	catcaagaccaagggccccagccgtacggtggccgctcccagcgtgttcatcttccca
	cctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaactt
	ctacccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggca
	acagccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagc
	agcaccctgacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcga
	agtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtg
	t
Binding Protein 47 Amino Acid Sequences
Heavy	Qvqlvqsgaevvkpgasvkvsckasgytftsyyihwvrqapgqglewigsiypgn	SEQ ID
chain	vntnyaqkfqgratltvdtsistaymelsrlrsddtavyyctrshygldwnfdvwgkg	NO: 422
A	ttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtf
	pavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcp
	apeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevh
	naktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgq
	prepqvytlppcqeemtknqvslwclvkgfypsdiavewesngqpennykttpp
	vldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Diqmtqspsslsasvgdrvtltcqasqniyvwlnwyqqkpgkapklliykasnlht	SEQ ID
chain	gvpsrfsgsgsgtdftltisslqpediatyycqqgqtypytfgqgtkleikrtvaapsvfi	NO: 423
A	fppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdsty
	slsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwmg	SEQ ID
chain	wishegdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakgskh	NO: 424
B	rlrdyalydddgalnwavdvdylsnlefwgqgtavtvsssqvqlvesgg
	gvvqpgrslrlscaasgftftkawmhwvrqapgkqlewvaqikdksnsy
	atyyadsvkgrftisrddskntlylqmnslraedtavyycrgvyyalspfdyw
	gqgtlvtvssrtastkgpsvfplapcsrstsestaalgclvkdyfpepvtvs
	wnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkv
	dkrveskygppcppcpapeflggpsvflfppkpkdtlmisrtpevtcvvvd
	vsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwln
	gkeykckvsnkglpssiektiskakgqprepqvctlppsqeemtknqvslsc
	avkgfypsdiavewesngqpennykttppvldsdgsfflvskltvdksrwq
	egnvfscsvmhealhnhytqkslslslgk
Light	Divmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvs	SEQ ID
chain	nrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikfkth	NO: 425
B	tdfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkgrspqlliylassr
	asgvpdrfsgsgsdkdftlkisrvetedvgtycmqgrespwtfgqgtkvdikdkth
	trtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvt
	eqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 47 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcgccgaggtcgtgaaacctggcgcctctgtgaagg	SEQ ID
chain	tgtcctgcaaggccagcggctacacctttaccagctactacatccactgggtgcgccag	NO: 426
A	gcccctggacagggactggaatggatcggcagcatctaccccggcaacgtgaacacc
	aactacgcccagaagaccagggcagagccaccctgaccgtggacaccagcatcagc
	accgcctacatggaactgagccggctgagaagcgacgacaccgccgtgtactactgc
	acccggtcccactacggcctggattggaacttcgacgtgtggggcaagggcaccacc
	gtgacagtgtctagcgcgtcgaccaagggcccctcggtgttccctctggccccttgcag
	cagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttccc
	gagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctacc
	agccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagc
	agcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacacc
	aaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagccc
	ctgaatactgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctga
	tgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcc
	cgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaa
	gcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctg
	caccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctg
	cccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctca
	agtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgtggt
	gtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttc
	ctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgacagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtcc
	ctgggcaag
Light	gacatccagatgacccagagccccagcagcctgtctgccagcgtgggcgacagagtg	SEQ ID
chain	accatcacctgtcaggccagccagaacatctacgtgtggctgaactggtatcagcagaa	NO: 427
A	gcccggcaaggcccccaagctgctgatctacaaggccagcaacctgcacaccggcgt
	gcccagcagattactggcagcggctccggcaccgacttcaccctgacaatcagctccc
	tgcagcccgaggacattgccacctactactgccagcagggccagacctacccctacac
	ctttggccagggcaccaagctggaaatcaagcgtacggtggccgctcccagcgtgac
	atcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgct
	gaacaacttctacccccgcgaggccaaggtgcagtggaaggtggacaatgccctgca
	gagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctac
	agcctgagcagcaccctgaccctgagcaaggccgactacgagaagcacaaggtgtac
	gcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccgg
	ggcgagtgt
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctctgtgaag	SEQ ID
chain	gtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgcactgggtgcgca	NO: 428
B	gcgtgccaggacagggactgcagtggatgggctggatcagccacgagggcgacaag
	aaagtgatcgtggaacggttcaaggccaaagtgaccatcgactgggacagaagcacc
	aacaccgcctacctgcagctgagcggcctgacctctggcgataccgccgtgtactactg
	cgccaagggcagcaagcaccggctgagagactacgccctgtacgacgatgacggcg
	ccctgaactgggccgtggatgtggactacctgagcaacctggaattctggggccaggg
	cacagccgtgaccgtgtcatctgacaaaacccatacccaggtgcagctggtggaatctg
	gcggcggagtggtgcagcctggcagaagcctgagactgagctgtgccgccagcggc
	ttcaccttcaccaaggcctggatgcactgggtgcgccaggcccctggaaagcagctgg
	aatgggtggcccagatcaaggacaagagcaacagctacgccacctactacgccgaca
	gcgtgaagggccggttcaccatcagccgggacgacagcaagaacaccctgtacctgc
	agatgaacagcctgcgggccgaggacaccgccgtgtactactgtcggggcgtgtacta
	tgccctgagccccttcgattactggggccagggaaccctcgtgaccgtgtctagtgataa
	gacccacaccgcttcgaccaagggcccatcggtgaccctctggccccttgcagcaga
	agcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactacccgagc
	ccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctttccagcc
	gtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagcagca
	gcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacaccaagg
	tggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagcccctgaa
	tttctgggcggaccctccgtgacctgaccccccaaagcccaaggacaccctgatgatc
	agccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcccgag
	gtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccca
	gagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctgcacca
	ggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctgcccag
	ctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctcaagtgtg
	taccctgccccctagccaggaagagatgaccaagaaccaggtgtccctgagctgtgcc
	gtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggccagccc
	gagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttcctggt
	gtccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgacagctgctc
	cgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtccctgg
	gcaag
Light	gacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcca	SEQ ID
chain	gcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctga	NO: 429
B	gctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtccaa
	cagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcacc
	ctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccagggc
	acccagtaccccttcacctaggcagcggcaccaaggtggaaatcaaggacaaaaccc
	ataccgacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagag
	cgccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta
	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggcca
	gcagcagagccagcggcgtgcccgatagattactggcagcggcagcgacaaggact
	tcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactgtatgca
	gggcagagagagcccctggacctaggccagggcaccaaggtggacatcaaggataa
	gacccatacccgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagc
	agctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgag
	gccaaagtgcagtggaaggtggacaacgccctgcagagcggcaacagccaggaaa
	gcgtgaccgagcaggacagcaaggactccacctacagcctgagcagcaccctgaca
	ctgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccag
	ggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 48 Amino Acid Sequences
Heavy	Qvqlvqsgaevvkpgasvkvsckasgytftsyyihwvrqapgqglewigsiypgn	SEQ ID
chain	vntnyaqkfqgratltvdtsistaymelsrlrsddtavyyctrshygldwnfdvwgkg	NO: 430
A	ttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtf
	pavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcp
	apeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevh
	naktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgq
	prepqvytlppcqeemtknqvslwclvkgfypsdiavewesngqpennykttpp
	vldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Diqmtqspsslsasvgdrvtltcqasqniyvwlnwyqqkpgkapklliykasnlht	SEQ ID
chain	gvpsrfsgsgsgtdftltisslqpediatyycqqgqtypytfgqgtkleikrtvaapsvfi	NO: 431
A	fppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvqlvesgggvvqpgrslrlscaasgftftkawmhwvrqapgkqlewvaq	SEQ ID
chain	ikdksnsyatyyadsvkgrftisrddskntlylqmnslraedtavyycrgvyy	NO: 432
B	alspfdywgqgtlvtvsssqvhltqsgpevrkpgtsvkvsckapgntlktydl
	hwvrsvpgqglqwmgwishegdkkviverfkakvtidwdrstntaylqls
	gltsgdtavyycakgskhrlrdyalydddgalnwavdvdylsnlefwgqgt
	avtvssrtastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgalt
	sgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvesk
	ygppcppcpapeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpe
	vqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykck
	vsnkglpssiektiskakgqprepqvctlppsqeemtknqvslscavkgfyp
	sdiavewesngqpennykttppvldsdgsfflvskltvdksrwqegnvfscs
	vmhealhnhytqkslslslgk
Light	Dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylassr	SEQ ID
chain	asgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikgqp	NO: 433
B	kaapdivmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliy
	kvsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikt
	kgpsrtvaapsvfifppsdeqlksgtasvcllnnfypreakvqwkvdnalqsgnsq
	esvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 48 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcgccgaggtcgtgaaacctggcgcctctgtgaagg	SEQ ID
chain	tgtcctgcaaggccagcggctacacattaccagctactacatccactgggtgcgccag	NO: 434
A	gcccctggacagggactggaatggatcggcagcatctaccccggcaacgtgaacacc
	aactacgcccagaagttccagggcagagccaccctgaccgtggacaccagcatcagc
	accgcctacatggaactgagccggctgagaagcgacgacaccgccgtgtactactgc
	acccggtcccactacggcctggattggaacttcgacgtgtggggcaagggcaccacc
	gtgacagtgtctagcgcgtcgaccaagggcccctcggtgttccctctggccccttgcag
	cagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttccc
	gagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctttcc
	agccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagc
	agcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacacc
	aaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagccc
	ctgaatttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctga
	tgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcc
	cgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaa
	gcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctg
	caccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctg
	cccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctca
	agtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgtggt
	gtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttc
	ctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttcagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtcc
	ctgggcaag
Light	gacatccagatgacccagagccccagcagcctgtctgccagcgtgggcgacagagtg	SEQ ID
chain	accatcacctgtcaggccagccagaacatctacgtgtggctgaactggtatcagcagaa	NO: 435
A	gcccggcaaggcccccaagctgctgatctacaaggccagcaacctgcacaccggcgt
	gcccagcagattactggcagcggctccggcaccgacttcaccctgacaatcagctccc
	tgcagcccgaggacattgccacctactactgccagcagggccagacctacccctacac
	ctttggccagggcaccaagctggaaatcaagcgtacggtggccgctcccagcgtgttc
	atcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgct
	gaacaacttctacccccgcgaggccaaggtgcagtggaaggtggacaatgccctgca
	gagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctac
	agcctgagcagcaccctgaccctgagcaaggccgactacgagaagcacaaggtgtac
	gcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccgg
	ggcgagtgt
Heavy	caggtgcagctggtggaatctggcggcggagtggtgcagcctggcagaagcctgaga	SEQ ID
chain	ctgagctgtgccgccagcggcttcaccttcaccaaggcctggatgcactgggtgcgcc	NO: 436
B	aggcccctggaaagcagctggaatgggtggcccagatcaaggacaagagcaacagc
	tacgccacctactacgccgacagcgtgaagggccggttcaccatcagccgggacgac
	agcaagaacaccctgtacctgcagatgaacagcctgcgggccgaggacaccgccgtg
	tactactgtcggggcgtgtactatgccctgagccccttcgattactggggccagggaac
	cctcgtgaccgtgtctagtagccaggtgcacctgacacagagcggacccgaagtgcg
	gaagcctggcacctctgtgaaggtgtcctgcaaggcccctggcaacaccctgaaaacc
	tacgacctgcactgggtgcgcagcgtgccaggacagggactgcagtggatgggctgg
	atcagccacgagggcgacaagaaagtgatcgtggaacggttcaaggccaaagtgacc
	atcgactgggacagaagcaccaacaccgcctacctgcagctgagcggcctgacctctg
	gcgataccgccgtgtactactgcgccaagggcagcaagcaccggctgagagactacg
	ccctgtacgacgatgacggcgccctgaactgggccgtggatgtggactacctgagcaa
	cctggaattctggggccagggcacagccgtgaccgtgtcatctcggaccgccagcaca
	aagggcccatcggtgaccctctggccccttgcagcagaagcaccagcgaatctacag
	ccgccctgggctgcctcgtgaaggactactacccgagcccgtgaccgtgtcctggaac
	tctggcgctctgacaagcggcgtgcacacctttccagccgtgctccagagcagcggcc
	tgtactctctgagcagcgtcgtgacagtgcccagcagcagcctgggcaccaagaccta
	cacctgtaacgtggaccacaagcccagcaacaccaaggtggacaagcgggtggaatc
	taagtacggccctccctgccctccttgcccagcccctgaatactgggcggaccctccgt
	gttcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccgaagtg
	acctgcgtggtggtggatgtgtcccaggaagatcccgaggtgcagttcaattggtacgt
	ggacggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagttcaaca
	gcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacggcaa
	agagtacaagtgcaaggtgtccaacaagggcctgcccagctccatcgagaaaaccatc
	agcaaggccaagggccagccccgcgagcctcaagtgtgtaccctgccccctagccag
	gaagagatgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctacccca
	gcgacattgccgtggaatgggagagcaacggccagcccgagaacaactacaagacc
	accccccctgtgctggacagcgacggctcattcttcctggtgtccaagctgaccgtgga
	caagagccggtggcaggaaggcaacgtgacagctgctccgtgatgcacgaggccct
	gcacaaccactacacccagaagtccctgtctctgtccctgggcaag
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagaggcc	SEQ ID
chain	agcatcagctgcaagagcagccactccctgatccacggcgaccggaacaactacctg	NO: 437
B	gcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggccagca
	gcagagccagcggcgtgcccgatagattactggcagcggcagcgacaaggacttca
	ccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactgtatgcagg
	gcagagagagcccctggacctaggccagggcaccaaggtggacatcaagggccag
	cccaaggccgcccccgacatcgtgatgacccagacccccctgagcctgagcgtgaca
	cctggacagcctgccagcatcagctgcaagagcagccagagcctggtgcacaacaac
	gccaacacctacctgagctggtatctgcagaagcccggccagagcccccagtccctga
	tctacaaggtgtccaacagattcagcggcgtgcccgacagattctccggcagcggctct
	ggcaccgacttcaccctgaagatcagccgggtggaagccgaggacgtgggcgtgtac
	tattgtggccagggcacccagtaccccttcacctaggcagcggcaccaaggtggaaat
	caagaccaagggccccagccgtacggtggccgctcccagcgtgacatcttcccacct
	agcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttcta
	cccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaaca
	gccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagcagc
	accctgacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtg
	acccaccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 49 Amino Acid Sequences
Heavy	Qvqlvqsgaevvkpgasvkvsckasgytftsyyihwvrqapgqglewigsiypgn	SEQ ID
chain	vntnyaqkfqgratltvdtsistaymelsrlrsddtavyyctrshygldwnfdvwgkg	NO: 438
A	ttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtf
	pavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcp
	apeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevh
	naktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgq
	prepqvytlppcqeemtknqvslwclvkgfypsdiavewesngqpennykttpp
	vldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Diqmtqspsslsasvgdrvtltcqasqniyvwlnwyqqkpgkapklliykasnlht	SEQ ID
chain	gvpsrfsgsgsgtdftltisslqpediatyycqqgqtypytfgqgtkleikrtvaapsvfi	NO: 439
A	fppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstys
	lsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvqlvesgggvvqpgrslrlscaasgftftkawmhwvrqapgkqlewvaq	SEQ ID
chain	ikdksnsyatyyadsvkgrftisrddskntlylqmnslraedtavyycrgvyy	NO: 440
B	alspfdywgqgtlvtvsssqvhltqsgpevrkpgtsvkvsckapgntlk
	tydlhwvrsvpgqglqwmgwishegdkkviverfkakvtidwdrstntay
	lqlsgltsgdtavyycakgskhrlrdyalydddgalnwavdvdylsnlefwg
	qgtavtvssrtastkgpsvfplapcsrstsestaalgclvkdyfpepvtvs
	wnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkv
	dkrveskygppcppcpapeflggpsvflfppkpkdtlmisrtpevtcvvvd
	vsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwln
	gkeykckvsnkglpssiektiskakgqprepqvctlppsqeemtknqvslsc
	avkgfypsdiavewesngqpennykttppvldsdgsfflvskltvdksrwq
	egnvfscsvmhealhnhytqkslslslgk
Light	Dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylassr	SEQ ID
chain	asgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikdkth	NO: 441
B	tdivmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvs
	nrfsgvpdrfsgsgsgtdftlkisrveadvgvyycgqgtqypftfgsgtkveikdkth
	trtvaapsvfifppsdeqlksgtasvcllnnfypreakvqwkvdnalqsgnsqesvt
	eqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 49 Nucleotide Sequences
Heavy	caggtgcagctggtgcagtctggcgccgaggtcgtgaaacctggcgcctctgtgaagg	SEQ ID
chain	tgtcctgcaaggccagcggctacacctttaccagctactacatccactgggtgcgccag	NO: 442
A	gcccctggacagggactggaatggatcggcagcatctaccccggcaacgtgaacacc
	aactacgcccagaagaccagggcagagccaccctgaccgtggacaccagcatcagc
	accgcctacatggaactgagccggctgagaagcgacgacaccgccgtgtactactgc
	acccggtcccactacggcctggattggaacttcgacgtgtggggcaagggcaccacc
	gtgacagtgtctagcgcgtcgaccaagggcccctcggtgttccctctggccccttgcag
	cagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttccc
	gagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctacc
	agccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagc
	agcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacacc
	aaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagccc
	ctgaatttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctga
	tgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcc
	cgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaa
	gcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctg
	caccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctg
	cccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctca
	agtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgtggt
	gtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttc
	ctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttcagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtcc
	ctgggcaag
Light	gacatccagatgacccagagccccagcagcctgtctgccagcgtgggcgacagagtg	SEQ ID
chain	accatcacctgtcaggccagccagaacatctacgtgtggctgaactggtatcagcagaa	NO: 443
A	gcccggcaaggcccccaagctgctgatctacaaggccagcaacctgcacaccggcgt
	gcccagcagattttctggcagcggctccggcaccgacttcaccctgacaatcagctccc
	tgcagcccgaggacattgccacctactactgccagcagggccagacctacccctacac
	ctttggccagggcaccaagctggaaatcaagcgtacggtggccgctcccagcgtgttc
	atcttcccacctagcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgct
	gaacaacttctacccccgcgaggccaaggtgcagtggaaggtggacaatgccctgca
	gagcggcaacagccaggaaagcgtgaccgagcaggacagcaaggactccacctac
	agcctgagcagcaccctgaccctgagcaaggccgactacgagaagcacaaggtgtac
	gcctgcgaagtgacccaccagggcctgtctagccccgtgaccaagagcttcaaccgg
	ggcgagtgt
Heavy	caggtgcagctggtggaatctggcggcggagtggtgcagcctggcagaagcctgaga	SEQ ID
chain	ctgagctgtgccgccagcggcttcaccttcaccaaggcctggatgcactgggtgcgcc	NO: 444
B	aggcccctggaaagcagctggaatgggtggcccagatcaaggacaagagcaacagc
	tacgccacctactacgccgacagcgtgaagggccggttcaccatcagccgggacgac
	agcaagaacaccctgtacctgcagatgaacagcctgcgggccgaggacaccgccgtg
	tactactgtcggggcgtgtactatgccctgagccccttcgattactggggccagggaac
	cctcgtgaccgtgtctagtgacaaaacccatacccaggtgcacctgacacagagcgga
	cccgaagtgcggaagcctggcacctctgtgaaggtgtcctgcaaggcccctggcaaca
	ccctgaaaacctacgacctgcactgggtgcgcagcgtgccaggacagggactgcagt
	ggatgggctggatcagccacgagggcgacaagaaagtgatcgtggaacggttcaagg
	ccaaagtgaccatcgactgggacagaagcaccaacaccgcctacctgcagctgagcg
	gcctgacctctggcgataccgccgtgtactactgcgccaagggcagcaagcaccggct
	gagagactacgccctgtacgacgatgacggcgccctgaactgggccgtggatgtgga
	ctacctgagcaacctggaattctggggccagggcacagccgtgaccgtgtcatctgata
	agacccacaccgccagcacaaagggcccatcggtgttccctctggccccttgcagcag
	aagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttcccgag
	cccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctttccagc
	cgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagcagc
	agcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacaccaag
	gtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagcccctga
	atttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctgatgat
	cagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcccga
	ggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagcc
	cagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctgcac
	caggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctgccc
	agctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctcaagt
	gtgtaccctgccccctagccaggaagagatgaccaagaaccaggtgtccctgagctgt
	gccgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggccag
	cccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttcct
	ggtgtccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttcagctg
	ctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtccct
	gggcaag
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcgcc	SEQ ID
chain	agcatcagctgcaagagcagccactccctgatccacggcgaccggaacaactacctg	NO: 445
B	gcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggccagca
	gcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaaggacttca
	ccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactgtatgcagg
	gcagagagagcccctggacctaggccagggcaccaaggtggacatcaaggacaaa
	acccataccgacatcgtgatgacccagacccccctgagcctgagcgtgacacctggac
	agcctgccagcatcagctgcaagagcagccagagcctggtgcacaacaacgccaaca
	cctacctgagctggtatctgcagaagcccggccagagcccccagtccctgatctacaa
	ggtgtccaacagattcagcggcgtgcccgacagattctccggcagcggctctggcacc
	gacttcaccctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtg
	gccagggcacccagtaccccttcacctaggcagcggcaccaaggtggaaatcaagg
	ataagacccatacccgtacggtggccgctcccagcgtgacatcttcccacctagcgac
	gagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccg
	cgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaacagccag
	gaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagcagcaccct
	gacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgaccca
	ccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 50 Amino Acid Sequences
Heavy	Qvqlqesgpglvkpsqtlsltctvsgfslsdygvhwvrqppgkglewlgviwaggg	SEQ ID
chain	tnynpslksrktiskdtsknqvslklssvtaadtavyycardkgysyyysmdywgq	NO: 446
A	gttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvht
	fpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppc
	papeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvev
	hnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakg
	qprepqvytippcqeemtknqvslwclvkgfypsdiavewesngqpennykttp
	pvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Divltqspaslavspgqratitcrasesveyyvtslmqwyqqkpgqppkllifaasn	SEQ ID
chain	vesgvparfsgsgsgtdftltinpveandvanyycqqsrkvpytfgqgtkleikrtvaa	NO: 447
A	psvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdsk
	dstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwmg	SEQ ID
chain	wishegdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakgskh	NO: 448
B	rlrdyalydddgalnwavdvdylsnlefwgqgtavtvsssqvqlvesgggv
	vqpgrslrlscaasgftftkawmhwvrqapgkqlewvaqikdksnsyatyy
	adsvkgrftisrddskntlylqmnslraedtavyycrgvyyalspfdywgqgt
	lvtvssrtastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgalt
	sgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvesk
	ygppcppcpapeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpe
	vqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykck
	vsnkglpssiektiskakgqprepqvctlppsqeemtknqvslscavkgfyp
	sdiavewesngqpennykttppvldsdgsfflvskltvdksrwqegnvfscs
	vmhealhnhytqkslslslgk
Light	Divmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvs	SEQ ID
chain	nrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikgpq	NO: 449
B	kaapdfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkgrspqlliyl
	assrasgvpdrfsgsgsdkdftlkisrvetedvgtycmqgrespwtfgqgtkvdikt
	kgpsrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsq
	esvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 50 Nucleotide Sequences
Heavy	caggtgcagctgcaggaatctggccctggcctcgtgaagcctagccagaccctgagcc	SEQ ID
chain	tgacctgtaccgtgtccggcttcagcctgagcgactacggcgtgcactgggtgcgcca	NO: 450
A	gccacctggaaaaggcctggaatggctgggcgtgatctgggctggcggaggcaccaa
	ctacaaccccagcctgaagtccagaaagaccatcagcaaggacaccagcaagaacca
	ggtgtccctgaagctgagcagcgtgacagccgccgataccgccgtgtactactgcgcc
	agagacaagggctacagctactactacagcatggactactggggccagggcaccacc
	gtgaccgtgtcatccgcgtcgaccaagggcccctcggtgaccctctggccccttgcag
	cagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactaccc
	gagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctttcc
	agccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagc
	agcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacacc
	aaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagccc
	ctgaatttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctga
	tgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcc
	cgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaa
	gcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctg
	caccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctg
	cccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctca
	agtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgtggt
	gtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttc
	ctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttcagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtcc
	ctgggcaag
Light	gacatcgtgctgacacagagccctgctagcctggccgtgtctcctggacagagggcca	SEQ ID
chain	ccatcacctgtagagccagcgagagcgtggaatattacgtgaccagcctgatgcagtg	NO: 451
A	gtatcagcagaagcccggccagccccccaagctgctgattttcgccgccagcaacgtg
	gaaagcggcgtgccagccagattttccggcagcggctctggcaccgacttcaccctga
	ccatcaaccccgtggaagccaacgacgtggccaactactactgccagcagagccgga
	aggtgccctacacctttggccagggcaccaagctggaaatcaagcgtacggtggccgc
	tcccagcgtgttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgt
	cgtgtgcctgctgaacaacttctacccccgcgaggccaaggtgcagtggaaggtggac
	aatgccctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaagg
	actccacctacagcctgagcagcaccctgaccctgagcaaggccgactacgagaagc
	acaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaaga
	gcttcaaccggggcgagtgt
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctctgtgaag	SEQ ID
chain	gtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgcactgggtgcgca	NO: 452
B	gcgtgccaggacagggactgcagtggatgggctggatcagccacgagggcgacaag
	aaagtgatcgtggaacggttcaaggccaaagtgaccatcgactgggacagaagcacc
	aacaccgcctacctgcagctgagcggcctgacctctggcgataccgccgtgtactactg
	cgccaagggcagcaagcaccggctgagagactacgccctgtacgacgatgacggcg
	ccctgaactgggccgtggatgtggactacctgagcaacctggaattctggggccaggg
	cacagccgtgaccgtgtcatcttctcaggtgcagctggtggaatctggcggcggagtg
	gtgcagcctggcagaagcctgagactgagctgtgccgccagcggcttcaccttcacca
	aggcctggatgcactgggtgcgccaggcccctggaaagcagctggaatgggtggccc
	agatcaaggacaagagcaacagctacgccacctactacgccgacagcgtgaagggc
	cggttcaccatcagccgggacgacagcaagaacaccctgtacctgcagatgaacagc
	ctgcgggccgaggacaccgccgtgtactactgtcggggcgtgtactatgccctgagcc
	ccttcgattactggggccagggaaccctcgtgaccgtgtctagtcggaccgcttcgacc
	aagggcccatcggtgttccctctggccccttgcagcagaagcaccagcgaatctacag
	ccgccctgggctgcctcgtgaaggactactacccgagcccgtgaccgtgtcctggaac
	tctggcgctctgacaagcggcgtgcacacctttccagccgtgctccagagcagcggcc
	tgtactctctgagcagcgtcgtgacagtgcccagcagcagcctgggcaccaagaccta
	cacctgtaacgtggaccacaagcccagcaacaccaaggtggacaagcgggtggaatc
	taagtacggccctccctgccctccttgcccagcccctgaatactgggcggaccctccgt
	gttcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccgaagtg
	acctgcgtggtggtggatgtgtcccaggaagatcccgaggtgcagttcaattggtacgt
	ggacggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagttcaaca
	gcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacggcaa
	agagtacaagtgcaaggtgtccaacaagggcctgcccagctccatcgagaaaaccatc
	agcaaggccaagggccagccccgcgagcctcaagtgtgtaccctgccccctagccag
	gaagagatgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctacccca
	gcgacattgccgtggaatgggagagcaacggccagcccgagaacaactacaagacc
	accccccctgtgctggacagcgacggctcattcttcctggtgtccaagctgaccgtgga
	caagagccggtggcaggaaggcaacgtgacagctgctccgtgatgcacgaggccct
	gcacaaccactacacccagaagtccctgtctctgtccctgggcaag
Light	gacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcca	SEQ ID
chain	gcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctga	NO: 453
B	gctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtccaa
	cagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcacc
	ctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccagggc
	acccagtaccccttcacctaggcagcggcaccaaggtggaaatcaagggccagccca
	aggccgcccccgacttcgtgctgacccagagccctcacagcctgagcgtgacacctg
	gcgagagcgccagcatcagctgcaagagcagccactccctgatccacggcgaccgg
	aacaactacctggcttggtacgtgcagaagcccggcagatccccccagctgctgatcta
	cctggccagcagcagagccagcggcgtgcccgatagattttctggcagcggcagcga
	caaggacttcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctacta
	ctgtatgcagggcagagagagcccctggacctaggccagggcaccaaggtggacat
	caagaccaagggccccagccgtacggtggccgctcccagcgtgttcatcttcccacct
	agcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttcta
	cccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaaca
	gccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagcagc
	accctgacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtg
	acccaccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 51 Amino Acid Sequences
Heavy	Qvqlqesgpglvkpsqtlsltctvsgfslsdygvhwvrqppgkglewlgviwaggg	SEQ ID
chain	tnynpslksrktiskdtsknqvslklssvtaadtavyycardkgysyyysmdywgq	NO: 454
A	gttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvht
	fpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppc
	papeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvev
	hnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakg
	qprepqvytippcqeemtknqvslwclvkgfypsdiavewesngqpennykttp
	pvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Divltqspaslavspgqratitcrasesveyyvtslmqwyqqkpgqppkllifaasn	SEQ ID
chain	vesgvparfsgsgsgtdftltinpveandvanyycqqsrkvpytfgqgtkleikrtvaa	NO: 455
A	psvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdsk
	dstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvhltqsgpevrkpgtsvkvsckapgntlktydlhwvrsvpgqglqwmg	SEQ ID
chain	wishegdkkviverfkakvtidwdrstntaylqlsgltsgdtavyycakgskh	NO: 456
B	rlrdyalydddgalnwavdvdylsnlefwgqgtavtvsssqvqlvesg
	ggvvqpgrslrlscaasgftftkawmhwvrqapgkqlewvaqikdksnsy
	atyyadsvkgrftisrddskntlylqmnslraedtavyycrgvyyalspfdyw
	gqgtlvtvssrtastkgpsvfplapcsrstsestaalgclvkdyfpepvtvs
	wnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkv
	dkrveskygppcppcpapeflggpsvflfppkpkdtlmisrtpevtcvvvd
	vsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwln
	gkeykckvsnkglpssiektiskakgqprepqvctlppsqeemtknqvslsc
	avkgfypsdiavewesngqpennykttppvldsdgsfflvskltvdksrwq
	egnvfscsvmhealhnhytqkslslslgk
Light	Divmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvs	SEQ ID
chain	nrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikdkth	NO: 457
B	tdfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkgrspqlliylassr
	asgvpdrfsgsgsdkdftlkisrvetedvgtycmqgrespwtfgqgtkvdikdkth
	trtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvt
	eqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 51 Nucleotide Sequences
Heavy	caggtgcagctgcaggaatctggccctggcctcgtgaagcctagccagaccctgagcc	SEQ ID
chain	tgacctgtaccgtgtccggcttcagcctgagcgactacggcgtgcactgggtgcgcca	NO: 458
A	gccacctggaaaaggcctggaatggctgggcgtgatctgggctggcggaggcaccaa
	ctacaaccccagcctgaagtccagaaagaccatcagcaaggacaccagcaagaacca
	ggtgtccctgaagctgagcagcgtgacagccgccgataccgccgtgtactactgcgcc
	agagacaagggctacagctactactacagcatggactactggggccagggcaccacc
	gtgaccgtgtcatccgcgtcgaccaagggcccctcggtgaccctctggccccttgcag
	cagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactaccc
	gagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctacc
	agccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagc
	agcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacacc
	aaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagccc
	ctgaatttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctga
	tgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcc
	cgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaa
	gcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctg
	caccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctg
	cccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctca
	agtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgtggt
	gtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttc
	ctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgacagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtcc
	ctgggcaag
Light	gacatcgtgctgacacagagccctgctagcctggccgtgtctcctggacagagggcca	SEQ ID
chain	ccatcacctgtagagccagcgagagcgtggaatattacgtgaccagcctgatgcagtg	NO: 459
A	gtatcagcagaagcccggccagccccccaagctgctgattacgccgccagcaacgtg
	gaaagcggcgtgccagccagattaccggcagcggctctggcaccgacttcaccctga
	ccatcaaccccgtggaagccaacgacgtggccaactactactgccagcagagccgga
	aggtgccctacacctaggccagggcaccaagctggaaatcaagcgtacggtggccgc
	tcccagcgtgacatcttcccacctagcgacgagcagctgaagtccggcacagcctctgt
	cgtgtgcctgctgaacaacttctacccccgcgaggccaaggtgcagtggaaggtggac
	aatgccctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaagg
	actccacctacagcctgagcagcaccctgaccctgagcaaggccgactacgagaagc
	acaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaaga
	gcttcaaccggggcgagtgt
Heavy	caggtgcacctgacacagagcggacccgaagtgcggaagcctggcacctctgtgaag	SEQ ID
chain	gtgtcctgcaaggcccctggcaacaccctgaaaacctacgacctgcactgggtgcgca	NO: 460
B	gcgtgccaggacagggactgcagtggatgggctggatcagccacgagggcgacaag
	aaagtgatcgtggaacggttcaaggccaaagtgaccatcgactgggacagaagcacc
	aacaccgcctacctgcagctgagcggcctgacctctggcgataccgccgtgtactactg
	cgccaagggcagcaagcaccggctgagagactacgccctgtacgacgatgacggcg
	ccctgaactgggccgtggatgtggactacctgagcaacctggaattctggggccaggg
	cacagccgtgaccgtgtcatctgacaaaacccatacccaggtgcagctggtggaatctg
	gcggcggagtggtgcagcctggcagaagcctgagactgagctgtgccgccagcggc
	ttcaccttcaccaaggcctggatgcactgggtgcgccaggcccctggaaagcagctgg
	aatgggtggcccagatcaaggacaagagcaacagctacgccacctactacgccgaca
	gcgtgaagggccggttcaccatcagccgggacgacagcaagaacaccctgtacctgc
	agatgaacagcctgcgggccgaggacaccgccgtgtactactgtcggggcgtgtacta
	tgccctgagccccttcgattactggggccagggaaccctcgtgaccgtgtctagtgataa
	gacccacaccgcttcgaccaagggcccatcggtgttccctctggccccttgcagcaga
	agcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttcccgagc
	ccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctttccagcc
	gtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagcagca
	gcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacaccaagg
	tggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagcccctgaa
	tttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctgatgatc
	agccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcccgag
	gtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagccca
	gagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctgcacca
	ggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctgcccag
	ctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctcaagtgtg
	taccctgccccctagccaggaagagatgaccaagaaccaggtgtccctgagctgtgcc
	gtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggccagccc
	gagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttcctggt
	gtccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttcagctgctc
	cgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtccctgg
	gcaag
Ligh	tgacatcgtgatgacccagacccccctgagcctgagcgtgacacctggacagcctgcca	SEQ ID
chain	gcatcagctgcaagagcagccagagcctggtgcacaacaacgccaacacctacctga	NO: 461
B	gctggtatctgcagaagcccggccagagcccccagtccctgatctacaaggtgtccaa
	cagattcagcggcgtgcccgacagattctccggcagcggctctggcaccgacttcacc
	ctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtggccagggc
	acccagtaccccttcacctttggcagcggcaccaaggtggaaatcaaggacaaaaccc
	ataccgacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagag
	cgccagcatcagctgcaagagcagccactccctgatccacggcgaccggaacaacta
	cctggcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggcca
	gcagcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaaggact
	tcaccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactgtatgca
	gggcagagagagcccctggacctttggccagggcaccaaggtggacatcaaggataa
	gacccatacccgtacggtggccgctcccagcgtgttcatcttcccacctagcgacgagc
	agctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccgcgag
	gccaaagtgcagtggaaggtggacaacgccctgcagagcggcaacagccaggaaa
	gcgtgaccgagcaggacagcaaggactccacctacagcctgagcagcaccctgaca
	ctgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgacccaccag
	ggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 52 Amino Acid Sequences
Heavy	Qvqlqesgpglvkpsqtlsltctvsgfslsdygvhwvrqppgkglewlgviwaggg	SEQ ID
chain	tnynpslksrktiskdtsknqvslklssvtaadtavyycardkgysyyysmdywgq	NO: 462
A	gttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvht
	fpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppc
	papeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvev
	hnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakg
	qprepqvytippcqeemtknqvslwclvkgfypsdiavewesngqpennykttp
	pvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Divltqspaslavspgqratitcrasesveyyvtslmqwyqqkpgqppkllifaasn	SEQ ID
chain	vesgvparfsgsgsgtdftltinpveandvanyycqqsrkvpytfgqgtkleikrtvaa	NO: 463
A	psvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdsk
	dstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvqlvesgggvvqpgrslrlscaasgftftkawmhwvrqapgkqlewvaq	SEQ ID
chain	ikdksnsyatyyadsvkgrftisrddskntlylqmnslraedtavyycrgvyy	NO: 464
B	alspfdywgqgtlvtvsssqvhltqsgpevrkpgtsvkvsckapgntlktydl
	hwvrsvpgqglqwmgwishegdkkviverfkakvtidwdrstntaylqls
	gltsgdtavyycakgskhrlrdyalydddgalnwavdvdylsnlefwgqgt
	avtvssrtastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgalt
	sgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvesk
	ygppcppcpapeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpe
	vqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykck
	vsnkglpssiektiskakgqprepqvctlppsqeemtknqvslscavkgfyp
	sdiavewesngqpennykttppvldsdgsfflvskltvdksrwqegnvfscs
	vmhealhnhytqkslslslgk
Light	Dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylassr	SEQ ID
chain	asgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikgqp	NO: 465
B	kaapdivmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliy
	kvsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycgqgtqypftfgsgtkveikt
	kgpsrtvaapsvfifppsdeqlksgtasvcllnnfypreakvqwkvdnalqsgnsq
	esvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 52 Nucleotide Sequences
Heavy	caggtgcagctgcaggaatctggccctggcctcgtgaagcctagccagaccctgagcc	SEQ ID
chain	tgacctgtaccgtgtccggcttcagcctgagcgactacggcgtgcactgggtgcgcca	NO: 466
A	gccacctggaaaaggcctggaatggctgggcgtgatctgggctggcggaggcaccaa
	ctacaaccccagcctgaagtccagaaagaccatcagcaaggacaccagcaagaacca
	ggtgtccctgaagctgagcagcgtgacagccgccgataccgccgtgtactactgcgcc
	agagacaagggctacagctactactacagcatggactactggggccagggcaccacc
	gtgaccgtgtcatccgcgtcgaccaagggcccctcggtgttccctctggccccttgcag
	cagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttccc
	gagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctttcc
	agccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagc
	agcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacacc
	aaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagccc
	ctgaatttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctga
	tgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcc
	cgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaa
	gcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctg
	caccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctg
	cccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctca
	agtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgtggt
	gtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttc
	ctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttcagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtcc
	ctgggcaag
Light	gacatcgtgctgacacagagccctgctagcctggccgtgtctcctggacagagggcca	SEQ ID
chain	ccatcacctgtagagccagcgagagcgtggaatattacgtgaccagcctgatgcagtg	NO: 467
A	gtatcagcagaagcccggccagccccccaagctgctgattttcgccgccagcaacgtg
	gaaagcggcgtgccagccagattttccggcagcggctctggcaccgacttcaccctga
	ccatcaaccccgtggaagccaacgacgtggccaactactactgccagcagagccgga
	aggtgccctacacctttggccagggcaccaagctggaaatcaagcgtacggtggccgc
	tcccagcgtgttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgt
	cgtgtgcctgctgaacaacttctacccccgcgaggccaaggtgcagtggaaggtggac
	aatgccctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaagg
	actccacctacagcctgagcagcaccctgaccctgagcaaggccgactacgagaagc
	acaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaaga
	gcttcaaccggggcgagtgt
Heavy	caggtgcagctggtggaatctggcggcggagtggtgcagcctggcagaagcctgaga	SEQ ID
chain	ctgagctgtgccgccagcggcttcaccttcaccaaggcctggatgcactgggtgcgcc	NO: 468
B	aggcccctggaaagcagctggaatgggtggcccagatcaaggacaagagcaacagc
	tacgccacctactacgccgacagcgtgaagggccggacaccatcagccgggacgac
	agcaagaacaccctgtacctgcagatgaacagcctgcgggccgaggacaccgccgtg
	tactactgtcggggcgtgtactatgccctgagccccttcgattactggggccagggaac
	cctcgtgaccgtgtctagtagccaggtgcacctgacacagagcggacccgaagtgcg
	gaagcctggcacctctgtgaaggtgtcctgcaaggcccctggcaacaccctgaaaacc
	tacgacctgcactgggtgcgcagcgtgccaggacagggactgcagtggatgggctgg
	atcagccacgagggcgacaagaaagtgatcgtggaacggttcaaggccaaagtgacc
	atcgactgggacagaagcaccaacaccgcctacctgcagctgagcggcctgacctctg
	gcgataccgccgtgtactactgcgccaagggcagcaagcaccggctgagagactacg
	ccctgtacgacgatgacggcgccctgaactgggccgtggatgtggactacctgagcaa
	cctggaattctggggccagggcacagccgtgaccgtgtcatctcggaccgccagcaca
	aagggcccatcggtgaccctctggccccttgcagcagaagcaccagcgaatctacag
	ccgccctgggctgcctcgtgaaggactactttcccgagcccgtgaccgtgtcctggaac
	tctggcgctctgacaagcggcgtgcacacctttccagccgtgctccagagcagcggcc
	tgtactctctgagcagcgtcgtgacagtgcccagcagcagcctgggcaccaagaccta
	cacctgtaacgtggaccacaagcccagcaacaccaaggtggacaagcgggtggaatc
	taagtacggccctccctgccctccttgcccagcccctgaatactgggcggaccctccgt
	gttcctgttccccccaaagcccaaggacaccctgatgatcagccggacccccgaagtg
	acctgcgtggtggtggatgtgtcccaggaagatcccgaggtgcagttcaattggtacgt
	ggacggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagttcaaca
	gcacctaccgggtggtgtccgtgctgaccgtgctgcaccaggactggctgaacggcaa
	agagtacaagtgcaaggtgtccaacaagggcctgcccagctccatcgagaaaaccatc
	agcaaggccaagggccagccccgcgagcctcaagtgtgtaccctgccccctagccag
	gaagagatgaccaagaaccaggtgtccctgagctgtgccgtgaaaggcttctacccca
	gcgacattgccgtggaatgggagagcaacggccagcccgagaacaactacaagacc
	accccccctgtgctggacagcgacggctcattcttcctggtgtccaagctgaccgtgga
	caagagccggtggcaggaaggcaacgtgacagctgctccgtgatgcacgaggccct
	gcacaaccactacacccagaagtccctgtctctgtccctgggcaag
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcgcc	SEQ ID
chain	agcatcagctgcaagagcagccactccctgatccacggcgaccggaacaactacctg	NO: 469
B	gcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggccagca
	gcttgagccagcggcgtgcccgatagattactggcagcggcagcgacaaggacttca
	ccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactgtatgcagg
	gcagagagagcccctggacctaggccagggcaccaaggtggacatcaagggccag
	cccaaggccgcccccgacatcgtgatgacccagacccccctgagcctgagcgtgaca
	cctggacagcctgccagcatcagctgcaagagcagccagagcctggtgcacaacaac
	gccaacacctacctgagctggtatctgcagaagcccggccagagcccccagtccctga
	tctacaaggtgtccaacagattcagcggcgtgcccgacagattctccggcagcggctct
	ggcaccgacttcaccctgaagatcagccgggtggaagccgaggacgtgggcgtgtac
	tattgtggccagggcacccagtaccccttcacctttggcagcggcaccaaggtggaaat
	caagaccaagggccccagccgtacggtggccgctcccagcgtgttcatcttcccacct
	agcgacgagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttcta
	cccccgcgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaaca
	gccaggaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagcagc
	accctgacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtg
	acccaccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt
Binding Protein 53 Amino Acid Sequences
Heavy	Qvqlqesgpglvkpsqtlsltctvsgfslsdygvhwvrqppgkglewlgviwaggg	SEQ ID
chain	tnynpslksrktiskdtsknqvslklssvtaadtavyycardkgysyyysmdywgq	NO: 470
A	gttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvht
	fpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppc
	papeflggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvev
	hnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakg
	qprepqvytippcqeemtknqvslwclvkgfypsdiavewesngqpennykttp
	pvldsdgsfflyskltvdksrwqegnvfscsvmhealhnhytqkslslslgk
Light	Divltqspaslavspgqratitcrasesveyyvtslmqwyqqkpgqppkllifaasn	SEQ ID
chain	vesgvparfsgsgsgtdftltinpveandvanyycqqsrkvpytfgqgtkleikrtvaa	NO: 471
A	psvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdsk
	dstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Heavy	Qvqlvesgggvvqpgrslrlscaasgftftkawmhwvrqapgkqlewvaq	SEQ ID
chain	ikdksnsyatyyadsvkgrftisrddskntlylqmnslraedtavyycrgvyy	NO: 472
B	alspfdywgqgtlvtvsssqvhltqsgpevrkpgtsvkvsckapgntlk
	tydlhwvrsvpgqglqwmgwishegdkkviverfkakvtidwdrstntay
	lqlsgltsgdtavyycakgskhrlrdyalydddgalnwavdvdylsnlefwg
	qgtavtvssrtastkgpsvfplapcsrstsestaalgclvkdyfpepvtvs
	wnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkv
	dkrveskygppcppcpapeflggpsvflfppkpkdtlmisrtpevtcvvvd
	vsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwln
	gkeykckvsnkglpssiektiskakgqprepqvctlppsqeemtknqvslsc
	avkgfypsdiavewesngqpennykttppvldsdgsfflvskltvdksrwq
	egnvfscsvmhealhnhytqkslslslgk
Light	Dfvltqsphslsvtpgesasiscksshslihgdrnnylawyvqkpgrspqlliylassr	SEQ ID
chain	asgvpdrfsgsgsdkdftlkisrvetedvgtyycmqgrespwtfgqgtkvdikdkth	NO: 473
B	tdivmtqtplslsvtpgqpasisckssqslvhnnantylswylqkpgqspqsliykvs
	nrfsgvpdrfsgsgsgtdftlkisrveadvgvyycgqgtqypftfgsgtkveikdkth
	trtvaapsvfifppsdeqlksgtasvcllnnfypreakvqwkvdnalqsgnsqesvt
	eqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec
Binding Protein 53 Nucleotide Sequences
Heavy	caggtgcagctgcaggaatctggccctggcctcgtgaagcctagccagaccctgagcc	SEQ ID
chain	tgacctgtaccgtgtccggcttcagcctgagcgactacggcgtgcactgggtgcgcca	NO: 474
A	gccacctggaaaaggcctggaatggctgggcgtgatctgggctggcggaggcaccaa
	ctacaaccccagcctgaagtccagaaagaccatcagcaaggacaccagcaagaacca
	ggtgtccctgaagctgagcagcgtgacagccgccgataccgccgtgtactactgcgcc
	agagacaagggctacagctactactacagcatggactactggggccagggcaccacc
	gtgaccgtgtcatccgcgtcgaccaagggcccctcggtgaccctctggccccttgcag
	cagaagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttccc
	gagcccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctacc
	agccgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagc
	agcagcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacacc
	aaggtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagccc
	ctgaatactgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctga
	tgatcagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcc
	cgaggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaa
	gcccagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctg
	caccaggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctg
	cccagctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctca
	agtgtataccctgcccccttgccaggaagagatgaccaagaaccaggtgtccctgtggt
	gtctcgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggcca
	gcccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttc
	ctgtactccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgacagct
	gctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtcc
	ctgggcaag
Light	gacatcgtgctgacacagagccctgctagcctggccgtgtctcctggacagagggcca	SEQ ID
chain	ccatcacctgtagagccagcgagagcgtggaatattacgtgaccagcctgatgcagtg	NO: 475
A	gtatcagcagaagcccggccagccccccaagctgctgattttcgccgccagcaacgtg
	gaaagcggcgtgccagccagattttccggcagcggctctggcaccgacttcaccctga
	ccatcaaccccgtggaagccaacgacgtggccaactactactgccagcagagccgga
	aggtgccctacacctttggccagggcaccaagctggaaatcaagcgtacggtggccgc
	tcccagcgtgttcatcttcccacctagcgacgagcagctgaagtccggcacagcctctgt
	cgtgtgcctgctgaacaacttctacccccgcgaggccaaggtgcagtggaaggtggac
	aatgccctgcagagcggcaacagccaggaaagcgtgaccgagcaggacagcaagg
	actccacctacagcctgagcagcaccctgaccctgagcaaggccgactacgagaagc
	acaaggtgtacgcctgcgaagtgacccaccagggcctgtctagccccgtgaccaaga
	gcttcaaccggggcgagtgt
Heavy	caggtgcagctggtggaatctggcggcggagtggtgcagcctggcagaagcctgaga	SEQ ID
chain	ctgagctgtgccgccagcggcttcaccttcaccaaggcctggatgcactgggtgcgcc	NO: 476
B	aggcccctggaaagcagctggaatgggtggcccagatcaaggacaagagcaacagc
	tacgccacctactacgccgacagcgtgaagggccggttcaccatcagccgggacgac
	agcaagaacaccctgtacctgcagatgaacagcctgcgggccgaggacaccgccgtg
	tactactgtcggggcgtgtactatgccctgagccccttcgattactggggccagggaac
	cctcgtgaccgtgtctagtgacaaaacccatacccaggtgcacctgacacagagcgga
	cccgaagtgcggaagcctggcacctctgtgaaggtgtcctgcaaggcccctggcaaca
	ccctgaaaacctacgacctgcactgggtgcgcagcgtgccaggacagggactgcagt
	ggatgggctggatcagccacgagggcgacaagaaagtgatcgtggaacggttcaagg
	ccaaagtgaccatcgactgggacagaagcaccaacaccgcctacctgcagctgagcg
	gcctgacctctggcgataccgccgtgtactactgcgccaagggcagcaagcaccggct
	gagagactacgccctgtacgacgatgacggcgccctgaactgggccgtggatgtgga
	ctacctgagcaacctggaattctggggccagggcacagccgtgaccgtgtcatctgata
	agacccacaccgccagcacaaagggcccatcggtgttccctctggccccttgcagcag
	aagcaccagcgaatctacagccgccctgggctgcctcgtgaaggactactttcccgag
	cccgtgaccgtgtcctggaactctggcgctctgacaagcggcgtgcacacctttccagc
	cgtgctccagagcagcggcctgtactctctgagcagcgtcgtgacagtgcccagcagc
	agcctgggcaccaagacctacacctgtaacgtggaccacaagcccagcaacaccaag
	gtggacaagcgggtggaatctaagtacggccctccctgccctccttgcccagcccctga
	atttctgggcggaccctccgtgttcctgttccccccaaagcccaaggacaccctgatgat
	cagccggacccccgaagtgacctgcgtggtggtggatgtgtcccaggaagatcccga
	ggtgcagttcaattggtacgtggacggcgtggaagtgcacaacgccaagaccaagcc
	cagagaggaacagttcaacagcacctaccgggtggtgtccgtgctgaccgtgctgcac
	caggactggctgaacggcaaagagtacaagtgcaaggtgtccaacaagggcctgccc
	agctccatcgagaaaaccatcagcaaggccaagggccagccccgcgagcctcaagt
	gtgtaccctgccccctagccaggaagagatgaccaagaaccaggtgtccctgagctgt
	gccgtgaaaggcttctaccccagcgacattgccgtggaatgggagagcaacggccag
	cccgagaacaactacaagaccaccccccctgtgctggacagcgacggctcattcttcct
	ggtgtccaagctgaccgtggacaagagccggtggcaggaaggcaacgtgttcagctg
	ctccgtgatgcacgaggccctgcacaaccactacacccagaagtccctgtctctgtccct
	gggcaag
Light	gacttcgtgctgacccagagccctcacagcctgagcgtgacacctggcgagagcgcc	SEQ ID
chain	agcatcagctgcaagagcagccactccctgatccacggcgaccggaacaactacctg	NO: 477
B	gcttggtacgtgcagaagcccggcagatccccccagctgctgatctacctggccagca
	gcagagccagcggcgtgcccgatagattttctggcagcggcagcgacaaggacttca
	ccctgaagatcagccgggtggaaaccgaggacgtgggcacctactactgtatgcagg
	gcagagagagcccctggacctttggccagggcaccaaggtggacatcaaggacaaa
	acccataccgacatcgtgatgacccagacccccctgagcctgagcgtgacacctggac
	agcctgccagcatcagctgcaagagcagccagagcctggtgcacaacaacgccaaca
	cctacctgagctggtatctgcagaagcccggccagagcccccagtccctgatctacaa
	ggtgtccaacagattcagcggcgtgcccgacagattctccggcagcggctctggcacc
	gacttcaccctgaagatcagccgggtggaagccgaggacgtgggcgtgtactattgtg
	gccagggcacccagtaccccttcacctttggcagcggcaccaaggtggaaatcaagg
	ataagacccatacccgtacggtggccgctcccagcgtgttcatcttcccacctagcgac
	gagcagctgaagtccggcacagcctctgtcgtgtgcctgctgaacaacttctacccccg
	cgaggccaaagtgcagtggaaggtggacaacgccctgcagagcggcaacagccag
	gaaagcgtgaccgagcaggacagcaaggactccacctacagcctgagcagcaccct
	gacactgagcaaggccgactacgagaagcacaaggtgtacgcctgcgaagtgaccca
	ccagggcctgtctagccccgtgaccaagagcttcaaccggggcgagtgt

TABLE A
CDR sequences of binding proteins
Ab	CDRH1	CDRH2	CDRH3
CD4BS “a”	dctin	wlkprggavnyarpl	gkncdynwdfeh
	(SEQ ID NO: 248)	qg	(SEQ ID NO: 250)
		(SEQ ID NO: 249)
CD4BS “b”	GYFTAHI	IKPQYGAV	drsygdsswalda
	(SEQ ID NO: 251)	(SEQ ID NO: 252)	(SEQ ID NO: 253)
MPER	gfdfdnaw	itgpgegwsv	tgkyydfwsgyppgeeyfqd
	(SEQ ID NO: 254)	(SEQ ID NO: 255)	(SEQ ID NO: 256)
V1/V2 dir. “a”	GNTLKTYD	ISHEGDKK	cakgskhrlrdyalyddd
	(SEQ ID NO: 257)	(SEQ ID NO: 258)	galnwavdvdylsnlefw
			(SEQ ID NO: 259)
V3 dir.	SGASISDSY	VHKSGDT	ARTLHGRRIYGIVAFNEWFT
	(SEQ ID NO: 260)	(SEQ ID NO: 261)	YFYMDV
			(SEQ ID NO: 262)
V1/V dir. “b”	QFRFDGYG	ISHDGIKK	CAKDLREDECEEWWSDYYDF
	(SEQ ID NO: 263)	(SEQ ID NO: 264)	GKQLPCAKSRGGLVGIADNW
			(SEQ ID NO: 265)
Anti-CD28	GYTFTSYY	IYPGNVNT	trshygldwnfdv
	(SEQ ID NO: 479)	(SEQ ID NO: 480)	(SEQ ID NO: 481)
Anti-CD28	GFSLSDYG	IWAGGGT	ardkgysyyysmd
	(SEQ ID NO: 482)	(SEQ ID NO: 483)	(SEQ ID NO: 484)
Anti-CD3	GFTFTKAW	IKDKSNS	rgvyyalspfdy
	(SEQ ID NO: 485)	(SEQ ID NO: 486)	(SEQ ID NO: 487)
Ab	CDRL1	CDRL2	CDRL3
CD4BS “a”	rtsqygsla	sgstraa	qqyef
	(SEQ ID NO: 266)	(SEQ ID NO: 267)	(SEQ ID NO: 268)
CD4BS “b”	QGVGSD	HTS	qvlqf
	(SEQ ID NO: 269)	(SEQ ID NO: 270)	(SEQ ID NO: 271)
MPER	rgdslrshyas	gknnrps	ssrdksgsrlsv
	(SEQ ID NO: 272)	(SEQ ID NO: 273)	(SEQ ID NO: 274)
V1/V2 dir. “a”	hslihgdrnny	las	cmqgrespwtf
	(SEQ ID NO: 275)	(SEQ ID NO: 276)	(SEQ ID NO: 277)
V3 dir.	SLGSRA	NNQ	HIWDSRVPTKWV
	(SEQ ID NO: 278)	(SEQ ID NO: 279)	(SEQ ID NO: 280)
V1/V dir. “b”	TSNIGNNF	ETD	atwaaslssarv
	(SEQ ID NO: 281)	(SEQ ID NO: 282)	(SEQ ID NO: 283)
Anti-CD28	QNIYVW	KAS	qqgqtypyt
	(SEQ ID NO: 488)	(SEQ ID NO: 489)	(SEQ ID NO: 490)
Anti-CD28	ESVEYYVTSL	AAS	qqsrkvpyt
	(SEQ ID NO: 491)	(SEQ ID NO: 492)	(SEQ ID NO: 493)
Anti-CD3	QSLVHNNANTY	KVS	gqgtqyp
	(SEQ ID NO: 494)	(SEQ ID NO: 495)	(SEQ ID NO: 496)

TABLE B
CDR sequences of parental antibodies
Ab	CDR_H1	CDR_H2	CDR_H3	CDR_L1	CDR_L2	CDR_L3
CD4BS	DCTLN	LKPRGGAVNYARP	GKNCDYNWDFEH	RTSQYGSLA	SGSTRAA	QQYEF
“a”	(SEQ ID NO: 248)	LQ	(SEQ ID NO: 250)	(SEQ ID NO:	(SEQ ID NO:	(SEQ ID NO:
		(SEQ ID NO: 497)		266)	267)	268)
CD4BS	GYTFTAHI	IKPQYGAV	DRSYGDSSWALDA	QGVGSD	HTS	QVLQF
“b”	(SEQ ID NO: 251)	(SEQ ID NO: 252)	(SEQ ID NO: 253)	(SEQ ID NO:	(SEQ ID NO:	(SEQ ID NO:
				269)	270)	271)
MPER	GFDFDNAW	ITGPGEGWSV	TGKYYDFWSGYPPGE	SLRSHY	GKN	SSRDKSGSRLSV
	(SEQ ID NO: 254)	(SEQ ID NO: 255)	EYFQD	(SEQ ID NO:	(SEQ ID NO:	(SEQ ID NO:
			(SEQ ID NO: 256)	500)	501)	274)
MPER_100W	GFDFDNAW	ITGPGEGWSV	TGKYYDFWWGYPPGE	SLRSHY	GKN	SSRDKSGSRLSV
	(SEQ 1D NO: 254)	(SEQ ID NO: 255)	EYFQD	(SEQ ID NO:	(SEQ ID NO:	(SEQ ID NO:
			(SEQ ID NO: 498)	500)	501)	274)
V1/V2	GNTLKTYD	ISHEGDKK	CAKGSKHRLRDYALY	HSLIHGDRNNY	LAS	CMQGRESPWTF
directed	(SEQ ID NO: 257)	(SEQ ID NO: 258)	DDDGALNWAVDVDYL	(SEQ ID NO:	(SEQ ID NO:	(SEQ ID NO:
“a”			SNLEFW	275)	276)	277)
			(SEQ ID NO: 259)
V1/V2	QFRFDGYG	ISHDGIKK	CAKDLREDECEEWWS	TSNIGNNF	ETD	ATWAASLSSARV
directed	(SEQ ID NO: 263)	(SEQ ID NO: 264)	DYYDFGKQLPCAKSR	(SEQ ID NO:	(SEQ ID NO:	(SEQ ID NO:
“b”			GGLVGIADNW	281)	282)	283)
			(SEQ ID NO: 265)
V3	GASISDSY	VHKSGDT	ARTLHGRRIYGIVAF	SLGSRA	NNQ	HIWDSRVPTKW
directed	(SEQ ID NO: 499)	(SEQ ID NO: 261)	NEWFTYFYMDV	(SEQ ID NO:	(SEQ ID NO:	V
			(SEQ ID NO: 262)	278)	279)	(SEQ ID NO:
						280)
CD28	GYTFTSYY	IYPGNVNT	TRSHYGLDWNFDV	QNIYVW	KAS	QQGQTYPYT
	(SEQ ID NO: 479)	(SEQ ID NO: 480)	(SEQ ID NO: 481)	(SEQ ID NO:	(SEQ ID NO:	(SEQ ID NO:
				488)	489)	490)
CD28_2	GFSLSDYG	IWAGGGT	ARDKGYSYYYSMD	ESVEYYVTSL	AAS	QQSRKVPYT
	(SEQ ID NO: 482)	(SEQ ID NO: 483)	(SEQ ID NO: 484)	(SEQ ID NO:	(SEQ ID NO:	(SEQ ID NO:
				491)	492)	493)
CD3	GFTFTKAW	IKDKSNS	RGVYYALSPFDY	QSLVHNNANTY	KVS	GQGTQYP
	(SEQ ID NO: 485)	(SEQ ID NO: 486)	(SEQ ID NO: 487)	(SEQ ID NO:	(SEQ ID NO:	(SEQ ID NO:
				494)	495)	496)

TABLE C
Variable domain sequences of parental antibodies
Ab Name	VH	VL
CD4BS “a”	QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAP	EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQ
	GKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAF	RPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNL
	LELRSLTVDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVS	TISNLESGDFGVYYCQQYEFFGQGTKVQVDIK
	S (SEQ ID NO: 502)	(SEQ ID NO: 512)
CD4BS “b”	RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAP	YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHW
	GRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIAY	YQHKPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTS
	MDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVV	FNLTISDLQADDIATYYCQVLQFFGRGSRLHIK
	VSA (SEQ ID NO: 503)	(SEQ ID NO: 513)
CD4BS “b”	RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAP	YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHW
(Aglycan)	GRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIAY	YQHKPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTS
	MDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVV	F LTISDLQADDIATYYCQVLQFFGRGSRLHIK
	VSA (SEQ ID NO: 503)	(SEQ ID NO: 514)
CD4BS “b”	RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAP	YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHW
(Δisomerization	GRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIAY	YQHKPGRAPKLLIHHTSSVE EGVPSRFSGSGFHTS
D55E)	MDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVV	FNLTISDLQADDIATYYCQVLQFFGRGSRLHIK
	VSA (SEQ ID NO: 503)	(SEQ ID NO: 515)
CD4BS “b”	RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAP	YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHW
(Δisomerization	GRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIAY	YQHKPGRAPKLLIFIHTSSVED VPSRFSGSGFHTS
G56A)	MDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVV	FNLTISDLQADDIATYYCQVLQFFGRGSRLHIK
	VSA (SEQ ID NO: 503)	(SEQ ID NO: 516)
CD4BS “b”	RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAP	YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHW
(Δglycan/	GRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIAY	YQHKPGRAPKLLIHHTSSVE GVPSRFSGSGFHTS
Δisomerization	MDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVV	F LTISDLQADDIATYYCQVLQFFGRGSRLHIK
D55E)	VSA (SEQ ID NO: 503)	(SEQ ID NO: 517)
MPER	EVRLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQP	ASELTQDPAVSVALKQTVTITCRGDSLRSHYASW
	PGKGLEWVGRITGPGEGWSVDYAESVKGRFTISRDNTKNTL	YQKKPGQAPVLLFYGKNNRPSGIPDRFSGSASGN
	YLEMNNVRTEDTGYYFCARTGKYYDFWSGYPPGEEYFQD	RASLTITGAQAEDEADYYCSSRDKSGSRLSVFGG
	WGQGTLVIVSS (SEQ ID NO: 504)	GTKLTVL (SEQ ID NO: 518)
MPER_100W	EVRLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQP	ASELTQDPAVSVALKQTVTITCRGDSLRSHYASW
	PGKGLEWVGRITGPGEGWSVDYAESVKGRFTISRDNTKNTL	YQKKPGQAPVLLFYGKNNRPSGIPDRFSGSASGN
	YLEMNNVRTEDTGYYFCAR	RASLTITGAQAEDEADYYCSSRDKSGSRLSVFGG
	WGQGTLVIVSS (SEQ ID NO: 505)	GTKLTVL (SEQ ID NO: 518)
V1/V2	QVHLTQSGPEVRKPGTSVKVSCKAPGNTLKTYDLHWVRSV	DFVLTQSPHSLSVTPGESASISCKSSHSLIHGDRNN
directed “a”	PGQGLQWMGWISHEGDKKVIVERFKAKVTIDWDRSTNTAY	YLAWYVQKPGRSPQLLIYLASSRASGVPDRFSGS
	LQLSGLTSGDTAVYYCAKGSKHRLRDYALYDDDGALNWA	GSDKDFTLKISRVETEDVGTYYCMQGRESPWTFG
	VDVDYLSNLEFWGQGTAVTVSS (SEQ ID NO: 506)	QGTKVDIK (SEQ ID NO: 519)
V1/V2	QVQLVESGGGVVQPGTSLRLSCAASQFRFDGYGNIHWVRQ	QSVLTQPPSVSAAPGQKVTISCSGNTSNIGNNFVS
directed “b”	APGKGLEWVASISHDGIKKYHAEKVWGRFTISRDNSKNTLY	WYQQRPGRAPQLLIYETDKRPSGIPDRFSASKSGT
	LQMNSLRPEDTALYYCAKDLREDECEEWWSDYYDFGKQLP	SGTLAITGLQTGDEADYYCATWAASLSSARVFGT
	CAKSRGGLVGIADNWGQGTMVTVSS	GTKVIVL (SEQ ID NO: 520)
	(SEQ ID NO: 507)
V3 directed	QMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSP	SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQ
	GKGLEWIGYVHKSGDTNYSPSLKSRVNLSLDTSKNQVSLSL	APSLIIYNNQDRPSGIPERFSGSPDSPFGTTATLTIT
	VAATAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVW	SVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVL
	GNGTQVTVSS (SEQ ID NO: 508)	(SEQ ID NO: 521)
CD28	QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYYIHWVRQA	DIQMTQSPSSLSASVGDRVTITCQASQNIYVWLN
	PGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTAYM	WYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSG
	ELSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSS	TDFTLTISSLQPEDIATYYCQQGQTYPYTFGQGTK
	(SEQ ID NO: 509)	LEIK (SEQ ID NO: 522)
CD28_2	QVQLQESGPGLVKPSQTLSLTCTVSGFSLSDYGVHWVRQPP	DIVLTQSPASLAVSPGQRATITCRASESVEYYVTS
	GKGLEWLGVIWAGGGTNYNPSLKSRKTISKDTSKNQVSLKL	LMQWYQQKPGQPPKLLIFAASNVESGVPARFSGS
	SSVTAADTAVYYCARDKGYSYYYSMDYWGQGTTVTVSS	GSGTDFTLTINPVEANDVANYYCQQSRKVPYTFG
	(SEQ ID NO: 510)	QGTKLEIK (SEQ ID NO: 523)
CD3	QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHWVRQ	DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNAN
	APGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNT	TYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGS
	LYLQMNSLRAEDTAVYYCRGVYYALSPFDYWGQGTLVTV	GSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFG
	SS (SEQ ID NO: 511)	SGTKVEIK (SEQ ID NO: 524)
CDR sequences are underlined.
Variable domain modifications are shown in bold and italicized.

Claims

1. A bispecific binding protein that specifically binds to two different HIV-1 Env protein epitopes, wherein the bispecific binding protein comprises a first and a second binding site; wherein the first binding site comprises VH1 and VL1, wherein VH1 is a first immunoglobulin heavy chain variable domain that comprises the amino acid sequence of SEQ ID NO:506, and wherein VL1 is a first immunoglobulin light chain variable domain that comprises the amino acid sequence of SEQ ID NO:519; andwherein the second binding site comprises VH2 and VL2, wherein VH2 is a second immunoglobulin heavy chain variable domain that comprises the amino acid sequence of SEQ ID NO:504, and wherein VL2 is a second immunoglobulin light chain variable domain that comprises the amino acid sequence of SEQ ID NO:518.

2. A bispecific binding protein that specifically binds to two different HIV-1 Env protein epitopes, wherein the bispecific binding protein comprises a first and a second binding site; wherein the first binding site comprises VH1 and VL1, wherein VH1 is a first immunoglobulin heavy chain variable domain that comprises the amino acid sequence of SEQ ID NO:503, and wherein VL1 is a first immunoglobulin light chain variable domain that comprises the amino acid sequence of SEQ ID NO:513; andwherein the second binding site comprises VH2 and VL2, wherein VH2 is a second immunoglobulin heavy chain variable domain that comprises the amino acid sequence of SEQ ID NO:506, and wherein VL2 is a second immunoglobulin light chain variable domain that comprises the amino acid sequence of SEQ ID NO:519.

3. A bispecific binding protein that specifically binds to two different HIV-1 Env protein epitopes, wherein the bispecific binding protein comprises a first and a second binding site; wherein the first binding site comprises VH1 and VL1, wherein VH1 is a first immunoglobulin heavy chain variable domain that comprises the amino acid sequence of SEQ ID NO:506, and wherein VL1 is a first immunoglobulin light chain variable domain that comprises the amino acid sequence of SEQ ID NO:519; andwherein the second binding site comprises VH2 and VL2, wherein VH2 is a second immunoglobulin heavy chain variable domain that comprises the amino acid sequence of SEQ ID NO:503, and wherein VL2 is a second immunoglobulin light chain variable domain that comprises the amino acid sequence of SEQ ID NO:513.